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Abstract
Light at night (LAN) is a major factor in disruption of SCN function, including
melatonin suppression. Melatonin has been linked to a variety of biological processes
such as lipid and glucose metabolism, vascular parameters, appetite, and behaviour.
However, few human studies have investigated the effect of LAN and suppressed
melatonin prior to and after an evening meal.
The current thesis aims to investigate the impact of light at night and/or mela-
tonin on hormones, metabolites, appetite, vascular function, and behaviour prior to
and after an evening test meal in healthy participants.
The first study investigated the effect of dim or bright light conditions on hor-
mones, metabolites, appetite, vascular function and behavioural responses. Glucose
tolerance and insulin sensitivity were reduced, lipid profiles altered and salivary
melatonin suppressed under bright light compared to dim light conditions. Subjec-
tive mood was improved and appetite scores increased in bright light. No differences
were seen in vascular parameters. Although clear differences were apparent it could
not be determined whether the effects were due to the light at night, the absence
of melatonin or a combination of the two.
The second study involved three conditions with the administration of exogenous
melatonin 90 mins before the evening test meal under bright and dim light conditions
compared to bright light alone with the consequent melatonin suppression. Glucose
tolerance and insulin sensitivity were reduced and lipid profile altered in bright light
when melatonin was suppressed compared to the two conditions with exogenous
melatonin. Mood was improved and appetite increased with lower leptin levels and
elevated wrist temperature with bright light and suppressed melatonin. Statistical
iii
analysis showed that the major effects were due to melatonin.
These studies demonstrate a possible role for melatonin in glucose tolerance,
insulin sensitivity and lipid metabolism when eating late at night which may have
implications for shift-workers.
iv
Acknowledgements
First and foremost, I would like to express my sincerest gratitude to my supervi-
sors, Dr. Benita Middleton and Dr. Shelagh Hampton, who have supported me
throughout my Ph.D with their patience and knowledge, whilst allowing me the
room to work in my own way. I would like to thank them for giving me a chance to
present my works in several international conferences, which allowed me to develop
various skills. Their positive outlook and confidence in my research inspired me
and boosted my confidence. Moreover, their careful editing contributed enormously
to the production of this thesis. One simply could not wish for better or friendlier
supervisors.
I would like to thank the Chronobiology group for their supports, assistance and
valuable feedbacks, which helped me to develop the research skills. Special thanks
goes to Prof Debra Skene for her valuable ideas and suggestions that contributed
to this project, my colleagues Dr. Cheryl Isherwood for being very helpful and
supportive throughout my Ph.D degree. I would like to thank for her assistance in
the clinical study and input with the study meal.
I would also like to sincerely thank Dr Peter Williams and Dr Daan Van der
Veen for their precious advices in statistics, Dr Fran Robertson and Joanna Sier
for helping me in the ILab experiments, Dr Bruce Griffin and Dr Barbara Fielding
for their suggestions and ideas about lipid data, Saeed Alqahtanti for helping me
get on the road to LATEX and providing an experienced ear for my doubts about
writing a thesis, and and last but not the least, the CRC nurses for data and sample
collection.
To all my friends, you should know that your support and encouragement was
v
worth more than I can express on paper, particularly Dr. Raed Alharbi, Dr Salem
Alhashmi, Dr. Skevoulla Christou, Imane Sarhani, Mahmoud Alsharafi, Jaber
Bawazir, Haytham Walid, Abdulatif Alkandari, Abdullah Aljohani, 19 AY 02 group,
Guildford group, and labmates.
I wish to thank Abu Dhabi Health Services Company (SEHA) in the United
Arab Emirates for funding this project.
Finally, I thank my parents and family for supporting me throughout all my
studies at the university, for their wise counsel and sympathetic ear, and for always
being there for me. I would like to express my deep appreciation to my beloved wife
for her patience, support and encouragement.
vi
Dedication
To my loving
Parents, Big Brother & Family...
whose affection, endless love, encouragements and prayers of days and
nights make me able to get success and honour.
vii
Contents
Declaration ii
Summary iii
Acknowledgements v
Dedication vii
Contents viii
List of Figures xviii
List of Tables xxi
Abbreviations xxiii
1 Introduction & Literature Review 2
1.1 Light and human physiology . . . . . . . . . . . . . . . . . . . . . . . 3
1.1.1 The eye & retina . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.1.2 Photoreceptors & pigments . . . . . . . . . . . . . . . . . . . 4
1.2 Non-image forming processes . . . . . . . . . . . . . . . . . . . . . . 6
1.2.1 Intrinsically photosensitive retinal ganglion cells . . . . . . . 7
1.2.2 Melanopsin as the major photopigment . . . . . . . . . . . . 7
1.2.3 Diversity of ipRGCs . . . . . . . . . . . . . . . . . . . . . . . 8
1.2.4 Axonal projections of ipRGC subtypes . . . . . . . . . . . . . 8
1.2.5 ipRGCs phototransduction . . . . . . . . . . . . . . . . . . . 10
1.2.6 Rods and cones action in NVRs . . . . . . . . . . . . . . . . . 11
viii
1.3 Retinal output pathway . . . . . . . . . . . . . . . . . . . . . . . . . 12
1.3.1 RHT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
1.3.2 The SCN . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13
1.3.2.1 Pathways to the SCN . . . . . . . . . . . . . . . . . 15
1.3.2.2 Output efferent pathways from SCN . . . . . . . . . 16
1.4 Circadian rhythms . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
1.5 Acute NIF effects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
1.5.1 The endogenous hormone melatonin . . . . . . . . . . . . . . 18
1.5.1.1 Melatonin synthesis . . . . . . . . . . . . . . . . . . 19
1.5.1.2 Melatonin catabolism . . . . . . . . . . . . . . . . . 20
1.5.1.3 Circadian rhythm of endogenous melatonin . . . . . 21
1.5.1.4 Melatonin as a marker of circadian phase . . . . . . 22
1.5.1.5 Melatonin measurements . . . . . . . . . . . . . . . 22
1.5.1.6 Melatonin receptors and distribution . . . . . . . . . 23
1.5.2 Non-photic factors affecting endogenous melatonin . . . . . . 24
1.5.2.1 Dietary intake . . . . . . . . . . . . . . . . . . . . . 25
1.5.2.2 Posture . . . . . . . . . . . . . . . . . . . . . . . . . 26
1.5.2.3 Physical exercise . . . . . . . . . . . . . . . . . . . . 26
1.5.2.4 Menstrual cycle and contraceptive pills . . . . . . . 27
1.5.2.5 Caffeine . . . . . . . . . . . . . . . . . . . . . . . . . 28
1.5.2.6 Alcohol . . . . . . . . . . . . . . . . . . . . . . . . . 29
1.5.2.7 Drugs . . . . . . . . . . . . . . . . . . . . . . . . . . 29
1.5.2.8 Nicotine . . . . . . . . . . . . . . . . . . . . . . . . . 30
1.5.3 Sleepiness and alertness . . . . . . . . . . . . . . . . . . . . . 30
1.5.3.1 Circadian rhythms and human sleepiness-alertness . 31
1.5.3.2 Light and human sleepiness-alertness . . . . . . . . 32
1.5.3.3 Measures of sleepiness-alertness . . . . . . . . . . . 33
1.5.4 Temperature . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
1.5.4.1 Acute light effects on body temperature . . . . . . . 35
1.5.5 Interaction between melatonin, sleepiness-alertness and body
temperature . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
1.5.6 Mood and comfort . . . . . . . . . . . . . . . . . . . . . . . . 37
ix
1.5.7 Cardiovascular function . . . . . . . . . . . . . . . . . . . . . 39
1.5.7.1 The risks of shift work . . . . . . . . . . . . . . . . . 40
1.5.7.2 Effect of melatonin on vascular function . . . . . . . 40
1.5.7.3 Effect of melatonin on vascular structure . . . . . . 41
1.5.7.4 Acute effects of light on vascular function . . . . . . 42
1.5.7.5 Arterial stiffness as clinical research tool . . . . . . 43
1.5.8 Short-term endocrine control of metabolism . . . . . . . . . . 44
1.5.8.1 Glucose physiology and rhythm . . . . . . . . . . . 44
1.5.8.2 TAGs, NEFAs and lipoproteins . . . . . . . . . . . . 45
1.5.8.3 Insulin physiology and rhythm . . . . . . . . . . . . 48
1.5.8.4 Glucose intolerance and insulin resistance . . . . . . 49
1.5.8.5 Effects of melatonin on glucose and insulin . . . . . 50
1.5.8.6 Melatonin and type 2 diabetes . . . . . . . . . . . . 52
1.5.8.7 Effects of light and/or melatonin on lipid profile . . 54
1.5.8.8 Glucagon and melatonin . . . . . . . . . . . . . . . 55
1.5.9 Long-term endocrine control of metabolism . . . . . . . . . . 55
1.5.9.1 Cortisol normal physiology and rhythm . . . . . . . 56
1.5.9.2 Catecholamines (adrenaline & noradreanline) . . . 57
1.5.9.3 Effects of light and/or melatonin on cortisol . . . . 58
1.5.10 Appetite hormones: leptin and ghrelin . . . . . . . . . . . . . 59
1.5.10.1 Leptin physiology . . . . . . . . . . . . . . . . . . . 59
1.5.10.2 Ghrelin physiology . . . . . . . . . . . . . . . . . . . 60
1.5.10.3 The effects of light and/or melatonin on appetite
hormones . . . . . . . . . . . . . . . . . . . . . . . . 61
1.6 Light parameters influencing non-visual responses . . . . . . . . . . . 62
1.6.1 Wavelength . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
1.6.2 Irradiance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 62
1.6.3 Duration . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 63
1.6.4 Timing and light history . . . . . . . . . . . . . . . . . . . . . 63
1.7 Biological factors influencing non-visual responses to light . . . . . . 63
1.7.1 Pupil size and age . . . . . . . . . . . . . . . . . . . . . . . . 64
1.7.2 Angle of gaze . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
x
1.8 Rationale of Study . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
1.9 Aim and hypothesis . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
2 STUDY SESSIONS 69
2.1 Ethical approval . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
2.2 Recruitment . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69
2.3 Study 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
2.3.1 Screening session . . . . . . . . . . . . . . . . . . . . . . . . . 71
2.3.2 Urine analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
2.3.3 Oral contraception . . . . . . . . . . . . . . . . . . . . . . . . 72
2.3.4 Meal distribution . . . . . . . . . . . . . . . . . . . . . . . . . 72
2.3.5 Study session . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
2.3.5.1 Saliva samples . . . . . . . . . . . . . . . . . . . . . 74
2.3.5.2 Plasma samples . . . . . . . . . . . . . . . . . . . . 74
2.3.5.3 Blood RNA analysis . . . . . . . . . . . . . . . . . . 75
2.3.5.4 Vicorder . . . . . . . . . . . . . . . . . . . . . . . . 75
2.3.5.5 Peripheral body temperature . . . . . . . . . . . . . 75
2.3.5.6 Continuous Glucose Monitoring (CGM) . . . . . . . 76
2.3.5.7 Visual analogue scale VAS PRO-Diary® . . . . . . 76
2.3.5.8 Mood and alertness questionnaire . . . . . . . . . . 76
2.4 Study 2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
2.4.1 Recruitment . . . . . . . . . . . . . . . . . . . . . . . . . . . . 78
2.4.2 Screening blood . . . . . . . . . . . . . . . . . . . . . . . . . . 78
2.4.3 Circadin intake . . . . . . . . . . . . . . . . . . . . . . . . . . 78
2.4.4 Study session . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
2.4.4.1 Visual analogue scale VAS PRO-Diary® . . . . . . 79
2.5 Facilities . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
2.5.1 Light intensity measurements . . . . . . . . . . . . . . . . . . 81
2.5.2 Spectral light composition . . . . . . . . . . . . . . . . . . . . 82
3 MATERIALS & EXPERIMENTAL METHODS 84
3.1 Radioimmunoassay technique . . . . . . . . . . . . . . . . . . . . . . 84
3.1.1 Radioimmumoassay accuracy and sensitivity . . . . . . . . . 85
xi
3.1.2 RIA of urinary 6-sulphatoxymelatonin (aMT6s) . . . . . . . . 87
3.1.3 Salivary melatonin . . . . . . . . . . . . . . . . . . . . . . . . 90
3.1.4 Plasma leptin . . . . . . . . . . . . . . . . . . . . . . . . . . . 92
3.1.5 Plasma Insulin . . . . . . . . . . . . . . . . . . . . . . . . . . 95
3.1.6 Plasma cortisol . . . . . . . . . . . . . . . . . . . . . . . . . . 99
3.2 Measurement of plasma metabolites . . . . . . . . . . . . . . . . . . 100
3.2.1 Plasma glucose . . . . . . . . . . . . . . . . . . . . . . . . . . 102
3.2.2 Plasma NEFAs . . . . . . . . . . . . . . . . . . . . . . . . . . 102
3.2.3 Plasma TAGs . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
3.3 KSS, mood and alertness . . . . . . . . . . . . . . . . . . . . . . . . 103
3.4 Assessment of food visual analogue scale . . . . . . . . . . . . . . . . 104
3.5 Continuous Glucose Monitoring (CGM) . . . . . . . . . . . . . . . . 105
3.6 Screening questionnaires . . . . . . . . . . . . . . . . . . . . . . . . . 106
3.7 Vascular function tests . . . . . . . . . . . . . . . . . . . . . . . . . . 107
3.8 Statistical analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
3.8.1 Power size calculation . . . . . . . . . . . . . . . . . . . . . . 108
3.8.2 Normality tests . . . . . . . . . . . . . . . . . . . . . . . . . . 108
3.8.3 Missing values . . . . . . . . . . . . . . . . . . . . . . . . . . 108
3.8.4 Analyses of variance (ANOVAs) . . . . . . . . . . . . . . . . 109
3.8.5 Students t-tests . . . . . . . . . . . . . . . . . . . . . . . . . . 110
3.8.6 Correlation test . . . . . . . . . . . . . . . . . . . . . . . . . . 110
3.8.7 Area under the curve (AUC) . . . . . . . . . . . . . . . . . . 111
3.8.8 aMT6s analysis . . . . . . . . . . . . . . . . . . . . . . . . . . 111
4 STUDY 1 113
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
4.2 Aims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
4.3 Objectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
4.4 Hypotheses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
4.5 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 115
4.5.1 Participant demographics & screening data . . . . . . . . . . 115
4.5.2 Calculation of salivary melatonin onset . . . . . . . . . . . . . 116
xii
4.5.3 Laboratory session . . . . . . . . . . . . . . . . . . . . . . . . 118
4.5.3.1 Light measurements . . . . . . . . . . . . . . . . . . 119
4.5.4 Assay procedures . . . . . . . . . . . . . . . . . . . . . . . . . 120
4.5.4.1 Radioimmunoassay . . . . . . . . . . . . . . . . . . 120
4.5.4.2 Measurements of the metabolites . . . . . . . . . . . 121
4.5.5 Statistical analyses . . . . . . . . . . . . . . . . . . . . . . . . 121
4.5.5.1 Time-points selection . . . . . . . . . . . . . . . . . 121
4.5.5.2 Basal levels . . . . . . . . . . . . . . . . . . . . . . . 122
4.5.5.3 Basal levels prior to the test meal (T=0) . . . . . . 122
4.5.5.4 Pre-prandial responses (T= -360 to T = 0) . . . . . 122
4.5.5.5 Post-prandial responses . . . . . . . . . . . . . . . . 123
4.5.5.6 Post-hoc test . . . . . . . . . . . . . . . . . . . . . . 123
4.5.5.7 AUC . . . . . . . . . . . . . . . . . . . . . . . . . . 123
4.5.5.8 Correlations with melatonin . . . . . . . . . . . . . 123
4.5.5.9 Measurement of insulin resistance . . . . . . . . . . 124
4.6 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 124
4.6.1 Participants demographic and screening . . . . . . . . . . . . 124
4.6.2 Sleep screening and basal hormone and metabolites . . . . . . 125
4.6.3 Subjective mood and alertness . . . . . . . . . . . . . . . . . 126
4.6.3.1 Basal levels prior to the test meal (T = 0) . . . . . 126
4.6.3.2 Pre-prandial mood and alertness (T= -330 to T=0) 126
4.6.3.3 Postprandial mood and alertness . . . . . . . . . . . 130
4.6.3.4 Pre and postprandial mood and alertness (T = -330
to T = +330) . . . . . . . . . . . . . . . . . . . . . 130
4.6.4 Plasma hormones and metabolites . . . . . . . . . . . . . . . 130
4.6.4.1 Hormones and metabolites levels prior to the test
meal (T = 0) . . . . . . . . . . . . . . . . . . . . . . 130
4.6.4.2 Pre-prandial hormone and metabolic responses (T-
360-0 min) . . . . . . . . . . . . . . . . . . . . . . . 134
4.6.4.3 Postprandial hormone and metabolic responses . . . 134
4.6.4.4 Pre- and Postprandial hormone and metabolic re-
sponses (T = -360 to T = +330 min) . . . . . . . . 134
xiii
4.6.4.5 TAUCs and IAUCs of hormones and metabolites . . 135
4.6.4.6 HOMA-PP and HOMA-IR . . . . . . . . . . . . . . 136
4.6.5 Vascular function tests . . . . . . . . . . . . . . . . . . . . . . 138
4.6.5.1 Pre-prandial vascular parameters (-285 & -120 min) 138
4.6.5.2 Post-prandial vascular parameters (+30 & +90 min) 140
4.6.5.3 Pre and postprandial vascular parameters (T = -285
to T = +90) . . . . . . . . . . . . . . . . . . . . . . 141
4.6.6 Continuous glucose monitoring: interstitial glucose . . . . . . 141
4.6.6.1 Pre-prandial and postprandial interstitial glucose . . 141
4.6.6.2 TAUC and IAUC of interstitial glucose . . . . . . . 142
4.6.7 Appetite data analysis . . . . . . . . . . . . . . . . . . . . . . 142
4.6.7.1 Subjective appetite parameters . . . . . . . . . . . . 143
4.6.7.2 Pre-prandial and postprandial plasma leptin . . . . 144
4.6.7.3 TAUC and IAUC of plasma leptin . . . . . . . . . . 145
4.6.8 Peripheral body temperature . . . . . . . . . . . . . . . . . . 146
4.6.8.1 Pre-prandial and postprandial wrist temperature . . 146
4.6.9 Interaction between melatonin, subjective mood-alertness and
wrist temperature . . . . . . . . . . . . . . . . . . . . . . . . 147
4.7 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
4.7.1 Participant demographics . . . . . . . . . . . . . . . . . . . . 150
4.7.2 Analysis of screening data . . . . . . . . . . . . . . . . . . . . 150
4.7.3 Cosinor analysis and melatonin onset . . . . . . . . . . . . . . 151
4.7.4 Salivary melatonin . . . . . . . . . . . . . . . . . . . . . . . . 152
4.7.5 Plasma glucose and insulin . . . . . . . . . . . . . . . . . . . 153
4.7.6 Plasma cortisol . . . . . . . . . . . . . . . . . . . . . . . . . . 155
4.7.7 Lipid profile . . . . . . . . . . . . . . . . . . . . . . . . . . . . 156
4.7.8 Mood and alertness . . . . . . . . . . . . . . . . . . . . . . . 157
4.7.9 Peripheral body temperature (WT) . . . . . . . . . . . . . . 158
4.7.10 Appetite analysis . . . . . . . . . . . . . . . . . . . . . . . . . 159
4.7.11 Vascular functions . . . . . . . . . . . . . . . . . . . . . . . . 161
4.7.12 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . 162
xiv
5 STUDY 2 164
5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 164
5.2 Aims . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 165
5.3 Objectives . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 165
5.4 Hypotheses . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 165
5.5 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 166
5.5.1 Participant demographics & screening data . . . . . . . . . . 166
5.5.2 Laboratory session . . . . . . . . . . . . . . . . . . . . . . . . 168
5.5.3 Light measurements . . . . . . . . . . . . . . . . . . . . . . . 168
5.5.4 Statistical analyses . . . . . . . . . . . . . . . . . . . . . . . . 169
5.5.4.1 Time-point selection . . . . . . . . . . . . . . . . . . 169
5.5.4.2 Basal levels . . . . . . . . . . . . . . . . . . . . . . . 170
5.5.4.3 Basal levels prior to the evening test meal (T = 0) . 170
5.5.4.4 Pre-prandial responses (T = -360 to T = 0) . . . . 170
5.5.4.5 Post-prandial responses . . . . . . . . . . . . . . . . 170
5.5.4.6 Area under the curve . . . . . . . . . . . . . . . . . 171
5.5.4.7 Correlation tests . . . . . . . . . . . . . . . . . . . . 171
5.5.4.8 Measurement of insulin resistance . . . . . . . . . . 171
5.5.4.9 Analysis of variance (ANOVA) . . . . . . . . . . . 172
5.6 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 172
5.6.1 Participant demographics and screening analyses in Study 2 . 172
5.6.1.1 Sleep screening and basal hormones and metabolites 172
5.6.2 KSS, mood and alertness . . . . . . . . . . . . . . . . . . . . 173
5.6.2.1 Basal levels prior to the test meal . . . . . . . . . . 173
5.6.2.2 Pre-prandial and postprandial KSS, mood and alert-
ness . . . . . . . . . . . . . . . . . . . . . . . . . . . 174
5.6.3 Hormones and metabolites . . . . . . . . . . . . . . . . . . . 175
5.6.3.1 Basal level prior to the test meal (T = 0) . . . . . . 175
5.6.3.2 Pre-prandial and postprandial hormones and metabo-
lites . . . . . . . . . . . . . . . . . . . . . . . . . . . 176
5.6.3.3 TAUC and IAUC of hormones and metabolites . . . 178
5.6.3.4 HOMA-IR and HOMA-PP . . . . . . . . . . . . . . 182
xv
5.6.4 Subjective appetite scores and plasma leptin . . . . . . . . . 182
5.6.4.1 Subjective appetite scores . . . . . . . . . . . . . . . 182
5.6.4.2 Pre-prandial and postprandial of plasma leptin . . . 184
5.6.4.3 TAUC and IAUC of plasma leptin . . . . . . . . . . 185
5.6.5 Peripheral temperature . . . . . . . . . . . . . . . . . . . . . 185
5.6.5.1 Pre-prandial and postprandial wrist temperature . . 185
5.6.5.2 TAUC and IAUC of wrist temperature . . . . . . . 186
5.6.6 Activity level . . . . . . . . . . . . . . . . . . . . . . . . . . . 188
5.6.6.1 Pre-prandial and postprandial activity level . . . . . 188
5.6.7 Relationship between melatonin and other parameters . . . . 190
5.7 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 190
5.7.1 Participant demographics & screening . . . . . . . . . . . . . 194
5.7.2 Salivary melatonin . . . . . . . . . . . . . . . . . . . . . . . . 195
5.7.3 Hormones and metabolites . . . . . . . . . . . . . . . . . . . 196
5.7.4 KSS, Mood and alertness . . . . . . . . . . . . . . . . . . . . 199
5.7.5 Appetite analysis . . . . . . . . . . . . . . . . . . . . . . . . . 200
5.7.6 Peripheral body temperature and activity levels . . . . . . . . 202
5.7.7 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . 203
6 GENERAL DISCUSSION 205
6.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 205
6.2 Strengths and considerations of the study protocol . . . . . . . . . . 206
6.3 Overall discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . 209
6.4 Limitation of the study . . . . . . . . . . . . . . . . . . . . . . . . . 211
6.4.1 Pre-study measurements . . . . . . . . . . . . . . . . . . . . . 211
6.4.2 Study design and protocol . . . . . . . . . . . . . . . . . . . 212
6.4.3 Statistical limitations . . . . . . . . . . . . . . . . . . . . . . 215
6.5 Future work . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 216
6.6 Applications of the current results . . . . . . . . . . . . . . . . . . . 218
6.7 Conclusion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 219
Bibliography 222
xvi
List of Publications 296
Appendices 309
xvii
List of Figures
1.1 The anatomy of the human eye . . . . . . . . . . . . . . . . . . . . . . . 4
1.2 Cross-section of the retina . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1.3 Spectral response of human retinal photopigments in vivo. . . . . . . . 6
1.4 Morphology and dendritic field of ipRGC subtypes . . . . . . . . . . . . 9
1.5 ipRGC projections to brain localizations and the associated circuits . . 10
1.6 Intracellular signalling mechanism within SCN . . . . . . . . . . . . . . 14
1.7 Neural inputs and outputs of the SCN . . . . . . . . . . . . . . . . . . . 16
1.8 Melatonin structure and biosynthesis pathway . . . . . . . . . . . . . . . 20
1.9 Melatonin phase curve . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
1.10 Major types of melatonin receptors . . . . . . . . . . . . . . . . . . . . . 24
1.11 Circadian rhythm of behavioural and physiological responses under con-
stant routine condition . . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
1.12 Metabolism of TAGs, NEFAs and lipoproteins . . . . . . . . . . . . . . 46
1.13 Insulin secretion from pancreatic β-cells . . . . . . . . . . . . . . . . . . 49
1.14 Melatonin-mediated signal transduction in pancreatic β-cells . . . . . . 53
1.15 Impact of leptin and ghrelin on energy balance and food intake . . . . . 60
2.1 Study 1 protocol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 77
2.2 Study 2 protocol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
2.3 Spectral composition of fluorescent light . . . . . . . . . . . . . . . . . . 82
2.4 Spectral composition of LED . . . . . . . . . . . . . . . . . . . . . . . . 82
4.1 Subjective mood and alertness at basal levels (T = 0) . . . . . . . . . . 127
4.2 Pre-prandial and postprandial subjective mood and alertness . . . . . . 128
xviii
4.3 Gender differences in subjective KSS, alertness and mood score . . . . . 129
4.4 Hormones and metabolites at basal levels (T = 0) . . . . . . . . . . . . 131
4.5 Pre-prandial and postprandial hormones and metabolites . . . . . . . . 132
4.6 Gender differences in plasma hormones and metabolites . . . . . . . . . 133
4.7 TAUC of hormones and metabolites . . . . . . . . . . . . . . . . . . . . 136
4.8 IAUC of hormones and metabolites . . . . . . . . . . . . . . . . . . . . . 137
4.9 HOMA-IR and HOMA-PP . . . . . . . . . . . . . . . . . . . . . . . . . 137
4.10 Brachial and carotid vascular parameters . . . . . . . . . . . . . . . . . 138
4.11 Vascular function parameters . . . . . . . . . . . . . . . . . . . . . . . . 139
4.12 Pre-prandial and postprandial interstitial glucose . . . . . . . . . . . . 141
4.13 Gender differences in interstitial glucose . . . . . . . . . . . . . . . . . . 142
4.14 TAUC and IAUC of interstitial glucose . . . . . . . . . . . . . . . . . . . 142
4.15 Subjective appetite questionnaires . . . . . . . . . . . . . . . . . . . . . 143
4.16 Pre-prandial and postprandial plasma leptin (Raw data) . . . . . . . . . 144
4.17 % basal leptin concentration . . . . . . . . . . . . . . . . . . . . . . . . 144
4.18 Gender differences in plasma leptin . . . . . . . . . . . . . . . . . . . . . 145
4.19 TAUC and IAUC of plasma leptin . . . . . . . . . . . . . . . . . . . . . 145
4.20 Pre-prandial and postprandial wrist temperature (◦C) . . . . . . . . . . 146
4.21 Pre-prandial (A) and postprandial (B) wrist temperature (◦C) . . . . . 147
4.22 Melatonin interaction with subjective KSS, alertness, mood scores and
wrist temperature in LS . . . . . . . . . . . . . . . . . . . . . . . . . . . 148
4.23 Melatonin interaction with subjective KSS, alertness, mood scores and
wrist temperature in DS . . . . . . . . . . . . . . . . . . . . . . . . . . . 149
5.1 Subjective mood and alertness at basal levels (T = 0) . . . . . . . . . . 176
5.2 Pre-prandial and postprandial subjective mood and alertness . . . . . . 177
5.3 Hormones and metabolites at basal levels (T = 0) . . . . . . . . . . . . 178
5.4 Pre-prandial and postprandial hormones and metabolites . . . . . . . . 179
5.5 TAUC of hormones and metabolites . . . . . . . . . . . . . . . . . . . . 180
5.6 IAUC of hormones and metabolites . . . . . . . . . . . . . . . . . . . . . 181
5.7 HOMA-IR and HOMA-PP . . . . . . . . . . . . . . . . . . . . . . . . . 182
5.8 Subjective appetite questionnaires . . . . . . . . . . . . . . . . . . . . . 183
xix
5.9 Plasma leptin at basal level (T = 0) . . . . . . . . . . . . . . . . . . . . 183
5.10 Pre-prandial and postprandial plasma leptin . . . . . . . . . . . . . . . . 184
5.11 % basal leptin concentration . . . . . . . . . . . . . . . . . . . . . . . . 184
5.12 TAUC and IAUC of plasma leptin . . . . . . . . . . . . . . . . . . . . . 185
5.13 Wrist temperature (◦C) at basal level (T = 0). . . . . . . . . . . . . . . 186
5.14 Pre-prandial and postprandial wrist temperature (◦C) . . . . . . . . . . 186
5.15 Pre-prandial and postprandial wrist temperature (◦C) at 15 min intervals187
5.16 Wrist temperature (◦C) for pre-prandial and postprandial periods . . . 187
5.17 TAUC and IAUC of wrist temperature (◦C) . . . . . . . . . . . . . . . . 188
5.18 Pre-prandial and postprandial activity levels . . . . . . . . . . . . . . . 189
5.19 Pre-prandial and postprandial activity levels . . . . . . . . . . . . . . . 189
5.20 Activity levels at pre-prandial and postprandial periods . . . . . . . . . 190
5.21 Melatonin interaction with subjective behavioural ratings, appetite scores,
wrist temperature and plasma leptin in LS . . . . . . . . . . . . . . . . 191
5.22 Melatonin interaction with subjective behavioural ratings, appetite scores,
wrist temperature and plasma leptin in DSC . . . . . . . . . . . . . . . 192
5.23 Melatonin interaction with subjective behavioural ratings, appetite scores,
wrist temperature and plasma leptin in LSC . . . . . . . . . . . . . . . . 193
xx
List of Tables
1.1 Melatonin receptor subtypes and distribution . . . . . . . . . . . . . . . 24
2.1 Contraceptive pill and menstrual phase . . . . . . . . . . . . . . . . . . 72
2.2 Carbohydrate, protein, fat, fibre and energy for each of the meals and
overall composition of all three meals . . . . . . . . . . . . . . . . . . . . 73
2.3 Light intensity in lux during dark and light sessions . . . . . . . . . . . 81
2.4 Light intensity in W/m2 during dark and light sessions . . . . . . . . . . 81
3.1 Radioimmunoassay aMT6s standards . . . . . . . . . . . . . . . . . . . . 87
3.2 Assay procedure flow chart for aMT6s RIA . . . . . . . . . . . . . . . . 89
3.3 Radioimmunoassay melatonin standards . . . . . . . . . . . . . . . . . . 90
3.4 Standard preparation for leptin RIA . . . . . . . . . . . . . . . . . . . . 92
3.5 Assay procedure flow chart for MT RIA . . . . . . . . . . . . . . . . . . 93
3.6 Standard preparation for insulin RIA . . . . . . . . . . . . . . . . . . . . 95
3.7 Assay procedure flow chart for leptin RIA . . . . . . . . . . . . . . . . . 96
3.8 Assay procedure flow chart for insulin RIA . . . . . . . . . . . . . . . . 98
3.9 Standard preparation for cortisol RIA . . . . . . . . . . . . . . . . . . . 99
3.10 Assay procedure flow chart for cortisol RIA . . . . . . . . . . . . . . . . 101
4.1 Screening questionnaire analysis in Study 1 . . . . . . . . . . . . . . . . 116
4.2 Estimated plasma melatonin onset and individualised meal times of the
participants in Study 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . 117
4.3 aMT6s urinary screening in Study 1 . . . . . . . . . . . . . . . . . . . . 118
4.4 Quality controls and coefficient of variation in Study 1 . . . . . . . . . . 121
xxi
4.5 Participant demographics in Study 1 . . . . . . . . . . . . . . . . . . . . 124
4.6 Screening sleep and basal hormone and metabolite data in Study 1 . . . 125
4.7 Screening correlation tests in Study 1 . . . . . . . . . . . . . . . . . . . 126
4.8 Analysis of appetite parameters . . . . . . . . . . . . . . . . . . . . . . . 143
5.1 Analysis of screening questionnaires in Study 2 . . . . . . . . . . . . . . 167
5.2 Plasma melatonin onset, Circadin and meal timing of the participants
in Study 2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 167
5.3 aMT6s urinary screening in Study 2 . . . . . . . . . . . . . . . . . . . . 168
5.4 Light measurements in LS, DSC and LSC (mean ± SEM) . . . . . . . . 169
5.5 Participant demographics in Study 2 . . . . . . . . . . . . . . . . . . . . 173
5.6 Screening sleep and basal hormones and metabolite data in Study 2 . . 174
5.7 Quality controls and coefficient of variation in Study 2 . . . . . . . . . . 175
5.8 Screening correlation tests in Study 2 . . . . . . . . . . . . . . . . . . . 175
xxii
Abbreviations
AAA Anterior amygdaloid area
AANAT aryl alkylamine N-acetyl transferase
ABP Arterial blood pressure
ACh Acetylcholine
ACTH Adrenocorticotropic hormone
AFMK N1-acetyl-N2-formyl-5-methoxykynuramine
AGI Augmentation index
AgRP Agouti-related peptide
AMPA -amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid
aMT6s 6-sulfatoxymelatonin
ANAT Arylamine-N-acetyltransferase
ANP Atrial natriuretic peptide
APP Arterial pulse pressure
ATP Adenosine triphosphate
β-AR beta-adrenoreceptor
BMI Body mass index
BNP Brain natriuretic peptide
BNST Bed nucleus of the stria terminals
B-PPI Brachial-pulse pressure index
B-PWV Brachial-pulse wave velocity
BSTL Bed nucleus of the stria terminals
Ca2+ Calcium ions
CaM Calcium-calmodulin protein kinase
xxiii
cAMP Cyclic adenosine monophosphate
CAT Catalase
CBT Core body temperature
CCK Cholecystokinin
CEs Cholesterol esters
CETP Cholesteryl ester transfer protein
CG Ciliary ganglion
cGMP Cyclic guanosine monophosphate
CHD Coronary heart disease
CHK1 Checkpoint protein
CIU Clinical investigation unit
CMs Chylomicrons
CO Cardiac output
-COOH Carboxyl
C-PAG Carotid-peripheral augmentation
C-PPI Carotid-pulse pressure index
C-PWV Carotid-pulse wave velocity
CREB cAMP response element-binding protein
CRH Corticotropin-releasing hormone
Cry Cryptochrome
CVD Cardiovascular disease
CVM Caudal ventrolateral medulla
CYP1A1 Cytochrome P450 1A1
CYP1A2 Cytochrome P450 1A2
CYP1B1 Cytochrome P450 1B1
D/D Constant dark
DAG diacyl-glycerol
DBP Diastolic blood pressure
DBP Diastolic blood pressure
dLGN Dorsolateral geniculate nucleus
DLMO Dim light melatonin onset
DMH Dorsomedial nuclei of the hypothalamus
xxiv
dmSCN Dorsomedial part-SCN
DS Dark session
DSC Dark session + Circadin
DST Distal temperature
ECG Electrocardiogram
EEG Electroencephalographic
EOG Electrooculographic
ESS Epworth sleepiness scale
EW Edinger-Westphal
FAs Fatty acids
FMD Flow-mediated dilatation
FP Follicular phase
G-6-P Glucose-6-phosphate
G6PD Glucose-6-phosphate dehydrogenase
GABA γ-Aminobutyric acid
GALP Galanin-like peptide
GCL Ganglion cell layer
GHT Geniculo-hypothalamic tract
GI Gastrointestinal tract
GIP Gastric inhibitory polypeptide
GLP-1 Glucagon-like peptide 1
GLUT Glucose transporter
GPx Glutathione peroxidase
GRd Glutathione reductase
GRP Gastrin releasing peptide
HADS Hospital anxiety and depression scale
HDL High-density lipoprotein
HF High frequency
HIOMT hydroxyl indole O-methyl transferase
HIP Histidine isoleucine peptide
HL Hepatic lipase
HPA Hypothalamus-pituitary axis
xxv
HR Heart rate
HRV Heart rate variability
HSL Hormone sensitive lipase
IAUC Incremental area under curve
IGL Intergeniculate leaflet
IML Intermediolateral nucleus
IML inter-mediolateral
INL Inner nuclear layer
IP3 Inositol trisphosphate
IPL Inner plexiform layer
ipRGC intrinsically photosensitive retinal ganglion cell
IRL Inner retinal layer
IRS Insulin receptor substrate
K+ Potassium ions
KSS Karolinska sleepiness scale
LAN Light at night
LC Locus coeruleus
LCAT Lecithin-cholesterol acyltransferase
LCFAs Long-chain fatty acids
LD Light/dark
LDL Low-density lipoprotein
LED Light emitting diode
LF Low frequency
LP Luteal phase
LPL Endothelial lipoprotein lipase
LS Light session
LSC Light session + Circadin
LVM Left ventricular mass
MAGs Monoglycerides
MAO Monoamine oxidase
MAP Mean arterial pressure
MDMA 3,4-Methylenedioxymethamphetamine
xxvi
MEL Melatonin
MPN Median preoptic nucleus
MPOA Medial preoptic area
MRI Magnetic resonance imaging
MRN Midbrain raphe nuclei
MSLT Multiple sleep latency test
MT Melatonin receptor
MTP Microsomal triglyceride protein
MWT Maintenance of wakefulness test
NA Noradrenaline
NE Norepinephrine
NEFAs Non-esterified fatty acids
NIF Nonimage-forming
NMDA N-methyl-D-aspartate
NO Nitric oxide
NPY Neuropeptide Y
NSAIDs Non-steroidal anti-inflammatory drugs
NSW Non-shift work
NVR Non-visual response
OGTT Oral glucose tolerance test
-OH Hydroxyl
ON Olivary pretectal nucleus
ONL Outer nuclear layer
OPL Outer plexiform layer
OPN Olivary pretectal nucleus
PAG Peripheral augmentation
PACAP Pituitary cyclase-activating peptide
PaPA Paraventricular hypothalamic nucleus, anterior parvicellular part
λ max Peak wavelength sensitivity
Per Period
PHI Peptide histidine isoleucine
PIP2 Phosphatidylinositol bisphosphate
xxvii
PKA Protein kinase A
PKC Protein kinase C
PKG Protein kinase G
PLC Phospholipase C
PLR Pupillary light reflex
PMDD Premenstrual dysphoric disorder
POMC Pro-opiomelanocortin
POT Primary optic tract
PP Pancreatic polypeptide
PP Pulse pressure
PRC Phase response curve
PTA Pretectal area
PVN Paraventricular nucleus
PWV Pulse wave velocity
RCh Retrochiasmatic area
REM Rapid eye movement
RGC Retinal ganglion cell
RHT Retinohypothalmic tract
RIA Radioimmunoassay
RNS Reactive nitrogen specie
ROR/RZR Retinoid orphan receptor/retinoid Z receptors
ROS Reactive oxygen species
RT-PCR Real-time polymerase chain reaction
RVM Rostral ventrolateral medulla
SAD Seasonal affective disorder
SBP Systolic blood pressure
SBP Systolic blood pressure
SC Superior colliculus
SCG Superior cervical ganglia
SCG Superior cervical ganglion
SCN Suprachiasmatic nucleus
SDNN Standard deviation of the normal to-normal interval
xxviii
SIGH-SAD Hamilton depression rating scale-seasonal affective disorder
SLV Superior lateral ventricle
SOD Superoxide dismutase
SOM Somatostatin
sPVZ Subparaventricular zone
SSRIs Selective serotonin inhibitors
SSS Stanford sleepiness scale
SV Stroke volume
SW Shift work
T1/2 Half-life
TAGs Triglycerides
tau Period
TAUC Total area under curve
TPH Tryptophan hydroxylase
TPR Total peripheral resistance
TRP Tryptophan
VIP Vasoactive intestinal polypeptide
VLDL Very low-density lipoprotein
VLPO Ventrolateral preoptic nucleus
vlSCN Ventrolateral part-SCN
VMH Ventromedial nuclei of the hypothalamus
VP Vasopressin
VPAC2 Vasoactive intestinal polypeptide receptor 2
WAT White adipose tissue
WT Wrist temperature
5-HT 5-hydroxytryptamine
xxix

CHAPTER 1
INTRODUCTION & LITERATURE
REVIEW
1
Introduction
Evolution has been greatly influenced by sunlight, and it is not surprising that all
living organisms, including humans, have developed a variety of physiological re-
sponses to the daily or seasonal variations in day length (Watson, 2011). These
subtle responses have determined the impact of sunlight or its artificial equivalents
on human physiology and metabolism. Inadequate or excessive sunlight exposure
has been linked to vitamin D deficiency; skin inflammation; psoriasis; jaundice
treatment; and, most importantly, alteration of circadian rhythms (Vitaterna et al.,
2001). A growing amount of evidence has shown that basic biochemical and hor-
monal rhythms are synchronized directly or indirectly by the daily cycle of light and
dark. This evidence has prompted several animal studies focused on the possibility
of using artificial light exposure to overcome some metabolic and cardiovascular
diseases (Benstead and Moore, 1988; ?)
The increasing occurrence of bright light at night outside and the growing num-
ber of people working inside under electric light both during night and day, override
the human biological adaptation to the natural cycle of light and dark. Therefore,
it is important to investigate the unintended adverse health consequences of elec-
tric lighting and establish the necessary intervention to mitigate harmful effects of
suboptimal light exposure. Researchers, including chronobiologists, have therefore
begun to investigate the biological impact of artificial light on mammalian physiol-
ogy such as behavioural responses, vascular changes, and alterations on hormones
and metabolites. Most of the published studies were performed in vitro or in vivo in
animal models such as rats, in disease groups (e.g., diabetes, cardiovascular disease
(CVD), psychological disorders), in simulated shift work conditions or shift workers,
involving administration of exogenous melatonin, continuous bright light or dark-
ness, and constant routine. To date, few human studies have been undertaken to
investigate the impact of acute light at night (LAN) on hormones and metabolites,
appetite control, vascular functions, and behaviours in healthy subjects imitating a
nocturnal lifestyle.
2
1.1 Light and human physiology
It has been known for a considerable time that the function of light is not confined to
vision but is involved in a diverse collection of biological outputs. Light effects vary
from basal physiology functions to higher order cognitive processes. The impact
of light can be classified into image-forming and nonimage-forming (NIF) visual
processes. The image-forming visual processes refer to the detection of objects or
organisms in the environment and distinguishing their physical characteristics, such
as size, shape, and direction of motion. In contrast, NIF visual processes provide a
measure of the ambient luminance to synchronize the mammalian biological clocks
with the environmental light-dark cycle (circadian photo-entrainment), control pupil
size (pupillary light reflex (PLR)) and locomotor behaviours (LeGates et al., 2014).
1.1.1 The eye & retina
The human eye is a complex fluid-filled spherical organ that performs two essential
functions. The eye serves as a sensory organ for vision and as the primary input
pathway for a non-visual response (Purves et al., 2012). The eye structure is di-
vided into three enclosed transparent coats: outermost layer (fibrous tunic), middle
layer (vascular tunic) and the innermost layer (retina) (Bloemendal et al., 2004).
The light passes through the transparent cornea, aqueous humour and lens that
refracts and converges it through the vitreous humour onto the enriched photore-
ceptor network within the retina. 100% of visible light is transmitted to the retina
as the cornea, aqueous humour and vitreous humour are clear tissue; however the
crystalline lens and macular pigment around the fovea region of the retina absorb
light at the short wavelength end of the spectrum. Consequently, light received at
the retina is in its least distorted form (Bonnel et al., 2003; Asbell et al., 2005)
(Figure1.1).
The retina is a highly vascularised photosensory layer that lies at the back
of the eye. The retinal structure is made up of an inner retinal layer (IRL), a
ganglion cell layer (GCL), an inner nuclear layer (INL) and outer nuclear layer
(ONL). The human retina contains 130 million photoreceptors, converging to 6
million bipolar cells which in turn are joined to ∼ 1 million ganglion cells (Martini
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Figure 1.1: The anatomy of the human eye
Schematic horizontal section of the anatomical structure of the adult human eye showing the major parts
of the eye, and the protective corneal layer as well as the constituents of the anterior and posterior chamber
(Modified from (Kolb, 2003).
et al., 2015). Light absorbed by photoreceptors therefore passes through the retinal
membrane of 4 different cells layers before reaching the photoreceptors. Bipolar,
horizontal and amacrine cells are all interneurons that combine and convey signals
from photoreceptors to ganglion cells. Ganglion cells transmit the signal in the form
of an action potential from the retina to the brain (østergaard et al., 2007; Hoshi
et al., 2009; Pickard et al., 2009; Prez de Sevilla Mller et al., 2010; Knop et al.,
2011) (Figure1.2).
1.1.2 Photoreceptors & pigments
The mammalian retina contains two different types of photoreceptors that are in-
volved in image-forming functions, rods and cones, known as classical photorecep-
tors. Rods and cones are a group of ciliary class photoreceptors composed of three
regions: synaptic terminals, cell body and an outer segment region that contains
photopigment. Although the human retina has a greater number of rods (∼ 91
million) than cones (∼ 4.5 million) throughout the retinal regions, in the fovea
(1.2 mm in diameter) cones outnumber rods. Both types contain photopigment
which is made of a light-sensitive protein namely opsin. The rod opsin is known
as rhodopsin, and in cones coneopsin. These structural differences explain their
functional differences. There is a single class of rods that aids vision in dim light,
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Figure 1.2: Cross-section of the retina
Schematic cross section of the human retina showing different types of retinal cells, retinal layers and their
connections. Photoreceptors are shown in green (rod, r, and cones, c). Horizontal cells (h, gray), bipolar
cells (b, blue), amacrine cells (a, white), a ganglion cell (g, purple). Bipolar cells receive input signals from
photoreceptors and synapse onto amacrine and ganglion cells (Adapted from website:(Lynch and Corbet,
2015)).
and three classes of cones involved in colour vision. The three classes of cones, S, M
and L cones, vary in maximum wavelength sensitivity which depends on the nature
of opsin protein attached to the chromophore. For instance, S-cones are sensitive
to short wavelength ’blue’ (419 nm), M-cones are sensitive to medium wavelength
’bluish-green’ (531 nm), and L-cones are sensitive to long wavelength ’yellowish-red’
(559 nm) light (Smith and Pokorny, 1975; Markwell et al., 2010; Purves et al., 2012).
Whereas the peak absorbance of rods is at 507 nm (Crawford, 1949; Markwell et al.,
2010). The absorption spectra of rods and cones have the same bell-shape known
as Dartnall nomogram, where the peak wavelength sensitivity (λ max) varies but
other general characteristics of the absorption profile remain constant (Dartnall,
1953) (Figure1.3). Rods are involved in scotopic vision as they are extremely sensi-
tive to light and have low spatial resolution, whereas cones mediate photopic vision
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due to their high spatial resolution and lower light sensitivity. Mesopic vision rep-
resents the point at which both rods and cones contribute towards light perception
during twilight (Dacey et al., 2005).
Figure 1.3: Spectral response of human retinal photopigments in vivo.
Schematic representation of the maximal spectral sensitivity and long wavelength limbs of human rods,
cones and intrinsically photosensitive retinal ganglion cells (ipRGC). S-cone, short-wavelength sensitive (λ
max = 440 nm), ipRGC (λ max = 482 nm), Rod (λ max = 507 nm), M-cone, middle-wavelength sensitive
(λ max = 543 nm), L-cone, long-wavelength sensitive (λ max = 566 nm). Cone spectral data from Smith
and Pokorny (Smith and Pokorny, 1975), rod spectral data from Crawford (Crawford, 1949), and ipRGC
spectral data collected in the Visual Science and Medical Retina Laboratory (Queensland University of
Technology (Adapted from (Markwell et al., 2010).
1.2 Non-image forming processes
NIF processes include regulation of basic physiology such as heart rate, body tem-
perature, and pupil diameter; modulation of more complex behavioural phenomena,
such as circadian rhythms and locomotor activity; and even higher order cognitive
processes such as mood, anxiety and alertness. Light can affect the physiology and
behaviour of mammals via two major processes: circadian response to light or acute
non-visual responses (NVR). Circadian responses to light involve the ability of light
to elicit phase shifts and synchronisation of the circadian system. Acute NVRs
include neuro-behavioural, neuro-physiological and neuro-endocrinological factors
that are acutely affected by light via areas in the brain (Gooley et al., 2003).
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1.2.1 Intrinsically photosensitive retinal ganglion cells
The classical view was that rods and cones were the only photosensitive cells in
the retina, until the discovery that blind individuals showed decreased melatonin
production despite having no conscious visual light perception (Czeisler et al.,
1995; Lockley et al., 1997). The idea of other retinal photoreceptors was boosted
when melanopsin was firstly identified by Provencio and colleagues in the dermal
melanophores of Xenopus laevis (Provencio et al., 1998). It was subsequently lo-
calised to a small subset of retinal ganglion cells (RGCs) in mouse and human
retinas (Provencio et al., 1998, 2000, 2002). Additional work found that melanopsin-
containing cells send their axons to the suprachiasmatic nuclei (SCN). Berson and
colleagues (2002) recorded whole-cell current from RGCs by retrogradely labelling
with a fluorescent dye from the SCN of wild-type rats. This experiment revealed
that these cells were able to respond to light even after surgical and pharmacolog-
ical isolation from rods and cones (Berson et al., 2002). Sekaran et al (2003) have
shown that ∼ 3 % of RGCs exhibit three types of light-evoked changes in Ca2+
influx (sustained, transient and repetitive), whereas only ∼ 1 % showed Ca2+ con-
centration fluctuations as a result of light trigger after elimination of rod and cone
input using pharmacological blockage of gap junctions (Sekaran et al., 2003). These
two experiments were the first to claim that those cells are bona fide photoreceptors,
with electrophysiological and spectral characteristics that match those observed in
measures of circadian photoentrainment (Berson et al., 2002).
1.2.2 Melanopsin as the major photopigment
Several studies investigated whether melanopsin is the photopigment in ipRGCs,
particularly after the presence of blue-light-absorbing flavoproteins, known as cryp-
tochrome, in plants and invertebrate animals, with earlier studies suggesting a role
for cryptochrome in the mammalian circadian system (Kavakl and Sancar, 2002;
Van Gelder et al., 2002). In melanopsin-knockout mice, RGCs retrogradely labelled
from the SCN showed no direct response to light (Lucas et al., 2003). Also, a
deficiency in pupillary constriction and photoentrainment was reported in animals
lacking the melanopsin gene (Panda et al., 2002; Ruby et al., 2002; Hattar et al.,
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2003; Lucas et al., 2003). A series of experiments involving the melanopsin gene
heterologously expressed in cells insensitive to light, resulted in melanopsin expres-
sion in these cells and a robust response to light. These experiments support the
idea that melanopsin is a bona fide photopigment in ipRGCs (Melyan et al., 2005;
Panda et al., 2005; Qiu et al., 2005).
1.2.3 Diversity of ipRGCs
ipRGCs act as the integration of intrinsic and extrinsic signals projecting to brain
areas involved in NVRs (Go¨z et al., 2008; Gu¨ler et al., 2008; Hatori et al., 2008).
There are five ipRGCs subtypes (M1-M5) identified by immunolabelling and ge-
netic mouse models which vary in their morphology, stratification, connectivity and
projections (Figure1.4) (Provencio et al., 2002). The morphological diversity within
ipRGCs suggests physiological variety in ipRGCS light-evoked responses shown by
multi-electrode arrays and calcium imaging. For instance, M1 cells have the largest
and most sensitive intrinsic light-evoked response, whereas M3 have a small and
intermediate intrinsic light response (Sekaran et al., 2003; Tu et al., 2005; Schmidt
and Kofuji, 2009; Berson et al., 2010). ipRGC photoreceptors can also receive ex-
trinsic rod/cone input via bipolar cells. RGCs stratifying in the outer sublamina of
the IPL receive excitatory synaptic signals from bipolar cells that respond to light
decrements (OFF pathway) such as M1 cells. In contrast, M2, M4 and M5 cells
receive synaptic input from bipolar cells that respond to light increments since their
dendritic stratification is in the inner sublamina of the IPL (ON pathway). Bistrat-
ified M3 cells receive synaptic input from both ON and OFF pathways (Belenky
et al., 2003; Viney et al., 2007; Wong et al., 2007).
1.2.4 Axonal projections of ipRGC subtypes
IpRGC subtypes send their axonal projections to different brain areas, involved in
the generation of NVRs. Hattar and colleagues (2006) characterised M1 projections
throughout the brain by using a transgenic mouse line whose ipRGCs express the
marker enzyme-galactosidase. M1-type ipRGCs showed dense projections to the
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Figure 1.4: Morphology and dendritic field of ipRGC subtypes
The classification of ipRGCs (M1, M2, M3, M4 and M5) is based on somatic size, morphology and dendritic
fields. ONL = Outer nuclear layer; OPL = Outer plexiform layer; INL = Inner nuclear layer; IPL = Inner
nuclear plexiform layer; GCL = Ganglion cell layer (Modified from (Do and Yau, 2010).
SCN, the intergeniculate leaflet (IGL), and the olivary pretectal nucleus (OPN)
(Hattar et al., 2006). The SCN and IGL mediate circadian photoentrainment,
whereas the OPN is involved in the PLR. M1 axonal fibres were detected at the
ventral portion of the subparaventricular zone (sPVZ) that controls the autonomous
nervous system, in addition scattered fibres reach the lateral and ventrolateral pre-
optic areas which are involved in reproductive hormone release from the pituitary
(Hattar et al., 2006). The projections of non-M1-type ipRGCs, M2, M4 and M5,
innervate the core of the OPN, the superior colliculus (SC) and the dorsolateral
geniculate nucleolus (dLGN) (Ecker et al., 2010). It is known that M1 and M2
ipRGCs project to the same targets (SCN and OPN), but the SCN is 80% inner-
vated by M1 with 20% by M2 cells, whereas the OPN is innervated with 45% of
M1 and 55% of M2 cells (Baver et al., 2008). M3 cell projections to the brain areas
involved in NVRs are currently unknown (Figure1.5).
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Figure 1.5: ipRGC projections to brain localizations and the associated circuits
Schematic diagram of projections from ipRGCs are shown in dark blue, and their principal brain targets
in red. Sympathetic pathways (orange) projecting from the SCN and synapsing at the paraventricular
nucleus (PVN), intermediolateral nucleus (IML) and superior cervical ganglion (SCG). The parasympathetic
pupillary pathway (light blue) synapses to the Edinger-Westphal nucleus (EW) and the ciliary ganglion (CG)
(taken from (Markwell et al., 2010)
1.2.5 ipRGCs phototransduction
There are multiple differences between ipRGCs and classical photoreceptors in in-
trinsic light responses. For instance, rods and cones hyperpolarize to light, whereas
the direct photoresponse of ipRGCs is depolarisation. ipRGCs are less sensitive to
light than classical photoreceptors with slower kinetic signalling (Berson et al., 2002;
Do et al., 2009). Provencio and colleagues suggested that the entire ipRGC popu-
lation creates a ”photosensitive net” as their dendrites (which contain melanopsin)
overlap widely to form a light-sensitive dendritic field that responds directly to light
(Provencio et al., 2002). Moreover, ipRGC photoreception is sensitive to light at
around 480 nm which is significantly different (≥ 20nm) from the wavelengths stim-
ulating classical photoreceptors (Figure 1.3) (Berson et al., 2002; Dacey et al., 2005;
Tu et al., 2005). Single-cell RT-PCR (real time-polymerase chain reaction) and im-
munocytochemistry as well as pharmacological experiments have shown that ipRGC
phototransduction utilises a rhabdomic-like phosphoinositide cascade, involving the
presence of a G protein known as Gq/11 and phospholipase C (PLC). Gq/11 and
PLC result in the breakdown of phosphatidylinositol bisphosphate (PIP2) leading
to the opening of the cation channel and membrane depolarization (Hardie, 2001;
Berson et al., 2002; Graham et al., 2008; Chew et al., 2014). The PLC intrinsic
light response was eliminated by knocking out the β4 isoform of PLC confirming
the importance of PLC in ipRGCs photoresponse (Xue et al., 2011). Circadian
photoreceptors and downstream pathways aid in integrating the total number of
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photons over prolonged durations, showing a less sensitive response to single brief
light flashes. Thus, enabling the circadian system to remain unresponsive to en-
vironmental noise that could consequently disrupt entrainment (Takahashi et al.,
1984; Nelson and Takahashi, 1991; Dacey et al., 2005; Weng et al., 2009).
1.2.6 Rods and cones action in NVRs
As discussed in section 1.1.1 rod and cone photic signals are transmitted via bipolar
cells, horizontal cells and the amacrine cells to the ipRGCs (Purves et al., 2012),
providing evidence of possible cross-talk between ocular photoreceptors involved in
image forming and NVR functions. Recent evidence in rodents indicated that the
contribution of classical photoreceptors to non-image forming responses to light was
primarily through mediating the ipRGCs (Wong et al., 2007; Gu¨ler et al., 2008).
The loss of rods and cones in rd/rd mice, especially in low irradiance (melanopsin
unable to compensate) has shown a decrease in the sensitivity of the PLR and pho-
toentrainment (Yoshimura and Ebihara, 1998; Lucas et al., 2003; Mrosovsky, 2003;
Thompson et al., 2008). Ablation of ocular photoreceptors results in undetectable
NVRs (Hattar et al., 2003), while the loss of melanopsin alone fails to abolish cir-
cadian photosensitivity and NVRs to light (Panda et al., 2002; Ruby et al., 2002).
Whilist, ablation of melanopsin-containing ipRGCs lessens NVRs (despite intact
visual response) suggesting that input for NVRs is not restricted to melanopsin-
containing ipRGCs (Gu¨ler et al., 2007, 2008). Therefore, non-melanopsin ipRGCs
that innervate the SCN (about 10 and 20% of RGCs) could convey their input from
rods and cones (Sollars et al., 2003). There is human evidence supporting the con-
tribution of rod and cone photoreceptors to NVRs. The S-cone contribution was
indicated in increased sensitivity of subjective alertness responses to a very short
wavelength (λ max 420nm) (Revell and Skene, 2007), whereas a considerable con-
tribution from the M-cone was shown in melatonin suppression and phase-shifting
when exposed to low irradiance (Gooley et al., 2010).
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1.3 Retinal output pathway
The retina conveys photoic information either via the primary optic tract (POT) or
retinohypothalmic tract (RHT). The POT sends photoic signals primarily from the
classical photoreceptors, rod and cones, to the occipital and cortex to mediate visual
sensation and reflexes. The RHT projects photoic information mainly from ipRGCs
to the suprachiasmatic nuclei (SCN). Evidence from rodent experiments revealed
other brain regions, the IGL, pretectal area (PTA), vSPZ and ventrolateral preoptic
nucleus (VLPO) receive signals from the RHT.
1.3.1 RHT
RHT projections to the SCN were first demonstrated in rats by Moore and Lenn
(1972), and further projections were verified in many mammalian species (cat, (Mu-
rakami et al., 1989); mouse, gerbil, hamster,(Mikkelsen, 1992); sheep (Tessonneaud
et al., 1994) and post-mortem in humans (Dai et al., 1998). The RHT originates
from a small set of M3 retinal ganglion cells due to its distinct dendritic distribution
across the retina and on its periphery (Pickard, 1980). It was shown that destruction
of the RHT abolishes photoentrainment (Johnson et al., 1988) while stable entrain-
ment was observed when the visual pathway was destroyed (Klein and Moore, 1979),
indicating the RHT function in transducing non-image forming information from
the retina directly to the SCN. Also, the majority of retinohypothalamic RGCs ex-
press melanopsin allowing it to drive a sustained depolarisation upon stimulation
by light (Gooley et al., 2001; Berson et al., 2002; Hannibal et al., 2001, 2002, 2004;
Hattar et al., 2002)
Growing evidence demonstrates that RHT terminals release multiple neurotrans-
mitters such as glutamate, substance P and pituitary cyclase-activating peptide
(PACAP) (Reviewed in (Ebling, 1996)). Glutamate is considered as the primary
neurotransmitter released by the RHT to the circadian clock. Blocking gluta-
mate receptors found in the SCN including N-methyl-D-aspartate (NMDA) and
-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) inhibit the effect of
light pulses. Also, AMPA receptor subunits exhibit circadian changes in the SCN
(Meijer et al., 1988, 1993; De Vries et al., 1993; Mikkelsen et al., 1993; Cagampang
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et al., 1996; Ebling, 1996; Golombek and Ralph, 1996; Chambille, 1999; Peytevin
et al., 2000). PACAP roles were proposed to be the diurnal or nocturnal modulator
of circadian rhythm (Hannibal et al., 1998; Harrington et al., 1999). New evidence
in mutant animals with null or over-expression of PACAP or its receptor revealed
the role of this neuropeptide in circadian entertainment (Shen et al., 2000; Colwell
et al., 2004; Hashimoto et al., 2006; Hannibal et al., 2008). Both glutamate and
PACAP play a determinant role in the photoentrainment of the biological clock
since they are capable of phase shifting circadian rhythms in vitro (Ding et al.,
1994; Harrington et al., 1999) and in vivo (Mintz et al., 1999; Piggins et al., 2001).
Other neurotransmitters that modulate photic responses such as γ-aminobutyric
acid (GABA) (Ralph and Menaker, 1989; Golombek and Ralph, 1994), histamine
(Jacobs et al., 2000) and acetylcholine (ACh) (Zatz and Herkenham, 1981; Colwell
et al., 1993; Buchanan and Gillette, 2005) are rhythmic.
1.3.2 The SCN
The SCN were discovered in the 1970s, and since then has been considered as
the central mammalian circadian pacemaker (Moore and Eichler, 1972; Stephan
and Zucker, 1972). The SCN are a tiny region of the anterior hypothalamus sit-
uated adjacent to the third ventricle and dorsal to the optic chiasm (Hofman and
Swaab, 2006). The SCN consists of a group of small parvocellular neurons (1mm3
in volume) which are distributed into two sub-regions in the SCN called the dor-
somedial part (dmSCN) or ”shell” and the ventrolateral part (vlSCN) or ”core”
(Van Den Pol, 1980). The shell of the SCN contains small elongated neurons with
large nuclei and few organelles, whereas the core contains spherical neurons with
organelle-rich cytoplasm (Leak et al., 1999). Due to complex synaptic arrangements
of axo-somatic contacts and dendro-dendritic apposition (Gu¨ldner and Wolff, 1996),
the SCN enable cell-cell communication through ephaptic interaction (Van Den Pol,
1980; Lehman and Boer, 2000). Ephaptic interaction refers to the ability of one cell
to generate an action potential when the membrane resistance is low. Thus, the neu-
ron will either elicit an action potential in the opposed neuron, or may change the
extracellular ions and/or neurotransmitter concentrations, consequently influencing
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the excitability of the opposed neuron (Van Den Pol et al., 1992). Neuropeptide
contents vary in these subareas, as vasopressin is the main peptide synthesised by
dmSCN (Swaab et al., 1975; Vandesande et al., 1975; Van Den Pol and Tsujimoto,
1985), whereas vlSCN synthesizes vasoactive intestinal polypeptide (VIP), peptide
histidine isoleucine (PHI) and gastrin releasing peptide (GRP) (Sims et al., 1980;
Card et al., 1981, 1988; Mikkelsen et al., 1991). Somatostatin (SOM) neuropeptide
synthesis occurs between these two cell populations (Card et al., 1988) (Figure 1.6).
Figure 1.6: Intracellular signalling mechanism within SCN
Schematic diagram indicating the release of GABA and co-localized neuropeptides such as VIP or GRP
at synaptic terminals due to action potential. VIP, for example, depolarize membrane of the neurons by
binding to VPAC2 receptors, elevating calcium and cAMP levels, phosphorylation of CREB, and induction
of Per and Cry transcription, thus alerting the intracellular oscillator. The gap junction assists in coupling
adjacent neurons in the SCN (Taken from (Welsh et al., 2010), after modified from (Liu et al., 2007)).
Several studies have been conducted to investigate the role of these abundant
neuropeptides such as GABA, vasopressin (VP), VIP, GRP and somatostatin, in
the regulation and generation of circadian rhythmicity . For instance, application
of GABA to the SCN exerts an inhibitory action at night and an excitatory action
during the day (Wagner et al., 1997). The role of VP in rhythm generation is un-
known, yet VP deficiency was associated with reduced amplitude and entraintability
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of the rhythm, and ultimately accounts for a lower amplitude in behavioral rhythms
(Brown and Nunez, 1989; Murphy et al., 1993). VIP and GRP were found to be
localized in the vlSCN and project outside the SCN, indicating their possible role in
conveying information about the LD cycles to areas outside the SCN (Piggins et al.,
1995). Somatostatin was shown to exert an intrinsic inhibitory role in modulating
rhythmic VIP expression (Fukuhara et al., 1994).
1.3.2.1 Pathways to the SCN
There are three main afferent pathways to the SCN, particularly the vlSCN, includ-
ing the RHT, IGL and raphe nuclei. vlSCN neurons are mostly VIPergic neurons
that receive glutamatergic input from the retina via the RHT (Moore and Lenn,
1972), neuropeptide Y (NPY) input from the IGL via the geniculo-hypothalamic
tract (GHT) (Swanson et al., 1974), and serotonergic (5-hydroxytryptamine, 5-HT)
input via the raphe nuclei (Bosler and Beaudet, 1985; Franois-Bellan and Bosler,
1992). Neurons in the dmSCN receive most of their non-photic input from the
cortex, basal forebrain and hypothalamus (Moga and Moore, 1996), as well as the
retinal input from retinal ganglion cells (Pickard, 1985; Treep et al., 1995). RHT
afferent input was described in section 1.3.1. The second indirect pathway is medi-
ated by a projection from the retina to NPY-immunoreactive neurons in the IGL,
which project through GHT to the SCN. Further studies suggested the presence
of an overlap between the RHT and GHT in the SCN projection areas, suggesting
that IGL modulates the response of the circadian system to light (Stopa et al.,
1994). Both the SCN and IGL are innervated by the same retinal ganglion cells,
and the retinorecipent neurons in the SCN are more responsive to NPY than other
neurons (Pickard, 1985; Treep et al., 1995). The third main input is 5-HT from the
median raphe nuclei. 5-HT activity during the daytime can explain the reduced
L-phase nadir levels of VIP mRNA, while no effect was seen on the D-phase peak
mRNA levels (Kawakami et al., 1995). Therefore, the serotonergic role is to modu-
late retinohypothalamic neurotransmission via postsynaptic 5-HT receptors on the
SCN neurons and via presynaptic 5-HT receptors on retinal axon terminals in the
SCN (Pickard, 1985) (Figure1.7).
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Figure 1.7: Neural inputs and outputs of the SCN
Schematic illustration of afferent inputs (red) to the SCN from retina via RHT, or indirect inputs from
IGL via VIPergic tract, and serotonergic input from the raphe nuclei. Other afferent inputs from the
hypothalamic nuclei and limbic system, hippocampus and brainstem. The major SCN efferents reach VMH,
DMH, sPVZ, and PVT. Other brain areas such as PaPA, paraventricular hypothalamic nucleus, anterior
parvicellular part; RCh, retrochiasmatic area; POA, preoptic area; AAA, anterior amygdaloid area; BNST,
bed nucleus of the stria terminals, and SLV, superior lateral ventricle receive SCN outputs (Modified from
(Morin, 2013))
1.3.2.2 Output efferent pathways from SCN
VIP or VP immunocytochemistry and lesion and tracing techniques were used in
many rat and hamster studies to identify the efferent projections of the SCN to the
brain. The majority of the SCN projections run dorsally to sPVz, PVN, as well as
extending fibers to the dorsomedial and ventromedial nuclei of the hypothalamus
(DMH and VMH) (Hoorneman and Buijs, 1982; Watts and Swanson, 1987; ?). In
contrast, human SCN projections are more focused on the ventral part of the PVN.
These regions contain neurons involved in sleep/wake regulation, hormone release
such as oxytocin and vasopressin, feeding and thermoregulation . SCN output varies
between the core and shell, as the core projects to the lateral sPVz, while the shell
extends to the medial sPVz and the DMH (Leak et al., 1999). Further areas such as
the limbic structure, bed nucleus of the stria terminals (BSTL), medial preoptic area
(MPOA) and ventro-lateral preoptic nucleus also receive efferent projections from
the SCN. The SCN sends minor projections to the IGL, olivary pretectal nucleus
(OPT) and the central grey matter (Leak and Moore, 2001). SCN projections to
the sPVz, median preoptic nucleus (MPN), PVN and DMH may allow the SCN to
modulate neuroendocrine and autonomous functions, as the PVN plays a key role in
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all autonomous circadian functions, whereas the MPN and PVT exert control over
fluid homeostasis, reproduction, thermoregulation and sleep and activity rhythms
(Buijs et al., 1999). Furthermore, the SCN can modulate its input through the
feedback loops provided by the SCN projections to the LGN and the raphe nuclei
(Watts and Swanson, 1987) (Figure1.7).
1.4 Circadian rhythms
Since the discovery of the internal biological clock in 1950 (Pittendrigh, 1950; Hal-
berg et al., 1959), the term circadian rhythm has been introduced to the field of
chronobiology. Circadian is derived from the Latin Circa dies which mean approx-
imately a day. It is a physiological component that is observed in almost all living
organisms from prokaryotes to humans (Vitaterna et al., 2001; Gronfier, 2013). It
refers to the changes in behaviour and physiology that occur across a 24 hour pe-
riod. Circadian rhythms are regulated by the master clock known as the SCN.
The major properties of SCN activity are that they are endogenously rhythmic
and can be synchronized to the 24 hour day (Moore and Eichler, 1972; Reppert
and Weaver, 2002; Dunlap et al., 2004). The SCN acts as an orchestra conduc-
tor, by synchronizing clocks in peripheral tissues in response to external cues or
”zeitgebers” such as light, temperature (VanSomeren, 2000) and food (Mendoza,
2007; Mendoza et al., 2010). Despite the importance of non-photic stimuli such as
food, social interactions, imposed rest-activity schedule and outside temperature in
entraining circadian rhythms (Klerman et al., 1998; Mistlberger and Skene, 2004,
2005), the light/dark cycle is considered to be the strongest zeitgeber. A human
study has shown that exposure to light alone is sufficient to significantly reset the
SCN (Zeitzer et al., 1997). Light can entrain the circadian clock through two main
model types: continuous (parametric or tonic) and discrete (non-parametric or pha-
sic). The continuous model is when the master clock perceives continuous light and
adjusts its period ”tau” in an intensity manner to align it with the environmental
period (Aschoff, 1960; Daan et al., 2001), whereas the discrete model suggests that
light pulses can cause sudden advance or delay phase shifts of the clock without
adjusting the intrinsic tau (Pittendrigh and Minis, 1964; Pittendrigh and Daan,
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1976; Wehr, 2001). This allows the clock to reset itself to align with the external
environment, and the magnitude of the resetting depends on the timing of the light
pulse which can be explained using a phase response curve (PRC) (Pittendrigh and
Daan, 1976). In the absence of external synchronization from the environment,
the internal circadian pacemaker would run at its intrinsic tau which is in general
slightly longer than 24 hour, in a phenomenon called ”free-run” (Czeisler et al.,
1989). This was observed in enucleated blind people who exhibited free running
rhythms close to 24 hours (Lockley et al., 1997).
1.5 Acute NIF effects
Light detected by retinal photoreceptors can also mediate acute effects in mam-
mals. Physiological effects include suppression of endogenous melatonin, pupillary
constriction, an elevation of CBT, alerting effect during the night and the day,
altering mood, and modulating vascular function.
1.5.1 The endogenous hormone melatonin
Melatonin (MEL) is a biogenic amine molecule that was first extracted from the
bovine pineal gland by dermatologist Aaron Lerner at Yale University (Lerner et al.,
1958). Melatonin is chemically identified as N -Acetyl-5-methoxy-tryptamine and is
found in all living creatures, from algae to humans (Caniato et al., 2003). Mela-
tonin is chemically represented as C13H16N2O2 and has a molecular mass of 232.23
g/mol (Hattori et al., 1995; Paredes et al., 2009). Although melatonin synthesis
has always been linked to the pineal gland, it is also produced in the retina, gas-
trointestinal tract (GI), testes, ovaries and lymphocytes. Melatonin produced by
extrapineal sites in either low or high amounts (such as in GI), appears to have no
significant chronobiological consequences (Carrillo-Vico et al., 2004; Iuvone et al.,
2005; Bubenik, 2008; Slominski et al., 2008). Melatonin is highly lipophilic and
hydrophilic in nature, allowing it to easily penetrate target organs. Approximately
70% of melatonin is bound to albumin and is released into capillaries to bind to
melatonin receptors (Cardinali et al., 1972; Macchi and Bruce, 2004) Figure 1.8.
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1.5.1.1 Melatonin synthesis
Pinealocytes are the major site of melatonin synthesis and possess all the features
necessary for the process. Exogenous or endogenous tryptophan (TRP) acts as
the immediate precursor of melatonin synthesis. Pinealocytes take up tryptophan
from the circulating blood and convert it to serotonin through hydroxylation and
decarboxylation. Within the pineal gland, serotonin is acetylated by aryl alky-
lamine N-acetyl transferase (AANAT) to yield N-acetyl serotonin, which in turn
undergoes a methylation reaction by the enzyme hydroxyl indole O-methyl trans-
ferase (HIOMT) to produce melatonin (Axelrod, 1974; Reiter, 1981; Klein et al.,
1997) (see Figure 1.8). Although Klein and Weller (1972) have shown that N-acetyl
transferase (AANAT) is the rate-limiting enzyme in melatonin production, recent
findings suggest the possibility of HIOMT being the controlling factor in noctur-
nal melatonin synthesis. For instance, melatonin levels in the pineal gland of the
Siberian hamster are linked to the activity of HIOMT. Furthermore, Liu and Bor-
jigin (2005) observed that the melatonin rhythm remains unaltered despite point
mutation causing AANAT deficiency, thereby indicating that AANAT is not the
rate-limiting factor of melatonin synthesis (Liu and Borjigin, 2005). In the light of
these contradictory findings, it may be that both AANAT and HIOMT are rate-
limiting factors for melatonin production (Liu and Borjigin, 2005).
Melatonin synthesis and secretion is highly influenced by light exposure. The
SCN responds to changes in the light/dark cycle by releasing inhibitory or stimu-
latory signals. Light detection by the retina results in GABA release causing an
inhibition of melatonin release (Kalsbeek et al., 1996, 1999, 2000). The SCN trans-
mits GABA-ergic signal inputs to the autonomic parvocellular subdivision of the
PVN, which in turn projects the impulses through the medial forebrain bundle and
reticular formation to the inter-mediolateral cell column (IML) of the cervical spinal
cord (Kalsbeek et al., 2000; Brainard et al., 2001). The IML transmits the input
to the SCG through preganglionic adrenergic fibres. The SCG are involved in com-
municating the signals to the pineal gland through the post-ganglionic sympathetic
nor-adrenergic fibres (Moore and Sibony, 1988; Moore, 1995).
In the absence of light (dark period), noradrenaline interacts with adrenergic re-
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ceptors on the pinealocyte membrane via the sympathetic multisynaptic pathway.
Noradrenaline (NE) binds to α and β adrenergic receptors to increase intracellu-
lar Ca2+, thus increasing and potentiating protein kinase C (PKC) and calcium-
calmodulin protein kinase (CaM kinase). The result is an increase in cAMP which
in turn phosphorylates the rate-limiting enzymes involved in melatonin synthesis
(Sugden, 1989) (Figure1.8).
Figure 1.8: Melatonin structure and biosynthesis pathway
Schematic representation of melatonin chemical structure, synthesis and secretion. The hormone MEL is
synthesised from tryptophan with the rate-limiting enzymes, AA-NAT and HIOMT, with the release of NE
from the SCG binding to the α and β adrenoceptors on the pinealocyte membrane (Watson, 2011)
1.5.1.2 Melatonin catabolism
The liver and kidneys are the main two sites of melatonin metabolism, where it
undergoes hydroxylation and then conjugation into the sulphate and glucuronide
(Lane and MOSS, 1985). Microsomal cytochrome P450 monooxygenase (CYP1A2,
CYP1A1, or CYP1B1) hydroxylate melatonin to 6-hydroxy-MEL (Skene et al.,
2001; Ma et al., 2005), which is then conjugated by sulphotransferase to form
6-sulphatoxy-MEL (aMT6s) and eliminated in urine (Arendt, 1994; Skene et al.,
2006), or catalysed by UDP-glucuronosyltransferase to form 6-hydroxymelatonin
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glucuronide as in mice (Kennaway et al., 2002; Ma et al., 2008). aMT6s can be
used to determine melatonin concentrations and estimate dim light melatonin on-
set (DLMO) since it accounts for more than 90% of the metabolised melatonin in
humans. Approximately 50-80% of aMT6s production appears in urine collected
overnight sample (2400 to 0800h), and levels tend to be undetectable in the af-
ternoon and early evening (Arendt, 1994). The changes in aMT6s concentration
are influenced by the duration, intensity, wavelength (blue is the most, and red is
the least) of the light pulse, tissues and species examined (Zawilska et al., 2009).
Melatonin can be measured in plasma and saliva, or its metabolite aMT6s in urine.
Salivary melatonin represents one-third of the plasma concentration (Arendt, 1994).
1.5.1.3 Circadian rhythm of endogenous melatonin
Melatonin exhibits a clear circadian rhythm, as evident from the mechanisms of
synthesis and secretion of the hormone. Melatonin is synthesised during the night
phase, with the amplitude of secretion (acrophase) being the highest between 02:00h
and 04:00h. Serum melatonin in humans during the day is non-detectable, whereas
at night 8-120 pg/ml measured with a high-specificity assay (Arendt, 1994). The
onset of melatonin secretion in adults takes place between 21:00-02:00 and the offset
between 07:00-09:00 (Arendt, 1994). The major urinary metabolite, aMT6s, is also
rhythmic with peak levels delayed by one or two hours from the plasma melatonin
peak (Arendt, 1994). The AANAT and HIOMT enzymes that mediate melatonin
synthesis are found at highest concentrations during the dark hours of the day-
night cycle (Srinivasan, 1999). This is linked to the high amplitude of nocturnal
melatonin secretion with the levels increasing steadily after 21:00 to reach the peak
at 02:00 (Cajochen et al., 2003). Plasma melatonin shows the lowest values in the
afternoon. For example, Klein and Weller (1972) have observed that rat AANAT
activity has a diurnal rhythm with the night-time peak being about 100 times higher
than the daytime values. This implies that the night-time intracellular rise in cAMP
causes the up-regulation of AANAT (Klein and Weller, 1972; Sugden et al., 1985;
Klein, 2009). Several studies have indicated that nocturnal melatonin levels can be
substantially reduced or abolished in animals maintained in constant light (Ghosh
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et al., 1994; Klein, 2009), whereas exposure to light during the night shifts delays
the timing of melatonin synthesis (Pittendrigh, 1981).
1.5.1.4 Melatonin as a marker of circadian phase
Melatonin is a chronobiotic molecule, and also called the hormone of darkness as it
signals the length of night, time of day and time of year in all tissues. Melatonin
can be defined as a substance that adjusts the timing of the central biological clock.
Studies have shown that administration of exogenous melatonin during the evening
or first half of the night causes a phase-advance of the circadian clock, whereas
early daytime or late night administration causes a phase-delay of the circadian clock
(Turek, 2004; Watson, 2011). The integrity of the melatonin signal is maintained by
an adequate SCN pathway to the pineal gland, appropriate stimulation of the pineal
terminals due to the rapid uptake of noradrenaline, rapid melatonin catabolism in
the liver, and the lipophilic and hydrophobic nature of melatonin (Shida et al., 1994;
Costa et al., 1995). Melatonin is used as a marker to indicate the timimg (phase)
of the master biological clock (Lewy et al., 1999).
Various parameters are used to define the melatonin profile such as melatonin
onset, acrophase (peak time), melatonin offset and mid-range crossing. Dim light
melatonin onset (DLMO) is defined as the time of melatonin onset. This can be
determined by either when melatonin reaches the threshold (10 pg/ml in plasma, or
3 pg/ml in saliva) (Lewy et al., 1985), or by 25% peak method. This method refers to
the time when melatonin concentrations reach 25% of the maximal level. Melatonin
offset can be determined in a similar way. Mid-range crossing (range) represents
the time when the melatonin concentration reaches 50% of maximum levels, and it
enables estimation of melatonin acrophase (Watson, 2011) (Figure1.9).
1.5.1.5 Melatonin measurements
Radioimmunoassay (RIA) is a technique used to analyse melatonin levels in plasma,
urine and saliva. It has been shown that urinary melatonin is highly correlated to
plasma melatonin due to the rapid catabolism of plasma melatonin in the liver into
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Figure 1.9: Melatonin phase curve
Schematic illustration of normal endogenous melatonin profile of plasma MEL secretions, including phase
advance and delay, based on published data of exogenous melatonin intake and using phase response curve
(Watson, 2011).
aMT6s (Markey et al., 1985; Bojkowski et al., 1987). Similarly, several studies have
reported a significant correlation between salivary melatonin and serum melatonin
for the assessment of circadian phase, melatonin onset, and acrophase time (Voult-
sios et al., 1997), and as a reliable index for serum melatonin concentrations (Nowak
et al., 1987). However, many potential factors should be considered during mela-
tonin sampling such as light exposure prior to or during sampling, posture, drugs,
exercise and caffeine (see section 1.5.2)
1.5.1.6 Melatonin receptors and distribution
The widespread melatonin response is attributed to the fact that its receptors are
expressed in a wide variety of tissues (Table 1.1). The functions of melatonin are
mediated through 4 different types of melatonin receptors (MT): MT-1, MT-2, MT-
3 and nuclear receptors. MT-1 and MT-2 belong to a group of G-protein-coupled,
seven transmembrane receptors (Slominski et al., 2012). In contrast, the MT-3
and nuclear receptors rely on the independent action of melatonin through signal
transduction due to its highly lipophilic nature or by active uptake mechanisms
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(Benitez-King and Anton-Tay, 1993; Finocchiaro and Glikin, 1998). Vincent et al.
(2010) found that the biological target of MT-3 is a cytosolic enzyme called quinone
reductase 2 (Vincent et al., 2010). Retinoid orphan receptor/retinoid Z receptors
(ROR/RZR) are the major nuclear receptors that mediate the biological effects of
melatonin (Becker-Andr et al., 1994; Carrillo-Vico et al., 2005) (Figure1.10).
Figure 1.10: Major types of melatonin receptors
MT1 and MT2 are transmembrane receptors, which exert their impact through cAMP and inositol trispho-
sphate (IP3). MT3 targets cytosolic quinone reductase 2, and RORa/RZR1 are the major nuclear receptors
for melatonin (Slominski et al., 2012).
Table 1.1: Melatonin receptor subtypes and distribution
Mel receptors Distributions
MT1 SCN, cerebellum, hippocampus, retina, ovary, testis, aorta, coro-
nary blood vessels, liver, kidney, adrenal gland, immune system,
skin, pancreas, endothelial cells and gallbladder
MT2 SCN, cerebellum, hippocampus, retina, lung, heart, duodenum,
granulosa cells, pancreas, endothelial cells and adipocytes
MT3 Liver, kidney, brain, heart, lung, intestine, muscle, brown adipose
tissue and eye
MT4 Brain, pineal and neurons and spinal cord
Table listing melatonin receptor distribution showing MT1 and MT2 are most widely distributed in mam-
malian tissues (Adapted from (Watson, 2011))
1.5.2 Non-photic factors affecting endogenous melatonin
Non-photic factors ranging from lifestyle choices such as caffeine, dietary intake, al-
cohol and nicotine, or physiological changes such as in posture, and menstrual cycle
and drugs, can modulate melatonin levels and rhythms. Therefore, it is very crucial
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to consider these factors during experimental protocol design to ensure consistent
and robust results as well as to minimise the possibility of any confounding factors.
1.5.2.1 Dietary intake
Several human studies have linked changes in dietary intake and energy restriction
to melatonin synthesis or concentration. Melatonin reduction by 20% was reported
after limited energy intake (< 300 kcal per day) for 2 to 7 days, with no changes in
aMT6s in urine. Levels returned to normal after short-term glucose supplementa-
tion indicating that pinelaocytes require glucose to function normally (?Ro¨jdmark
et al., 1992; Michalsen et al., 2003). Melatonin has been detected in remarkable
amounts in vegetables such as tomatoes, olives, barely, rice and walnuts. For in-
stance, morning consumption of vegetables was associated with increased urinary
aMT6s excretion (Oba et al., 2008). An increase in the mean of urinary aMT6s
in Japanese women by 16% was reported with high vegetable intake compared to
those with the lowest intake. The increase in melatonin levels is more likely to be
due to stimulatory effects of ingested products rather than absorption of dietary
enriched-melatonin food (Nagata et al., 2005). Melatonin is found in milk, partic-
ularly in milk produced at night (Castro et al., 2011; Engler et al., 2012). This
explains the physiological relevance linked to night-time lactation in an infants diet.
It is postulated that maternal melatonin may pass through the milk to the infant
resulting in improved nocturnal sleep (Engler et al., 2012). Improvement in sleep
parameters and increased urinary metabolites of serotonin were reported in infants
drinking TRP-enriched commercial infant milk (Cubero et al., 2006; Aparicio et al.,
2007).
The correlation between nutrient availability and melatonin levels in plasma and
urine have been reported mainly in animal studies. Decreased plasma melatonin in
rodents was associated with folate, magnesium and zinc deficiency (Fournier et al.,
2002; Bediz et al., 2003; Billyard et al., 2006; Belviranli and Baltaci, 2008). Folate
and vitamin B6 act as coenzymes needed to form serotonin from TRP, whereas zinc
and magnesium increase AANAT affinity to bind to serotonin and form melatonin
(Morton and James, 1985; Morton, 1989). The majority of human studies have
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reported no correlation between vitamins or minerals such as folate, zinc (Schern-
hammer et al., 2009), vitamin B6 (Luboshitzky et al., 2002) and magnesium (Murck
and Steiger, 1998), with changes in melatonin level in plasma or urine.
1.5.2.2 Posture
Changes in posture have been linked with cardiac autonomic drive in humans. Stud-
ies have reported changes in heart rate between supine and sitting (Kalinik et al.,
2001), supine and standing (Sipinkova et al., 1996) supine, standing, and head-up
and -down tilt positions (Radhakrishna et al., 2000; Siebert et al., 2004). Changes
in autonomic balance were clearly seen with posture changes from supine to vertical
posture (standing or sitting). Changes in posture influence blood volume, as blood
redistribution, takes place when changing from supine to standing posture. Sham-
suzzaman et al. (1998) have shown that antigravity muscle activity varies during
postural changes, and these muscles are important in vasomotor and vascular ac-
tivity (Shamsuzzaman et al., 1998). These observations and explanations raise a
question of possible changes in melatonin levels (plasma, urine and saliva) through
different postures. Plasma and salivary melatonin were decreased when moving
from supine to standing position, and increased when these positions were reversed
(Deacon and Arendt, 1994). Another study reported increased plasma melatonin
levels in the sitting position yet no differences were reported with a change in pos-
ture from a siting to a standing position (Nathan et al., 1998). Conversely, a recent
study has shown an increase in salivary melatonin levels in standing position com-
pared to siting when samples were collected at 01:00h, yet no differences were seen
at 00:25h (Kozaki et al., 2013).
1.5.2.3 Physical exercise
The ability of physical exercise to influence endogenous melatonin remains contro-
versial, yet most of the human studies have demonstrated that exercise can modulate
endogenous melatonin in two ways; by affecting the melatonin rhythm and changing
melatonin levels in physiological fluids. There is a consensus that night-time exercise
26
can phase delay melatonin onset (Van Reeth et al., 1994; Buxton et al., 1997). This
was reported with moderate and high intensity exercise, under a constant routine
(Barger et al., 2004), in dark or dim light condition, in both young and older par-
ticipants (Baehr et al., 2003). Reports of exercise-induced phase advance are rare;
however, studies have reported a phase advance with morning compared to evening
exercise (Miyazaki et al., 2001). In addition to its phase-shifting effects, exercise can
acutely alter melatonin levels. Circulating melatonin was increased transiently after
an exercise bout (Atkinson et al., 2003; Knight et al., 2005). However, that short
increase was attenuated by regular and vigorous training, or as training progressed
such as in a treadmill study (Skrinar et al., 1989).
Exercise induces a marked increase in the sympathetic nervous system and cate-
cholamine secretion, which potentially could modulate melatonin secretion. Exercise
also stimulates the midbrain raphe nuclei (MRN) which transmits serotoninergic sig-
nals to the IGL. The IGL can communicate with the SCN via NPY release (section
1.3.2.1). The MRN is arousal-dependent as serotonin levels in the SCN follow the
daily pattern of locomotor activity in both diurnal and nocturnal rodents (Challet,
2007). Since serotonin can, directly and indirectly, influence the SCN, this suggests
that the ability of exercise to improve mood could be due to its ability in resetting
the SCN.
1.5.2.4 Menstrual cycle and contraceptive pills
Changes in melatonin levels have been shown across the menstrual cycle. An in-
crease in plasma melatonin was reported in women during the luteal phase (LP)
compared to follicular phase (FP) (Webley and Leidenberger, 1986). Melatonin
levels were also increased in those taking a 3-phase contraceptive pill (Webley and
Leidenberger, 1986; Wright and Badia, 1999). These findings were supported by an
increase in urinary aMT6s during the LP (Brun et al., 1987). However, a 24-hour
area under the curve of plasma melatonin was significantly decreased in LP, with no
changes in other timing measures (Shibui et al., 2000). This suggests the possible
interaction between progesterone and melatonin, as well as melatonin, acting as a
modulator of the menstrual cycle.
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Further evidence of melatonin interaction with sex hormones comes from the co-
localization of melatonin receptors with oestrogen and progesterone receptors in the
brain and periphery, as well as the wide spread of melatonin receptors (Table 1.1)
in reproductive tissues. A marked increase in melatonin secretion was reported in
women taking oral contraceptive (synthetic progesterone), and melatonin treatment
can be applied to enhance human chronic gonadotropin-stimulated progesterone
production in human granulosa cells (Woo et al., 2001). Conversely, oophorectomy
in premenopausal women and a low- oestrogen environment resulted in a significant
increase in melatonin secretion (Okatani et al., 1999). Oestrogen treatment reduced
melatonin synthesis in rat pinealocytes (Hernandez-Diaz et al., 2001), and reduced
melatonin receptors (MT1) in the rat ovaries (Clemens et al., 2001). Premenstrual
dysphoric disorder (PMDD) patients have been reported to have low serotonin levels
(Taylor et al., 1984; Rapkin et al., 1987), with an alteration in timing and amount
of nocturnal melatonin secretion (Parry et al., 1997). This raises the question as
to whether low serotonin (precursor of melatonin synthesis) could alter melatonin
production in the pineal gland.
1.5.2.5 Caffeine
Although a cup of coffee was estimated to contain 40 µg of melatonin, the role
of caffeine in circulating melatonin concentrations is still unclear. Some clinical
studies have shown a single dose of 200 mg caffeine capsules causes a reduction in
nocturnal melatonin secretion, while another study reported an increase of 32% in
plasma melatonin (Wright et al., 1997; Babkoff et al., 2002; Ursing et al., 2003).
A reduction of 7% in nocturnal melatonin was seen in healthy young adults after
repeated administration of a 400 mg caffeine capsule at 1-week intervals (MacKenzie
et al., 2007). Similarly, when subjects consumed coffee, a reduction of 50% of night-
time aMT6s excretion was found with caffeinated coffee compared to decaffeinated
coffee (Shilo et al., 2002). Animal models were used to investigate the stimulatory
and inhibitory mechanism of caffeine affecting melatonin levels. It is believed that
caffeine acts as an adenosine antagonist which inhibits intracellular cAMP activity,
thus the production of AANAT (Babey et al., 1994). Melatonin and caffeine are
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metabolised both by liver cytochrome P450 enzymes, which could result in reduced
melatonin break-down, giving higher serum melatonin levels after large doses of
caffeine (Ursing et al., 2003; Kot and Daniel, 2008). Several confounding factors
were not considered in these studies such as gender differences, age, menstruation
and contraceptive pills.
1.5.2.6 Alcohol
Wine and beer contain notable amounts of melatonin that could influence the level of
melatonin in body fluids (50-230 pg/ml & 52-170pg/ml respectively). However, the
influence of acute or chronic alcohol consumption on melatonin levels is inconsistent.
Social drinking (10-100 g of ethanol per day) was shown to reduce melatonin levels
in blood in three studies (Ekman et al., 1993; Ro¨jdmark et al., 1993; Rupp et al.,
2007), but not in a fourth study (Danel and Touitou, 2006). Another study involved
heavy beer consumption (24-48 g of ethanol) in males and females which caused a
significant increase in serum melatonin, possibly due to the high melatonin content
in beer (Maldonado et al., 2009). In contrast, single or repeated daily doses of
15-120 g ethanol were found to cause a reduction of aMT6s over a 24-h period
with increasing alcohol doses (Stevens et al., 2000). This agreed with categorical
analysis that revealed no effect of one drink, two drinks resulting in 9% reduction,
15% reduction with three drinks, and four or more drinks causing 17% reduction
(Peuhkuri et al., 2012). These studies considered confounding factors such as age,
darkness hour, and use of medications.
1.5.2.7 Drugs
Conventional, prescribed and recreational drugs have been shown to have various
effects on melatonin synthesis and secretion. Beta- blockers such as propranolol
and atenolol, have proved to reduce nocturnal aMT6s excretion through inhibi-
tion of 1-AR (?). Atenolol was also associated with greater light-induced phase
delays of melatonin onset in human (Deacon et al., 1998). Antidepressant and
psychotropic drugs are linked to changes in melatonin levels and pineal function.
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Some types of selective serotonin inhibitors (SSRIs) such as Fluvoxamine caused
an increase in plasma melatonin concentrations (Skene et al., 1994), whereas oth-
ers like Citalopram had no effect (Von Ba¨hr et al., 2000). Fluvoxamine is a potent
CYP1A2 inhibitor which can alter melatonin metabolism in the liver (Ha¨rtter et al.,
2001). Tricyclic antidepressants (such as Desipramine) advanced melatonin onset
and increased nocturnal plasma melatonin in humans by acting as a noradrenaline
re-uptake inhibitor (Palazidou et al., 1989).
1.5.2.8 Nicotine
Cigarettes contain polycyclic aromatic hydrocarbons which are known to induce
CYP1A2 activity which is needed for melatonin metabolism in the liver (Schrenk
et al., 1998; Skene et al., 2001). This could explain the reduced melatonin levels
in habitual smokers (Zevin and Benowitz, 1999). Chronic nicotine administration
results in further increases in CYP1A2 levels and enzymatic activity (Wardlaw
et al., 1998). These observations were documented to be greater in smokers than
non-smokers (Woolridge et al., 2004). Experiments conducted in smokers before and
after smoking abstinence revealed no changes in endogenous melatonin levels. After
oral melatonin administration (25 mg) at night, melatonin levels were significantly
higher when not smoking compared to when smoking (Ursing et al., 2005).
1.5.3 Sleepiness and alertness
There is no consensus among chronobiologists over the best description of the terms
sleepiness and alertness. Sleepiness and alertness are widely assumed to be recipro-
cal state of consciousness. They are interchangeably used as the same phenomenon
by either emphasizing the sleep propensity or drowsiness (i.e., sleepiness) or wake
propensity or attentiveness (i.e., alertness). The difficulty in agreeing on a specific
definition is due to challenges in defining a state which alternates between full sleep
and fully awake. Secondly, there is the use of the term fatigue to describe sleepi-
ness, although fatigue does not seem identical to being sleepy. Sleepiness, alertness
and fatigue depend on the circumstances in which they are measured such as shift
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work, or controlled conditions (Cajochen et al., 2014). In health care providers,
fatigue is defined as a subjective sensation of weariness overlapping with negative
feelings of heaviness and general malaise, as well as linked to the symptoms of
medical conditions (Krupp et al., 1989; Fischler, 1999; Gibson et al., 2005). Sleepi-
ness is referred to as the tendency to change the behavioral state into sleep (Kim
et al., 2012). Alertness is described as a subjective state of responsivity to both
interoceptive and external stimuli that have independent psychometric properties
(Moller et al., 2006). However, sleepiness and alertness are subjective terms that
can be interpreted differently from one person to another, indicating the difficulty
in establishing a standard definition for these physiological states.
1.5.3.1 Circadian rhythms and human sleepiness-alertness
The human sleep-wake cycle sustains a relatively stable level of wakefulness (16
hours) followed by 8 hours of sleep (Tobler, 1995). This cycle fluctuates considerably
depending on physical activity, mental state, body posture, sleep-wake history, indi-
vidual chronotype and environmental influences (e.g., light and temperature). The
regulation of sleep-wake cycle was firstly explained by Alexander Borbe`ly in two-
process models; circadian rhythm (process C) and sleep-wake homoeostasis (process
S). Process C indicates the circadian drive for arousal and circadian alerting system,
whereas process S indicates the accumulation of hypnogenic substances in the brain
which drives a homoeostatic sleep (Borbe´ly et al., 2016). Despite environmental and
individual influences, sleep-alertness shows diurnal modulation with a close tempo-
ral association to diurnal core body temperature, with its maximum in the evening
and nadir in the early morning (Cajochen et al., 2014). Further evidence of the
circadian clock contribution is that sleepiness-alertness can be shifted by light just
like core body temperature and melatonin; also subjective alertness can be quan-
tified as rhythmic under constant routine and desynchrony protocols (Dijk et al.,
1992; Wyatt et al., 1999). It is conceptualized in the ”opponent process” model
that to maintain stable and high alertness, the circadian system timing opposes the
wake-dependent deterioration of alertness indicating that the circadian process acts
to balance the accumulating homeostatic drive for sleep during wakefulness (Edgar
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et al., 1993; Dijk and Czeisler, 1994; Cajochen et al., 2004). The circadian regu-
lation of the sleep-wake cycle is controlled by the SCN which connects to various
sleep-wake regulatory centres in the brain such as the VLPO, lateral hypothalamus
and SPZ (Abrahamson et al., 2001; Leak and Moore, 2001).
1.5.3.2 Light and human sleepiness-alertness
Despite the significant influence of light on circadian photoentrainment, light can
also evoke an ”acute”, ”direct” or ”non-circadian” effect. An early study of the
alerting properties of bright light exposure was performed by Baida et al (1991),
who showed an increase in core body temperature, EEG beta-activity during wake-
fulness, and performance levels during bright light episodes (Badia et al., 1991).
This agrees with observations during night-shift work, where workers are more alert
during their break in well-lit rooms (Lowden et al., 2004). In simulated night
shift using low intensity, bright light and moderate blue light exposure, alertness
was improved during prolonged performance testing (Campbell and Dawson, 1990;
Phipps-Nelson et al., 2009). In day workers, 4-weeks of blue-enriched light exposure
in the office improved alertness, well-being and sleep quality compared to non-blue
enriched light conditions (Viola et al., 2008). Light evokes an alerting response
depending on the time of day, wavelength, intensity, duration of light exposure and
light-dark history (?Lockley et al., 2006; Phipps-Nelson et al., 2009; Chang et al.,
2013). Alerting responses were reported within 10 to 20 mins when the light at
night was of sufficient intensity and when melatonin secretion was active (Cajochen
et al., 2000), whereas no significant changes in behavioural response, was reported
with monochromatic light of lower intensity (Vandewalle et al., 2009). Light also
stimulates some brain areas such as subcortical and cortical structures in volun-
teers performing tasks (Vandewalle et al., 2009), indicating that light can exert
some effects on brain regions before any behavioural signs are seen. Moreover, blue-
enriched or monochromatic 460nm light can evoke alerting responses and increase
cognitive performance in dark-adapted volunteers, compared to non-blue enriched
and monochromatic light at 550 nm, despite using light as low as 40 lux (Chel-
lappa et al., 2011). Interestingly, the use of light emitting diodes (LED) during
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simulated evening shifts in the laboratory resulted in a significant increase in the
alerting response, and cognitive task performance in comparison to the non-LED
screen of similar intensity (Cajochen et al., 2011). Despite the positive impact
of high intensity light leading to greater alertness, extra light can delay circadian
rhythms, including entrainment of the sleep-wake cycle, in relation to the natural
light-dark cycle, which ultimately results in daytime sleepiness and cognitive per-
formance decrements. This raises a debatable point whether exposure to ”extra
light” has a positive or negative effect, especially based on epidemiological evidence
that LAN has a negative impact on human health (Schernhammer and Thompson,
2011).
Light can influence sleepiness-alertness via non-SCN routes such as the direct
route to the VLPO. The VLPO regulates sleep-wakefulness by integrating with the
reticular activating system that regulates wakefulness and arousal. The VLPO is
activated by serotonin and adenosine, to release inhibitory signals such as GABA
and glanin, thus suppressing the arousal system and inducing sleep. The VLPO
can also receive inhibitory neurotransmitters (such as norepinephrine and acetyl-
choline) from the diffuse modulatory system (part of arousal system), which results
in inhibition of sleep and promotion of wakefulness (Cajochen et al., 2014). The
light signal via the RHT can directly influence hypocretin/orexin neurons which
promote wakefulness by exciting various brain areas involved in arousal (Canteras
et al., 2011; LeSauter et al., 2011). Light has also been shown to activate the locus
coeruleus (LC) which is known as a noradrenergic wake-promoting brain region (As-
tonJones and Cohen, 2005; Vandewalle et al., 2007). Finally, magnetic resonance
imaging (fMRI) studies have shown that blue light exposure enhances activity in
the pulvinar nucleus (posterior hypothalamus) which contributes to visual attention
and alertness (Vandewalle et al., 2007).
1.5.3.3 Measures of sleepiness-alertness
Several tests (such as the Karolinska Sleepiness Scale (KSS), Stanford Sleepiness
Scale (SSS), and Epworth Sleepiness Scale (ESS)) have been validated for use in
clinical studies to measure sleepiness and alertness by subjective rating scales .
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These subjective rating scales can be used to measure sleep propensity under field
conditions (Johns, 1991; Cajochen et al., 2014), unlike the multiple sleep latency
test (MSLT) and maintenance of wakefulness test (MWT) which take place in the
controlled sleep laboratory environment. The MSLT measures sleep propensity
under particular test conditions, whereas MWT measures wake propensity under
similar conditions (Mitler et al., 1982; Carskadon and Dement, 1992; Thorpy et al.,
1992).
Objective measures of sleepiness-alertness, such as eye movement, variability
in pupillary diameter and performance lapses can be measured under laboratory
conditions. Electrooculography (EOG), measuring eye movement, and electroen-
cephalography (EEG), measuring electrical activity in the brain, Both with the
high temporal resolution to allowing the detection of micro-sleeps, or performance
lapses in the range of seconds (Cajochen et al., 1999; Regen et al., 2013). The
interruption of ongoing activity and interference-prone nature of these techniques
show the significant disadvantages in real-life settings. Recent methods involving
the use of video cameras to film a persons eyes and infrared reflectance oculography
allow measurement of the speed and duration of eyelid movements during blinks
allowing detection of changes in alertness and performance along the alert-drowsy
continuum (Dinges et al., 1998; Johns et al., 2008).
1.5.4 Temperature
Body temperature is a complex physiological state that is regulated by alternating
between heat production and heat loss. The preoptic-anterior hypothalamus is the
thermoregulatory centre in the human body which maintains the body and brain
temperature within a limited range to sustain body physiology and metabolism. It
acts by influencing cutaneous vasodilation, peripheral vasoconstriction and basal
metabolism, to alter the rate of heat loss and gain (Krauchi and Wirz-Justice,
1994; Wright et al., 2002). Several masking factors can contribute to variability in
body temperature over the 24-hour day such as age (Carrier et al., 1996), gender,
menstrual cycle (Baker et al., 2001) and behaviours including muscular exertion
and eating (Krauchi and Wirz-Justice, 1994).
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Under constant routine conditions, distal skin temperature increases in the
evening, whilst proximal skin temperature and core body temperature (CBT) de-
creases, with the reverse occurring in the morning (Krauchi and Wirz-Justice, 1994).
A bright light pulse prior to sleep attenuates the nocturnal decrease in body temper-
ature (Badia et al., 1991; Dijk et al., 1991). Other human studies have revealed that
a light stimulus in the late biological day/early biological night causes a phase delay
shift, whereas a phase advance shift was seen when the light stimulus was presented
in the late biological night/early biological day (Duffy and Czeisler, 2009a). Posi-
tive correlation was observed between temperature and performance with high levels
during wake and low levels during habitual sleep times (Badia et al., 1991). This
correlation was also documented when body temperature was externally manipu-
lated, showing improvement in cognitive function with increased temperature above
normal, while low temperature decreased cognitive function (Wright et al., 2002).
The relationship between temperature and changes in neurobehavioral performance
was hypothesized by Kleitman (1963). He postulated that increased temperature
can cause an increase in the rate of chemical reaction, which then speeds up the
process. It is speculated that chemical process refers to either mental processes or
the speed of thinking which relies on the metabolic activity of cerebral cortex cells
(Kleitman, 1963).
1.5.4.1 Acute light effects on body temperature
Light exerts dual effects on body temperature by entraining the circadian rhythm in
temperature or by an acutely elevating effect. As mentioned in the previous section
1.5.4, temperature is known to decrease at night, however, bright light exposure (500
to 5000 lux) at night has been shown to increase core body temperature (Wright Jr
et al., 2000; Burgess et al., 2001), and early morning bright light exposure resulted
in increased CBT (Morita et al., 1997). However, bright light exposure (5000 lux) in
the afternoon showed no effects on body temperature (Badia et al., 1991; ?). This
indicates that light intensity and time of exposure are critical factors in influencing
body temperature. Human evidence has shown that CBT is more sensitive to 2-h
nocturnal exposure to short-wavelength (460 nm) compared to green (550 nm) light
(Cajochen et al., 2005).
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1.5.5 Interaction between melatonin, sleepiness-alertness and body tem-
perature
It has been suggested that melatonin suppression is solely responsible for changes
in alertness and CBT. This assumption came from human studies that showed
increased body temperature and performance in both nocturnal bright light and
caffeine administration when melatonin was suppressed (Wright Jr et al., 2000).
Other studies showed a reduction in body temperature and alertness during the
day following melatonin administration (Cagnacci et al., 1992; Deacon and Arendt,
1995; Kra¨uchi et al., 1997a). Therefore, the alerting effects of LAN could be due
to an increase in CBT resulting from endogenous melatonin suppression. To test
this hypothesis, a study involving the administration of exogenous melatonin si-
multaneously with bright light was performed, but the alerting, and temperature
effects of light were not completely blocked by exogenous melatonin. This suggests
that acute alerting and temperature effects of light are not exclusively mediated by
melatonin (Kra¨uchi et al., 1997a). Moreover, Dollins et al. (1993) have shown that
light-induced melatonin suppression did not lead to an increase in alertness, prov-
ing that melatonin suppression is not the only factor modulating alertness (Dollins
et al., 1993). Alertness response curve in relative to melatonin suppression curve
illustrates that melatonin could determine alertness, similar to CBT response curve
shown in Figure1.11.
The changes in both body temperature and melatonin associated with bright
light could contribute to variations in the level of alertness. For instance, bright light
and caffeine both act as stimuli to increase alertness. Caffeine enhances alerting
responses by blocking adenosine receptors, while bright light can act directly by
enhancing the promoting system of alertness (section 1.5.3.2), or via modulating
CBT and endogenous melatonin (Wright Jr et al., 2000). Therefore, caffeine and
bright light can exert an additive effect via different mechanisms using more than
one input pathway (Wright et al., 1997). As mentioned previously in section 1.5.3.2,
light can directly influence the VLPO which in turn innervates all nuclei involved
in wakefulness and EEG arousal. Also, other potential direct inputs from the SCN,
IGL and the pretectal area could contribute to alerting responses (Cajochen et al.,
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2000).
Figure 1.11: Circadian rhythm of behavioural and physiological responses under
constant routine condition
Plasma melatonin (A), CBT (B) and subjective alertness (C) rhythm as indicated by reaction time, with
dotted line representing the peak time of melatonin, nadir temperature and alertness under constant routine
condition (Rajaratnam and Arendt, 2001).
1.5.6 Mood and comfort
Several human studies have been conducted to investigate the impact of natural
light on health. For instance, depressed mood has been linked to short daily light
exposure, since it was found in industrialised countries that people spent less time
(4% of each 24 h) in illumination greater than 1000 lux, and more time (50% of
each24 h) in illuminance level between 0.1 to 100 lux (Wehr, 1991; Espiritu et al.,
1994; Kripke et al., 1994). Participants reported better mood during the daytime
with light levels of 2000 lux, compared to below 300 lux (Daurat et al., 1993).
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Increased vitality and mood in winter months was also reported in Finnish partic-
ipants exposed to bright light boxes (Partonen and Lo¨nnqvist, 2000), similarly in
people participating in an 8-week exercise programme (1 hr 2-3 times per week)
under bright light (2500-4000 lux) compared to ordinary light (400-600 lux) (Parto-
nen et al., 1998). Furthermore, using a lightbox in the workplace for 2 hours either
in the morning or evening was associated with improved mood in people with sub-
syndromal seasonal affective disorder (Avery et al., 2001). This raises an issue of the
best illuminance levels for interiors, as some investigators believe that higher levels
are more desirable (Begemann et al., 1997), whereas others indicated that lower or
consistent lighting codes and standards are more suitable (Veitch and Newsham,
2000). In addition to light intensity, light wavelengths have been examined using 9
point scales in healthy non-depressed volunteers, and the results from these studies
were mixed. Revell et al (2006) have shown that participants were more depressed
during monochromatic light of 440 nm, compared to 470 nm (Revell et al., 2006).
Another study reported increased scores for calmness, cheerfulness and elation in
both blue (λ 456 nm) and green (λ 548 nm) monochromatic light, with significant
differences between the light conditions (Sletten et al., 2009). However, when mood
scores were examined in short and long wavelength monochromatic light (λ 437
nm, 479 nm, 532 nm) or polychromatic light conditions (4000 K and 17000 K), no
differences in calmness, cheerfulness and depression were reported (Revell et al.,
2010)
Seasonal affective disorder (SAD) refers to depressive symptoms shown particu-
larly during the shorter days of autumn and winter. Symptoms of SAD include low
mood, decreased concentration, low energy, fatigue and increased appetite. Bright
light therapy (12 week daily light therapy) was associated with significant reduc-
tion of anxiety in 58 patients and mood symptoms using the Hospital Anxiety and
Depression Scale (HADS) (Baxendale et al., 2013), yet no differences were reported
between low and high light intensity. Using LED with short wavelength narrow band
light (λ 470 nm) was more effective than red light (max 650 nm) in lessening the
depressive symptoms (Strong et al., 2009). Also, using as low intensity as 750 lux
of blue-enriched polychromatic light (17000 K) was as effective mood treatment as
standard 10 000 lux of polychromatic light (5000 K), using the structured interview
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guide for the Hamilton depression rating scale-seasonal affective disorder (SIGH-
SAD) (Meesters et al., 2011). Using fMRI, short wavelength monochromatic light
(λ 473 nm) gave greater responses in the right amygdala compared to green light
(λ 527 nm). The amygdala in humans is a part of the limbic system that includes
the hypothalamus and hippocampus. The limbic system is involved in motivation,
emotion, learning and memory. Thus, it has been suggested that blue light can
modulate emotional processes via the amygdala (Vandewalle et al., 2007).
1.5.7 Cardiovascular function
Cardiovascular disease represents a general class of diseases that involves the heart
and/or blood vessels. It principally includes cardiac diseases, vascular diseases of
the brain and kidney, as well as peripheral arterial diseases (Kelly et al., 2010). It
has been suggested that inflammation and endothelial dysfunction causing vascular
damage can also contribute to increased peripheral resistance. There are either fixed
or modifiable risk factors that are associated with CVDs. The fixed factors include
genetic composition, age, menopausal status and gender, while the modifiable fac-
tors are environmental cues and lifestyle such as diet, smoking, sleep deprivation,
light at night and concurrent diseases (Mozaffarian et al., 2008).
Many non-invasive techniques have been used in clinical studies to assess vascu-
lar function including flow-mediated dilatation (FMD), heart rate variability (HRV),
and pulse wave velocity (PWV). FMD uses ultrasound recordings to evaluate en-
dothelial function, by measuring the ability of a large artery (e.g., brachial artery) to
respond to a shear stress stimulus. FMD compares the diameter of the artery at rest
and with the diameter during shear stress-induced dilatation that produces a nitric
oxide (NO) dependent response; thus it is a direct biomarker of NO bioavailability
(Clarkson et al., 1997; Fathi et al., 2004; Charakida et al., 2005). FMD was reported
to be lower in diabetes and coronary heart disease (CHD) than in healthy popula-
tions (Bots et al., 2005). HRV refers to the variation in the time interval between
consecutive heart beats that can be obtained from an electrocardiogram (ECG).
Low frequency (LF), high frequency (HF) power and LF/HF ratio are widely used
to assess sympathetic and parasympathetic modulation. An increase in the LF/HF
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ratio reflects sympathetic dominance, whereas a low LF/HF ratio corresponds to
parasympathetic dominance (Buccelletti et al., 2009; Thayer et al., 2010). PWV is
a new assessment tool to examine the velocity of a waveform travelling from one
site to another (section 1.5.7.5).
1.5.7.1 The risks of shift work
Shift work (SW) has been associated with CVD which is considered to be the pri-
mary cause of morbidity and mortality (Townsend et al., 2015). SW was associated
with higher levels of triglycerides (TAGs) and total cholesterol, leading to the con-
clusion that SW increased the risk of CVD by 40% (Bøggild and Knutsson, 1999).
Other cross-sectional data has shown increased diastolic blood pressure and morning
concentration of fasting insulin and TAGs in shift workers (Sookoian et al., 2007).
Also, the prevalence of coronary artery disease (CAD), myocardial infarction (MI)
and hypertension is twice as great in SW than NSW (Ellingsen et al., 2007). Many
factors contribute to the cardiovascular consequences of SW such as short sleep
duration (or sleep deprivation) and light at night; both involved in circadian desyn-
chrony. Endothelial function, heart rate variability and blood pressure exhibit 24-h
daily rhythm. Walters et al., (2006) reported lower FMD in the morning and higher
in the evening, under constant routine conditions (Walters et al., 2006). A circadian
rhythm was also shown in HRV parameters such as LF, HF and standard deviation
of NN intervals (SDNN). SDNN peak between 04:45 and 07:00h (Viola et al., 2002;
Bonnemeier et al., 2003; Vandewalle et al., 2007), in addition to LF peaks seen at
06:15h and 05:16 h for HF (Vandewalle et al., 2007), however no circadian peak
was shown for LF/HF (Viola et al., 2002; Vandewalle et al., 2007). Blood pressure
exhibits high levels in the morning and noon, with a decline of 10-20% in the late
evening (Smolensky and Haus, 2001; Guo and Stein, 2003).
1.5.7.2 Effect of melatonin on vascular function
Several animal studies have been conducted to examine the role of melatonin in mod-
ulating vascular function, particularly heart rate and blood pressure. Intravenous
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melatonin (30-60 mg/kg) administered to rats reduced serotonin release in the cor-
pus striatum and hypothalamus resulting in sympathetic inhibition and parasym-
pathetic stimulation, leading to hypotension and bradycardia (Chuang et al., 1993).
Hypertensive rats were infused with melatonin using an osmotic mini-pump, which
led to a reduction in blood pressure and heart rate (Kawashima et al., 1987). Sim-
ilarly, administration of melatonin reduced pinealectomy-induced hypertension, as
well as reducing renin concentrations in rats with pineal lesions (Holmes and Sug-
den, 1976). Although the mechanism of melatonin action is still unknown, a num-
ber of possible pathways can be postulated. First, it is already known that the
SCN, PVN and intermedilateral nucleus are responsible for sympathetic excitation
in the SCG that regulates pineal melatonin synthesis. Therefore, modulation of
SCN activity by melatonin can alter sympathetic tone, and may lessen excessive
sympathetic activation (Reppert et al., 1988). Second, melatonin was reported to
enhance GABA-ergic signalling which is involved in PVN inhibition by the SCN and
inhibition of the rostral ventrolateral medulla (RVM) via the caudal ventrolateral
medulla (CAM). Consequently, inhibition of these nuclei can decrease sympathetic
tone (Kalsbeek et al., 2000; Patel et al., 2001; Wang et al., 2003). Third, melatonin
induces NO production, which enhances the GABA-ergic inhibitory effect on the
RVM and PVN (Patel et al., 2001; Rossi et al., 2004).
1.5.7.3 Effect of melatonin on vascular structure
Melatonin could improve vascular morphology by reducing oxidative stress mecha-
nisms. Melatonin has been shown to exert some antioxidative actions in rats such
as neutralisation of reactive oxygen species (ROSs) and free radicals, stimulating
oxidative enzymes and enhancing the efficacy of classic antioxidants (Gitto et al.,
2001). Several theories have been proposed to explain the free-radical-scavenging
actions of melatonin without its being pro-oxidant. For instance, Martinez et al.
(2005) suggested that melatonin acts as an electron donor as it possesses an electron-
rich aromatic indole ring (Martinez et al., 2005). Thus, melatonin can reduce and
repair the electrophilic hydroxyl radicals resulting in the formation of N1-acetyl-N2-
formyl-5-methoxykynuramine (AFMK), which donates its electron and neutralizes
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radical species such as single oxygen (O.−2), hypochlorus acid, superoxide and hy-
drogen peroxide (Tan et al., 2001). AFMK can interact with ROS and reactive
nitrogen species (RNS) to form AMK, resulting in a further cascade of free-radical-
scavenging actions (Schaefer and Hardeland, 2009). Tan et al. (2007) pointed out
that up to 10 ROS/RNS molecules can be scavenged by a single melatonin molecule
(Tan et al., 2007).
Another aspect of the anti-oxidative action of melatonin can be explained by its
ability to stimulate antioxidant enzymes. Several anti-oxidative enzymes, includ-
ing superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx),
glutathione reductase (GRd) and glucose-6-phosphate dehydrogenase (G6PD), are
stimulated by melatonin as demonstrated in vivo and in vitro studies (Tengattini
et al., 2008). Melatonin has been shown to down-regulate the pro-oxidant enzymes
such as nitric oxide synthase and lipoxygenase (Hardeland, 2005). Oxidative stress
can be generated as a result of the inhibition of the mitochondrial complexes (com-
plex I), which results in electron leakage and the resultant generation of the (O.−2)
(Adams et al., 1993). Melatonin stimulates complex I and thus limits the molecular
destruction of essential molecules by ROS (Absi et al., 2000; Martin et al., 2000).
1.5.7.4 Acute effects of light on vascular function
Heart rate, temperature and blood pressure are known to decrease during the night,
however, light at night such as in SW can modulate heart rate, temperature and
blood pressure. For instance, exposure to bright light at night (500 to 5000 lux)
results in increased heart rate (Scheer et al., 1999) and body temperature (Dijk
et al., 1991; Burgess et al., 2001; Wright Jr et al., 2000). Similar results were shown
in children exposed to high light intensity levels which caused an increase in arterial
blood pressure (systolic (SBP) and diastolic (DBP)) and tympanic temperature
(Hadeel et al., 2012). Exposure to low light intensity also led to increments in blood
pressure and tympanic temperature suggesting the involvement of melatonin. Scheer
et al., (2004) have shown an increase in heart rate under early morning bright light
exposure, however, no heart rate response was shown in the afternoon after bright
light exposure (5000 lux) (Scheer et al., 2004). In addition to the light irradiance-
dependency, heart rate and CBT were more responsive to short wavelength (460
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nm) with 2 h nocturnal exposure causing a greater reduction compared to green
light (550 nm) (Cajochen et al., 2005). Systolic blood pressure was higher in red
light exposure (Kaiser, 1984), and lower in blue light (Wolfarth and Sam, 1982).
1.5.7.5 Arterial stiffness as clinical research tool
Blood pressure measurements have been used widely in clinical trials since the 1800s
as a major indicator of CVD risk. For instance, an increase in blood pressure by
20 mmHg has been associated with a 10.6 g increase in left ventricular mass (LVM)
(Levy et al., 1989; Goldberg et al., 1996). However, there are some disadvantages
to the measurement of blood pressure. For instance, blood pressure is measured in
the branched artery (brachial artery), which does not develop atherosclerosis, and
the left ventricle is mainly influenced by the pressure in the ascending aorta, rather
than that in the brachial artery (Westerhof and O’Rourke, 1995; Vlachopoulos and
O’Rourke, 2000). The ascending aortic pressure is defined as the sum of incident and
reflected wave from the periphery (brachial artery) to the central blood vessels (e.g.,
aorta), whereas brachial BP record is removed from the BP in the ascending aorta.
Therefore, the assessment of the pulse pressure wave enables a better estimation of
the ascending aortic pressure wave compared to the assessment peripherally in the
brachial artery (Davies and Struthers, 2003).
The pressure waveform of blood circulation allows for the use of a new assess-
ment tool, namely pulse wave velocity (PWV), which refers to the rate at which
the pressure wave moves down the blood vessel. This movement during systolic
ejection results in the dilation of the arterial walls, thus indicating arterial compli-
ance (Vlachopoulos and O’Rourke, 2000). The change in the wave speed indicates
the changes in the arterial wall, for example, the speed is increased when the walls
become stiffer. PWV can be measured using a Vicorder, which relies on the appla-
nation tonometry technique that calculates the time needed for a pressure wave to
travel between two different sites (usually the carotid and brachial or carotid and
femoral arteries) (Davies and Struthers, 2003). Applanation tonometry is a highly
reproducible (Liang et al., 1998), simple to learn technique, with a repeatability co-
efficient of over 90% (0.947) (Asmar et al., 1995). This technique can also provide
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other parameters of pulse wave analysis such as the augmentation index, systolic
and diastolic pressure and arterial pulse pressure. Although no human study has
compared invasive PWV measurement with non-invasive PWV measurement us-
ing applanation tonometry, several clinical trials have shown a clear association
between cardiovascular events and an increase in PWV. An example of this is a
study in Paris that involved 2000 hypertensive patients with no previous CVD and
diabetic history, which showed a strong relationship of aortic PWV in increments
of 5 m/s with cardiovascular mortality, independent of age (Laurent et al., 2001).
1.5.8 Short-term endocrine control of metabolism
Short-term endocrine control represents fast-release hormones such as insulin and
glucagon. These hormones are involved in fast-regulatory actions to maintain blood
glucose in both postprandial and fasting states. In contrast, long-term endocrine
control refers to cortisol and catecholamines which reinforce the short-term hormone
actions.
1.5.8.1 Glucose physiology and rhythm
Glucose or D-glucose is a monosaccharide form of carbohydrate that is absorbed
into the bloodstream during digestion. Pre-prandial plasma glucose levels are nor-
mally about 5.5mM (5.5 mmol/L or 100mg/dl), and typically peak at 7.8 mmol/L
in the postprandial state. Glucose concentration is balanced by the rate of glu-
cose entering and leaving the circulation. The rate of glucose appearance in the
circulation is derived from gastric emptying, glycogenolysis and gluconeogenesis.
After 8-12 hours of fasting, glycogenolysis which is promoted by the α-cells hor-
mone, glucagon, increases glucose levels in the circulation. Over a longer period
of fasting, glucagon enhances glucose synthesis from lactate, pyruvate and glyc-
erol which is then released from the liver via gluconeogenesis. The main source of
glucose during the fasting period is the liver, however, renal gluconeogenesis con-
tributes to the systemic pool of glucose during extreme starvation. Other tissues
have the potential to break down glycogen to glucose; however the liver and kidney
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possess glucose-6-phosphatase (G-6-P) which is the rate-limiting enzyme in glucose
production (Aronoff et al., 2004).
In the fed state, glucose concentrations reach peak levels but this is tightly reg-
ulated to return to fasting levels after several hours. Plasma glucose is converted
to lactate in non-hepatic tissue (e.g., the gut), and to pyruvate in the liver. Lac-
tate is involved in anaerobic glycolysis providing energy in the form of adenosine
triphosphate (ATP) during short and intense exercise, whereas pyruvate contributes
to aerobic glycolysis to provide between 30 to 36 ATP molecules. Pyruvate can be
converted back to glucose via gluconeogenesis. As an immediate response to the
post-feeding state, circulating glucose is removed into skeletal muscles, and adipose
tissue by the action of insulin. Insulin is delivered into the liver via the portal vein
suppressing gluconeogenesis. Paracrine signalling between α and β cells in the pan-
creas results in glucagon suppression in the fed state (Aronoff et al., 2004). Other
regulatory hormones are involved in glucose metabolism such as amylin, gastric hor-
mones (Glucagon-like peptide (GLP-1) and gastric inhibitory polypeptide (GIP)),
epinephrine, cortisol and growth hormone (Aronoff et al., 2004; Association, 2004).
1.5.8.2 TAGs, NEFAs and lipoproteins
Triglycerides (or triacylglycerols, TAGs) are esters of three fatty acids (FAs) and
glycerol that belong to simple lipids. It is formed by ester bonds between the
hydroxyl (-OH) groups of glycerol and the carboxyl (-COOH) groups of the fatty
acid. Non-esterified fatty acids (NEFAs) belong to a derived lipid group and are
produced by hydrolysis of simple or compound lipids. Dietary lipids, mostly TAGs,
act as fuels, and are associated with energy metabolism rather than structural
components. Dietary TAGs digestion takes place in three phases, known as gastric,
duodenal and illeal phases. TAGs digestion involves emulsification in the stomach,
lipolysis and solubilisation in the duodenum and, absorption into the epithelial cells
or enterocytes of the small intestine or ileum. Lipid homeostasis is mediated through
the balance of lipogenesis, the synthesis of TAGs from their constituent FFAs or
NEFAs, and lipolysis which is the breakdown of TAGs to produce NEFAs (Griffin
and Cunnane, 2009).
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During fasting, both glycogen and protein are hydrolysed in the liver to pro-
vide glucose as the primary source of energy. Brain and red blood cells use the
circulating glucose for energy whereas resting muscle relies mainly on fatty acids
as an energy source. In contrast, exercising muscle relies on both fatty acids and
glucose for energy (Cerretelli, 1992). The stored fats in adipose tissue are hydrol-
ysed by hormone-sensitive lipase (HSL) to release glycerol and fatty acids during
both fasting and exercise. The resulting glycerol is converted to glucose in the liver,
whereas FFAs are used directly as an energy source in most tissues with mitochon-
dria (Kraemer and Shen, 2006). Fatty acids can be converted to ketone bodies in
the liver during prolonged starvation. All tissue containing mitochondria use ketone
bodies as an energy source. During the fasting state, TAGs are secreted from the
liver as very low-density lipoprotein (VLDL), and the rate of VLDL production and
secretion depends on the delivery of FFAs (mainly NEFAs) from the circulation to
the liver (Griffin and Cunnane, 2009) (Figure 1.12).
Figure 1.12: Metabolism of TAGs, NEFAs and lipoproteins
Schematic illustrations of the metabolism and clearance of dietary fats, and the role of regulatory enzymes
including HSL and LPL, and the role of LDL, HDL and VLDL (Hegele, 2009)
After digestion of dietary fat in the stomach emulsified fat ”chyme” produced
by the stomach enters the duodenum. This triggers the release of cholecystokinin
(CCK) from the gallbladder, bile acids produced in the liver and released by the
gallbladder, and pancreatic lipase from the pancreas. CCK inhibits gut motility,
whereas pancreatic lipase stimulates TAGs lipolysis yielding free fatty acids and
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monoglycerides (MAGs). Short and medium-chain (14 carbons) fatty acids are di-
rectly absorbed into the portal circulation and transported bound to albumin to
the liver. Long-chain fatty acids (LCFAs) (e.g., TAGs and cholesterol) and MAGs
are solubilized by bile salts to form mixed micelle, then absorbed in enterocytes
for further processing and re-esterification into TAGs-rich apolipoprotein (chylomi-
crons (CMs)). Chylomicrons are released into the circulation via lymphatic vessels,
resulting in postprandial lipaemia. Postprandial TAGs measured in serum represent
TAG-rich lipoproteins, which peak between 3 and 4 hours postprandially and return
to basal levels after 5-6 hours. Postprandial plasma TAGs are either bi-polyphasic
or monophasic. Monophasic postprandial TAGs show one single peak and usually
occur after an overnight fast, whereas daytime postprandial TAGs show more than
one peak. Polyphasic postprandial TAGs show an early peak (within 30 mins) as a
result of preformed lipid from previous metabolism, as well as peaks produced from
ingested lipid (Griffin and Cunnane, 2009). TAGs-rich CM (from the intestine) and
VLDL (from the liver) are lipolysed into FFAs by either endothelial lipoprotein
lipase (LPL) in adipose tissue and skeletal muscles or hepatic lipase (HL). Insulin
inhibits the release of NEFAs from adipose tissue by suppressing HSL. FFAs de
novo can be synthesized in both the liver and adipose tissue by the catabolism of
carbohydrates, yet the contribution of this process in western diet is less significant
(Griffin and Cunnane, 2009).
The major function of lipoproteins, CMs, VLDL, low-density lipoprotein (LDL)
and high-density lipoprotein (HDL) is to produce, transport and release TAGs and
remove cholesterol from the circulation. LDL is derived from the lipolysed TAGs-
rich CM and VLDL, resulting in the formation of cholesterol-rich remnants and
ultimately LDL. LDL carries fats including TAGs, cholesterol and phospholipid, in
the circulation to peripheral tissue, and binds to the LDL receptor allowing LDL
particle degradation and cholesterol uptake by endocytosis. In contrast, HDL is
produced by the liver and the gut by the action of lecithin-cholesterol acyltrans-
ferase (LCAT). LCAT converts free cholesterol into cholesterol esters (CEs), which
are then sequestered into lipoprotein particles. HDL can remove cholesterol from
the circulation by transporting cholesterol to the liver and steroidogenic organs.
Cholesteryl ester transfer protein (CETP) exchanges the TAGs of VLDL with CEs
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of HDL. VLDL is processed to LDL which is removed from the circulation by the
LDL receptor pathway, whereas TAGs in HDL is degraded by HL. The remnant
small HDL particles begin uptake of cholesterol from cells again (Griffin and Cun-
nane, 2009) (Figure 1.12).
1.5.8.3 Insulin physiology and rhythm
Insulin is a peptide hormone that consists of two polypeptide chains (A & B) linked
by disulfide bonds. It is synthesised by beta cells of the islet of Langerhans in
the pancreas. Insulin plays a vital role within an interconnected system that in-
volves the synthesis and removal of glucose, TAGs and NEFAs. Pancreatic β-cells
release insulin in two different phases: phase 1 occurs within two minutes of nutri-
ent ingestion and lasts for 10 to 15 minutes, whereas the second phase peaks 2 to
3 hours after a meal, and sustains insulin release until normoglycemia is restored
(Gerich, 1993; Cryer et al., 2008). Insulin secretion occurs when circulating glu-
cose enters β-cells via glucose transporter 2 (GLUT2). Glucose is phosphorylated
into glucose-6-phosphate (G-6-P) which produces ATP via the glycolytic pathway,
resulting in increased ATP:ADP ratio which in turn causes a closure of the ATP-
sensitive-K-channel. This prevents potassium ions (K+) from leaving the cells and
builds up intracellular K+; thus the cell becomes less negative, and depolarization
occurs. Upon depolarization, calcium ion (Ca2+) channels open, allowing Ca2+ in-
flux, increasing intracellular Ca2+. Intracellular Ca2+ can also be increased from the
intracellular stores, and through activation of PLC resulting from a ligand (hormone
or neurotransmitter) binding to a G-protein-coupled membrane receptor. This al-
lows the release of intracellular insulin into the circulation via secretary vesicles in
a process called exocytosis. Therefore, postprandial glucose elevation is considered
as the primary stimulus for insulin secretion, and the major target tissues of insulin
are liver, muscle and adipose tissue, and to a minor extent the kidney (Aronoff
et al., 2004; Silverthorn et al., 2009)(Figure 1.13).
Insulin inhibits glucose production and glycogen breakdown and stimulates glyco-
gen synthesis and glycolysis in the liver. It also stimulates glucose uptake by the
splanchnic tissues, muscle and adipose tissue. The outcome is lowering of circulating
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Figure 1.13: Insulin secretion from pancreatic β-cells
Illustration of glucose induction of insulin secretion in pancreatic β-cells. Glucose is taken up via the Glut1
and phosphorylated by glucokinass (GCK). An increase of Ca2+ because of KATP closure, causes insulin
secretion via exocytosis (Ashcroft and Rorsman, 2012)
glucose until normoglycemia is achieved. Insulin also regulates lipid metabolism by
acting on liver and adipose tissue. Insulin inhibits intracellular lipolysis of stored
TAGs in adipose tissue by inhibiting HSL and oxidation of FAs in the liver. This will
cause a reduction in plasma postprandial NEFAs levels. In contrast, insulin stimu-
lates LPL in adipose tissue, thereby activating removal of TAGs from the plasma.
It also enhances de novo lipogenesis and TAGs synthesis in liver and adipose tissue.
Additionally, it stimulates cholesterol synthesis and suppresses VLDL release from
the liver. (Aronoff et al., 2004; Griffin and Cunnane, 2009; Silverthorn et al., 2009).
1.5.8.4 Glucose intolerance and insulin resistance
Insulin resistance refers to elevated insulin levels due to diminished ability of cells
in liver, fat and muscle to respond properly to insulin, resulting in increased blood
glucose and insulin. The related abnormalities and physical outcomes that occur in
tissue as results of differences in insulin dependence and sensitivity are known as
insulin resistance syndrome (Wilcox, 2005). Insulin secretion is mediated by neural
stimuli, nutrient and hormonal interplay. Insulin responses to glucose and lipid are
considered as the major key factors in insulin secretion. Although excess secretion of
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counter-regulatory hormones such as glucagon, glucocorticoids and catecholamines,
may contribute to insulin resistance, it is believed that most cases are due to cellular
level mechanisms including down-regulation, genetic defects of tyrosine phosphory-
lation or insulin receptors, or abnormalities of GLUT 4 function (Wheatcroft et al.,
2003; Wilcox, 2005). The term insulin resistance also refers to impairment of insulin
action at insulin-target tissues such as muscle, adipocyte or liver. In muscle, glyco-
gen synthesis is impaired due to reduced intracellular glucose translocation, and
reduced activity of the glucose transporter (Choi et al., 1991). The effects of insulin
resistance on adipocytes are similar, however the excess fatty acid flux into the
liver promotes hepatic VLDL production, whilst ketogensis remains suppressed as a
result of hyperinsulinemia. Additionally, impairment of LPL, an insulin-dependent
enzyme, by insulin resistance results in diminished peripheral uptake of TAGs from
circulating VLDL explaining the observed hypertriglyceridemia of insulin resistance
(Grundy, 2004). Adipocytes from insulin resistant individuals show a reduction in
GLUT4 translocation and impaired intracellular signalling due to reduced insulin
receptor substrate (IRS-1) gene and insulin-stimulated PIP-3 kinase and Akt (pro-
tein kinase B) (Smith, 2002).
1.5.8.5 Effects of melatonin on glucose and insulin
Food consumption at relatively fixed times may in part, whether during the day for
humans or at night for rats, explain the synchronization of digestive and metabolic
systems to environmental conditions (Bach and Peschke, 2011). Clinically signifi-
cant changes in hormones and metabolites were observed in individuals with either
loss or desynchronisation of biological rhythms. Prolonged light exposure at night
(10 weeks) disrupted circadian clock function of rat islet cells through impairment in
the amplitude, phase, and inter-islet synchrony of clock transcriptional oscillations
(Qian et al., 2013). The absence of the nocturnal melatonin signal can result in the
desynchronisation or dysfunction of pancreatic islets. Experimental animal models
in vivo and studies in vitro have suggested a role for melatonin in regulating glucose
homeostasis (Prunet-Marcassus et al., 2003; Hussein et al., 2007), with insulin resis-
tance and glucose intolerance in pinealectomized rats (Lima et al., 1998; Zanquetta
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et al., 2003). However, melatonin administration in obese insulin-resistant rats
resulted in a reduction in body weight, low plasma glucose and insulin (Prunet-
Marcassus et al., 2003). Melatonin was also reported to reduce hyperglycemia,
hyperinsulinemia and hyperleptinemia in type 2 diabetic rats, yet the underlying
mechanism of melatonin actions are not fully understood. This agrees with recent
studies that showed melatonin ameliorates glucose hyperglycemia by improving in-
sulin and cell function in nocturnal animals (Agil et al., 2012). This raises a question
whether feeding during the dark phase in nocturnal animals when melatonin lev-
els are high could augment physiological responses to food. In contrast, feeding
in humans occurs during the light phase when melatonin is not present, therefore
exogenous melatonin could interfere with physiological response to food intake. For
example, Rubio-Sastre et al., (2014) showed a significant increase in plasma glucose
in the morning and evening following an oral glucose tolerance test (OGTT) as a re-
sult of exogenous melatonin, whereas an increase in plasma insulin was only shown
in the evening. The authors suggested that in the morning, melatonin decreased
glucose tolerance primarily by reducing insulin release, while in the evening, by
decreasing insulin sensitivity (Rubio-Sastre et al., 2014). This study was consistent
with a previous study conducted in the morning in postmenopausal women which
showed an increase in plasma glucose after exogenous melatonin without a signif-
icant change in insulin levels indicating a decrease in insulin sensitivity (Cagnacci
et al., 2001). The effects of melatonin on glucose and insulin is still controversial,
and the underlying mechanism of melatonin actions are not yet fully understood.
Not until the observations of reduced melatonin production, increased insulin secre-
tion and the decrease in insulin sensitivity of peripheral tissues and pancreatic cells
in aged human (Ferrari et al., 1995; Touitou and Haus, 2000; Barbieri et al., 2003).
Therefore, several animal studies investigated the role of melatonin in modulating
insulin secretion.
It has been shown in animal models that melatonin modulates insulin secretion
from the pancreatic cells by activating three major intracellular signalling cascades:
3‘-5‘cyclic adenosine monophosphate (cAMP) cascade (Peschke et al., 2002; Pici-
nato et al., 2002), 3‘-5‘cyclic guanosine monophosphate (cGMP) cascade (Stumpf
et al., 2008, 2009), and inositol-1,4,5 triphosphate (IP3) cascade (?Peschke and
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Mhlbauer, 2010). This hypothetical action was strengthened by the detection of
MT1 and MT2 receptors in the pancreatic tissue of rats and human (Peschke et al.,
2007; Bouatia-Naji et al., 2009). Melatonin-induced inhibition of cAMP and cGMP
signalling cascades results in the inhibition of insulin secretion, whereas melatonin-
mediated activation of IP3 promotes insulin secretion (Figure 1.12). Melatonin
down-regulates adenylate or guanylate cyclase activity, thereby leading to the at-
tenuation of the activity of PKA and protein kinase G (pKG), which are crucial for
Ca2+ influx and insulin secretion. Moreover, a reduction in insulin secretion can
also lead to the down-regulation of CREB, which is necessary for cAMP and Ca2+
production (Peschke et al., 2013).
In contrast, the melatonin-promoted IP3 cascade causes the activation of PLC,
which along with PKC and IP3 induces the Ca2+ mobilization needed to trigger
insulin secretion (Peschke et al., 2013). Melatonin can only exert inhibitory or stim-
ulatory effects in combination with either stimulants (such as glucose, acetylcholine
or forskolin) or inhibitors (glucagon and somatostatin) (McClenaghan and Flatt,
1999). This explains the modulation of postprandial insulin secretion, since after
food consumption, local intestinal melatonin synthesis causes a short-term insulin
release and, subsequently, the cAMP-mediated inhibitory effect prevents excessive
insulin secretion (Figure 1.14).
1.5.8.6 Melatonin and type 2 diabetes
The association between melatonin and insulin may therefore suggest a possible
relationship between melatonin and type 2 diabetes. As mentioned in the previous
section 1.5.8.5 melatonin inhibits glucose-induced insulin secretion, and melatonin
suppression by nocturnal light exposure, needs to be considered in the develop-
ment type 2 diabetes. Melatonin has also been linked to modulation of glucose
homoeostasis in mice by stimulating insulin release to induce glucose uptake. The
vast majority of studies agree there is both a direct and an indirect role of melatonin
on insulin secretion in vivo and in vitro, and night-time melatonin levels modulate
night-time insulin concentration in patients with diabetes (Reviewed by (Espino
et al., 2011; Sharma et al., 2015)).
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Figure 1.14: Melatonin-mediated signal transduction in pancreatic β-cells
A: Melatonin acts via inhibitory G-protein-coupled receptor MT1 on the activity of AC, B: Melatonin acts
via the MT2 receptor on the activity of GC in an inhibitory fashion. C: Melatonin influences the activity
of IP3 and Ca2+ and via paracrine glucagon receptors and somatostatin receptors (Adapted from (Sharma
et al., 2015).
Other studies suggest that melatonin may be involved in the development of
diabetes (Peschke et al., 2006) with alterations in melatonin secretion and/or sup-
pression seen in T2D. Genomic studies proposed an association between the allelic
variant of MT2 and glycaemic traits such as elevated fasting glucose, impaired
insulin secretion and risk of T2D (Staiger et al., 2008; Prokopenko et al., 2009). Ir-
regular reduction of melatonin levels was related to diabetes, suggesting that mela-
tonin regulation is involved in maintaining glucose homoeostasis (Peschke et al.,
2006, 2007). In contrast, melatonin has been shown to prevent insulin resistance.
Insulin resistance refers to the impairment of the insulin signalling cascade, causing
an inhibition of glucose uptake by skeletal muscle, a reduction in glucose-consuming
glycogen synthesis and reduced blood supply to the skeletal muscles. There have
been several suggestions to explain the mechanisms whereby melatonin prevents
insulin resistance. Firstly, melatonin enhances glucose uptake by liver cells and
promotes glycogen synthesis (Shieh et al., 2009). Secondly, melatonin increases the
activity of insulin receptor kinase in skeletal muscle, resulting in the phosphorylation
of insulin receptor substrates and enhanced insulin action on muscles (Nishida, 2005;
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Ha et al., 2006). Sartori et al. (2009) reported that melatonin supports insulin-
mediated vasodilation in skeletal muscle and thereby increases glucose utilization
(Sartori et al., 2009). Most importantly, the anti-oxidative property of melatonin
is sufficient to improve glucose homeostasis, restore hepatic insulin signalling, and
ultimately ameliorate insulin resistance in a rat model of a high-fat diet.
1.5.8.7 Effects of light and/or melatonin on lipid profile
Research has shown that melatonin suppresses secretion of insulin, which is a vital
postprandial hormone in lipid metabolism. In a fed state, insulin inhibits the syn-
thesis of HSL and stimulates that of LPL, FFA and TAGs (Figure 1.12). The end
product of insulin action is decreased FFA levels in plasma and decreased TAGs ex-
ported as VLDL from the liver to the blood. The levels of LPL, an insulin-activated
enzyme, are reduced in the presence of the melatonin-induced reduction in nocturnal
levels of insulin in rats (Sparks and Sparks, 1993). It is suggested that lower in-
sulin sensitivity at night could lower LPL activity, and thus impair TAGs clearance.
Therefore, nocturnal insulin resistance could be associated with higher circulating
TAG levels of hepatic origin. Also, hypertriglyceridemia in diabetic patients has
been reported to be due to low LPL activity (Taskinen et al., 1982; Cianflone et al.,
2008).
A study on mutant mice with ”Clock(mt/mt)” has shown a constant high level
of TAGs over the course of the day due to disruption of CLOCK that modulates
microsomal triglyceride protein (MTP). MTP plays a role in the delivery of TAGs
into the bloodstream, which may possibly explain the impaired TAGs clearance and
high nocturnal TAGs levels at night (Pan et al., 2010). Ba¨hr et al. (2011) reported
that melatonin increases glucagon expression and secretion both in vivo and in
vitro. Glucagon stimulates HSL leading to increased NEFA levels (Ba¨hr et al., 2011).
Melatonin shows an inhibitory effect on the transport of fatty acids into adipocytes,
thus influencing the direct precursors of TAGs accumulation (Sauer et al., 2001). A
molecular study has demonstrated that the expression of clock genes such as Clock,
Bma11 and Per1 in cultured adipocytes was influenced by rhythmic exposure to
melatonin with the peak occurring during the night (Sato et al., 2004; Qasim and
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Maulood, 2009). Reaven et al. (1988) suggested that there may be a daily rhythm
of plasma NEFA levels, in which NEFA levels are highest in the morning, decrease
during the day and increase again overnight (Reaven, 1988). Asaradnam et al.
(2002) reported a diurnal variation in LPL due to changes in insulin levels after
a simulated abrupt 9h phase advance (Arasaradnam et al., 2002). These studies
indicate the importance of insulin in regulating FFAs and TAGs in circulation.
1.5.8.8 Glucagon and melatonin
Glucagon, an antagonistic hormone for insulin, is synthesized by pancreatic α
cells under hypoglycaemic conditions to stimulate the hepatic glucose output. As
reviewed by Ruiter et al. (2003), it is suggested that the circadian rhythm of
plasma glucagon secretion is independent of feeding conditions and governed by
SCN (Ruiter et al., 2003). A reduction in plasma glucagon levels has been shown in
humans with total sleep loss and sleep restriction (Schmid et al., 2007; Schmidt and
Kofuji, 2009), however melatonin levels were not investigated in these studies. PCR
analyses and immunochemical investigations of isolated human α- cells revealed
the presence of MT1 receptors, which could explain the mechanism of melatonin
impact on cells (Nagorny et al., 2011), despite the paracrine effects of adjacent
islets of Langerhans (β, δ, or PP [pancreatic polypeptide]). Melatonin exerts its
effect via the activation of PLC, resulting in the release of IP3 and DAG. IP3, in
turn, induces Ca2+ secretion from intracellular stores, thus causing glucagon secre-
tion (Gromada et al., 1997). Furthermore, the peripheral clock in the liver induces
circadian variations in hepatic gluconeogenesis and glycogen stores, and an associa-
tion has been shown between the disruption of the hepatic clock and alterations in
glucose homeostasis and gluconeogenesis (Stokkan et al., 2001).
1.5.9 Long-term endocrine control of metabolism
Long-term control of metabolism refers to a group of hormones synthesised to rein-
force short-term insulin and glucagon action. Long-term control involves groups of
hormones such as cortisol from the adrenal cortex, catecholamine from the adrenal
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medulla, thyroid hormone from the thyroid gland, and growth hormone from the
anterior pituitary. Other hormones and cytokines such as CCK and GIP are in-
volved in metabolic control, yet their effects are difficult to understand since they
are secreted from isolated cells and present in the blood at the same time as insulin
and glucagon.
1.5.9.1 Cortisol normal physiology and rhythm
Cortisol is a steroid hormone that is produced from cholesterol. It belongs to the glu-
cocorticoid family synthesised and secreted by the adrenal cortex, particularly the
zona fasciculata. The name glucocorticoid comes from the ability of these hormones
to raise plasma glucose concentrations. Cortisol synthesis and release is regulated
by adrenocorticotropic hormone (ACTH) from the anterior pituitary, which in turn
is controlled by the brain through corticotropin-releasing hormone (CRH). Cortisol
counteracts insulin actions and contributes to hyperglycaemia by causing hepatic
gluconeogenesis, and decreasing translocation of glucose transporters (GLUT4) to
the cell membranes. It also enhances proteolysis in skeletal muscle to provide a
substrate for gluconeogenesis. Cortisol promotes lipolysis to provide FFAs to be
used as an energy source in peripheral tissues. Despite cortisol facilitating glucose
production, it conversely stimulates glycogen synthesis which decreases circulating
glucose; thus cortisol carefully controls circulating glucose levels in the bloodstream.
In the absence of cortisol, glucagon is unable to respond adequately to the hypo-
glycaemic state; therefore, cortisol is critical to boost glucagon and catecholamine
effects. This means that glucagon is the leading cause of glycogenolysis, rather than
cortisol (Silverthorn et al., 2009).
Cortisol has a definite and reproducible circadian rhythm. It was shown in 33
normal individuals that cortisol levels start to rise around 02:00 to 03:00h, and
reach the peak at around 08:30h (approximately 399 nmol/l). Then, cortisol lev-
els decrease to the nadir (< 50 nmol/l), and reach the lowest levels around mid-
night (Debono et al., 2009). In addition to physical and emotional stressors, the
hypothalamus-pituitary axis (HPA) receives inputs from the SCN, which controls
the circadian release of CRH, consequently the release of cortisol from the adrenal
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cortex (Oster et al., 2006). Also, clock genes are expressed in the zona fasciculata,
indicating that cortisol production is transcriptionally regulated by the circadian
clock (Oster et al., 2006).
1.5.9.2 Catecholamines (adrenaline & noradreanline)
Adrenal medullary hormones are intended for rapid response, unlike the cortisol
response which requires several hours. The adrenal medulla has a pool of ready-
made hormones which are synthesized and stored in chromaffin granules allowing
immediate release upon stimulation. The major two hormones are adrenaline and
noradrenaline which are synthesized from tyrosine through tyrosine hydroxylase.
The adrenal medulla produces and releases 80% adrenaline and 20% noradrenaline,
while adrenergic neurons are responsible for the majority of noradrenaline produc-
tion. Adrenaline and noradrenaline are involved in the ”fight or flight” response
mediated by α and β adrenergic receptor. β receptors (β1 and β2) are the pri-
mary receptor for adrenaline which use cAMP as a second messenger, whereas
noradrenaline main receptors are α adrenergic receptors (α1 and α2). α1 receptor
stimulates phosphatidyl inositol hydrolysis, and α2 inhibits adenylyl cyclase. Both
hormones stimulate glycogen breakdown in the liver and skeletal muscles by acti-
vating phosphorylase. Adrenaline increases the activity of fructose-bis-phosphatase,
and decreases phosphofructokinase activity, thus stimulaing gluconeogenesis and
glucose release to the circulation. In adipose tissue, adrenaline and noradrenaline
enhance the activity of HSL which in turn stimulates lipolysis (Silverthorn et al.,
2009; Lieberman et al., 2013).
Adrenaline and noradrenaline also act directly on the pancreas to inhibit insulin
production. This is mediated by α-adrenergic receptors expressed on β-cells. During
chronic stress, adrenaline acts to protect the pancreas from exhaustion by reducing
the necessity for insulin production to compete with the production of the adrenal
medulla (Boron and Boulpaep, 2012). Unlike cortisol, adrenaline acts to increase
the activity of existing enzymes whereas cortisol increases the synthesis of a given
enzyme. For instance, adrenaline increases the activity of HSL, whereas cortisol
stimulates the production of HSL. In muscle, cortisol decreases glucose utilization
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and uptake by the muscles, while adrenaline stimulates glucose use (Silverthorn
et al., 2009; Lieberman et al., 2013). In rodents, administration of exogenous mela-
tonin decreased adrenaline and noradrenaline levels (Annik et al., 1998; Wang et al.,
2001; Girouard et al., 2003), which was also reported in avian species (babbler, bul-
bul and pigeon) (Mahata and De, 1991). However, in young human subjects, 1
or 2 mg of exogenous melatonin decreased plasma levels of noradrenaline but not
adrenaline (Cagnacci et al., 1998; Arangino et al., 1999; Nishiyama et al., 2001).
1.5.9.3 Effects of light and/or melatonin on cortisol
The effects of light seen on cortisol levels have been inconsistent. Acute bright
light exposure before sleep time (20:00 to 02:00h) reduced plasma cortisol levels
compared to room lighting (Kostoglou-Athanassiou et al., 1998). Other studies
reported an increase in plasma cortisol in the morning after the transition from
dim light to bright light (Leproult et al., 2001). Similarly, bright light exposure
compared to continuous darkness during bed rest was reported to elevate saliva
cortisol levels the following morning (Ku¨ller and Wetterberg, 1993; Scheer et al.,
1999). Other studies reported little or no effect of light on cortisol levels in plasma
or saliva samples (Lavoie et al., 2003; Ru¨ger et al., 2006; Cheung et al., 2016). The
principal mechanism for the impact of acute light exposure on cortisol levels are
not entirely understood, however, the discovery of adrenoglomerulotropin in the
pineal extracts of rats suggest melatonin-adrenal interaction (Demisch et al., 1988;
Touitou et al., 1989). The antagonistic relationship between melatonin and the
adrenal was reinforced by experimental and clinical findings which suggested the
possible protective role of melatonin against stress-induced pathologies such as in
gastric ulceration Khan et al. (1990), involution of the thymus (Maestroni et al.,
1988), and age-associated stress induced diseases (Huether, 1996). This assump-
tion was strengthened by the expression of MT1 receptors in the adrenal gland
of primates and rats indicating that melatonin may influence cortisol production.
They also reported that melatonin inhibits ACTH-stimulated cortisol production
by acting on the MT1 receptors (Torres-Farfan et al., 2003). Konakchieva et al.
(1997) reported melatonin reduced the adrenocortical response to stress by altering
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the biosynthesis, release and glucocorticoid response to hypothalamic ACTH secre-
tion (Konakchieva et al., 1997). Also, increased pinealocytes processes, melatonin
forming HIOMT enzyme and pineal endocrine activity were reported in adrenolec-
tomized rats (Deußen-Schmitter et al., 1976).
1.5.10 Appetite hormones: leptin and ghrelin
Leptin and ghrelin have been associated with energy homeostasis. Leptin is se-
creted by white adipose tissues (WAT), whereas ghrelin, a 28-amino-acid peptide,
is secreted by the stomach (Figueiro et al., 2012). Leptin exhibits a strong circa-
dian pattern, with its levels being the highest at night and lowest in the middle of
the day (Dallman et al., 1999; Mastronardi et al., 2000a), irrespective of feeding
time and presence or absence of adrenalectomy in rats (Kalsbeek et al., 2001). In
contrast, ghrelin levels were highest during the daytime and lowest at night (Yildiz
et al., 2004). Ghrelin, an appetite inducer, is expressed at the highest levels before a
meal and at the lowest levels after the meal (Cummings et al., 2004), whereas leptin
inhibits neurons containing NPY agouti-related peptide (AgRP), which stimulates
hunger (Baicy et al., 2007).
1.5.10.1 Leptin physiology
Interestingly, leptin functions as the feedback mechanism on regulatory centres
found in the hypothalamus to inhibit food intake, regulate body weight and energy
homeostasis. Studies in mice and rats indicated that leptin could bind to recep-
tors on the hypothalamus, thus influencing the activity of hypothalamic neurons
and the expression of orexigenic and anorexigenic neuropeptides (Schwartz et al.,
1996; Tscho¨p et al., 2001). Orexigenic peptides include neuropeptide Y (NPY),
agouti-related protein (AgRP) and galanin-like peptide (GALP) (Kumano, 2003),
whereas anorexigenic peptides such as pro-opiomelanocortin (POMC) and CRH are
appetite suppressant (Tritos et al., 1998) (Figure 1.15). The interaction between
orexigenic and anorexigenic peptides suggests the possible action of leptin in the
hypothalamus (Sahu, 2003). Leptin is produced in small amount by the stomach
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suggesting its potential to play a role in the control of meal size in cooperation with
other satiety peptides, thus exerting short-term regulation of food intake (Lewin
and Bado, 2001; Attele et al., 2002) (Figure 1.15).
1.5.10.2 Ghrelin physiology
Ghrelin exerts its actions via three different pathways; 1) by crossing the blood
brain barrier to bind to its receptor in the hypothalamus (Tortorella et al., 2003),
2) reaching the brain through the vagal nerve and tractus solitarus (Ueno et al.,
2005), 3) being produced locally in the hypothalamus (Korbonits et al., 2004).
Ghrelin simulates neurones expressing APY, AgRP and orexin (Kamegai et al.,
2001) and inhibits POMC neurones and CRH-producing neurones (Cowley et al.,
2003) (Figure 1.15). Consequently, ghrelin attenuates leptin-induced reduction in
food intake and enhances appetite. It was also shown that injection of ghrelin
intravenously induces hunger and food intake among healthy and obese humans
(Wren et al., 2001) (Figure 1.15).
Figure 1.15: Impact of leptin and ghrelin on energy balance and food intake
This schematic drawing shows the pathways by which leptin and ghrelin may reach the hypothalamus, to
have an effect on food intake and body weight. Anorexic and orexic effects are the primary targets for
appetite hormones (Klok et al., 2007)
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1.5.10.3 The effects of light and/or melatonin on appetite hormones
Short term bright light treatment has been shown to reduce the frequency and size
of binge eating compared to a dim light control (Remick, 1994; Blouin et al., 1996;
Braun et al., 1999). The significant variation in daily subjective hunger was il-
lustrated with a 17% difference between morning trough and evening peak (Scheer
et al., 2013). This suggests the effects of light exposure on hunger should be studied
at different times of the day. A recent study investigated subjective hunger, leptin
and ghrelin responses in the morning and the evening after blue-enriched light ex-
posure. The study showed no significant differences in hunger, leptin and ghrelin
between blue enriched light and dim light either in the morning or evening, or even
between morning and evening times (Cheung et al., 2016). A limitation of this study
was that sampling occurred when melatonin was not present, which has been linked
to changes in appetite hormones in animal studies. Ablation of the SCN in rats
resulted in the disruption of leptin rhythmicity indicating that the SCN contains
the central circadian clock of leptin gene expression (Kalsbeek et al., 2001). Daily
low-dose melatonin (0.4 g melatonin/ml of water) in middle-aged rats resulted in a
reduction in plasma leptin, visceral fat and non-fasting insulin (Rasmussen et al.,
1999). Also, intraperitoneal melatonin administration in goldfish (Carassius au-
ratus) caused a reduction in plasma leptin, and this effect was reversed by the
administration of a melatonin antagonist (Pinillos et al., 2001), whereas constant
light exposure in mice resulted in an increase in food intake, higher body weight,
and decreased energy expenditure compared to normal light/dark cycle (Mustonen
et al., 2001).
It is known that melatonin regulates the sleep wakefulness rhythm by its actions
on the SCN via MT1 and MT2 receptors (Clarkson et al., 1997). This raises a
question whether a modulation of melatonin levels due to irregular sleep or sleep
debt can alter appetite hormones during chronic or acute sleep restriction (Chaput
et al., 2007; Motivala et al., 2009). These postulations also support the findings of
Spiegel et al. (2004), which indicated that sleep restriction is associated with an
increased sense of hunger. Figueiro et al. (2012) showed that morning light exposure
causes an increase in leptin and a decrease in ghrelin in sleep-restricted individuals;
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however, their study did not measure the melatonin levels, which could explain
the changes in the leptin and ghrelin levels (Figueiro et al., 2012). To summarize,
individuals with short sleep had reduced leptin levels and elevated ghrelin levels
(Taheri et al., 2004), which are likely to increase appetite and explain the increased
body mass index (BMI) observed in subjects with short sleep.
1.6 Light parameters influencing non-visual responses
Many light factors must be considered prior to running clinical studies. These
factors or parameters include wavelength, irradiance, duration, timing and previous
light history.
1.6.1 Wavelength
The majority of NVR such as phase-delay shift (Wright and Lack, 2001; Lockley
et al., 2003), melatonin suppression (Brainard et al., 2001; Thapan et al., 2001),
mood and alertness (Cajochen et al., 2005; Lockley et al., 2006), heart rate and
CBT (Cajochen et al., 2005) and phase-advance shift (Warman et al., 2003; Revell
et al., 2005) are mostly sensitive to short wavelength blue light. In this project, we
utilised broad spectrum light with a wavelength range between 350nm to 750nm
such as light experienced in the work place.
1.6.2 Irradiance
Several mammalian studies have demonstrated that NVRs are an intensity-dependent
response to light (Sharma et al., 1999; Brainard et al., 2001). Human evidence has
also linked the degree of melatonin suppression with the intensity of the light stim-
ulus (Bojkowski et al., 1987; Mclntyre et al., 1989). It should be noted that most of
these studies were conducted in dark or dim light adapted individuals, which cannot
rule out the influence of light history which may sensitise the circadian system (see
section 1.6.4). The light intensity given in this project was > 500 lux during the
light session, and < 5 lux in the dark session.
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1.6.3 Duration
Studies in rodents have indicated that the circadian photoreceptive system sum-
mates the total number of photons over time of exposure, and the sensitivity to the
light exposure during saturation tends to decrease in comparison to the initial light
exposure (Comas et al., 2007). Further human studies investigated the degree of re-
sponse to equal light intensity of different duration of light exposure. For instance, a
single short pulse (0.2h) of bright light (10 000 lux) is more effective at phase delay-
ing the circadian system than a 4 h light exposure of equal intensity (Chang et al.,
2012). These data suggest a non-linear relationship between the magnitude of light
response and the duration of the light stimulus. 12h of light exposure of relatively
fixed intensity was used in this project during both light and dark sessions.
1.6.4 Timing and light history
Light administration in the late biological night results in a phase-advance, whereas
light stimulus in the early biological night causes a phase-delay of melatonin. How-
ever, both nocturnal and diurnal organisms are more responsive to a light stimulus
during the biological night (Duffy and Czeisler, 2009b). Both animal and human ev-
idence has shown that prior light history can alter the NVR. For example, prior light
exposure can decrease the response to a subsequent light pulse; thus the amount
of time spent in darkness prior to the light exposure can determine the magnitude
of the circadian phase shift (Comas et al., 2007). Light history and timing were
controlled in this project during both light and dark session.
1.7 Biological factors influencing non-visual responses to light
In addition to light parameters, biological parameters such as pupil size, age-related
factors, and angle of gaze can affect the degree of light impact. These biological
parameters have been shown to be crucial in affecting non-visual responses to light.
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1.7.1 Pupil size and age
Pupil size in adults (20-29 years) is approximately between 5 to 7 mm (Birren
et al., 1950) when artificially dilated to ensure that all photons in a light pulse
can reach the retina (Gamlin et al., 2007). It has been shown that alteration in
pupil size can modulate the threshold of melatonin suppression induced by light
(Gaddy et al., 1993). Therefore, pupil dilation can ensure maximum responses
under a range of light wavelengths and irradiances, and determine the magnitude
of the photic signal sent to the SCN by regulating retinal illumination (Nissen
and Sander, 2012). A reduction in pupil diameter with age, was responsible for
a twofold decrease in retinal illumination in a 70-year-old eye (Charman, 2003).
In addition, the lens undergoes some changes with ageing such as developing a
yellow pigmentation which lessens the amount of light reaching retina (Lerman,
1987). Brainard et al. (1997) have shown that aged lenses (60-69 year) transmit
significantly less short wavelength 440-540 nm light than lenses from young humans
(20-29 years) (Brainard et al., 1997). Variation in pupil size, and the age range of
lens crystallization of the participants completed this study was between 18 to 30
years.
1.7.2 Angle of gaze
The dynamic nature of the eye such as eye blink, closure and rotation have been
linked to changes in responses to photic stimulus. It was reported by Gaddy (1990)
that corneal illuminance dropped by 60% when subjects rotate 45, and by 80% at 90
from the light source (Gaddy, 1990). This indicates that it is possible to modulate
the light entering the eye by altering the direction of gaze. Light intensity during the
study was measured in both the vertical plane (direction of gaze) and horizontal
plane (facing the light source) to ensure that participants were surrounded with
sufficient amount of light.
1.8 Rationale of Study
Light is involved in many non-image-forming functions that can primarily be clas-
sified into either circadian or acute NIF processes. The majority of animal and
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human studies have established and investigated the role of light in modulating the
circadian system, as well as altering endocrine functions, behavioural and vascular
responses. Acute NIF processes have been investigated in both animals and hu-
mans such as shift-workers (Anjum et al., 2014), diabetic patients (Knutson et al.,
2006) or participants with psychological disorders (Baxendale et al., 2013). Most
of these studies involved in vivo or in vitro tissues, or strict laboratory condition
such as constant routine, simulated shift work, administration of exogenous mela-
tonin, specific wavelength light, or continuous bright light exposure. Many of the
results obtained from animal studies or clinical studies were contradictory. The
majority of these studies linked the observed changes to the action of melatonin,
since melatonin receptors are widely distributed in the body tissues. To the authors
knowledge, no previous study has been performed to assess the impact of light at
night (bright broad spectrum light) and/or both endogenous and exogenous mela-
tonin on behavioural responses, appetite responses, vascular function and metabolic
responses.
A pilot study was conducted as part of MSc project to investigate the effect
of endogenous melatonin on vascular function , hormone and metabolic responses.
This pilot study had two clinical sessions (bright light ¿ 100 lux, and dim light ¡ 5
lux) between 18:00h to 02:00h the next day. No significant changes were reported
in hormones, metabolites and vascular function, however a trend toward significant
increases of plasma NEFA and salivary melatonin were reported in dim light session.
The major limitation of the pilot study was the light intensity used in the bright
light session, and the duration of the clinical session which was too short to observe
the complete postprandial lipid and endogenous melatonin responses. Therefore, a
new clinical study was designed to be conducted during the PhD.
This PhD project was divided into two major studies. Study 1 focused on
the impact of light at night and endogenous melatonin by exposing 17 healthy
participants (male and females) into two light conditions: light (> 500 lux) and
dark (< 5 lux). The melatonin onset of each participant was determined as a part
of the screening protocol; the evening test meal was given as melatonin levels were
rising to investigate the effect of endogenous melatonin on postprandial hormones
and metabolite responses, as well as changes in behavioural responses and vascular
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function. During the pre-prandial period, melatonin levels would be low; thus any
changes seen would be mainly due to light.
Study 2 was mainly designed to investigate the changes obtained in subjective
behaviours, as well as reduced glucose tolerance and insulin insensitivity during light
session. Study 1 could not elucidate whether the absence of endogenous melatonin or
the presence of bright light caused these observations. Therefore, administration of
slow release exogenous melatonin (Circadin 2 mg) was the ideal solution to elucidate
the previous changes. In Study 2, male participants (n = 9) were exposed to three
conditions: light (> 500 lux), light (> 500 lux) + exogenous melatonin, and dark
(< 5 lux) + exogenous melatonin. This will illustrate whether melatonin is the key
factor behind changes seen in Study 1.
1.9 Aim and hypothesis
The PhD project focuses on three major areas: hormones and metabolic responses,
appetite control, vascular function, and behavioural responses to melatonin and/or
light at night. Firstly, hormone and metabolic investigation were preprandial and
postprandial hormones and metabolites such as glucose, insulin, NEFAs, TAGs, cor-
tisol, leptin and melatonin. Arterial stiffness parameters (mainly PWV), heart rate,
blood pressures, peripheral body temperature and other vascular parameters were
studied to determine vascular function. Lastly, behavioural responses, parameters
such as sleepiness, alertness, mood, and activity were investigated.
The general aim of the studies is to investigate the impact of light at night and/or
melatonin on hormone and metabolic responses, appetite control, vascular function,
and behavioural responses, prior to and after an evening test meal in healthy young
subjects.
The main objectives of this PhD project was to assess the effect of LAN on:
• Hormones and metabolites such as melatonin, glucose, insulin, NEFAs, TAGs
and leptin.
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• Vascular function parameters such arterial stiffness (PWV, augmentation in-
dex and peripheral augmentation index) and heart rate and blood pressure.
• Subjective behavioural responses, such as mood and alertness, using subjective
questionnaires.
• Appetite parameters such as subjective hunger, desire to eat and fullness
rating, and plasma leptin.
• Peripheral temperature and activity levels.
The working hypothesis of the current studies were:
Hypothesis 1: Light at night via the action of melatonin alters hormones and
metabolic responses, vascular function and behavioural responses prior to and after
an evening test meal in healthy young participants.
Hypothesis 2: Melatonin alters behavioural responses, hormones and metabolites
prior and after an evening test meal in healthy male participants.
We hypothesise that LAN:
• LAN reduces glucose tolerance and insulin sensitivity.
• LAN increases circulating plasma lipid profiles such as NEFAs and TAGs.
• LAN improves mood and alertness, by increasing the mood (cheerfulness,
elation and calmness) and alertness score.
• LAN increases the arterial stiffness score, and blood pressure.
• LAN increases activity levels and decreases peripheral temperature.
• LAN increases the subjective appetite scores, and decreases leptin levels.
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CHAPTER 2
STUDY SESSIONS
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Introduction
This chapter details the recruitment of participants and procedures involved in the
laboratory sessions carried out in this PhD project. This involved running two clin-
ical studies: Study 1:- The impact of light at night on hormones, metabolites, ap-
petite control, vascular function, and behavioural responses. Study 2:- The impact
of light at night and/or exogenous melatonin on hormones, metabolites, appetite
control, and behavioural responses. Both studies had similar protocol with a few
alterations, removes and additions in the second study.
2.1 Ethical approval
The University of Surrey Ethics committee gave a favourable ethical opinion for
all aspects of the two studies (Study 1 EC/2013/93/FHMS; Appendix-A, Study 2
UEC/2015/021/FHMS; Appendix-B). All participants gave signed written consent
prior to each study stating that they agreed to all assessments and were aware of
any potential risks and possible discomfort of the studies. Participants had the
right to withdraw from the study at any time without stating a reason. Random
numbers were allocated to all participants coded alphanumerically (e.g S005) to en-
sure confidentiality. Participants were reimbursed for their time and inconvenience
after completing Study 1 and Study 2, those who did not complete the study re-
ceived payment pro rata. All participants data were coded and held in the strictest
confidence in compliance with the Data Protection Act (1998).
2.2 Recruitment
Both studies were advertised via University email (surrey 365), posters and the
Gumtree website (Appendix-C (Study 1) & D (Study 2)). All participants were
students at the University of Surrey. Strict inclusion and exclusion criteria were
applied during recruitment. Participants who were eligible to take part in the study
were provided with the study participant information sheet (Study 1 - Appendix-E
and Study 2 - Appendix-F).
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The inclusion criteria were as follows:
• Aged between 18-60 years
• BMI between 18.5-28.0 kg/m2
• Maintenance of selected regular sleep–wake cycle
• Sleep duration between 6.5 and 8.0 hours
• Must refrain from alcohol, caffeine, heavy exercise and carbonated drinks 24
hours before each session
• All females were on contraceptive pill.
The exclusion criteria were as follows:
• Confirmed or possible pregnancy
• Familial or personal history of psychiatric disorders
• History of infectious conditions
• History of drug or alcohol abuse.
• History of taking any medication other than minor analgesics within 2 weeks
prior to the study
• Participation in any experimental drug trial within the last 3 months before
the start of the study
• Donation of blood within the last 3 months before the start of the study.
Participants who met the inclusion and exclusion criteria were required to at-
tend an induction session where the study protocol and experimental design were
explained to them. All participants received an oral and written explanation of the
study requirements and design. The participants were also given an opportunity
to ask questions before providing written informed consent. If participants were
interested, they were asked to complete screening procedures to determine their
eligibility to take part. Verbal and written consent for participation was obtained
from each participant (Appendix-G (Study 1) & H (Study 2)).
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2.3 Study 1
All procedures performed in Study 1 including screening session and study session
will be discussed in the following sections. This section illustrate the procedures
followed during screening session, and sample and data collection during the study
1.
2.3.1 Screening session
Volunteers were asked to fill out the pre-study general health questionnaire (Appendix-
I) to assess their medical history, daily and weekly consumption of caffeine, carbon-
ated drinks as well as alcohol. Females were asked to provide details about their
menstrual cycle and type of oral contraception. Only females taking oral contracep-
tive were accepted. Volunteers were also asked to complete a Horne-O¨stberg (HO¨)
questionnaire (Appendix-J), this questionnaire was used to determine whether they
were morning or evening chronotype of individuals (Horne and O¨stberg, 1975).
Other questionnaires were completed as follows:- the Pittsburgh sleep quality in-
dex (PSQI) (Appendix-K) to assess sleep quality and disturbances over a 1-month
time preceding the session (Buysse et al., 1989), and Munich chronotype question-
naire (MCTQ) (Appendix-L) to assess the sleep schedule during work days and free
days (Roenneberg et al., 2003). Volunteers wore Actiwatches and iButtons for two
weeks prior to the study, as well as completing a daily sleep diary (Appendix-M).
According to the Actiwatch analysis results, those who did not maintain a regular
sleep-wake cycle were excluded.
2.3.2 Urine analysis
All selected participants were asked to carry out a 48-hour sequential urine col-
lection prior to the initial clinical study in order to estimate individual melatonin
onset, amplitude and acrophase of melatonin synthesis and secretion. This was to
determine that each participant had a measurable amount of melatonin and to en-
sure it would be present when eating the late evening meal. The major melatonin
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metabolite in urine, 6-Sulphatoxymelatonin (aMT6s) was measured by radioim-
munoassay and the evening meal time for each participant was determined from
this data. Participants were provided with an instruction sheet for urine collection
(Appendix-N). They were asked to provide a sequential 48-hour urine collection,
record time of collection, period of collection, volume and transfer a small urine
sample of each time collected into small tubes. Urine aMT6s data underwent a
computerised cosinor analysis, using a program developed by Dr D S Minors at
the University of Manchester, UK, to ascertain calculated peak times of melatonin
secretion (acrophase). From this the onset of melatonin secretion was estimated.
2.3.3 Oral contraception
Only females taking oral contraceptive were recruited in Study 1. Females were not
allowed to join the study session during their menses phase. Menstrual phase and
contraceptive pill details were collected (Table 2.1). Females had to be in the same
menstrual period in both sessions.
Table 2.1: Contraceptive pill and menstrual phase
Participant Contraceptive pill DS* LS*
S003 Nigenda 6 12
S010 Selene 12 8
S011 Microgynon 1 7
S013 Microgynon 14 12
S014 Millinette 12 6
S016 Millinette 7 14
S017 Co-cyprindiol 9 16
S018 Atywia 2 5
*Pill number reported by each participants during LS and DS. All reported pills were combined contraceptive
2.3.4 Meal distribution
Participants consumed isocaloric and noncarbonated meals as shown in Table 2.2.
A set breakfast was provided at 08:00h, whereas lunch and the evening test meal
”supper” were individualised on the basis of the acrophase time of urinary aMT6s.
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The average fasting period between lunch and evening test meal was 9-10 hours.
Further details about the macronutrients in each meal are shown in Appendix-O.
The plasma melatonin acrophase is known to occur approximately one hour
prior to urinary 6-sulphatoxymelatonin acrophase with melatonin onset occurring 4
hours earlier. The evening test meal time was allocated at 30 mins after estimated
melatonin onset, with lunch time 9 to 10 hours earlier.
The following calculations were used to determine meal timing for each partici-
pant:
Plasma acrophase = Urinary acrophase - 1(h) DLMO = Plasma Acrophase - 4(h)
Supper time = DLMO + 30(mins) Lunch Time = Supper time - 10(h)
Table 2.2: Carbohydrate, protein, fat, fibre and energy for each of the meals and
overall composition of all three meals
Meal/g Energy Kcal Protein (g) CHO (g) Fat (g) Fibre (g)
Breakfast 627 15 98 16 14
Lunch 927 25 115 38 19
Test meal”Supper” 1066 38 104 54 7
Total 2620 78 317 105 40
% composition* 15% 59% 19% 7%
*Percentages were calculated proportionally from the total daily consumption
2.3.5 Study session
All participants arrived at 08:00h and were given breakfast in the clinical investiga-
tion unit (CIU), after which they could leave, returning at lunch time. After lunch,
participants were not allowed to leave and remained in the CIU until the end of
the study session. They were not allowed to have visitors, but they were allowed to
know clock time and to make phone calls, watch television, listen to music, read or
use their laptop except during Vicorder tests. Participants were also not allowed to
eat or drink except water between breakfast, lunch and the evening test meal.
The investigation was designed as a randomised crossover study. For Study 1,
each participant attended the CIU for two sessions: dark session (DS) (< 5 lux)
and light session (LS) (> 500 lux), with an interval of at least 7 days between each
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session. Participants were randomised to group A or B. Group A underwent the
light session first followed by the dark session, while Group B completed the sessions
in the reverse order. Figure 2.1 shows the protocol for Study 1.
Body posture and movement were strictly controlled throughout the study. All
participants were asked to remain in a semi-recumbent position (the bed at approx-
imately 45◦). During sampling, Vicorder readings and mood and alertness or food
VAS questionnaire collection, participants were not allowed to get out of bed.
Physical activity was restricted during blood and saliva sampling which was
performed in a semi-recumbent position on a hospital bed. Studies have shown that
saliva and plasma samples can be influenced by changes in body posture (Fawcett
and Wynn, 1960; Deacon and Arendt, 1994; Kozaki et al., 2013), therefore partici-
pants were allowed to use the toilet immediately after a sample collection but were
required to return to a semi-recumbent position at least 15 min before the next
sample collection.
This meant that participants were in bed all the time except when using the
bathroom. This was to ensure that body movement and energy expenditure were
similar for all participants during the study sessions.
2.3.5.1 Saliva samples
Saliva samples were collected into Mini-scintillation vials (Fisher Scientific UK Ltd)
every 30 minutes from 18:00 h to 06:00 h the next day. In total, 25 saliva samples
were collected in each session from each participant. The saliva samples were stored
at -20 ◦C used to measure melatonin levels.
2.3.5.2 Plasma samples
At 17:30 h, an indwelling cannula was inserted by a trained doctor or nurse, and
blood samples were collected every 60 minute from 18:00 h until the evening test
meal time. After test meal, blood samples were collected every 15 minutes for the
first hour, then at 30 minute intervals until the end of the session. In total, 22 blood
samples were collected in each session from each participant. Blood samples were
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collected to investigate blood metabolites and hormones; glucose, leptin, insulin,
cortisol, triglycerides (TAGs) and non-esterified fatty acids (NEFAs).
Each blood sample (8 ml) was collected into 3 different collection tubes. 1 ml
fluoride oxalate tubes (Teklab Ltd., Sarcriston, UK) for glucose, 3ml tripotassium
EDTA tubes (Teklab Ltd.) for TAG and NEFA, and 8 ml lithium heparin tubes
(Teklab Ltd.) for leptin, insulin and cortisol. The tubes were centrifuged at 1750 g,
4 ◦C for 10 min and the resulting supernatant aliquoted into 1 ml microcentrifuge
tubes (Apex® plus, Alpha Laboratories Ltd., Eastleigh, UK) and stored at -20
◦C until analysis. Directly after each blood sample the cannula was flushed with
0.9% w/v sterile sodium chloride (MacoPharma Ltd., Twickenham, UK) to keep
the cannula patent.
2.3.5.3 Blood RNA analysis
Blood samples were collected in four PAXgene Blood RNA System tubes at 270
and 150 minutes before the estimated test meal time and 120 and 240 minutes after
the test meal time. These samples were collected for genomic analysis.
2.3.5.4 Vicorder
Vascular function tests were conducted at 285 minutes and 120 minutes prior to
evening test meal time and at 30 minutes and 90 minutes after finishing the test
meal. Vascular function tests including pulse-wave velocity (PWV) and pulse-wave
analysis (PWA) were measured by using a Vicorder® (SMT medical, Germany).
Other parameters were measured such as heart rate, systolic and diastolic pressure,
aortic blood pressure, aortic pulse pressure, peripheral augmentation index, aug-
mentation index, cardiac output and mean arterial pressure. Triple readings were
conducted at each time point to ensure reproducibility.
2.3.5.5 Peripheral body temperature
Participants wore an iButton RTC (real time clock), which is small device attached
to a wrist strap. The iButton was in direct contact with inner wrist skin. The
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iButton RTC (Maxim Integrated, USA) was used to provide information in the
real-time clock/calendar binary format with a high clock accuracy of greater than
±2 minutes per month at 25 ◦C, with an operating temperature range from -40◦C
to +85◦C. Participants wore the iButton during the clinical sessions from 18:00h
to 06:00h the next day. The iButtons recorded peripheral temperature every 200
seconds.
2.3.5.6 Continuous Glucose Monitoring (CGM)
Continuous glucose monitoring (CGM) (Medtronic Ltd, Watford, UK) system was
used to measure the interstitial glucose response. It has a tiny sensor (eyelash size)
that was inserted under the skin in the abdominal area at 16:00 h and removed at
the end of the session. CGM recorded glucose levels every 5 minutes from 18:00h
to 06:00h the next day.
2.3.5.7 Visual analogue scale VAS PRO-Diary®
The score of the visual analogue scales for appetite were recorded using a PRO-
Diary® (CamNtech Ltd, Cambridge, UK). A Pro-Diary® is small electronic device
that is loaded with the food VAS questionnaire (Appendix-P). Participants com-
pleted the food VAS questionnaire 15 minutes before the evening test meal, every
15 minutes after the supper for 3 readings and at 30 minutes intervals thereafter
until 13 readings were obtained.
2.3.5.8 Mood and alertness questionnaire
Mood and alertness questionnaires (Appendix-Q) were completed at the same time
as saliva samples, every 30 minutes during the study session. This questionnaire
assessed the mood and alertness of the participants at different time intervals.
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2.4 Study 2
Study 2 was designed to elucidate the results obtained from Study 1. Study 2 fo-
cused on the impact of light at night and/or exogenous melatonin on hormones,
metabolites, appetite control, and behavioural responses, therefore vascular func-
tion tests were not included. The same procedures were applied in Study 2 for
urine analysis (see section 2.3.2), meal distribution (section 2.3.4), saliva samples
(section 2.3.5.1), plasma samples (section 2.3.5.2), peripheral body temperature
(section 2.3.5.5), VAS PRO-Diary®, and mood and alertness questionnaires (sec-
tion 2.3.5.8). Alterations and additions applied in Study 2 will be addressed in the
following sections except for Vicorder and CGM which were not included in Study
2.
2.4.1 Recruitment
Participant selection followed similar screening procedures as for Study 1 (see section
2.2), except in this study only males were recruited.
2.4.2 Screening blood
Screening blood samples for haematological tests were collected prior to Study 2.
Blood samples were collected in potassium EDTA (K2EDTA) for complete blood
count to ensure that all selected participants had haemoglobin levels within the
normal range.
2.4.3 Circadin intake
Circadin, prolonged release melatonin (Neurim Pharmaceuticals Ltd), containing
2 mg melatonin was used in Study 2 and is available on prescription. Circadin
is chemically manufactured from 5-methoxytryptamine with excipients used in the
formulation such as ammonio methacylate copolymer Type B, calcium hydrogen
phosphate dehydrate, lactose monohydrate, colloidal anhydrous silica, talcum and
magnesium stearate. It was developed to ensure an 8-10 hour period of elevated
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melatonin levels. According to an assessment report for Circadin published by the
European Medicine Agency (EMA 2007), Circadin 2 mg oral administration results
in Tmax occurring after 1.6 hours, with a 5.1 h plateau time during a fasting period.
Therefore, in Study 2 Circadin was administrated orally 90 mins prior to the evening
test meal, to ensure elevated melatonin levels until the end of the session.
2.4.4 Study session
For Study 2, participants were required to attend three sessions: light session (LS)
(>500 lux), light + Circadin session (LSC) (> 500 lux) and dark + Circadin session
(DSC) (< 5 lux), with an interval of at least 7 days between each session. Partic-
ipants were randomised to group A or B. Group A underwent LS first followed
by DSC and then LSC session, while group B started with LSC session followed
by DSC session and then LS (Randomisation procedure is shown in appendices R
and S). The data were statistically assessed for sequencing effects. Study protocol
procedures are shown in Figure 2.2.
2.4.4.1 Visual analogue scale VAS PRO-Diary®
In Study 2, food VAS questionnaires were completed every 30 minutes prior to the
evening test meal, every 15 minutes after the test meal for 3 readings and then at
30 minutes intervals until the end of the session.
2.5 Facilities
The study was carried out in the Clinical Investigation Unit (CIU) at the University
of Surrey, Guildford, UK. The CIU is equipped with all facilities such as commu-
nication (telephone and internet), sleeping and toilet/shower as well as being light
and temperature controlled. The three daily meals in both studies were consumed
in the CIU. Participants were fully supervised by the medical/nursing staff and
research investigators throughout the clinical studies.
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2.5.1 Light intensity measurements
Light levels in the dark session was < 5 lux, whereas the light session was > 500 lux.
Light intensity was measured at vertical plane (in direction of gaze) and horizontal
plane (facing the light source) to ensure that participants were surrounded with
a sufficient amount of light. Light measurements for each participant were taken
at semi-recumbent position during the beginning of the session (18:00h), middle
(midnight) and at the end of each experimental session (04:00h) to make sure that
the light intensity remained constant. The light intensity was also measured in
the toilet and corridor to make sure that participants obtained the right intensity
throughout the clinical unit. Lighting levels were controlled electronically with each
light fitment adjusted independently and the settings saved to ensure all sessions
were identical. Table 2.3 shows the light intensity data collected from 11 sessions
(4 DS, 7 LS, 3 LSC, and 3 DSC) and 3 observations (triplicate readings) on each
participant in each session. In total, there were 612 observations in each light
condition in Study 1, and 243 observations in Study 2. Irradiance was measured in
W/m2 using R203 power meter as shown in Table 2.4.
Table 2.3: Light intensity in lux during dark and light sessions
Study Condition Vertical plane Horizontal plane
Study 1
DS (n = 612) 1.06 ± 0.06 1.21 ± 0.13
LS (n = 612) 305 ± 10.1 552.7 ± 16
Study 2
LS (n = 243) 342 ± 12.2 563 ± 12
DSC (n = 243) 1.02 ± 0.1 1.32 ± 0.2
LSC (n =243) 350 ± 10.5 548 ± 10
Data are presented as mean and standard error of mean
Table 2.4: Light intensity in W/m2 during dark and light sessions
Device Condition Vertical plane Horizontal plane
Power meter
LS 0.73 w/m2 0.981 w/m2
DS 0.0008 w/m2 0.0012 w/m2
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2.5.2 Spectral light composition
The light source for both studies was fluorescent light and LED (light emitting
diode) during the light session and only LED during dark sessions. The lighting
used in both studies was polychromatic as shown in Figure 2.3 and Figure 2.4.
Further details about the spectral composition of both sessions are provided below:
Figure 2.3: Spectral composition of fluorescent light
Figure 2.4: Spectral composition of LED
This chapter discussed the recruitments and the procedures of clinical sessions to
collect the samples from the participants. The data collected from Study 1 were
analysed first, then Study 2. Laboratory techniques and statistical analyses applied
in this project will be addressed in the following chapter.
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CHAPTER 3
MATERIALS & EXPERIMENTAL
METHODS
83
Introduction
This chapter covers the laboratory techniques used to analyse hormones and metabo-
lites after the completion of clinical studies (Study 1 and Study 2). The major
laboratory techniques used in this PhD project were radioimmunoassay and spec-
trophotometry. Also, data analyses of wrist temperature, Vicorder, food VAS,
CGM, mood and alertness will be illustrated in this chapter. This chapter will also
discuss the general statistical tests applied to analyse the data.
3.1 Radioimmunoassay technique
Radioimmunoassay (RIA) is a very sensitive in vitro assay methodology used to
measure antigen levels (such as hormones; insulin, melatonin, leptin and cortisol)
using specific antibodies. It is based on the use of a radiolabelled antigen and spe-
cific antibody utilising the immunochemical antigen-antibody reaction. A sample
containing unknown amount of antigen is incubated with a fixed amount of anti-
serum specific to the antigen and a fixed amount of radio-labelled antigen. This
results in a competitive reaction between labelled (Ag∗) and unlabelled antigen (Ag)
for the limited number of antibody (Ab) binding sites. Once equilibrium is reached,
the ratio of the free (F) and antibody bound (B) fractions of the antigen will be a
constant (K) described by the law of mass action [AgAb = K (Ag) (Ab)]. After an
incubation period the free and bound antigens are separated using either a specific
second antibody or non-specific separation such as dextran-coated charcoal, which
will remove the unbound antigens but not the larger antigen-antibody complex.
Prior to testing unknown samples, a series of standard solutions of known antigen
concentration is plotted, and then the radioactivity of free or bound antigen is mea-
sured and compared against the standard curve. Consequently, the concentration
of the antigen in the samples can be determined by extrapolation (Bartalena et al.,
2012).
RIA can measure hormones in a variety of body fluids such as serum, plasma,
urine and saliva. All tubes were run in duplicate to ensure reliability. A standard
was prepared fresh for each set of samples, and were prepared in an antigen-free
matrix to minimise the presence of any substances in samples that can interfere with
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the binding. For instance, for urine 6-sulphatoxymelatonin RIA the standards were
made up in aMT6s-free urine. Standards that are used in RIA should be stable,
available in large quantities, and should be highly purified. The zero point on the
standard curve is set up in quadruplicate as this is the anchor point for the whole
standard curve and must be as reliable as possible. It also allows calculation of limit
of detection for each assay (see section 3.1.1).
All samples from each participant in each study were run in duplicate and on
the same day using the same reagents. Thus, all the samples from one participant
(n = 50 in Study 1 and n = 75 in Study 2) were analysed in one assay to allow
direct comparison of the analyte values at each time point and to minimise assay
variability.
3.1.1 Radioimmumoassay accuracy and sensitivity
Quality control (QC) tubes were treated in a similar manner as the biological sam-
ples. QC samples were run in duplicate and included in all assays. This is essential
to ensure reproducibility and to reduce the so called grey area between definite
abnormal values and values which are normal. The QC samples contain known
concentrations of the antigen, in the matrix being measured, and a range of QCs
(low, medium and high) were used to cover the range of the standard curve. QC
samples were run in duplicate at the start, middle and the end of the samples to
be measured. This determined the inter-assay and intra-assay variation (Coefficient
of variation (CV)) which expresses the precision, and reproducibility of each assay.
Comparison of the QC values placed at different positions in the assay assesses the
presence of assay drift. However, comparison of QC values between assays (Inter-
assay CV) monitors the precision of entire clinical study samples. Inter-assay CV%
of less than 15 are generally acceptable, and intra-assay CV% should be less than
10 (Taylor and Harris, 2014).
Intra-assay Coefficient (CV %) was calculated as follows:
Intra− assay Coefficient = QCs SD
QCs mean
X100
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Inter-assay Coefficient was calculated as an expression of consistency between
different assays, as follows:
Inter − assay Coefficient = Mean of QCs SD
Mean of QCs mean
X100
To monitor the accuracy of the RIA, total count tubes which contain only ra-
diolabel was not decanted in the separation stage. Total count tubes gives the
amount of radioactivity added per tube allowing calculation of maximum binding
(zero standard).
Non-specific binding tube (NSB) containing buffer, tracer, and precipitating
reagent, but not antibody, yield the lowest cpm (or highest if counting free as in
aMT6s) in the assay. The percentage of NSB must be as low as possible (< 10%)
for high quality assay, as it indicates if binding are not due to antibody. NSB is
calculated as follows:
NSB =
Total cpm−NSB cpm
Total cpm
X100
The 0 ng/ml standards that contain tracer, buffer, antibody but not antigen
indicates the maximum tracer binding in the presence of antibody. The maximum
binding is calculated as follows:
Maximum binding =
Total cpm− Zero binding cpm
Total cpm
X100
The limit of detection (LOD) was also calculated to determine the sensitivity
(i.e. the minimum concentration that could be accurately detected) in each assay.
The following steps were used to calculate the limit of detection (e.g. urinary RIA):
• Mean cpm of 0 ng/ml standards.
• Standard deviation (SD) of cpm of 0 ng/ml standards.
• Calculate 2 x SD of 0 ng/ml.
• Calculate cpm limit of detection = mean (0 ng/ml) + 2 x SD (0 ng/ml)
• Calculate m (counts per ng) = (mean of 0.5 ng/ml standard - mean 0 ng/ml
cpm) / 0.5.
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• LOD = (mean cpm 0 ng/ml cpm LOD) / m
3.1.2 RIA of urinary 6-sulphatoxymelatonin (aMT6s)
The major metabolite of melatonin, 6-sulphatoxymelatonin (aMT6s), was measured
in urine samples from both clinical studies using RIA described by Arendt et al.,
(1985) and modified by Aldhous and Arendt (1988) (Arendt et al., 1985; Aldhous
and Arendt, 1988). This in-house assay uses iodinated aMT6s and a dextran-
charcoal separation system to precipitate unbound aMT6s fraction with the charcoal
pellet counted in a gamma counter.
Table 3.1: Radioimmunoassay aMT6s standards
aMT6s standard 200 pg/ml (µl) aMT6s-free urine 1:250 dilution (µl) aMT6s concentration (ng/ml)
0 500 0
5 495 0.5
10 490 1
20 480 2
40 460 4
70 430 7
100 400 10
200 300 20
500 0 50
The standard curve, made up by diluting the top standard 50 ng/ml in charcoal-
stripped urine (1:250 in tricine buffer, pH 5.5), was set up in duplicate with a total
volume of 500l in standard assay tubes. The concentrations of standard tubes were:
0, 0.5, 1, 2, 4, 7, 10, 20, and 50 ng/ml (Table 3.1). The NSB tubes contained 500l
charcoal stripped urine, 200 µl tricine buffer (700 µl) and iodinated aMT6s, whereas
total tubes contained only iodinated aMT6s. The urine and QC samples were
diluted 1:250 with tricine buffer using an automatic diluter (Hamilton Microlab,
USA).
Fresh working antiserum solution (200 µl) was added to all assay tubes except
total and NSB tubes. The antiserum was prepared by adding 100 µl of sheep-aMT6s
antiserum to 20ml of tricine buffer sufficient for 100 assay tubes. The tubes were
then vortexed and incubated at room temperature for 30 minutes. After 30 minutes,
a fresh working solution of iodinated aMT6s was prepared by diluting 30 µl of stock
radiolabel to 10ml of tricine buffer which was sufficient for 100 assay tubes. The
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diluted iodinated aMT6s (100 µl) was then added to all assay tubes, vortexed and
left to incubate at 4◦C for 18 hours.
The antibody-bound aMT6s fraction was separated from the free fraction by
adding 100 µl of dextran-coated charcoal to all tubes, except totals, and incubating
the tubes for 15 minutes at 4◦C. The tubes were then centrifuged at 3500 rpm
(revolutions per minute) for 15 minutes, and the supernatant was decanted and
discarded. The unbound aMT6s fraction in the charcoal pellet was counted in a
gamma counter, and the aMT6s concentration in the urine samples was determined
from the dose response curve and automated software Multi-Calc (Perkin Elmer,
Wizard Gamma Counter, UK). The summary of assay procedure is shown in Table
3.2.
Preparation of reagents
• All water used was reverse osmosis water (RO).
• Tricine buffer (product no T0377, Sigma Chemical Co. Ltd., Poole, Dorset).
Tricine was made up at 0.1 M with 0.9% NaCl (code no. S9625-500G, Sigma-
Aldrich Co. LLC., Germany) and 0.1% gelatine (code no. G/0150153, Fisher
Scientific, UK). Gelatine was dissolved in the buffer by stirring on a hot plate
for 30 mins. All buffers are stored at 4◦C and made up fresh weekly.
• Antiserum: Sheep antiserum (code no. G/S/118-23884, Stockgrand Ltd.,
University of Surrey, UK). Supplied freeze-dried and reconstituted with 1 ml
of RO water and 9 ml of tricine buffer providing an intermediate dilution of
1:100. 100µl aliquots were further diluted up to 20 ml (1:200) with tricine
buffer providing enough antiserum for 100 tubes.
• Radiolabelled antigen: 125I-aMT6s (Stockgrand Ltd., University of Surrey,
UK) was made up fresh for each assay by diluting 125I-aMT6s with tricine
buffer to give approximately 8000-10000 cpm per 100µl.
• Charcoal stripped urine: supplied in freeze-dried 100 µl aliquots and reconsti-
tuted with 25ml (1:250) of tricine buffer.
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3.1.3 Salivary melatonin
The melatonin concentrations of saliva were measured using a direct RIA modified
from Vakkuri et al. (1984) (Vakkuri et al., 1984). The standard curve, made up
freshly for each assay, was set up in duplicate with a total volume of 500 µl in each
tubes, with further dilution of assay buffer (tricine pH 8.0) to provide a series of
standard concentrations: 0, 1, 2, 4, 10, 20, 50, 100, 200pg/ml (Table 3.3). The NSB
tubes contained 600 µl of tricine buffer, whereas total tubes contained iodinated
melatonin only.
Table 3.3: Radioimmunoassay melatonin standards
MT standard 0.2 ng/ml(µl) Assay buffer (µl) Saliva MT concentration (pg/ml)
0 500 0
2.5 497.5 1
5 495 2
10 490 4
25 475 10
50 450 20
125 375 50
250 250 100
500 0 200
All saliva samples were run in duplicate and 500µl saliva were added to assay
tubes. Similarly, 500µl of prepared QCs (low, medium and high) were run in du-
plicate at the start and the end of each assay. Additional assay buffer was added
to saliva tubes when sample size was limited so that the volume was equivalent to
500µl in all sample tubes.
A fresh working rabbit melatonin antiserum was prepared by diluting 150 µl
aliquot to 15ml with assay buffer for 150 assay tubes. Antiserum solution (100µl)
was added to all assay tubes except total and NSB tubes. The tubes were then
vortexed and incubated at room temperature for 30 minutes.
100 µl of a working dilution 125I-melatonin (4µl of stock to 10ml = 100 assay
tubes) was added to all tubes. Then, all assay tubes were vortexed and incubated
at 4◦C for 15-18 hours (see Table 3.5).
After 18 hours the antibody bound melatonin fraction was separated from the
free melatonin fraction by adding 100 µl of a solid phase second antibody to rabbit
IgG to all assay tubes except total tubes. All samples were vortexed and incubated
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for 1h at room temperature with intermittent mixing (every 15mins). Then, 1ml
Brij/saline wash was added and assay tubes were centrifuged at 3000 rpm for 15
mins. Immediately after centrifugation, all assay tubes except total were decanted
and their supernatants were discarded. The remaining pellets were counted using
gamma radiation counter, and the melatonin concentration were determined from
the dose response curv, and automated software ”Multi-Calc” (Perkin Elmer, Wiz-
ard Gamma Counter, UK). The summary of assay procedure is shown in Table
3.5.
Preparation of reagents
• All water used was reverse osmosis water (RO).
• Tricine buffer (product no T0377, Sigma Chemical Co. Ltd., Poole, Dorset)
is made up at 0.1M, pH 8.0 with 0.9% NaCl (code no. S9625-500G, Sigma-
Aldrich Co. LLC., Germany) and 0.2% gelatin (code no. G/0150153, Fisher
Scientific, UK). This is prepared by dissolving 17.9g tricine, 9.0g NaCl and
2.0g gelatin at 1L of RO, and then heated at 50◦C for 30min to dissolve the
gelatin. The pH 8.0 was achieved by adding certain amount of 1M NaOH. All
buffers are stored at 4◦C and made up fresh weekly.
• Rabbit anti-melatonin antiserum (code no. R/R19540-16876, Stockgrand
Ltd., University of Surrey, UK) is supplied freeze dried. The contents of
vial (133µl) are reconstituted with 2ml RO water and 150µl aliquots stored
at -20◦C. The working dilution for 150µl assay tubes is prepared by diluting a
150l aliquot to 15ml assay buffer. These working dilution are prepared fresh
daily. Brij® /saline wash solution is prepared by dissolving 9g NaCl in 998ml
RO water and adding 2ml Brij® 35 (code no. B4184-1L, Sigma-Aldrich Co.
LLC., USA).
• Standards melatonin (product no. M5250, Sigma-Aldrich Ltd, Dorset, UK)
solution is made up at 1mg/ml by dissolving 10mg melatonin in 0.5ml absolute
ethanol and adjusting the volume to 10ml with DGDW. The daily working
standards are prepared from this ethanolic stock as follow: 100µl of 1mg/ml
to 100ml in DGDW to make 1µg/ml, then 500µl (1µg/ml) to 50 ml to make
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10ng/ml, and 50µl (10ng/ml) to 2.5ml in assay buffer to give MT standard
0.2ng/ml.
• Solid phase separation system (code no AA-SAC1, IDS, Ltd., UK): solid phase
2nd antibody raised against rabbit IgG stored at 2-8◦C. It contains preserva-
tive sodium azide 0.09%, 200ml is sufficient for 2000 tests.
3.1.4 Plasma leptin
The plasma leptin concentrations were assayed using human leptin RIA kits supplied
by Millipore Company (Billerica, MA, USA). In this assay 125I-labeled human leptin
and human leptin antiserum were utilized to determine the level of leptin in plasma
by the double antibody/PEG separation technique.
The standards vials (100ng/ml) provided by Millipore were ready to use, however
further serial dilutions were performed to complete a range of standard concentra-
tions consisting of 7 tubes. 1.0ml of assay buffer (pH 7.4) was added to all standard
tubes (n = 7), then 1.0ml of the 100ng/ml standard was added to tube 1, mix well
and transfer 1.0ml of tube 1 to tube 2 and so on. A series of standard concentration
were obtained in the range 50, 25, 12.5, 6.25, 3.125, 1.56, 0.78 ng/ml. All standards
were set up in duplicate (total n = 14) with a total volume of 100µl added in each
tube (Table 3.4). The NSB tubes contained 300µl of 0.05 phosphosaline buffer,
whereas reference (B0) tubes contained 200µl, and 100µl for total tubes.
Table 3.4: Standard preparation for leptin RIA
Tube # Standard concentration Volume of assay buffer to add Volume of standard to add
1 50ng/ml 1.0ml 1.0ml of 100ng/ml
2 25ng/ml 1.0ml 1.0ml of 50ng/ml
3 12.5ng/ml 1.0ml 1.0ml of 25ng/ml
4 6.25ng/ml 1.0ml 1.0ml of 12.5ng/ml
5 3.125ng/ml 1.0ml 1.0ml of 6.25 ng/ml
6 1.56ng/ml 1.0ml 1.0ml of 3.125ng/ml
7 0.78ng/ml 1.0ml 1.0ml of 1.56ng/ml
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Plasma samples and controls were run in duplicate with a total volume of 100µl
in each tube. 100µl of 125I-Human leptin was added to all assay tubes, followed
by pipetting 100µl of human leptin antibody to all tubes except total count tubes
and NSB tubes. All assay tubes were then vortexed and incubated overnight (20-24
hours) at 4◦C.
On day two, 1.0 ml of cold (4◦C) precipitating reagent was added to all tubes
(except Total count tubes) and vortexed and incubated for 20 minutes at 4◦C.
Then, all assay tubes (except Total) were centrifuged for 20 minutes at 2000-3000
rpm. Immediately after centrifugation, supernatant of assay tubes was aspirated
and assay tubes were counted in a gamma counter. The concentration (ng/ml) of
human leptin in the unknown samples was determined using the dose response curve
and automated software Multi-Calc (Perkin Elmer, Wizard Gamma Counter, UK).
The summary of assay procedure is shown in Table 3.7.
Preparation of leptin reagents
Each kit was sufficient to run 250 tubes and contained the following reagents:
• Assay buffer: 0.05 Phosphosaline pH 7.4 containing 0.025M EDTA, 0.08%
Sodium Azide, 1% RIA Grade BSA and 0.05% Triton X-100. No preparation
was required and the quantity provided in each vial was 40ml.
• Human leptin antibody: Rabbit anti-human leptin serum in assay buffer was
ready to use. The quantity provided was 26mL/vial.
• Labelling hydrating buffer: assay buffer containing normal rabbit IgG as a
carrier (ready to use). It is used to hydrate 125I-Human leptin. The quantity
provided was 27 mL/vial.
• 125I-Human leptin: 125I-Human leptin label (27 mL/vial upon hydration),
HPLC purified (specific activity 135µCi/µg) lyophilized for stability. Lyophilized
contents were hydrated with entire contents of label hydrating buffer. The
working solution was then incubated at room temperature for 30 minutes,
with intermitting gentle mixing.
• Human leptin standards: purified recombinant human leptin (ready to use,
2 ml/vial) in assay buffer at the following concentration: 100 ng/ml. further
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serial dilution were performed to prepare 7 standard tubes with the following
concentrations: 50, 25, 12.5, 6.25, 3.125, 1.56, 0.78 ng/ml.
• Quality controls 1 & 2: purified recombinant human leptin in assay buffer (1
ml/vial).
• Precipitating reagent: Goat anti-rabbit IgG serum, 3% PEG and 0.05% Triton
X-100 in 0.05M phosphosaline, 0.025M EDTA, 0.08% sodium Azide. Precipi-
tating reagent was chilled to 4◦C, and quantity provided was 260 ml/vial.
3.1.5 Plasma Insulin
The plasma insulin samples were assayed utilising 125I-labeled human insulin and
a human insulin antiserum supplied by Millipore Company (Billercia, MA, USA)
following the double antibody/PEG technique.
Insulin RIA procedures were similar to leptin RIA and variations are shown in
Table 3.8.
Table 3.6: Standard preparation for insulin RIA
Tube # Standard concentration Volume of assay buffer to add Volume of standard to add
1 100µUl/ml 1.0ml 1.0ml of 200µUl/ml
2 50µUl/ml 1.0ml 1.0ml of 100µUl/ml
3 25µUl/ml 1.0ml 1.0ml of 50µUl/ml
4 12.5µUl/ml 1.0ml 1.0ml of 25µUl/ml
5 6.25µUl/ml 1.0ml 1.0ml of 12.5µUl/ml
6 3.125µUl/ml 1.0ml 1.0ml of 6.25µUl/ml
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Preparation of insulin reagents:
• Assay buffer: 0.05 phosphosaline pH 7.4 containing 0.025M EDTA, 0.08%
Sodium Azide, and 1% RIA Grade BSA. No preparation was required and the
quantity provided in each vial was 40ml.
• Human insulin antibody: Guinea Pig anti-human insulin specific serum in
assay buffer was ready to use. The quantity provided was 26ml/vial.
• Label hydrating buffer: assay buffer containing normal Guinea pig serum as
a carrier. It was used to hydrate 125I-insulin. This reagent was ready to use
and the quantity provided was 27ml/vial.
• 125I-Insulin: 125I-insulin label, HPLC purified (specific activity 367µCi/µg)
lyophilized for stability. Lyophilized contents were hydrated with entire con-
tents of label hydrating buffer. The working solution was then incubated at
room temperature for 30 minutes, with intermitting gentle mixing.
• Human insulin standards: purified recombinant human insulin (ready to use,
2 ml/vial) in assay buffer at the following concentration: 200µU/mL. Further
serial dilutions were performed to prepare 7 standard tubes with the following
concentrations: 200, 100, 50, 25, 12.5, 6.25, 3.125 µU/mL (Table 3.6).
• Quality controls 1 & 2: purified recombinant human insulin in assay buffer (1
ml/vial).
• Precipitating reagent: Goat anti-Guinea pig IgG serum, 3% PEG and 0.05%
Trition X-100 in 0.05M phosphosaline, 0.025M EDTA, 0.08% Sodium Azide.
Precipitating reagent was chilled to 4◦C, and quantity provided was 260
mL/vial.
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3.1.6 Plasma cortisol
Plasma cortisol was analysed using a direct radioimmunoassay adapted from Read
GF et al (1977) (Read et al., 1977). The standards were made up from a stock 1500
nmol/L in CSP provided as a top standard. This solution is further diluted to give
working standards of 0, 11.5, 23, 47, 94, 188, 375, 750 and 1500nmol/L (Table 3.9).
The NSB tubes contained 20 µl of CSP and 200 µl of Citrate/phosphate buffer,
whereas total tubes contained no buffer nor CSP.
Table 3.9: Standard preparation for cortisol RIA
Tube # Standard concentration Volume of CSP to add Volume of standard to add
1 1500nmol/l 0 150µl of 1500nmol/l
2 750nmol/l 150µl 150µl of 1500nmol/l
3 375nmol/l 150µl 150µl of 750nmol/l
4 188nmol/l 150µl 150µl of 375nmol/l
5 94nmol/l 150µl 150µl of 188nmol/l
6 47nmol/l 150µl 150µl of 94nmol/l
7 23nmol/l 150µl 150µl of 47nmol/l
8 11.5nmol/l 150µl 150µl of 23nmol/l
20 µl of plasma were added to all sample tubes. Similarly, 20µl of prepared
QCs lyphochecks (low, medium and high) from BioRad Ltd (Watford, UK) were
added to QCs tubes. All assay tubes were run in duplicate. Rabbit antiserum was
supplied from (Biogenesis Ltd, catalogue number 2330-5105, Dorset, UK). 10 mls of
assay buffer was added to each vial contained liquid ammonium sulphate fractioned
antiserum and 100µl aliquots stored at -20◦C. The working solution was prepared by
adding 20ml buffer to each aliquot enough for 100 tubes. Antiserum solution (200
µl) was added to all assay tubes except total and NSB tubes. 200µl of a working
diluted 125I-cortisol (4 µl to 20ml = 100 assay tubes) was added to all assay tubes.
Then all assay tubes were vortexed and incubated at room temperature overnight.
The free and antibody bound fractions were separated the next day by adding
100µl of SAC-CEL anti-rabbit solid phase antibody (Immunodiagnostic systems
Ltd, Tyne & Wear, UK). All assay tubes were vortexed and incubated at room
temperature for 1h, with intermittent mixing every 15min. Then, 1ml Brij/saline
wash was added and assay tubes were centrifuged at 3000 rpm for 15 mins. Su-
pernatants were decanted and discarded and the antibody bound fraction in the
pellet was counted in gamma radiation counter. The cortisol concentration in the
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samples were then determined using dose response curve and automated software
Multi-Calc (Perkin Elmer, automatic Gamma Counter, UK).
Preparation of reagents
• Buffer: 0.1M citrate / phosphate pH 4.0 buffer. Buffer is made fresh by adding
13.0g citric acid, 8.9g Na2HPO anhydrous, 1.0g gelatin and 0.2g thiomersal
to 1L with DGDW. The buffer is stored at 4◦C.
• Rabbit antiserum was supplied from (Biogenesis Ltd, catalogue number 2330-
5105, Dorset, UK). The conjugate used to produce the antiserum was Anti-
cortisol-3-O-(carboxymethyl) oxime bovine serum albumin. Each vial was
made up to 11mls with assay buffer and 100 µl aliquots kept at -20◦C.
• Radiolabel: Cortisol-3-O-(carboxymethyl)-oximino-125iodohistamine (Insti-
tute of Isostopes) is diluted in assay buffer so that 200 µl contains 10,000
cpm.
• Solid phase separation system: ready to use SacCell (IDS Ltd, UK)
• Quality control: Low, medium and high from BioRad Ltd (Watford, UK).
3.2 Measurement of plasma metabolites
Plasma metabolites were analysed using an automated spectrophotometer. The
assay principle is as follows: metabolite concentrations are determined after an
enzymatic reaction which releases hydrogen peroxide to form a dye with the pig-
ment reagents. The colour intensity of the final product is measured at a specific
wavelength and is directly proportional to the analyte concentration in the sample.
Glucose, TAGs and NEFAs were measured by colourimetric assay using an I-
Lab650 (Instrumentation Laboratory, Warrington, UK). All reactions were enzy-
matic and based on the spectrophotometry concept, in which the absorbance of the
outcome coloured products was directly proportional to the metabolite concentra-
tion.
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All plasma samples were initially thawed and centrifuged at 1500 g for 5 min at
4◦C. To optimise the clarity of the samples the supernatants were then re-aliquoted
into new plain tubes and placed in the I-Lab 650. Calibration of the I-Lab650 was
carried out every day before the measurements were taken, and the quality control
with a known concentration was measured and checked before each run of samples.
QCs (low and high) were run in duplicate in the beginning and at the end of each
batch of samples to assess intra- and inter assay variability. All samples from one
participant whether in Study 1 (LS and DS) or Study 2 (LS, DSC and LSC) were
randomised and run in one assay to minimise the effect of assay variation.
3.2.1 Plasma glucose
Plasma glucose was determined using the GLUOX analysis kit (IL TestTM, cat-
alogue number 0018250840, Instrumentation Laboratory, Werfen Ltd, Warring-
ton, UK). Glucose was oxidised by glucose oxidase forming hydrogen peroxidase,
which under catalysis of peroxidase with phenol and 4-amniophenazone forms a
quinoneime dye. The absorbance of quinoneime was measured biochromatically at
a wavelength of 510nm and also at blanking wavelength of 600nm (see below).
(β-D–glucose) + (O2 + H2O)
glucose oxidase
gluconic + H2O
2 H2O + 4-amino antipyrine + phenol
peroxidase
quinoneimine dye + 4 H2O
3.2.2 Plasma NEFAs
NEFAs were measured using Randox NEFA analysis kit (Randox Laboratories Ltd.,
Crumlin, County Antrim, UK). NEFA was converted to acetyl-CoA by acyl-CoA
synthase enzyme to produce Acyl CoA. Acyl CoA is oxidised then to produce hy-
drogen peroxidase which was then condensed by peroxidase to form a quinoneimine
dye which is directly proportional to the NEFA concentration. The absorbance of
the quineoneimine was measured at 550nm (see below).
NEFA + ATP + CoA
acyl CoA synthase
acyl CoA + AMP + PPi
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acyl CoA + O2
acyl CoA oxidase
2,3 trans enoyl CoA + H2O
H2O + TOOS + 4-amino antipyrine
peroxidase
quinoneimine dye + H2O
TOOS= N-ethyl-N-(2hydroxy-3-sulphopropyl) m-toluidine
3.2.3 Plasma TAGs
TAG was measured using IL TestTM TAG analysis kit (Catalogoue number 0018255-
640, Instrumentation Laboratory, Werfen Ltd, Warrington, UK). TAG in EDTA
plasma was converted to quineoneimine by a series of chemical reactions involving
many enzymes. TAG was lipolysed into glycerol and Fatty acids by lipoprotein li-
pase. Glycerol was converted by glycerol kinase to form glycerol-3-phosphate, which
was oxidised to dihydroxyacetone phosphate. The last step was the production of
quineoneime dye by peroxidase. The absorbance of quineoneimine dye (measured
biochromatically at 505/692nm was directly proportional to the TAG concentra-
tions (see below).
Triglycerides
lipoprotein lipase
glycerol + fatty acids
glycerol + ATP
glycerol kinase
glycerol–3-phosphate + ADP
glycerol–3-phosphate+O2
glycerophosphate oxidase
dihydroxyacetone phosphate+H2O
H2O + 4-chlorolphenol + 4-amino antipyrine
peroxidase
quinoneimine dye + H2O
3.3 KSS, mood and alertness
The impact of light on sleepiness, mood and alertness was assessed using a subjective
self-rated questionnaire of four 9-point mood scales and the Karolinska sleepiness
scale (KSS).The Karolinska sleepiness scale was originally developed to establish a
one-dimensional scale of sleepiness and was validated against alpha and theta elec-
troencephalographic (EEG) activity as well as eye movement electrooculographic
(EOG) activity (A˚kerstedt and Gillberg, 1990).
In these studies, mood scales were categorised into 3 mood scales and 1 alertness
scale as following:
• Alertness: 1 is very alert, 9 is very sleepy
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• Mood A: 1 is very cheerful, 9 is very miserable.
• Mood B: 1 is very calm, 9 is very tense.
• Mood C: 1 is very depressed, 9 is very elated.
• Karolinska sleepiness scale: 1 - very alert, 3 - alert, normal level, 5 neither
alert nor sleepy, 7 sleepy but no effort to stay awake, 9 very sleepy, great
effort to stay awake.
Participants were asked to complete mood and alertness questionnaires (on pa-
per) every 30 minutes from 18:00h to 06:00h the next day. The data obtained
from all sessions were then assessed. The data were entered onto spreadsheets, and
subjected to statistical analyses (see section 3.8).
3.4 Assessment of food visual analogue scale
The food visual analogue scale (VAS) are linear questionnaires with two extreme
cases of varied questions adapted from the Hull and Blundell (1986) model (Stubbs
et al., 2000). In these studies, questions were programmed into an electronic pa-
tient reported outcome diary (PRO-Diary®) which was then used to complete the
questionnaires. The PRO-Diary is wrist-worn electronic device for participant self-
report of feeding behaviour. It has an integrated monitor activity with a touch
sensitive screen to allow a participant to slide the on-screen icon either left, which
signifies low level of hunger or to the right which signifies high level of hunger on a
scale of 0 to 10 as shown in Appendix-P. It also recorded the exact time at which
the questionnaire was completed. The questions were presented in a randomised
order, which meant each time point has different question order. The data was then
exported to a computer for analysis. Using the PRO-Diary is a more convenient and
accurate technique compared to pen and paper (P&P) VAS method, as it reduces
errors from manual measurement and entry onto electronic spreadsheets.
Questions used in these studies included how hungry do you feel? to assess
hunger, how full do you feel? to assess fullness or satiety after a standard meal
and how much do you think you can eat? to assess prospective food consumption
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(Stubbs et al., 2000; Kral, 2006). Additional questions were included such as: ”how
thirsty do you feel?” and would you like to eat something ’sweet’, ’salty’, ’fatty’
and, ’savoury’? (Appendix-P). In Study 1, participants were asked to complete the
questionnaires 15 minutes before the evening test meal, and then every 15 minutes
after the evening test meal for 3 readings and at 30 minutes intervals thereafter
until 13 readings were obtained in all. Whilst in Study 2, participants completed
the questionnaires every 30 minutes until the evening test meal time, then every 15
mins for first hour, then at 30 mins interval until 06:00h the next day. The data
were exported onto CSV file, and underwent statistical analyses such as repeated
measures ANOVA, paired t-test, one-way ANOVA.
3.5 Continuous Glucose Monitoring (CGM)
The continuous glucose monitoring (CGM) system is commonly used by diabetic
patients to monitor glucose levels in interstitial tissue fluid (ISF). CGM uses a tiny
sensor inserted under the skin and measures ISF glucose levels every 3-5 minutes.
CGM devices are produced by Abbott, DexCom, and Medtronic and have been
approved by the U.S. Food and Drug Administration (FDA). CGM consists of a
sensor, a transmitter and monitor.
The sensor soaks up fluid from ISF containing oxygen and glucose. During the
initial wetting period (5 minutes), the fluid (oxygen and glucose) diffuses through
the membrane and reacts with glucose oxidase resulting in gluconic acid and H2O2.
H2O2 interacts with the electrode to produces a current that is measured as the
sensor signal (ISIG). This energy signal is turned into a glucose number. The
transmitter sends glucose information via radio waves from the sensor to a pager
like wireless monitor. A blood sample collected at the same time was checked with
a glucose meter (GM) and used to calibrate the device (Mastronardi et al., 2000b).
In Study 1 only, the CGM was inserted 2 hours prior to the session, and the
ISF glucose was monitored every 5 minutes from 18:00h to 06:00h the next day.
All data were converted into mmol/l, and sensor glucose (SG) reading errors were
adjusted using the ISIG formula [SG = ISIG / CAL factor] [CAL factor = GM /
ISIG] (Mastrototaro, 2000).
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3.6 Screening questionnaires
Assessment sheets were used to analyse the responses to the screening question-
naires: Horne-O¨stberg questionnaire (HO¨), Pittsburgh sleep quality index (PSQI)
and Munich chronotype (MCTQ). More details about the assessment sheets are
included in Appendices T and U .
The Horne-O¨stberg uses a self-assessment of 19 items to be answered that was
used to determine the morningness and eveningness of the participants (Horne and
O¨stberg, 1975) (Appendix-T). The scores were defined as follows:
Definitely morning 70-86 Moderately morning type 59-69 Neither type 42-58
Moderately evening type 31-41 Definitely evening type 16-30
The PSQI is a self-rated questionnaire to assess sleep quality for the preceding
one month period (Buysse et al., 1989). It is composed of 17 questions that produce
7 component scores about: subjective sleep quality, sleep latency, sleep duration,
habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime
dysfunction. The 7 component scores are summed to produce a global PSQI score
which if it is greater than 5 is an indication of poor sleep quality (Appendix-U).
MCTQ is a self-rated chronotype questionnaire that was developed by Till Roen-
neberg et al., (2003). MCTQ categorizes participants into one of seven chronotype
groups (Extreme Early, Moderate Early, Slightly Early, Normal, Slightly Late, Mod-
erate Late, and Extreme Late) (Roenneberg et al., 2003, 2015). The questions focus
on work day and free day sleep schedules, work details and lifestyle to understand
how biological clocks work within normal life to determine a participants chrono-
type. Mid-sleep time on free days (MSF) and mid-sleep on work day (MSW) was
calculated, and the following computation was used to determine the chronotype
Adapted from (Roenneberg et al., 2003):
• If sleep duration in free day (SDf) ≤ sleep duration in work day (SDw):
Chronotype = MSF.
• If SDf > SDw : Chronotype = MSF - (SDf SDw) / 2
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3.7 Vascular function tests
Vascular function was assessed during Study 1 using a Vicorder. The Vicorder was
used to determine pulse wave velocity (PWV) and pulse wave analysis (PWA). PWV
is considered as a new ”gold standard” to measure arterial stiffness. The Vicorder
uses a non-invasive technique known as applanation tonometry to simultaneously
record the travelling pulse pressure wave from two distinct points (carotid-femoral
or brachial-femoral). Applanation tonometry methods involve the observation of
oscillation in the cuff which is caused by oscillations of blood flow by the function of
a micromanometer-tripped probe. The artery is compressed between the sensor and
underlying structures, and the intra-arterial pulse pressure is transmitted through
the arterial wall to the sensor (Hickson et al., 2009).
PWV is determined by calculating the transit time taken for the pressure wave-
form (sum of incident wave and reflected wave) to travel from point A to point B. In
Study 1, PWV was measured between the carotid and femoral arteries by placing
the cuff on the femoral site and a neck pad on the neck. The distance between
the neck pad to the sternal notch, and between the top of the femoral cuff and the
sternal notch were measured, and entered into the Vicroder software. The Vicorder
uses applanation tonometry to automatically calculate the velocity of the waveform
based on the velocity equation (velocity = distance / time cm/s). Brachial-femoral
PWV was measured using the distance between the brachial cuff and the sternal
notch, and between the femoral cuff and the sternal notch. The data were saved as
CSV format, and vascular parameters of each individuals, at each time point during
the LS and DS were averaged and plotted as a column chart. The data sets were
analysed to find differences using repeated measures ANOVA (see section 3.8).
3.8 Statistical analysis
Statistical software packages used were SPSS 22 (SPSS Inc., IBM Company, Chicago,
Illinos, USA), Graphpad Prism 6 (GraphPad Software Inc., La Jolla, San Diego,
California, USA), PS software (Vanderbilt University, Tennessee, USA), Statistica
12 (StatSoft Inc, Tulsa, Oklahoma, USA) and SAS-student version (SAS Insititute
Inc, NC, USA). Analysis of variance (ANOVAs repeated measures ANOVA) were
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performed using in Statistica, SPSS and SAS, but post hoc tests (Tukey test) were
only performed using Statistica. One way ANOVA, Two-tailed paired t-test and
area under the curve (AUC) were carried out in GraphPad Prism, and the power
size calculation was performed using PS software.
3.8.1 Power size calculation
Power calculation was performed using PS software with a power of 80% and a
significance level of 0.05. NEFAs data obtained from a previous pilot investigation
(MSc project (2012), University of Surrey, UK) was used to determine the number
of participants needed for Study 1. In Study 2, the NEFA data obtained from Study
1 was used to calculate participant numbers. Power size calculation showed that
Study 1 requires at least 18 participants, whereas study 2 needs 12 participants.
3.8.2 Normality tests
In order to perform parametric tests, normality tests were initially carried out. All
data were checked for normality using DAgostino and Pearson omnibus normality
test in Graphpad Prism and Kolmogorov-Smirnova using Statistica and/or SPSS.
Normality tests were carried out per group, time and treatment to make sure that
none of these interventions had influenced the normal distribution of the data. A p
value ≤ 0.05 indicates that the distribution is significantly different from normal. All
data were normally distributed, thus parametric tests were carried out. Variances,
outliers, skewness and kurtosis were also checked before running any parametric
tests. Variance between groups were similar (variance ratio 1:1), skewness and
kurtosis was between -3 and +3, and no influential outliers were defined. Histograms
were also drawn to ensure that data gave a bell-shaped curve indicating a normal
distribution (Bland, 2015).
3.8.3 Missing values
For hormone and metabolite measures, missing values were replaced by either using
linear interpolation for the middle missing values, or linear extrapolation for missing
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values at the beginning or end of the clinical sessions. The percentage of values
which needed to be inter-/extrapolated was as follows: Study 1 (melatonin 3.1%,
cortisol 2.3%, leptin 2.7%, insulin 2.8%, glucose 3.3%, NEFA 3.5%, and TAGs 3.2%)
and Study 2 (melatonin 2.9%, cortisol 1.6%, leptin 1.3%, insulin 1.5%, glucose 1.3%,
NEFA 2.5% and TAG 1.2%) . Inter-/extrapolation has many limitations especially
when the missing data occurs where the postprandial peak is expected, however,
the missing values in Study 1 and Study 2 did not occur during postprandial peaks.
3.8.4 Analyses of variance (ANOVAs)
Prior to performing analysis of variance (ANOVA), the data sets were tested for
violation of sphericity which refers to the condition where the difference in variance
between all related groups (levels) are equal (i.e., an increase in the type 1 error
rate). Mauchlys test of sphericity is a formal way of testing the violation assumption
of sphericity using SPSS. If sphericity is not violated, then the F-statistic is valid
and can be used in statistical significance. However, if sphericity is violated, then
the F-statistic is invalid, the type 1 error rate is increased and corrections to the
degrees of freedom (df) must be applied. Therefore, Greenhouse-Geisser correction
was chosen to counter violation of sphericity (Bland, 2015).
Two types of analysis of variance were used in this project: one-way ANOVA
and repeated measures ANOVA. One-way ANOVA was used in Study 2 due to
the presence of three treatment factors (LS, DSC & LSC). Analyses of variance
were conducted in Statistica, SAS and confirmed by SPSS. One-way ANOVA was
used to investigate the difference in baseline samples, total area under the curve
(TAUC) and incremental area under the curve (IAUC). The reason for using One-
way ANOVA instead of conducting multiple t-tests was to reduce the probability
of type 1 error. As conducting multiple t-tests (3 t-tests in Study 2) would lead
to an increase in the probability of type 1 error by 0.14 which is greater than the
p level set at 0.05. Therefore, one-way ANOVA was conducted to investigate the
difference between several groups in one model and to reduce the number of pairwise
comparisons (Bland, 2015).
The overall data sets were suitable for testing with repeated measures ANOVAs.
In Study 1, the complex design of 3 factors (gender, treatment and time) repeated
109
measures ANOVA with between subject factors was analysed using STATISTICA.
Within-subject factors (time) and between-subject factors (gender) ANOVA was
applied. In Study 2, three-factors (time, light and melatonin) repeated measures
ANOVA was conducted using SAS. Since Study 2 consisted of three sessions with
two major treatments (light and melatonin), the data sets were arranged based on
the presence or absence of light and melatonin, thereby ascertaining the effect of
light and melatonin separately.
Tukeys honest significance difference (Tukeys HSD) post hoc tests were per-
formed after ANOVA tests (repeated measures ANOVA and one-way ANOVA) to
identify significant differences between gender, treatment and time. This test was
only used if a significant difference was shown in ANOVA test (Bland, 2015).
3.8.5 Students t-tests
Students t-test is used to test a hypothesis of normally distributed samples when
the standard deviation is unknown. T-test determines whether there is difference
in the mean values between two groups of samples (Bland, 2015). In this project
paired t-test was used mainly in Study 1 since the same measurements were tested
under two different conditions in the same individuals.
3.8.6 Correlation test
Pearson product-moment correlation coefficient, is a test used to measure the linear
dependence between two variables X and Y. the correlation coefficient value ranges
between -1 to +1. +1 implies positive relationship between variables, Y increases as
X increases. -1 implies a negative relationship, Y increases as X decreases, whereas
a value of 0 represent no linear correlation (relationship) between the variables
(Bland, 2015). Since melatonin is considered as the major hormone influenced by
light/dark cycle, it was of interest to assess whether there was a correlation between
melatonin and other parameters such as subjective food VAS, mood and alertness.
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3.8.7 Area under the curve (AUC)
Area under the curve is mainly used to quantify the measureable effects of a phe-
nomenon. In this project, AUC was used to measure the area above X-axis that
represent concentration of various metabolites and hormones using Graphpad Prism.
Prism draws a straight line between adjacent points (point of (x,y)) to define the
curve. Then, the curve is divided into regions which can be calculated using the
trapezoid rule. The trapezoid rule used in Prism is simply defined by this formula
((X * (Y1+Y2)/2). The area is computed from the user specified baseline and the
curve starting from the first X values to the last X value (Bland, 2015). TAUC was
used to estimate the area above X axis (Y = 0), whereas IAUC to estimate the area
above baseline point (Y = first collected sample).
3.8.8 aMT6s analysis
Urine aMT6s levels were subjected to a computerised cosinor analysis, using a pro-
gram developed by Dr D S Minors at the University of Manchester, UK, to ascertain
calculated peak times of aMT6s secretion (acrophase). Urine aMT6s concentrations
from RIA, volume and time of collection provided by participants were inserted in
this program. The samples were divided into three sections in the program: section
1 (from 1 to 24 hours), section 2 (from 24 to 48 hours) and section 3 (from 1 to
48 hours). By using mathematical equations, mesor (ng/min), amplitude (ng/min),
acrophase (h), rhythmicity (%) and P-value. The confidence limit (P-value) chosen
was < 0.05, and the % rhythm > 60 were accepted. aMT6s acrophase obtained
from this calculation was used to estimate the melatonin onset of plasma.
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CHAPTER 4
THE EFFECT OF LAN ON HORMONES,
METABOLITES, APPETITE CONTROL,
VASCULAR FUNCTION AND
BEHAVIOURAL RESPONSEs
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4.1 Introduction
Human NVRs to light such as melatonin suppression (section 1.5.1.1), elevation of
body temperature (section 1.5.4.1), alteration of vascular function (section 1.5.7.4
and 1.5.7.5), appetite control (section 1.5.10.3), endocrine control (section 1.5.8 and
1.5.9), and behavioural responses including sleepiness, alertness (section 1.5.3.2)
mood and comfort (section 1.5.6) are primarily mediated via a subset of ipRGCs
in the inner retina as has been discussed in section 1.2.1. The ipRGCs innervate,
directly and indirectly, the brain regions responsible for the generation of acute
NVRs (section 1.3). Recent evidence has shown the role of classical photoreceptors,
rods and cones, in modulating NVRs (section 1.2.6).
It has been reported that melatonin is the key hormone influenced by changes in
light/dark exposure. Also, melatonin has been associated with changes in vascular
function (section 1.5.7.2) and structure (section 1.5.7.3) indicating the protective
role of melatonin against cardiovascular disease. Other human studies have linked
melatonin administration to the reduction in alertness and body temperature (sec-
tion 1.5.5) as well as a treatment for depressive symptoms such as SAD (section
1.5.6). Melatonin action on the endocrine system is still controversial, as some
studies have shown that melatonin reduces glucose tolerance and insulin sensitivity,
whereas other studies have linked melatonin to improved insulin resistance (section
1.5.8.5). There is a paucity of human studies that have investigated the role of
melatonin in appetite control. However, animal studies have shown that melatonin
modulates appetite hormones such as leptin and ghrelin (section 1.5.10.3).
To date, most of the human experiments investigating the role of light on vas-
cular function, behavioural, hormone and metabolic responses were conducted by
altering melatonin hormone or using either short or long wavelength light. Other
studies were conducted in animal models, in vitro and in vivo, or humans using
constant routine protocols and exogenous melatonin administration. There has not
been a study to investigate the impact of light at night by suppressing endogenous
melatonin levels, in healthy young participants. This chapter will focus on the
impact of light at night and/or endogenous melatonin on hormones, metabolites,
appetite control, vascular function, and behavioural responses.
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4.2 Aims
This chapter aims to investigate the influence of light at night (LAN) on pre- and
postprandial hormones and metabolites, appetite control, vascular function, and
behavioural responses by exposing healthy young participants to two light condi-
tions: dark (<5 lux) and light (>500 lux), before and after an appropriately timed
evening test meal.
4.3 Objectives
• To recruit 18 healthy participants (9M + 9F) with no medical history and
BMI between 18.0 ± 28.0 kg/m2.
• To evaluate sleep/activity and light exposure prior to study sessions using
Actiwatch.
• To assess arterial stiffness parameters (PWV and PWA) and compare the
results obtained between the two light conditions.
• To investigate the impact of light on mood and alertness.
• To interpret the data obtained from the VAS for appetite in relation to specific
hormones (e.g., leptin)
• To assess peripheral body temperature using iButton and link these data to
the findings regarding melatonin levels.
• To measure concentrations of plasma hormones and metabolites such as glu-
cose, insulin, leptin, TAGs, NEFA and cortisol.
• To assess saliva melatonin suppression.
• To define gender effect in hormones, metabolites, appetite control and be-
havioural responses.
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4.4 Hypotheses
It was hypothesised that:
• LAN reduces glucose tolerance and insulin sensitivity.
• LAN increases plasma NEFAs and TAGs.
• LAN increases arterial stiffness (PWV & PWA) and other vascular functions.
• LAN improves mood scores, increases alertness and decreases sleepiness scores.
• LAN enhances appetite by increasing hunger and desire to eat scores, and
reduces plasma leptin.
• LAN increases peripheral temperature readings.
4.5 Methods
The specific methods for Study 1 are described below. For general methods see
Chapter 2.
4.5.1 Participant demographics & screening data
Participants involved in this study were students from the University of Surrey,
aged between 18 to 30 years. Strict criteria were included and described in details
in Chapter 2 (section 2.2). 21 individuals (males and females) were screened and
pre-study measurements were taken as part of screening session to ensure that
participants are eligible to join the study (section 2.3.1). Only 17 participants,
9 males and 8 females, completed the study sessions, and the screening data and
results for these individuals are shown in the following sections.
Screening questionnaires were analysed prior to joining the study, and the data
are shown below (Table 4.1) (refer to section 2.3.1 and section 3.6).
All participants showed good sleep quality in the PSQI assessment. Using the
Horne-O¨stberg questionnaire, three participants (S003, S012 and S018) were found
to be evening types and three participants (S004, S011 and S017) were morning
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Table 4.1: Screening questionnaire analysis in Study 1
Subject Gender Pittsburgh Score (≤5) Horne-O¨stberg Score Mid-sleep time
S001 M 2 57 04:30h
S003 F 4 41 05:00h
S004 F 2 60 03:30h
S005 M 3 47 04:15h
S006 M 2 44 07:00h
S007 M 5 47 04:30h
S008 M 4 56 04:00h
S010 F 5 42 05:00h
S011 F 3 62 02:40h
S012 M 4 36 04:35h
S013 F 4 49 05:00h
S014 F 3 70 03:30h
S015 M 3 56 03:40h
S016 F 2 55 04:45h
S017 F 5 59 05:00h
S018 F 5 41 05:30h
S019 M 5 58 03:45h
types, the remaining participants (n = 11) were classified as neither type. The mid-
sleep time during free days was measured using Munich Chronotype assessment and
ranged between 03:30h to 07:00h hours for all participants.
Urinary aMT6s amplitude, estimated melatonin onset, and timing of meals for
each participant are shown in Table 4.2. Further screening data are presented in
Table 4.4 (see section 2.3.2). The standard evening test meal was given between 30
mins to 1 hour after the estimated plasma melatonin onset, to ensure the presence
of endogenous melatonin. The fasting period ranged between 9 to 10.5 hours (10:15
± 00:06 (mean ± SEM)) to show the adequate profile of pre-prandial hormones and
metabolites, and to obtain similar baseline values between participants.
4.5.2 Calculation of salivary melatonin onset
Melatonin onset was also determined from salivary melatonin data to check that the
meal timing determined by urinary melatonin onset was correct, and to make sure
that test meal had been given during endogenous melatonin secretion The following
equations were used to calculate melatonin onset from salivary melatonin data:
1. Calculate mean of the baseline samples.
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Table 4.2: Estimated plasma melatonin onset and individualised meal times of the
participants in Study 1
Subject Acrophase aMT6s(h) Acrophase Plasma (h) DLMO (h) Lunch (h) Supper (h)
S001 05:25 04:25 00:25 15:00 01:00
S003 06:00 05:00 01:00 15:00 01:30
S004 02:48 01:48 21:48 14:00 23:00
S005 03:30 02:30 22:30 14:00 23:30
S006 05:42 04:42 00:42 14:30 01:00
S007 05:12 04:12 00:12 14:00 00:30
S008 04:06 03:06 23:06 13:00 23:30
S010 04:12 03:12 23:12 13:00 23:30
S011 02:38 01:38 21:38 12:30 23:00
S012 03:28 02:28 22:28 12:45 23:15
S013 05:00 04:00 00:00 14:00 00:30
S014 03:35 02:35 22:35 14:00 00:00
S015 05:00 04:00 00:00 14:00 00:15
S016 04:00 03:00 23:00 13:45 00:00
S017 05:11 04:11 00:11 14:00 00:30
S018 03:30 02:30 22:30 13:30 23:30
S019 05:01 04:01 00:01 14:00 00:45
The evening test meal ”supper” was given between 30 mins to 1 hour of plasma melatonin onset, to ensure
sufficient melatonin was present. The fasting period between the lunch and evening test meal ranged
between 9 to 10.5 hours to show an adequate profile of pre-prandial hormones and metabolites.
2. Calculate the SD.
3. Then, 2 x SD
4. Threshold = (2 x SD) + mean
5. Threshold value determine the position of time point (e.g 23:00 (B) and 23:30
(C).
6. Melatonin level at (C) - melatonin level at (B) = A
7. Calculate rate/min = A / 30
8. Rate/min x 60 = minutes
9. Minutes calculated from step 8 must be added to time point B to get DLMO.
Table 4.3 shows the average excretion rate and amount of aMT6s excreted over
24 hours. Participants showed a substantial amount of aMT6s produced before
joining the study as a part of screening procedures. Estimated melatonin onset
obtained from urinary aMT6s was compared with salivary melatonin onset (from
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Table 4.3: aMT6s urinary screening in Study 1
Subject Average aMT6s excretion rate ng/h aMT6s ng S-melatonin onset U-melatonin onset
S001
1st day 866 1st day 6306
23:33 00:25
2nd day 1315 2nd day 9191
S003
1st day 744 1st day 6030
00:32 01:00
2nd day 823 2nd day 6553
S004
1st day 460 1st day 4330
21:30 21:48
2nd day 1173 2nd day 12903
S005
1st day 1129 1st day 3339
22:00 22:30
2nd day 793 2nd day 2758
S006
1st day 1215 1st day 9660
23:05 00:42
2nd day 572 2nd day 5316
S007
1st day 622 1st day 4784
22:00 00:12
2nd day 537 2nd day 2766
S008
1st day 360 1st day 2392
22:03 23:06
2nd day 581 2nd day 4236
S010
1st day 339 1st day 2713
22:36 23:12
2nd day 414 2nd day 2571
S011
1st day 367 1st day 2294
21:02 21:38
2nd day 393 2nd day 2980
S012
1st day 429 1st day 3462
20:35 22:28
2nd day 377 2nd day 2561
S013
1st day 780 1st day 6083
23:03 00:00
2nd day 1389 2nd day 7203
S014
1st day 7579 1st day 44257
21:07 22:35
2nd day 3646 2nd day 44950
S015
1st day 818 1st day 3240
22:12 00:00
2nd day 1243 2nd day 6907
S016
1st day 495 1st day 3454
21:35 23:00
2nd day 763 2nd day 5546
S017
1st day 2767 1st day 8807
22:03 00:11
2nd day 1241 2nd day 9568
S018
1st day 1396 1st day 9304
21:30 22:30
2nd day 2336 2nd day 17099
S019
1st day 336 1st day 1992
23:07 00:01
2nd day 403 2nd day 1994
DS) which was calculated as described in section 2.3.4. There was at least 1-
hour differences (01:13 ± 00:10h (mean ± SEM)) between the estimated urinary
melatonin onset and salivary melatonin onset with salivary melatonin onset being
earlier.
4.5.3 Laboratory session
All participants were randomised to a two-way cross-over design protocol: dark
(<5 lux) (DS) and light (>500 lux) (LS) sessions between 18:00 to 06:00h the next
day (see protocol: Figure 2.1). Participants were kept awake and semi-recumbent
throughout the study session, except during visits to the toilet (see section 2.3.5 for
further details).
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4.5.3.1 Light measurements
Light intensity was measured at two different positions: horizontal level (direction
of gaze) (DS 1.06 ± 0.06 lux, LS 305 ± 10.1 lux; mean ± SEM) and vertical level
towards the lights (DS 1.2 ± 0.13, LS 552.7 ± 16). Similarly, the irradiance of light
sources was measured at the horizontal level (LS 0.981 w/m2, and DS 0.0012 w/m2)
and vertical level (LS 0.73 w/m2, and DS 0.0008 w/m2) (Table 2.3). The spectral
composition of LS and DS are shown in Figure 2.3 & 2.4.
As mentioned in section 2.5.2, lights during the LS were both fluorescent and
LED, whereas only the LED lights were used in the DS. To test the biological effec-
tiveness of the light source, which depends on the number of photons administered,
photon flux was calculated for both light sources.
The photon flux between 18:00h to 0600h (12 hours) was calculated using the
irradiance toolbox (Excel sheet) designed by Robert Lucas et al., (University of
Manchester). The main formula was utilised as follows:
Irradiance (W/cm2) was converted into photon flux for a light source of a specific
wavelength using the following equation:
Photons/cm2 = irradiance (µW/cm2) / energy of 1 photon of a specific wavelength
The amount of energy in one photon (E) is calculated as
• h = Plancks constant (6.626 x 10−34 W/sec2)
• n = frequency of the wave (n = c/λ)
• c = is the speed of light in a vacuum which equal 3 x 1017 nm/sec, λ = is the
light wavelength in nm.
For instance to calculate the number of photons in a 5 µW/cm2 light stimulus of
350 nm, the following calculation are used:
Firstly, the energy of 1 photon of 350 nm light is:
= (6.626 x 1034 W/sec2) x ((3 x 1017 nm/sec) / 350 nm)
= 5.69 x 1019 µW/sec2/photon
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Second, the number of photons in 5 W/cm2 = (5 µW/cm2) / (5.69 x 1019 µW/sec2/photon)
= 2.84 x 1018 photons/cm2/sec
To calculate the number of photons administered over a given duration, the total
number of seconds of light administration has to be determined:
For instance, in a 2-hour monochromatic light pulse (350 nm):
number of secs in 1 min = 60secs x 1 ⇒ number of secs in 1 hour = 60secs x 60
mins ⇒ number of of secs in 2 hours = 60 secs x 120 mins
Therefore the total number of photons delivered in the 2 hour light pulse = 2.84 x
1018 x 7200 = 2.13 x 1014 photons/cm2/sec
Therefore, the total number of photon delivered between 18:00h and 06:00h of both
light sources was calculated first, and the total photon flux delivered to each par-
ticipant are shown below:
Condition Fluorescent LED LS DS
Photon flux photons/cm2/sec 4.97 x 1018 2.63 x 1019 3.12 x 1019 2.63 x 1019
4.5.4 Assay procedures
The main assay procedures used in this study were radioimmunoassay and spec-
trophotometric enzymatic assays iLab-650. The principles of assay techniques were
discussed in Chapter 3.
4.5.4.1 Radioimmunoassay
This technique was used to analyse salivary melatonin, urinary aMT6s melatonin,
plasma insulin, plasma cortisol and plasma leptin. All quality control results are
shown in Table 4.4. See section 3.1.1 to 3.1.6 for further details.
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4.5.4.2 Measurements of the metabolites
Other metabolites such as glucose, NEFAs and TAGs were analysed using spec-
trophotometric enzymatic assay iLab-650. See section 3.2.1 to 3.2.3 for further
details.
Table 4.4: Quality controls and coefficient of variation in Study 1
Parameter QC Mean Inter-assay CV (%) (n = 17) Intra-assay CV (%)
Salivary melatonin
Low 6.5 pg/ml 6.7 3.5
Medium 24.5 pg/ml 6.7 5.7
High 49.6 pg/ml 6.9 6.2
Cortisol
Low 90.42 nmol/l 5.3 5.2
Medium 500.31 nmol/l 3.9 8.2
High 837.1 nmol/l 5.7 4.2
Insulin
Low 100.3 pmol/l 7.7 4.4
High 332.2pmol/l 8.7 8.6
Leptin
Low 7.73 ng/ml 3.6 6.5
High 24.38 ng/ml 9.8 6.1
Glucose
QC1 6.75 mmol/l 4.2 0.1
QC2 17.33 mmol/l 4.7 0.1
NEFA
QC1 1.77 mmol/l 2.5 0.1
QC2 1.21 mmol/l 2.9 0.1
TAG
QC1 1.12 mmol/l 2.5 0.1
QC2 2.87 mmol/l 2.6 0.1
aMT6s
Low 2.4 ng/ml 9.4 8.9
Medium 16.7 ng/ml 12.6 8.9
High 22.6 ng/ml 11.5 10.4
Quality controls were run in duplicate (aMT6s, melatonin, insulin, leptin and cortisol), or triplicate (glucose,
NEFA and TAG). QCs were also run before, middle and after the samples
4.5.5 Statistical analyses
General statistics were described in section 3.8. Methods detailed below hold for all
hormones and metabolites unless otherwise stated. Data from different participants
were aligned to meal time (T = 0), pre-prandial time points were indicated as (-)
and postprandial time points as (+).
4.5.5.1 Time-points selection
A minimum of 22 samples were collected during every session from each participant,
time scale between -360 to +360 mins was used in statistical analyses. This was
determined to ensure that all participants had samples in that period, as the number
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of samples collected from each participant varied due to different evening test meal
times. The analysis time window selected for each parameter examined in this
chapter are as follow:
• Hormones and metabolites ( -360 to +330 min)
• Mood and alertness (-330 to +330 min)
• CGM (-230 to +300 min)
• Pro-Diary (-15 to +285 min)
• Ibutton (-285 to +285 min)
• Vicorder (-285, -120, +30 and +90 min)
4.5.5.2 Basal levels
Basal levels of all metabolites, hormones, mood and alertness, and appetite param-
eter for each study session are shown in Table 4.6. Basal levels were compared
between LS and DS using 2-tailed paired Students t-test.
4.5.5.3 Basal levels prior to the test meal (T=0)
Basal levels of hormones, metabolite and subjective mood and alertness were deter-
mined from samples collected immediately before the meal (T = 0). Basal levels at
T=0 were compared between LS and DS using 2-tailed paired students t-test.
4.5.5.4 Pre-prandial responses (T= -360 to T = 0)
Data for hormones, metabolites, mood and alertness, iButton, and CGM were anal-
ysed prior to the evening test meal between T= -360 to T = 0. Preprandial data
of Vicorder were analysed at T = -285 and T = -120. Repeated measures ANOVA
was applied to compare between LS and DS. This analysis was used to identify any
significant differences between the lighting conditions during fasting periods.
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4.5.5.5 Post-prandial responses
Data of all parameters were statistically tested immediately after the evening test
meal to identify the influence of the meal on hormones, metabolic, behavioural
responses between T = +15 to T = 330, whereas postprandial vascular responses
were analysed at T = +30 and T = +90. Repeated measure ANOVA was applied
to compare the LS and DS.
4.5.5.6 Post-hoc test
Tukeys honest significance difference (Tukeys HSD) post-hoc tests were performed
after the ANOVA tests (repeated measures ANOVA) to locate the differences be-
tween genders, treatments and time points only when statistically significant differ-
ences were found.
4.5.5.7 AUC
TAUC and IAUC were applied to confirm the results obtained from the ANOVA
analyses. TAUC was used to calculate the area above X axis (Y = 0), whereas IAUC
was used to calculate the area above baseline point (Y = first collected sample).
Refer to section 3.8.7 for further details of this test.
4.5.5.8 Correlations with melatonin
Since melatonin is considered as the major hormone influenced by light/dark cy-
cle, it was of interest to assess whether there was a correlation between melatonin
and other hormones, metabolic and behavioural responses. In this chapter, correla-
tion tests were assessed between melatonin and subjective mood and alertness and
wrist temperature (WT). Also, correlation tests were used to assess the correlation
between melatonin and WT versus subjective appetite scores at 30 min intervals.
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4.5.5.9 Measurement of insulin resistance
An index of fasting insulin resistance (HOMA-IR) and postprandial insulin resis-
tance (HOMA-PP) was determined in both LS and DS. For each session, group
means are shown as histograms (mean ± SEM). HOMA-IR was calculated using
the HOMA calculator based on HOMA model 2 developed by Jonathan Levy (Levy
et al., 1998). HOMA-PP was calculated as the incremental area under the curve
(IAUC) glucose (mmol/l.min) X IAUC insulin (mU/l.min). This equation has been
validated against the intravenous glucose tolerance test (Caumo et al., 2000).
4.6 Results
Table 4.5: Participant demographics in Study 1
Parameter Male (n = 9) Female (n = 8) p (M Vs F)
Age, y 22.3 ± 3.6 22.6 ± 2.2 0.84
Body weight, Kg 68.4 ± 7.9 63.8 ± 8.5 0.26
Height, m 1.8 ± 1.7 1.7 ± 0.1 0.14
BMI, kg/m2 22.9 ± 2.5 22.7 ± 2.2 0.88
Caffeine/wk 10.1 ± 6.2 11.4 ± 9.1 0.74
Alcohol/wk 2.8 ± 2.3 3.8 ± 4.2 0.56
PSQIa 3.3 ± 1.2 4.1 ± 1.5 0.24
HO¨a 51.2 ± 8.1 52.4 ± 10.9 0.81
MCTQa (h) 4.7 ± 1.2 4.9 ± 1.1 0.87
Values are mean ± SDs, Calculated by 2-tailed unpaired Students t-test. aValues given are those obtained
during the screening session
4.6.1 Participants demographic and screening
The demographics of the participants (n =17) are shown in Table 4.5. The mean
age, body weight, height and BMI of 9 males and 8 females in this study were
matched. Caffeine and alcohol consumption over the two weeks prior to the study
were not significantly different between male and female groups. Both genders were
classified as neither morning nor evening types by the HO¨, and all reported a good
sleep quality over the month before the study using the PSQI. The mid-sleep times
from the MCTQ during free-days were not significantly different between males and
females.
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Table 4.6: Screening sleep and basal hormone and metabolite data in Study 1
Parameter LS DS p
Sleep starta, h:min 23:54 ± 00:14 00:18 ± 00:14 0.10
Sleep enda, h:min 07:21 ± 00:10 07:35 ± 00:09 0.10
Sleep durationa, h 06:37 ± 00:16 06:24 ± 00:14 0.50
% Sleep efficiencya 81.9 ± 2.8 78.06 ± 3.5 0.40
Sleep latencya, h:min 00:35 ± 00:12 00:48 ± 00:12 0.50
Fragmentation indexa 26.4 ± 2.9 28.81 ± 3.4 0.50
Basal glucoseb, mmol/L 4.9 ± 0.3 4.8 ± 0.2 0.70
Basal insulinb, pmol/L 107 ± 34 105 ± 28 0.90
Basal NEFAsb, mmol/l 0.75 ± 0.1 0.91 ± 0.1 0.07
Basal TAGsb, mmol/L 1.1 ± 0.1 1.2 ± 0.2 0.40
Basal melatoninb, pg/ml 1.8 ± 0.4 2.6 ± 0.6 0.05
Basal leptinb, ng/ml 110.3 ± 5.1 106.3 ± 3.9 0.31
Basal cortisolb, 197.6 ± 29.6 184.5 ± 34.5 0.68
Sleepinessc 2.76 ± 0.34 2.68 ± 0.36 0.83
Alertnessc 2.76 ± 0.30 2.88 ± 0.37 0.76
Mood 1c 2.76 ± 0.36 2.94 ± 0.34 0.54
Mood 2c 2.29 ± 0.21 2.35 ± 0.21 0.85
Mood 3c 6.94 ± 0.42 6.62 ± 0.34 0.24
CGMd, mmol/l 4.26 ± 0.2 4.21 ± 0.2 0.91
Wrist temperature (C) 32.17 ± 0.36 31.92 ± 1.18 0.71
Values are mean ± SEM, calculated by 2-tailed paired Students t-test. aValues are obtained from 7 days
prior to LS and DS sessions. bValues represented the basal samples (T = -360min) during each clinical
session. cValues are obtained from 9 point mood and Karolinska sleepiness scales at -330 min. dCGM value
is obtained at -230 min during each clinical session. Sleep parameters were analysed based on data collected
from sleep diaries and the Actiwatch. * p < 0.05. Sleep parameters n = 15, Hormone and metabolic basal
data n = 17, wrist temperature n = 11.
4.6.2 Sleep screening and basal hormone and metabolites
Sleep parameters were obtained from 15 participants due to missing data (∼11.7%)
from S003 and S005. The data were collected over seven days prior to LS and DS.
Participants reported no significant difference in sleep prior to LS and DS. Sleep
parameters were analysed based on data obtained from sleep diaries and Actiwatch
(Table 4.6).
Basal plasma samples (T = -360 min) showed no significant differences in all
measured hormones and metabolites (Table 4.6). Mood and alertness questionnaires
basal reading at -330 min, showed no significant differences in subjective sleepiness,
alertness and three mood questions. Similarly, basal CGM (T = -230 min) and
wrist temperature showed no significant difference between LS and DS (p = 0.83
and p = 0.91) respectively (Table 4.6).
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Table 4.7: Screening correlation tests in Study 1
Parameters r2 p
MSF vs. MEQ -0.6 0.01
U. melatonin onset vs MCTQ 0.5 0.01
U. melatonin onset vs MEQ -0.2 0.10
U. melatonin onset vs sleep start 0.7 0.01
U. melatonin onset; Urinary melatonin onset, MSF; Mid-sleep in free days
Correlation tests were performed to establish the relationship between urinary
melatonin onset and other screening parameters such as MCTQ, MEQ and sleep
start. No correlation was reported between urinary melatonin onset and MEQ,
whereas a positive correlation with MCTQ and sleep start was observed. MSF was
negatively correlated with MEQ (r2 = -0.6, p = 0.01).
4.6.3 Subjective mood and alertness
4.6.3.1 Basal levels prior to the test meal (T = 0)
Basal levels of KSS, alertness, and 3 mood ratings collected immediately prior to
the meal (T = 0 min) are shown in Figure 4.1. No significant difference was seen
in basal KSS (p = 0.44), alertness (p = 0.79) and 3 mood ratings (p = 0.79, p =
0.31 and p = 0.46) respectively (Figure 4.1).
4.6.3.2 Pre-prandial mood and alertness (T= -330 to T=0)
There were no significant differences between LS and DS in sleepiness, alertness,
mood 1 and mood 2. Pre-prandial mood 3 showed that participants were more
depressed in DS than LS (p = 0.03). The post-hoc test indicates that pre-prandial
mood 3 showed significant differences at time-points (T = -60 and -30 min). Statis-
tical analyses showed a significant gender x time interaction in KSS, mood 1, mood
2 and mood 3 (p <0.001, p = 0.015, p = 0.02 and p = 0.005 respectively) (Figure
4.2).
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Figure 4.1: Subjective mood and alertness at basal levels (T = 0)
Subjective KSS (A), alertness (B), mood 1 (C), mood 2 (D) and mood 3 (E) (mean ± SEM) prior to the
evening test meal (T = 0 min) in all participants (n = 17) during LS ( ) and DS ( ) sessions.
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Figure 4.2: Pre-prandial and postprandial subjective mood and alertness
Subjective KSS (A), alertness (B), mood 1 (C), mood 2 (D) and mood 3 (E) (mean ± SEM) ratings prior to
and after the evening test meal (time = 0 black dotted line) during LS ( ) and DS ( ) in males (n=9),
females (n=8) and all participants (n=17).
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Figure 4.3: Gender differences in subjective KSS, alertness and mood score
Pre-prandial and postprandial subjective KSS (A & B), alertness (C & D) and 3 mood scores (E-I) (mean
± SEM) of 9 males ( ) and 8 females ( ) in LS and DS.
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4.6.3.3 Postprandial mood and alertness
Postprandial sleepiness, alertness, mood 1 and mood 2 showed no significant differ-
ences between LS and DS. There was a significant difference in mood 3 between LS
and DS (p = 0.04) shown at +120 min (Figure 4.2).
4.6.3.4 Pre and postprandial mood and alertness (T = -330 to T =
+330)
Graphical representation of the females, males and combined participants during LS
and DS are shown in Figure 4.2. No significant differences were shown in sleepiness,
alertness, mood 1 and mood 2 (p = 0.74, p = 0.42, p = 0.77, and p = 0.55)
respectively. Participants were significantly more depressed (mood 3) in DS than
LS (p = 0.03). Post-hoc tests showed significant differences at -60, -30 and +120
min. All 5 subjective questions showed significant effects of time (p < 0.001),
whereas no significant effects of gender were observed.
In order to assess the gender effects in overall scores, data collected from fe-
males and males were compared in LS and DS (Figure 4.3). Females showed higher
sleepiness score than males in both LS and DS, however the differences were not
significant. There was a significant interaction (gender x time) in subjective KSS
during LS (p < 0.001), and a trend toward significant interaction (gender x time)
in DS (p = 0.08). In alertness scores, males showed a trend toward a significant
decrease (p = 0.08) in alertness during DS. There was a significant interaction (gen-
der x time) in mood 2 score in LS compared to females (p = 0.001). There was a
trend toward significant interaction (gender x time) in mood 3 in both LS and DS
(p = 0.07).
4.6.4 Plasma hormones and metabolites
4.6.4.1 Hormones and metabolites levels prior to the test meal (T = 0)
Basal levels of plasma insulin, glucose, TAGs, NEFAs and cortisol from samples
collected immediately before the evening test meal (T = 0 min) are shown in Figure
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4.4. Basal glucose and insulin showed no significant differences between LS and DS.
Basal NEFAs were significantly higher in DS than LS (p = 0.02). No significant
difference was observed in basal TAGs and cortisol levels between DS and LS (p =
0.81 and p = 0.93). Basal melatonin levels were significantly greater in DS than in
LS (p < 0.001) as expected (Figure 4.4).
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Figure 4.4: Hormones and metabolites at basal levels (T = 0)
Plasma glucose (A), insulin (B), NEFAs (C), TAGs (D), cortisol and salivary melatonin (F) levels (mean
± SEM) prior to the evening test meal at time = 0 in all participants (n =17) during LS ( ) and DS
( ). * p < 0.05, and *** p < 0.001.
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Figure 4.5: Pre-prandial and postprandial hormones and metabolites
Plasma glucose (A), insulin (B), NEFAs (C), TAGS (D), cortisol (E) and salivary melatonin (F) (mean ±
SEM) levels prior to and after the evening test meal (time = 0 min black dotted line) during LS ( ) and
DS ( ) sessions in males (n=9), females (n=8) and all participants (n=17).
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Figure 4.6: Gender differences in plasma hormones and metabolites
Pre-prandial and postprandial plasma glucose (A & B), insulin (C & D), NEFA (E & F) , TAG (G & H),
cortisol (I & J) and salivary melatonin (K & L) (mean ± SEM) of 9 males ( ) and 8 females ( ) in LS
and DS.
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4.6.4.2 Pre-prandial hormone and metabolic responses (T-360-0 min)
There were no significant differences between the LS and DS in plasma glucose,
insulin, TAGs, and cortisol concentrations prior to evening test meal. Pre-evening
meal NEFAs showed significantly higher levels in DS compared to LS (p = 0.03).
Similarly, salivary melatonin showed significantly higher levels in DS (p < 0.001)
(Figure 4.5).
4.6.4.3 Postprandial hormone and metabolic responses
Postprandial plasma glucose and insulin responses to the evening test meal were
significantly higher in LS compared to DS (p = 0.01, p = 0.008) respectively. Sali-
vary melatonin was significantly greater in DS than in LS (p < 0.001). There were
no differences in postprandial TAGs and cortisol (Figure4.5).
4.6.4.4 Pre- and Postprandial hormone and metabolic responses (T =
-360 to T = +330 min)
Graphical representations of the female, male and all participants during DS and
LS are shown in Figure 4.5. Plasma insulin levels were significantly greater in LS
than in DS (p = 0.001). Post-hoc tests showed significant differences at +180, +210
and +270 min time points. Similarly, plasma glucose showed significantly higher
levels in LS compared to DS (p = 0.02). The post-hoc test showed significant differ-
ences at +180 and +210 min after the evening test meal. In contrast, pre-prandial
plasma NEFAs were significantly higher in DS (p = 0.005). Post-hoc tests showed
the difference before the evening test meal (T = 0 min). Plasma TAGs and cortisol
showed no significant difference between the DS and LS (p = 0.39 and p = 0.37).
All 5 plasma parameters showed significant effects of time, whereas no significant
effects of gender were shown. However, time x gender interactions were observed in
plasma glucose, and TAGs (p = 0.01 and p < 0.001) respectively.
Salivary melatonin levels were significantly greater in DS than in LS (p < 0.001).
Post-hoc tests showed significant differences at pre-prandial and postprandial time
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points between -120 to +330 min. Both males and females showed a similar increase
in salivary melatonin in DS compared to LS; however females showed higher levels
of salivary melatonin than males although they were not significantly different (p =
0.1). Also, a significant time x gender interaction was shown in salivary melatonin
(p = 0.005) (Figure 4.5).
The differences between males and females in both light conditions were plotted
in Figure 4.6. Females showed higher levels of cortisol (LS: p = 0.06 and DS: p
= 0.12) and melatonin (LS: p = 0.81 and DS: p = 0.23) compared to the males
in both light conditions but not statistically significant. In contrast, males showed
higher TAG levels than females in LS and DS (Gender x time interaction p <
0.001). No differences were observed in NEFA (LS: p = 0.71 and DS: p = 0.06), or
insulin responses (LS: p = 0.61 and DS: p = 0.81), but a significant gender x time
interaction (p < 0.001) was observed indicating higher postprandial glucose levels
in males compared to the females in LS.
4.6.4.5 TAUCs and IAUCs of hormones and metabolites
TAUCs for, insulin, glucose, NEFAs, TAGs and melatonin were calculated between
-360 to +330 min, and are shown in Figure 4.7. TAUCs for NEFAs were significantly
lower in LS (290 ± 17 mmol/l.min) compared to DS (350 ± 18 mmol/l.min) (p =
0.009). In contrast, significantly higher TAUCs for plasma insulin and glucose were
shown in LS compared to DS (p = 0.004 and p = 0.03) respectively. TAUC of
plasma insulin was 109875 ± 9817 in DS and 129119 ± 10343 pmol/l.min in LS,
whereas TAUCs of plasma glucose were 3985 ± 73 mmol/l.min in LS and 3805.76
± 60 mmol/l.min in DS. No significant differences were observed in plasma TAGs
and cortisol responses (p = 0.91 and p = 0.69 respectively). TAUC of salivary
melatonin was significantly lower in LS 10362 ± 1777 pg/ml.min versus DS 3171 ±
530 pg/ml.min (p < 0.0001).
IAUCs for melatonin, insulin, glucose, NEFAs, TAGs and cortisol were calcu-
lated between -360 to +330 min, are shown in Figure 4.8. IAUCs for salivary mela-
tonin and plasma NEFA were significantly greater in DS than in LS (p = 0.0002
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Figure 4.7: TAUC of hormones and metabolites
TAUCs for glucose (A), insulin (B), NEFAs (C), TAGs (D), cortisol (E) and melatonin (F) (mean ± SEM)
during LS ( ) and DS ( )in all participant (n=17) (T = -360 to T = +330 min). *p < 0.05, ** p <
0.01, ***p < 0.001.
and p = 0.0086 respectively). In contrast, IAUC for plasma insulin was higher in
LS than in DS (p = 0.0004). IAUCs for plasma glucose, TAGs and cortisol were
not significantly different between the two sessions (p = 0.3, p = 0.4 and p = 0.3
respectively).
4.6.4.6 HOMA-PP and HOMA-IR
HOMA-PP and HOMA-IR are shown in Figure 4.9. HOMA-PP was greater but
not significant in LS (49802 ± 6428) than DS (41607 ± 6141) (p = 0.09). Similarly,
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Figure 4.8: IAUC of hormones and metabolites
IAUCs for glucose (A), insulin (B), NEFAs (C), TAGs (D), cortisol (E) and melatonin (F) (mean ± SEM)
during LS ( ) and DS ( )in all participant (n=17) (T = -360 to T = +330 min). p < 0.05, ** p < 0.01,
***p < 0.001.
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Figure 4.9: HOMA-IR and HOMA-PP
HOMA-IR (A) and HOMA-PP (B) (mean SEM) during LS ( ) and DS ( ) in all participant (n = 17)..
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Figure 4.10: Brachial and carotid vascular parameters
Pre-prandial and postprandial B-PWV (A), C-PWV (B), C-PAG (C), AGI (D), B-PPI (E), and C-PPI (F)
(mean ± SEM) during LS ( ) and DS ( ) in all participants (n=17) (T = -285 to T = +90 min).
HOMA-IR was higher, yet not significant, in LS (1.2 ± 0.1) compared to DS (1.1
± 0.1) (p = 0.3).
4.6.5 Vascular function tests
4.6.5.1 Pre-prandial vascular parameters (-285 & -120 min)
Pre-prandial vascular parameters in Figures 4.10 & 4.11 showed no significant dif-
ferences between LS and DS apart from a significantly higher SV in DS compared
to LS (p = 0.04), and a trend towards a significant increase in APP in DS compared
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Figure 4.11: Vascular function parameters
Pre-prandial and postprandial HR (A), SBP (B), DBP (C), PP (D), ABP (E), APP (F), CO (G), TPR
(H), SV (I), and MAP (J) (mean ± SEM) during LS ( ) and DS ( ) in all participants (n = 17) (T =
-285 to T = +90 min).
139
to LS (p = 0.06). Also, no differences in gender or time points at pre-prandial levels
were observed.
4.6.5.2 Post-prandial vascular parameters (+30 & +90 min)
There were differences between LS and DS at the postprandial time such as in CO,
TPR, APP, HR, C-PPI and AGI, yet not significant. The significance difference
was only shown at PAG (p = 0.03) at the postprandial time (Figure 4.10 & 4.11).
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4.6.5.3 Pre and postprandial vascular parameters (T = -285 to T =
+90)
PAG was significantly higher in DS than in LS (p = 0.04), and the difference was
only shown at postprandial times (T = +30 and +90 min). Other vascular parame-
ters showed no significant differences between LS and DS. However, a trend toward
a significant difference in SV and APP was shown between LS and DS (p = 0.06 and
p = 0.07) There were significant effects of time in all vascular parameters except in
PWV, MAP and C-PPI. No significant difference between male and females in all
measured parameters (Figure 4.10 & 4.11).
4.6.6 Continuous glucose monitoring: interstitial glucose
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Figure 4.12: Pre-prandial and postprandial interstitial glucose
Interstitial glucose (mean ± SEM) levels prior to and after the evening test meal (time = 0 min black dotted
line) during LS ( ) and DS ( ) in males (n = 9), females (n = 8) and all participants (n=17). The data
plotted in Figure 4.12 are between -230 to +300 min..
4.6.6.1 Pre-prandial and postprandial interstitial glucose
Interstitial glucose showed no significant differences between LS and DS (p = 0.2).
There was a trend for increased pre-prandial interstitial glucose in LS compared
to DS (p = 0.07), but no difference at post-prandial times. There were significant
effects of time (p < 0.01), but not gender (p = 0.77) (Figure 4.12). However, Figure
4.13 showed that males tend to have higher postprandial interstitial glucose levels
than females (LS: p = 0.83 and DS: p = 0.41), whereas pre-prandial interstitial
glucose were non-significantly higher in females than males.
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Figure 4.13: Gender differences in interstitial glucose
Pre-prandial and postprandial interstitial glucose (mean ± SEM) of 9 males ( ) and 8 females ( ) in
LS (A) and DS (B). The data plotted in Figure 4.13 are between -230 to +300 min.
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Figure 4.14: TAUC and IAUC of interstitial glucose
TAUC (A) and IAUC (B) for interstitial glucose (mean SEM) during LS ( ) and DS ( ) in all partici-
pants (n = 17)..
4.6.6.2 TAUC and IAUC of interstitial glucose
Figure 4.14 shows the TAUC and IAUC of interstitial glucose in LS and DS between
-230 to +300 min. TAUC of interstitial glucose were 528 ± 26 mmol/l.min in LS,
and 499 ± 19 mmol/l.min in DS. No significant differences were observed in TAUC
of interstitial glucose between LS and DS (p = 0.2), nor in IAUC between LS (111
± 15 mmol/l.min) and DS (99 ± 10 mmol/l.min) (p = 0.4).
4.6.7 Appetite data analysis
Three main questions from the food VAS scales completed on the Pro-Diary were
analysed. These were hunger, desire to eat and fullness scores. Statistical analysis
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was carried out and the results are shown below. Table 4.8 shows repeated measures
ANOVA of the appetite parameters.
-15 15 45 105 165 225 285
0
5
10
Time (mins)
In
cr
ea
si
n
g
H
u
n
g
er
A  Hunger score
p = 0.01
-15 15 45 105 165 225 285
0
5
10
Time (min)
In
cr
ea
si
n
g
d
es
ir
e
to
ea
t
B  Desire to eat score
p = 0.009
-15 15 45 105 165 225 285
0
5
10
Time (min)
In
cr
ea
si
n
g
F
u
lln
es
s
C  Fullness score
p = 0.88
Figure 4.15: Subjective appetite questionnaires
Subjective hunger (A), desire to eat (B), and fullness (C) ratings (mean ± SEM) after the evening test meal
(time = 0 black dotted line) during LS ( ) and DS ( ) all participants (n = 17).
Table 4.8: Analysis of appetite parameters
Factor / Parameter Hunger (p-Value) Desire to eat (p-Value) Fullness (p-Value)
Gender 0.107 0.264 0.882
Treatment 0.013* 0.009** 0.572
Time point <0.001** <0.001** <0.001**
*p < 0.05; ***p < 0.001
4.6.7.1 Subjective appetite parameters
Figure 4.15 plots the effect of LAN on how hungry the participants felt (A), how
much participants wanted to eat (B), and how full the participants felt (C) after the
evening test meal in LS and DS. Participants felt more hungry in LS than DS (p =
0.01), and post-hoc tests showed significant differences at 0, +15, +30 and +45 min
after the meal. Similarly, a significantly higher score in desire to eat in LS compared
to DS (p = 0.009), and post-hoc test showed significant differences at +15 and +30
min after the meal. No significant differences was seen in fullness score between LS
and DS (p = 0.57), but there was a significant interaction of treatment x time in the
fullness rating (p = 0.01). There was a significant effect of time in all three scores,
yet no significant effects of gender (Table 4.8). Females in LS had an increase in
hunger, desire to eat, and fullness compared to DS. However, this increase was not
significant in the female group and interaction. Additionally, data obtained did not
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demonstrate a clear difference in the effect of LAN on subjective appetite score in
the male group.
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Figure 4.16: Pre-prandial and postprandial plasma leptin (Raw data)
Plasma leptin (mean ± SEM) levels prior to and after the evening test meal (time = 0 min black dotted
line) during LS ( ) and DS ( ) in males (n = 9), females (n = 8) and all participants (n = 17) (T =
-360 to T = +330 min).
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Figure 4.17: % basal leptin concentration
% basal lepin concentration directly prior to the test meal (T = 0 min) (A), and at time -360 min (B),
prior to and after the evening test meal (time = 0 min black dotted line) during LS ( ) and DS ( )in
all participants (n = 17) (T = -360 to T = +330 min).
4.6.7.2 Pre-prandial and postprandial plasma leptin
Plasma leptin responses are shown in Figure 4.16. Plasma leptin showed a trend
toward a significant increase in LS compared to DS (p = 0.08) on the raw data.
Plasma leptin was significantly greater in females than in males (p < 0.001). A
significant interaction between time x gender (p < 0.001) and treatment x time (p
= 0.03) were observed. There was a significant effect of time (p < 0.001). When
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Figure 4.18: Gender differences in plasma leptin
Pre-prandial and postprandial plasma leptin (mean ± SEM) of 9 males ( ) and 8 females ( ) in LS (A)
and DS (DS) (T = -360 to T = +330 min).
the data was calculated as % leptin of T = 0 or -360 min, responses were greater
at postprandial time, but not significant, in DS compared to LS (p = 0.59 and p =
0.95) respectively (Figure 4.17). Figure 4.18 shows a significant difference between
males and females in both light conditions, as females had higher levels of plasma
leptin than males in LS (p = 0.02) and DS (p = 0.01).
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Figure 4.19: TAUC and IAUC of plasma leptin
TAUC (A) and IAUC (B) for plasma leptin (mean SEM) during LS ( ) and DS ( ) in all participants
(n = 17).
4.6.7.3 TAUC and IAUC of plasma leptin
Figure 4.19 shows the TAUC and IAUC of plasma leptin in LS and DS between
-360 to +330 min. TAUC of plasma leptin in LS was 8711.58 ± 2081.27 ng/ml.min,
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and 7506.88 ± 1582.48 ng/ml.min in DS. No significant difference was reported in
TAUC of plasma leptin between LS and DS (p = 0.17), nor was there a significant
difference of IAUC between LS (1104.98 ± 302.14 ng/ml.min) and DS (932.24 ±
225.54 ng/ml.min) (p = 0.42).
4.6.8 Peripheral body temperature
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Figure 4.20: Pre-prandial and postprandial wrist temperature (◦C)
Wrist temperature (mean ± SEM) levels prior to and after the evening test meal (time = 0 min black dotted
line) during LS ( ) and DS ( ) in all participants (n=11; 4 males & 7 females). A: wrist temperature
data -285 to +285 min, B: averaged data 15 min epochs -285 to +285 min.
4.6.8.1 Pre-prandial and postprandial wrist temperature
Raw data of wrist temperature obtained from 11 participants are shown in Figure
4.20. Wrist temperature was similar in both study session (p = 0.16). The data
were averaged every 15 mins, to show a more detailed representation of differences in
both sessions. Also, data were analysed across pre-prandial (A) and postprandial
(B) periods to identify the impact of the evening test meal (Figure 4.21). No
significant difference was shown for the pre-prandial period between LS and DS (p
= 0.47), whereas a trend toward higher wrist temperature during the postprandial
period was seen in LS compared to DS (p = 0.08, and condition x time p < 0.001).
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Figure 4.21: Pre-prandial (A) and postprandial (B) wrist temperature (◦C)
Wrist temperature (mean ± SEM) levels prior to and after the evening test meal supper (time = 0 black
dotted line) during LS ( ) and DS ( ) in all participants (n=11; 4 males & 7 females) at 15 min intervals.
A: wrist temperature between -285 to 0 mins, B: wrist temperature between +15 to +285. Abbreviation:
WT (wrist temperature).
4.6.9 Interaction between melatonin, subjective mood-alertness and wrist
temperature
Figure 4.22 and 4.23 showed the interaction between salivary melatonin levels and
subjective KSS, alertness, mood scores and wrist temperature in LS and DS. As
melatonin levels rise during DS, KSS, mood scores and wrist temperature increase,
whereas the alertness score decrease. Similarly, KSS, mood scores, WT increased,
and alertness decreased, as salivary melatonin slightly increased during LS. Cor-
relation tests were applied between melatonin versus WT, and subjective mood
and alertness. As included in appendix V, no correlations were reported between
salivary melatonin and the previous parameters in both lighting conditions.
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Figure 4.22: Melatonin interaction with subjective KSS, alertness, mood scores
and wrist temperature in LS
Data are presented as mean. For the purpose of comparison, melatonin levels were plotted against wrist
temperature (A), KSS (B), alertness (C), mood 1 (D), mood 2 (E), and mood 3 (F). Schematic figure
represents pre-prandial and postprandial data for all participants (n = 17) (T = -300 to T = +330).
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Figure 4.23: Melatonin interaction with subjective KSS, alertness, mood scores
and wrist temperature in DS
Data are presented as mean. For the purpose of comparison, melatonin levels were plotted against wrist
temperature (A), KSS (B), alertness (C), mood 1 (D), mood 2 (E), and mood 3 (F). Schematic figure
represents pre-prandial and postprandial data for all participants (n = 17) (T = -300 to T = +330).
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4.7 Discussion
Few studies have investigated the influence of light at night on hormones, metabo-
lites, appetite control, vascular function, and behavioural responses in healthy young
individuals, since a majority of the studies reported have either been carried out
on experimental animals (Kawashima et al., 1987; Coomans et al., 2013) or under
restricted conditions in humans such as a constant routine (Kra¨uchi et al., 1997a;
Mazepa et al., 1999; Scheer et al., 2009; Wehrens et al., 2010; Peschke et al., 2013)
and/or involved the administration of exogenous melatonin (Cagnacci et al., 2001;
Nishida et al., 2003; Chuang et al., 1993; Koziro´g et al., 2011). This is the first study
to investigate the effects of bright light exposure at night on hormones, metabolites,
appetite control, vascular function, and behavioural responses prior to and after an
evening test meal in healthy young individuals by exposing them to two light con-
ditions: light (> 500lux), equivalent to light intensity in the workplace, and dark
(< 5 lux) equivalent to candlelight.
4.7.1 Participant demographics
Seventeen participants, 9 males and 8 females, completed this study. There were no
significant differences in anthropometric data between males and females. This is
important as differences in anthropometric data can influence hormone, metabolic,
and vascular data. Males and females reported no significant differences in alcohol
and caffeine consumption per week over a month prior to the study session; however,
no caffeine, alcohol or carbonated drinks consumption was allowed 24-hours prior
the study session to exclude their effects. All participants were healthy, with no
significant medical history or food allergies. All participants were non-smokers
and within the criteria of age and BMI. All female participants were taking oral
contraceptive pills, and they were at the same menstrual phase during light and
dark sessions to minimise the variations in sex hormones (Table 2.1).
4.7.2 Analysis of screening data
Our participants reported a good sleep quality over a month before the study ses-
sion, and no differences reported from actigraphy data between males and females.
150
According to MEQ, our participants were neither morning nor evening chronotype.
It is crucial to define the chronotype of participants as some studies have linked
chronotype to metabolic risks (Reutrakul et al., 2013; Yu et al., 2015). Participants
who reported morning or evening chronotype were analysed carefully, to identify
whether they exhibited any differences in metabolic or vascular patterns. Our re-
sults showed that morning type participants reported an early mid-sleep time in
comparison to other chronotypes (Table 4.1). Mid-sleep time obtained from Mu-
nich chronotype ranged between 03:30h to 07:30h, yet no differences were reported
between male and females. It is understandable that a student lifestyle is not as
stable as a worker, therefore a wide range of mid-sleep times would be expected in
students compared to workers who need to compensate for sleep deprivation during
weekdays. Our results are in accordance with Zavada et al. (2005) with a strong
correlation between MSF and MEQ as reported during screening (r = -0.6, and
p = 0.01 ) (Zavada et al., 2005). Our results agree with the correlation reported
between physiological phase markers such as melatonin and chronotype question-
naires including MCTQ (Andrade et al., 1992; Dijk and Duffy, 1999; Bailey and
Heitkemper, 2001). We reported positive correlation between melatonin onset and
MCTQ (r = 0.5, p = 0.01), but not MEQ (r = -0.2, p = 0.10) (Table 4.7).
There were two sessions with a week gap in Study 1, yet participants were
requested to keep a consistent sleep pattern. Therefore, sleep parameters derived
from actiwatch data were analysed a week prior to each clinical session. Participants
reported consistent sleep patterns as shown in Table 4.7. Sleep parameters such as
duration, sleep start and end, efficiency, latency, and fragmentation index showed
no significant difference over the week before LS or DS (see Table 4.7). This is
important to ensure no changes in circadian phase as determined from the urine
collection prior to session one. An irregular sleep pattern may alter melatonin
onset, as a positive correlation between sleep start and urinary melatonin onset was
observed (r = 0.7, p = 0.01).
4.7.3 Cosinor analysis and melatonin onset
Melatonin onset was estimated from the sequential 48-h urine collection at least
5 days before the study session to define the test meal time, and determine the
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fasting period between lunch and supper time. The test meal was given 30 mins
after estimated melatonin onset to ensure that sufficient amount of plasma mela-
tonin circulating at the meal time. Several studies have shown a high degree of
correlation between the nocturnal measurement of urinary aMT6s and plasma and
serum melatonin levels (Graham et al., 1998; Cook et al., 2000; Pa¨a¨kko¨nen et al.,
2006). Urinary aMT6s measurement is non-invasive and highly reproducible. Lev-
allois et al. (2001) measured urinary aMT6s over two consecutive days and found
a high correlation (r = 0.92) (Levallois et al., 2001). The longest time period over
which urinary melatonin was investigated was 5-years, and the reported correlation
was 0.56 (Travis et al., 2003). To ensure that melatonin onset determined from
urine collection was accurate, the salivary melatonin data was used to retrospec-
tively determine the actual melatonin onset in LS and DS, allowing comparison of
the melatonin onset derived from salivary data with the estimated melatonin onset
from urine samples (Table 4.3). The estimated urinary melatonin onset was at least
1 hour in later of the salivary melatonin onset. As shown in Figure 4.5 and 4.6,
and Table 4.3 , all participants showed sufficient rising of salivary melatonin before
the evening test meal indicating that evening test meal timing was targeted after
melatonin onset (Table 4.3).
4.7.4 Salivary melatonin
The results demonstrate that salivary melatonin levels are reduced significantly
by bright light exposure at night (p < 0.001). The light intensity delivered to
participants eyes during the LS was 305 lux (horizontally) and 552.7 lux (vertically)
in the angle of gaze, which is similar to lighting levels in an office environment.
This led to a dramatic reduction of salivary melatonin concentration by 69% in
comparison to DS. The amplitude of the melatonin rhythm in LS was 9.56 pmol/ml
and 25.32 pmol/ml in DS, indicating a reduction in melatonin amplitude in LS
by 62%. Melatonin onset during the LS was delayed by about 1.5h agreeing with
Gooley et al. (2010) who reported an earlier melatonin onset by more than an hour
(1.78 h) in dim light compared to bright light (Gooley et al., 2010). Melatonin
offset in this study was not possible to determine as sampling ended at 06:00h
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before levels returned to baseline (Figure 4.5). In this study, light exposure began
at 18:00h and finished at 06:00h the next day, covering the usual period of nocturnal
melatonin secretion and the expected suppression of melatonin was seen. To ensure
that melatonin levels were not affected by body position, participants remained in
semi-recumbent position, as Kozaki et al. (2013) reported a significant increase of
salivary melatonin concentration in standing position than in sitting position (?).
Participants were kept under normal room light (between 100 to 50 lux) between
lunch time and beginning of the session and were not allowed to leave the controlled
lighting area which might have potentially modulated the melatonin suppression
response to electrical light at night (sensitisation).
Our results indicate that salivary melatonin concentration is greater but not
statistically significant in females than in males under both light conditions (Figure
4.8). This agrees with Cain and colleagues (2010) who showed a significantly higher
melatonin amplitude in females than males (Cain et al., 2010). They also showed
earlier DLMO in females than males by 96 minutes, whereas in our study the females
DLMO was earlier than males by 31 minutes, however, this was only a small number
of participants.
4.7.5 Plasma glucose and insulin
Plasma glucose responses were significantly elevated three hours after the meal in the
LS (p = 0.02), confirmed by TAUC and IACU analysis. Increases in postprandial
plasma glucose responses following both meals in LS and DS were followed by a
rise in insulin levels. Insulin levels were significantly elevated after the meal in LS
compared to the DS (Figure 4.5). Raised glucose and insulin responses suggest
changes in glucose tolerance and insulin sensitivity. Calculation of HOMA-PP and
HOMAIR confirmed these findings although significance was not achieved (Figure
4.9). Our present data agrees with recent studies that showed decreased blood
glucose and insulin in constant darkness (Arasteh et al., 2010; Zhang et al., 2006),
whereas only increased blood glucose in constant light (Challet et al., 2004; Arasteh
et al., 2010) was reported compared to both plasma glucose and insulin in our
present study. Our results are also in accordance with recent evidence observed in
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sleep deprivation (Spiegel et al., 1999; Saper et al., 2005; Wehrens et al., 2010) and
circadian misalignment (Scheer et al., 2009) such as in jet lag and shift work, which
have shown an increase in postprandial glucose at the same time as increased insulin
which denotes insulin insensitivity and failure of beta cell compensation (Kreier
et al., 2006). In our present study, participants were sleep deprived in both light
sessions indicating that postprandial changes obtained are unlikely to be mainly due
to sleep deprivation or circadian misalignment. Moreover, plasma cortisol was not
statistically different between the two light sessions, however, postprandial cortisol
levels are higher, but not significant, in LS compared to DS. This could contribute
to an increase in postprandial plasma glucose, as cortisol is known to counteract
insulin action and increase glucose levels. As mentioned in Chapter 1, epinephrine
and norepinephrine enhance glucose release into the circulation and inhibit insulin
production in the pancreas. However, both epinephrine and norepinephrine were
not investigated in this study. Plasma glucagon analysis would aid explanation of
plasma glucose changes, as it has been reported that melatonin can induce glucagon
secretion via IP3 and DAG (Gromada et al., 1997; Peschke et al., 2013).
The differences observed in glucose tolerance, and insulin sensitivity could be
due to the presence of melatonin in the DS, as melatonin has been reported to
inhibit insulin secretion, thus influencing blood glucose levels (Peschke et al., 2002;
Picinato et al., 2002). Our results agree with Sartori et al. (2009) that melatonin
administration ameliorates impaired glucose tolerance and insulin resistance in high-
fat-diet-fed insulin resistant mice by enhancing insulin-mediated vasodilation in
skeletal muscle thereby increasing glucose utilization (Sartori et al., 2009). This was
supported by other findings that melatonin prevents insulin resistance by enhancing
glucose uptake and promoting glycogen synthesis (Shieh et al., 2009).
Our results are in disagreement with recent findings that showed melatonin
administration increased plasma glucose and insulin (Cagnacci et al., 2001; Rubio-
Sastre et al., 2014). Rubio-Sastre et al. (2014) reported a human study that gave
exogenous melatonin before an oral glucose tolerance test (OGTT) in the morning
and evening which resulted in raised insulin and glucose responses in the evening
compared to placebo (Rubio-Sastre et al., 2014). They used a single dose of im-
mediate release exogenous melatonin and the oral glucose tolerance test, whereas
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in our study endogenous melatonin, light at night, and a standard test meal were
incorporated. The sleep-wake cycle of participants in the Rubio-Sastre (2014) study
was not recorded, which could influence metabolite changes. Using a single dose of
immediate release melatonin would saturate melatonin receptors with supraphysio-
logical melatonin levels. Variability of absorption rates in the oral glucose tolerance
test (OGTT) compared to our study that provided a standard evening meal could
contribute to the result differences observed (Rubio-Sastre et al., 2014). The in-
corporation of a meal in our study resulted in hormone and metabolic responses
involved in lipid metabolism as well as carbohydrate metabolism.
4.7.6 Plasma cortisol
Plasma cortisol showed no significant difference between LS and DS (Figure 4.5).
The study duration covers the end of descending phase and beginning of the as-
cending phase of the cortisol rhythm. Pre-prandial cortisol was higher, yet not
significant, in DS than in LS. Jung et al. (2010) reported higher cortisol levels in
dim light compared to bright light exposure during the descending phase, which is
equivalent to the preprandial part of our study. Whereas, the slight rise in post-
prandial cortisol in LS could be a normal physiological response to the evening meal
(Jung et al., 2010). High postprandial cortisol could explain the significant increase
in postprandial plasma glucose. Low cortisol levels in DS can be explained by
the inhibitory effect of melatonin on ACTH-stimulated cortisol production, as high
MT1 expression was reported in the adrenal gland (?Torres-Farfan et al., 2004).
Female participants showed higher plasma cortisol than males (p = 0.039) (Figure
4.6), which is consistent with other previous studies in older people (Gusenoff et al.,
2001; Laughlin and Barrett-Connor, 2000). Cortisol levels vary based on gender,
age, cortisol measurements (total cortisol or free cortisol), and time of sample col-
lection (Karlamangla et al., 2013). This could explain the inconsistencies in cortisol
levels between male and females.
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4.7.7 Lipid profile
Plasma NEFA in the DS was significantly increased during the fasting period prior
to the meal which could be due to the stimulatory effect of melatonin on glucagon
(Ba¨hr et al., 2011; Peschke and Mhlbauer, 2010). The main significant difference
was clearly observed just before the test meal when melatonin levels were already
raised (Figure 4.5). Melatonin has also been linked to increased sympathetic action
which in turn induces HSL activity (Song and Bartness, 2001). For instance, cate-
cholamine influences lipolysis, by binding to β-adrenoreceptors, resulting in activa-
tion of HSL, thus increasing lipolysis action (Langin et al., 2000; Holm, 2003). This
could explain the possible impact of catecholamines on pre-prandial NEFA changes.
Also, the absence of the inhibitory effects of insulin on HSL, either due to melatonin
or the fasting state, is considered the major activating factor for HSL. Additionally,
the hyperinsulinaemic state could enhance hepatic conversion of NEFAs to TAGs
and suppress lipid mobilisation by LPL (DeFronzo, 1988), which could explain why
no changes in postprandial NEFA were observed. Despite the significant increase of
insulin in LS, there appears to be no increase in LPL activity as TAG levels are sim-
ilar in both light conditions (Figure 4.5). Monitoring TAG responses for longer may
have been useful since levels normally take ∼9h to return to basal levels after a meal
(Ribeiro et al., 1999; Lund et al., 2001; Sopowski et al., 2001). Melatonin inhibits
LPL activity, and may favourably affect lipid metabolism in hyperlipdaemic sub-
jects but not in normolipidaemic subjects (Reaven, 1988; Wakatsuki et al., 2001).
In contrast, LAN in an uncontrolled home setting was associated with higher TAGs,
LDL and odds ratio (OR) of obesity and dyslipidaemia than dim light in elderly par-
ticipants. Interestingly, no significant difference in urinary melatonin was reported
indicating that LAN is associated with impaired lipid parameters independent of
nocturnal urinary melatonin, or even plasma melatonin (Obayashi et al., 2012).
Our data reported no differences in NEFA levels between males and females,
whereas males showed higher TAGs levels than females in both light conditions
(Figure 4.6). BMI was matched between the genders indicating no correlation be-
tween BMI and TAGs levels. TAUC and IAUC confirmed the significant increase
in NEFA levels in DS compared to LS, whereas no difference was reported in TAG
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levels between LS and DS (Figure 4.7 and 4.8).
4.7.8 Mood and alertness
Our results show no significant difference in subjective KSS and alertness between
LS and DS as shown in Figure 4.2. This disagrees with other researches that showed
an increase in the alerting response and a reduction in sleepiness in bright light
exposure (Cajochen et al., 2005, 2011; Chellappa et al., 2011; Mu¨nch et al., 2011;
Cheung et al., 2016). This discrepancy could be due to the different study design,
monochromatic short wavelength light by Cajochen et al. (2005), while the study
reported here used polychromatic fluorescent light. Also, white fluorescent light was
used in our study in comparison to blue-enriched light (Chellappa et al., 2011), and
LED light (Cajochen et al., 2011). The data were also analysed separately over the
pre-prandial, and postprandial periods to investigate the effect of the meal since
food intake has been associated with alertness and performance (Paz and Berry,
1997; Wells et al., 1998). Our results showed no significant differences in KSS and
alertness during preprandial and postprandial time indicating that the meal exerted
no effect on subjective KSS and alertness.
Melatonin interacts with body temperature and alerting response in our study.
Our results showed a significant difference in endogenous melatonin between LS and
DS, however, no difference was observed in peripheral temperature. No correlation
was reported between melatonin and subjective mood and alertness in either LS
and DS (Appendix-6.7). This indicates that despite the significant differences in
endogenous melatonin, no alteration in subjective sleepiness and alertness was ob-
served. These results are in agreement with other studies that showed light-induced
melatonin suppression was not related to an increase in alertness (Dollins et al.,
1993). Thus, melatonin suppression is not the only factor modulating alertness,
or melatonin would determine alertness to some extent. No gender differences in
sleepiness and alertness were reported between LS and DS. However, the females
felt sleepier than males in both LS and DS (Figure 4.2 and 4.3). There was a trend
towards gender differences in subjective alertness, yet not statistically significant.
This could be explained by the differences in salivary melatonin levels between male
and females.
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Our results showed no significant differences in cheerfulness and calmness rat-
ings (Figure 4.2 and 4.3), which contradicts the increased scores of calmness and
cheerfulness in both blue (λ 456 nm) and green (λ 548 nm) monochromatic light,
where significant differences were reported between light conditions (Sletten et al.,
2009). However, our participants felt more depressed in DS compared to LS in-
dicating the possible therapeutic effects of light for depressive symptoms. Bright
light was reported to decrease anxiety and mood symptoms in 58 patients (Bax-
endale et al., 2013) agreeing with our recent results. Light, particularly blue light,
can modulate emotional processes via the amygdala structure in the brain which is
involved in motivation, and emotion (Vandewalle et al., 2007) (section 1.5.5). Our
data reported no significant effects of gender on calmness, cheerfulness or depres-
sion in either light conditions (Figure 4.3). It was expected that mood scores would
fluctuate across the study period, and significant effects of time (p < 0.001) were
observed in all subjective mood scores. Calmness, cheerfulness and depression were
assessed over the pre-prandial and postprandial periods, and no significant effects
of meal intervention were seen (Figure 4.2 & 4.3).
Our results indicate that participants felt more depressed in the dark where
endogenous melatonin levels were significantly higher. This result agrees with higher
melatonin levels reported in SAD patients compared to healthy controls (Danilenko
et al., 1994; Wehr, 2001). In addition to melatonin, elevated cortisol levels were
observed in studies showing elevated mood and alertness as an effect of bright light
intervention (Monk et al., 1997; Kakooei et al., 2010). This implies that increased
levels of cortisol might be the cause of enhanced mood and alertness. However,
our study reported no significant differences in plasma cortisol between LS and DS
indicating that cortisol is not the key to the higher elation score in LS.
4.7.9 Peripheral body temperature (WT)
The circadian rhythm of DST is inversely related to the CBT circadian profile (Sara-
bia et al., 2008; Martinez-Nicolas et al., 2013), this is related to the physiological
response of the periphery to maintaining a stable CBT. Therefore, a positive corre-
lation between melatonin level and DST (WT) was expected inducing physiological
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sleepiness and reduce body alertness, however our results showed no correlation be-
tween melatonin and WT (Appendix-V). Our data showed that WT is greater, yet
not significant, in LS than in DS (Figure 4.20). This contradicts with many stud-
ies that showed melatonin suppression by bright light resulted in increased CBT
(Wright Jr et al., 2000; Burgess et al., 2001). This raises a question, if melatonin
causes temperature drops in CBT during night time in earlier studies, then should
the DST increase to facilitate the heat loss of CBT? This could be more obvious at
the postprandial time, since melatonin onset occurs around 1 to 1.5 h prior to the
evening meal. However, DST increases slightly during LS compared to DS, indicat-
ing that as melatonin level drops, DST increases. At pre-prandial time, WT showed
higher readings, yet not significant, in LS than in DS, despite the low level of mela-
tonin. This raise a major question if LAN is the major key in DST changes and not
the endogenous melatonin. In this study, we could not ultimately relate the change
in DST to endogenous melatonin, or LAN alone, or the physiological response of
CBT. Masking factors such as room temperature were controlled during LS and DS
to avoid environmental effects on body temperature. Behavioural masking was less
controlled, as if certain participants preferred to stay underneath blankets at times
thus causing an increase in WT. The average room temperature was documented
(T ∼ 25 ◦C), however an hourly documented temperature is needed to correlate
outside temperature to changes in WT.
4.7.10 Appetite analysis
The effect of LAN on satiation to a standard test meal showed a significant increase
in subjective hunger and the desire to eat in the LS compared to the DS (Figure
4.15). This is consistent with findings from experiments in rats that showed an
increase in food intake as a result of constant light exposure (Mustonen et al.,
2001). Since LAN results in melatonin suppression, the impact of melatonin on
appetite must be considered. The inhibitory effect of melatonin on food intake
was shown in goldfish after intraperitoneal injection (Pinillos et al., 2001). It is
suggested that melatonin acts directly on the digestive tract by influencing the
biomarkers of satiation that are secreted in the digestive tract (Cummings and
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Overduin, 2007; Kostoglou-Athanassiou, 2013), or a possible action of the CNS
is feasible. A study by Bubenik and Pang hypothesised that melatonin acts in
conjunction with serotonin to induce the anorexic effect (Bubenik and Pang, 1994;
Pinillos et al., 2001).
Our results showed a trend toward increased plasma leptin in LS compared to
DS (Figure 4.16). Plasma insulin was significantly higher postprandially in LS com-
pared to the DS, which could result in increased plasma leptin in LS, as insulin has
been reported to stimulate leptin levels in rats and humans (Kolaczynski et al.,
1996; Barr et al., 1997). The raw leptin results are difficult to interpret as lower
leptin levels in the dark compared to light contradicts the subjective satiation re-
sults. % basal leptin concentration resulted in raised levels during the dark session
that could contribute to the significant increase in hunger and desire to eat in light
compared to dark (Figure 4.17). This is consistent with reduced plasma leptin as
a result of melatonin administration that has been reported in middle-aged rats
(Rasmussen et al., 1999) and goldfish (Pinillos et al., 2001).
Our results showed no significant effect of light on subjective fullness (Figure
4.15). This could be due to individual differences in the meal portion size they
were accustomed to eat, which could have influenced their fullness in the controlled
laboratory condition. Also, factors like occupational and sporting activities were not
taken into consideration. For instance, individuals like gymnasts, athletes and ballet
dancers adopt a particular eating pattern to maintain a constant satiation even in
the presence of external cues (Haworth-Hoeppner, 2000). Moreover, different eating
patterns amongst the mixed cultural backgrounds of our participants could play a
part (Kral, 2006; Su and Arab, 2006; Ohkuma et al., 2013). PRO-Diary results
showed no significant differences between male and females in subjective hunger,
desire to eat and fullness. However, there was a significantly greater leptin response
in females than in males (Figure 4.18). This agrees with other studies that reported
higher leptin levels in females than males (Hickey et al., 1996; Kennedy et al., 1997),
as circulating leptin is primarily a function of adiposity and proportional to adipose
distribution.
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4.7.11 Vascular functions
B-PWV and C-PWV increased in LS during the postprandial time, whereas pre-
prandial B-PWV and C-PWV showed an inconsistent increase in DS compared to
LS (Figure 4.10). Our data are in accordance with Yildiz et al. (2006) who showed
a reduction in carotid-femoral PWV in the supine position in healthy young men
as a result of melatonin administration (Yildiz et al., 2006). This could explain the
postprandial decrease of C-PWV and B-PWV in DS, which could be due to the
rise in endogenous melatonin prior to the evening test meal. Central or peripheral
augmentation is another index of arterial stiffness. Our data showed a significant
increase in postprandial PAG but not in AGI during DS. A similar increase was
shown in C-PPI and F-PPI, however, no significant differences were achieved. Our
data is in disagreement with the cardiovascular risk associated with LAN, as higher
PAG and AGI are observed in DS compared to LS. Moreover, AGI is inversely
proportional to PPI (Shimizu and Kario, 2008), yet PPI is greater in DS than LS,
indicating possible device errors. Add to this PAG is defined as the ratio of late
systolic pressure (P2) to early systolic pressure (P1), yet no difference was observed
in systolic pressure between LS and DS (Figure 4.11). AGI is directly proportional to
diastolic pressure and high cholesterol levels (Fantin et al., 2007), however, diastolic
pressure showed no differences between LS and DS, and plasma cholesterol was not
investigated in this study (Figure 4.11).
A slight increase in heart rate in LS compared to DS, but not significant, agrees
with human studies that have shown an increase in heart rate with bright light
exposure (Scheer et al., 1999). It is known that heart rate is inversely proportion to
stroke volume (CO = HR X SV). This could explain the trend towards an increase
in stroke volume in DS compared to LS. It also indicates the direct proportion
between SV and CO which show an increase in DS. It was shown that melatonin
administration results in sympathetic reduction and parasympathetic stimulation
which leads to reduced heart rate and blood pressure (Reppert et al., 1988; Chuang
et al., 1993). Blood pressure parameters showed no consistent patterns either both
light session, indicating that neither LAN (LS) nor endogenous melatonin cause
changes in blood pressure. Our data disagreed with recent studies that suggested
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the role of melatonin in reducing sympathetic tone by either enhancing GABA-ergic
signalling (Kalsbeek et al., 2000; Patel et al., 2001; Wang et al., 2003) or altering
serotonin levels (Chuang et al., 1993). Consequently, total peripheral resistance
which ultimately varies with changes in blood pressure, showed no differences be-
tween LS and DS, as TPR is directly proportional to pressure. Despite the trend
for an increase in APP and SV in DS compared to LS, it is noteworthy that PWA
methods, which the Vicorder relies on, assume that SV is proportional to APP (or
pulse pressure) (Ishihara et al., 2004; Convertino et al., 2006; Bataille et al., 2012).
Therefore pulse pressure has been widely used as a convenient surrogate of SV in
diagnostic and therapeutic procedures such as fluid therapy (Papaioannou et al.,
2012). This also clearly explains the slight increase in pulse pressure in DS, despite
no clear differences in SBP or DBP (Figure 4.11).
4.7.12 Conclusion
In conclusion, the current study indicates a substantial impact of light at night on
hormones, metabolites, appetite control, and behavioural responses, but no signifi-
cant changes in vascular function. This study indicates that LAN can exert an acute
effect on subjective mood (depression), subjective appetite, hormones (insulin and
melatonin) and metabolites (glucose and NEFA). The acute effect of LAN on mood
tends to be positive which agrees with many studies indicating the use of light in
SAD treatment. However, the acute effects of LAN on subjective appetite, hormone
and metabolic responses suggest the possible development of metabolic disorders
with long-term LAN exposure. Our current data agree with the changes in metabo-
lites and hormones reported in night-shift workers. However, the exact mechanism
of action of LAN on hormones and metabolites is still unclear. This study focused
on the possible role of endogenous melatonin, and whether melatonin-suppression
by LAN could be the reason for changes in behavioural and metabolic responses.
Therefore, it is important to investigate the role of melatonin in particular, on
hormones, metabolites, appetite and behaviours, as it is unclear whether changes
observed were due to melatonin or light at night or a combination of the two. For
this reason, exogenous melatonin administration will illustrate whether melatonin
is the key factor in previous changes or LAN via unknown NVR pathway.
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CHAPTER 5
THE EFFECT OF LAN AND/OR
EXOGENOUS MELATONIN ON
HORMONES, METABOLITES, APPETITE
CONTROL AND BEHAVIOURAL
RESPONSEs
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5.1 Introduction
The impact of LAN on hormones, metabolites, appetite control, and behavioural
responses was investigated in Study 1. We found that LAN influences hormones
and metabolites (section 4.6.4), subjective depression (section 4.6.3),and subjective
appetite (section 4.6.7), however, it was difficult to define whether this was due
to the light or the difference in melatonin level. The major effect of LAN is the
suppression of melatonin which could be a major reason for these observed changes.
The nature of melatonin and distribution of its receptors allows it to easily penetrate
and target different tissues to perform its functions (section 1.5.1.6).
The actions of melatonin on hormones and metabolites are controversial. Mela-
tonin administration in insulin-resistant rats resulted in reduced blood glucose and
insulin (Prunet-Marcassus et al., 2003), whereas in healthy women an increase in
plasma glucose and insulin was observed (Rubio-Sastre et al., 2014). In our first
study, endogenous melatonin suppression by LAN was associated with reduced glu-
cose tolerance and insulin sensitivity (section 4.6.4). There was also an increase in
plasma NEFAs associated with the evening rise in melatonin (Figure 4.5), indicating
the possible action of melatonin on enzymes regulating lipid metabolism (section
1.5.8.7). An increase in subjective hunger and desire to eat score with LAN was
also reported, despite no changes in plasma leptin. The suppression of endogenous
melatonin by LAN may contribute to changes in mood levels, as bright light is
recommended in the treatment of SAD individuals (section 1.5.3.2).
It was not possible to separate the effects of light from those of endogenous
melatonin in Study 1. Therefore, a second study including administration of exoge-
nous melatonin was performed. This study involved three conditions: light session
(> 500 lux), dark (< 5 lux) + exogenous melatonin, and light (> 500 lux) + exoge-
nous melatonin. This study was designed to determine if LAN influences hormones,
metabolites, subjective appetite, and behavioural responses by altering melatonin
levels.
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5.2 Aims
To investigate the influence of exogenous melatonin in the absence or presence of
bright light on preprandial and postprandial hormones, metabolic and behavioural
responses prior to and after an evening test meal by exposing participants to three
different conditions: light (>500 lux), dark (<5 lux) with exogenous melatonin and
light (> 500 lux) with exogenous melatonin.
5.3 Objectives
• To recruit 12 healthy male participants with a BMI between 18.0-28.0 kg/m2.
• To monitor and evaluate sleep/activity and light exposure prior to and during
the study session.
• To investigate the impact of exogenous melatonin and LAN on mood and
alertness.
• To assess peripheral body temperature.
• To investigate the effects of exogenous melatonin on glucose tolerance and
insulin sensitivity.
• To assess the effects of exogenous melatonin on lipid parameters such as NE-
FAs and TAGs.
• To assess the effects of exogenous melatonin on subjective appetite scores and
plasma leptin.
• To assess the effects of exogenous melatonin on subjective mood and alertness.
5.4 Hypotheses
It was hypothesised that:
• Exogenous melatonin reduces postprandial plasma glucose and insulin.
165
• LAN induces glucose intolerance and insulin insensitivity by altering mela-
tonin levels.
• Exogenous melatonin induces sleepiness and decreases alertness rates.
• Exogenous melatonin suppresses mood scores.
• LAN increases subjective appetite scores, and reduces plasma leptin.
• Exogenous melatonin increases plasma leptin and reduces satiation.
• Exogenous melatonin lowers wrist temperature.
• LAN increases activity and thus influences sleepiness and alertness.
• Exogenous melatonin reduces plasma TAGs, or LAN increases lipid profile.
• Exogenous melatonin increases preprandial plasma NEFAs.
5.5 Methods
The methods specific for Study 2 are addressed below. For general methods refer
to Chapter 2.
5.5.1 Participant demographics & screening data
Only male participants were recruited from the University of Surrey, aged between
18 to 30 years. Strict criteria were applied and described in detail in Chapter 2
(section 2.2). In this study, 12 individuals were screened and pre-study measure-
ments were carried out to ensure the eligibility of the participants, yet only nine
participants were recruited (section2.3.1).
Table 5.1 shows the screening questionnaire data for each participant. All par-
ticipants reported good sleep quality from PSQI. Three participants were found
to be moderately morning type (S004, S009 & S011), whereas 6 participants were
classified as neither type. The mid-sleep time during the free days ranged between
03:30h to 06:30h for all participants. Moderate early morning participants reported
earlier mid-sleep time compared to neither type participants.
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Table 5.1: Analysis of screening questionnaires in Study 2
Participant PSQI HO¨ Mid-sleep time (h)
S001 4 45 06:00
S002 3 47 06:30
S004 1 68 03:30
S006 5 54 04:30
S007 3 48 04:45
S008 4 57 04:15
S009 5 60 03:40
S011 3 63 03:45
S012 4 49 06:00
Table 5.2: Plasma melatonin onset, Circadin and meal timing of the participants
in Study 2
Participant Acrophase aMT6s (h) Acrophase plasma (h) DLMO (h) Circadin (h) Lunch (h) Supper (h)
S001 04:15 03:15 23:15 21:15 14:45 23:45
S002 03:45 02:45 22:45 21:45 14:15 23:15
S004 03:35 02:35 22:35 21:30 14:00 23:00
S006 03:00 02:00 22:00 20:00 13:30 22:30
S007 03:30 02:30 22:30 21:30 14:00 23:00
S008 04:00 03:00 23:00 22:00 14:30 23:30
S009 04:45 03:45 23:45 22:30 15:00 00:00
S011 05:45 04:45 00:45 23:45 15:15 01:15
S012 05:00 04:00 00:00 23:00 15:00 00:30
Urinary aMT6s acrophase, estimated melatonin onset, and timing of Circadin
and meals for each participant are shown in Table 5.2. Refer to section 2.3.2 for the
calculation used to determine meal timing. Further screening data are presented in
Table 5.5.
The evening test meal was given between 30 mins to 1 hour of estimated plasma
melatonin onset, to ensure the presence of endogenous melatonin. The fasting
period between lunch and evening test meal ranged between 9 to 10 hours (09:10
± 00:07 (mean ± SEM)) to show the adequate profile of pre-prandial hormones
and metabolites. Circadin was administrated orally 90 mins prior to the evening
test meal, to ensure elevated melatonin levels until the end of the session. Refer to
section 2.4.3 for further details about Circadin intake.
Table 5.3 shows the average excretion rate and amount of aMT6s excreted over
24 hours. All participants showed a substantial amount of aMT6s produced recorded
from the screening assessment. Estimated melatonin onset obtained from urinary
aMT6s was compared with salivary melatonin onset which was calculated as de-
scribed in section 2.3.4. There was at least 1-hour differences (01:12 ± 00:10 (mean
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Table 5.3: aMT6s urinary screening in Study 2
Subject Average aMT6s excretion rate ng/h aMT6s ng S-melatonin onset U-melatonin onset
S001
1st day 390 1st day 2128
22:02 23:15
2nd day 464 2nd day 4211
S002
1st day 1063 1st day 37933
20:32 22:45
2nd day 737 2nd day 23922
S004
1st day 2021 1st day 39250
21:50 22:35
2nd day 1002 2nd day 26394
S006
1st day 995 1st day 25736
20:35 22:00
2nd day 1073 2nd day 32043
S007
1st day 767 1st day 39568
21:05 22:30
2nd day 1021 2nd day 40154
S008
1st day 530 1st day 3490
22:30 23:00
2nd day 387 2nd day 11860
S009
1st day 160 1st day 5895
23:00 23:45
2nd day 207 2nd day 5639
S011
1st day 258 1st day 11105
23:00 00:45
2nd day 336 2nd day 19121
S012
1st day 1323 1st day 24927
23:05 00:00
2nd day 667 2nd day 14822
Abbreviation: S-melatonin onset, salivary melatonin onset; U-melatonin onset, Urinary melatonin onset.
± SEM)) between urinary melatonin onset and salivary melatonin onset. Salivary
MT onset was earlier than the onset estimated from urinary aMT6s data.
Melatonin onset was also determined from salivary melatonin data to check that
the meal timing determined by urinary melatonin onset was correct, and to make
sure that evening meal was given while sufficient circulating melatonin in the body.
Refer to section 4.5.2 for further details about the calculation of salivary melatonin
onset.
5.5.2 Laboratory session
All participants were randomised to a three-way cross-over design protocol: light (>
500 lux) (LS), dark (< 5 lux) + exogenous melatonin (DSC), and light (> 500 lux)
+ exogenous melatonin (LSC) between 18:00h to 06:00h the next day (see protocol:
Figure 2.2). Refer to section 2.4 for further details about the study protocol.
5.5.3 Light measurements
To ensure the participants received sufficient amount of light, light intensity and
irradiance of light source were measured at horizontal (facing the light source) and
vertical (in the direction of gaze) levels (Table 5.4). The spectral composition of
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light sources (LED and fluorescent) are shown in Figure 2.3 and 2.4. Also, total
photon flux between 18:00h and 06:00h of both light sources (Fluorescent = 4.97
x 1018 photons/cm2/sec and LED = 2.63 x 1019 photons/cm2/sec), during each
session and for each participants are included in table 5.4.
Table 5.4: Light measurements in LS, DSC and LSC (mean ± SEM)
Parameter Direction LS DSC LSC
Light intensity lux
Horizontal (n = 243) 563 ± 12 1.32 ± 0.2 548 ± 10
Vertical (n = 243) 342 ± 12.2 1.02 ± 0.03 350 ± 10.5
Light irradiance w/m2
Horizontal 0.981 0.0012 0.981
Vertical 0.73 0.0008 0.73
Photon flux photons/cm2/sec NA 3.12 x 1019 2.63 x 1019 3.12 x 1019
Abbreviation: S-melatonin onset, salivary melatonin onset; U-melatonin onset, Urinary melatonin onset.
5.5.4 Statistical analyses
General statistical methods were described in section 3.8. Further details specific
for data analyses used in this chapter are addressed below. Methods detailed hold
for all metabolites, hormones, and other data unless otherwise stated.
5.5.4.1 Time-point selection
Since the distribution of samples collected from each participant across the time
series varied due to different test meal times, time scales between -360 to +360 were
used for statistical analyses. The time-point selection in this chapter are as follow:
• Hormones and metabolites (-360 to +330 min)
• Mood and alertness (-330 to +360 min)
• Pro-Diary (-330 to +360 min)
• Ibutton (-285 to +285 min)
• Activity levels (-300 to +300 min)
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5.5.4.2 Basal levels
The basal readings at the beginning of each session for all hormones, metabolites
and other assessments were determined and shown in Table 5.6. Basal levels were
compared between LS, DSC and LSC using one-way ANOVA. Time selection for
basal readings was at -360 for hormones and metabolites, -330 min for Pro-Diary,
mood and alertness, -285 min for Ibutton and -300 min for activity levels (See Table
5.6).
5.5.4.3 Basal levels prior to the evening test meal (T = 0)
Basal levels of all assessments were also tested immediately prior to the evening test
meal (T = 0) to investigate the impact of the evening test meal. Basal levels at T
= 0 were compared between the three sessions using one-way ANOVA.
5.5.4.4 Pre-prandial responses (T = -360 to T = 0)
To test pre-prandial responses data collected between -360 to 0 min for hormones
and metabolites, -330 to 0 min for appetite and behavioural responses, -300 to 0
min for activity levels, and -285 to 0 min for wrist temperature data were analysed.
Three-factors repeated measures ANOVA (melatonin, light and time) was applied
using SAS software to ascertain the effect of light and melatonin separately in all
three sessions. Since Circadin was given -90 mins prior to the evening test meal,
the melatonin effect was assessed from -90 min to the end of the study.
5.5.4.5 Post-prandial responses
Data of all parameters were statistically tested immediately after the evening test
meal to determine the meal effects on hormone, metabolic, behavioural, and appetite
responses. Three-factors (melatonin, light and time) repeated measure ANOVA was
applied to compare between LS, DSC and LSC.
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5.5.4.6 Area under the curve
TAUC and IAUC were assessed for all parameters collected in LS, DSC and LSC.
AUC data were statistically analysed using one-way ANOVA to identify the presence
of any significant differences between the study sessions. Refer to section 3.8.7 for
further details of this test.
5.5.4.7 Correlation tests
In this study melatonin is hypothesised as the major contributing factor to changes
seen in hormonal, metabolic, behavioural, peripheral temperature, activity and ap-
petite responses. Therefore, correlation tests were used to assess melatonin versus
mood, alertness, subjective appetite, and wrist temperature and activity levels. WT
underwent correlation tests versus other parameters to investigate the link between
changes in peripheral temperature and activity level, subjective behavioural and
appetite responses. The correlation coefficient value ranges between -1 to +1, and
the significance level was set at P < 0.05. Refer to section 3.8.6 for further details
about the correlation test.
Due to exogenous melatonin intake in DSC and LSC, which resulted in supra-
physiological melatonin levels, melatonin data between -90 to 0 mins were excluded
from the correlation test. Therefore, similar time points (-90 to 0 mins) for other
parameters involved in this correlation test were also excluded.
5.5.4.8 Measurement of insulin resistance
HOMA-IR and HOMA-PP were individually calculated for the three clinical ses-
sions. The mean values of insulin resistance were plotted as a histogram, then
analysed using one-way ANOVA to define the significance levels between LS, DSC
and LSC. Refer to section 4.5.5.9 for equations and methods used in HOMA-IR and
HOMA-PP.
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5.5.4.9 Analysis of variance (ANOVA)
Two types of analysis of variance were used in Study 2: one-way and repeated
measures ANOVAs. The reason for using one-way ANOVA was to investigate the
difference between the groups (LS, DSC and LSC) of one model (e.g., glucose) and
to reduce the number of pairwise comparisons. Also, using one-way ANOVA instead
of multiple t-tests was to minimise the probability of type 1 error.
In Study 2, the overall data sets were suitable for testing with repeated measures
ANOVA, with a complex design of 3 factors (light, melatonin and time) using SAS
software (SAS Institute Inc, UK). The data were classified according to the presence
of melatonin (melatonin or no melatonin) and type of light (dark or light). Factor
interactions including light x time, melatonin x time, were also reported. Melatonin
x light interaction or melatonin x light x time was not possible to calculate because
of the study design, resulting in too few degrees of freedom. To address this a further
dark session with neither endogenous nor exogenous melatonin would be needed.
However, this was not possible because of timescale and validity of the result. Also,
to completely suppress or remove melatonin effects, beta blockers such as atenolol
would be required, which could also influence other hormones and metabolites.
5.6 Results
5.6.1 Participant demographics and screening analyses in Study 2
Only 9 participants completed screening measurements and were eligible to attend
the clinical sessions. Haematology tests were assessed, and body composition anal-
yser (Tanita Corporation, Japan) was used to analyse body composition results are
shown in Table 5.5.
5.6.1.1 Sleep screening and basal hormones and metabolites
Sleep parameters were collected using Actiwatch L for the seven days prior to all
sessions (LS, DSC and LSC). Participants reported no significant differences in sleep
parameters. Participants maintained a sleep duration of approximately 6 hours,
172
Table 5.5: Participant demographics in Study 2
Parameter All participants (n = 9) (mean ± SEM)
Age, y 26 ± 1.3
Body weight, Kg 75.3 ± 3.1
Height, m 1.7 ± 0.02
BMI, kg/m2 24.8 ± 0.8
Caffeine/wk 6.2 ± 2.5
Alcohol/wk 0.2 ± 0.2
PSQIa 3.5 ± 0.4
HO¨a 54.5 ± 2.6
MCTQa (h) 04:46 ± 00:22
RBCa (103/mm3) 5.1 ± 0.1
WBCa (103/mm3) 5.6 ± 0.4
PLTa (103/mm3) 235 ± 11.7
Hgba (g/dl) 14.2 ± 0.4
Values are mean ± SD. RBC, red blood cell; WBC, white blood cell; PLT, platelet; HGB, haemoglobin.
avalues given are those obtained during the screening session.
with sleep efficiency above 70%, and fragmentation index over 40. No significant
differences were reported in sleep latency, efficiency and fragmentation index prior
to each sessions (Table 5.6).
Basal plasma samples (T = -360) showed no significant differences in all mea-
sured hormones and metabolites (Table 5.6). Similarly, KSS, alertness and mood
scores showed no differences at -330min. Also, wrist temperature and activity levels
showed no significant differences at basal levels (p = 0.3 and p = 0.8) respectively.
Correlation tests were performed to establish the relationship between urinary
melatonin onset and other screening parameters such as MCTQ, MEQ and sleep
start. No correlation was reported between urinary melatonin onset and MCTQ
or MEQ, whereas a positive correlation with sleep start was observed. MSF was
negatively correlated with MCTQ (r2 = -0.6, p = 0.01).
5.6.2 KSS, mood and alertness
5.6.2.1 Basal levels prior to the test meal
Basal levels of KSS, alertness, and 3 mood ratings collected immediately prior to
the test meal (T = 0) are shown in Figure 5.1. No significant difference was seen
in basal KSS, alertness, mood 2 and 3 (p = 0.3, p = 0.3,p = 0.8 and p = 0.1)
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Table 5.6: Screening sleep and basal hormones and metabolite data in Study 2
Parameter LS DSC LSC p
Sleep starta, h:min 24:40 ± 00:23 24:48 ± 00:16 24:51 ± 00:24 0.9
Sleep enda, h:min 07:47 ± 00:23 07:58 ± 00:23 07:57 ± 00:26 0.9
Sleep durationa, h:min 05:46 ± 00:14 05:53 ± 00:15 05:50 ± 00:19 0.9
% Sleep efficiencya 77.4 ± 2.6 74.9 ± 2.5 75.9 ± 3.2 0.2
Sleep latencya, h:min 00:17 ± 00:03 00:42 ± 00:10 00:30 ± 00:14 0.1
Fragmentation indexa 41.48 ± 5.4 40.1 ± 5.1 41.2 ± 6.7 0.6
Basal glucoseb, mmol/l 4.8 ± 0.2 4.9 ± 0.2 4.8 ± 0.3 0.9
Basal insulinb, pmol/l 82.6 ± 14.9 76.1 ± 11.1 78.8 ± 12.4 0.7
Basal NEFAsb, mmol/l 0.2 ± 0.04 0.3 ± 0.04 0.3 ± 0.05 0.6
Basal TAGsb, mmol/l 1.2 ± 0.2 1.2 ± 0.2 1.1 ± 0.2 0.6
Basal melatoninb, pg/ml 1.5 ± 0.2 1.7 ± 0.4 1.1 ± 0.3 0.1
Basal cortisolb, nmol/l 139.4 ± 17.9 173.5 ± 31.5 143.1 ± 18.5 0.4
Basal leptinb, ng/ml 7.2 ± 1.1 7.3 ± 1.3 7.7 ± 1.7 0.7
Sleepinessc 2.3 ± 0.3 2.1 ± 0.5 2.4 ± 0.3 0.7
Alertnessc 2.1 ± 0.4 2.4 ± 0.4 2.6 ± 0.3 0.4
Mood 1c 2.8 ± 0.6 2.8 ± 0.5 3.1 ± 0.6 0.8
Mood 2c 2.6 ± 0.6 2.6 ± 0.5 3.4 ± 0.6 0.2
Mood 3c 6.8 ± 0.5 6.7 ± 0.5 6.8 ± 0.4 0.8
Wrist temperatured (C) 31.6 ± 0.6 32.3 ± 0.4 32.2 ± 0.5 0.3
Activity levele 182.1 ± 87.1 293.1 ± 95.4 252.7 ± 117.8 0.8
Values are mean ± SEM, calculated by one-way ANOVA (n = 9). aValues were obtained from 7 days prior
to LS, DSC and LSC sessions. bValues represented the basal samples (T = -360 min) during each clinical
session. cValues were obtained from 9 point mood and Karolinska sleepiness scales at -330 min. dBasal
readings of wrist temperature were collected at -285 min, and -300 min for activity levele
respectively. Mood 1 was significantly greater in LSC compared to LS (p = 0.01)
and DSC (p = 0.04).
5.6.2.2 Pre-prandial and postprandial KSS, mood and alertness
Figure 5.2 shows subjective KSS, alertness and mood scores at pre-prandial and
postprandial times during LS, DSC and LSC. No significant differences were re-
ported in KSS and mood 2 (p = 0.2 and p = 0.5) respectively. Participants were
significantly more alert in LS compared to DSC and LSC (p = 0.006 and p <
0.0001). Post-hoc tests showed that the significance was at postprandial times (T
= +180 and T = +300). Participants were more miserable in LS than in DSC and
LSC (p < 0.0001), with significant differences at postprandial period ( T = 0, +30,
+60, +90, +120, +180, +210, +270, +300). Depression score were significantly
higher (more depressed) in DSC and LSC than in LS (p < 0.0001). Post-hoc test
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Table 5.7: Quality controls and coefficient of variation in Study 2
Parameter QC Mean Inter-assay CV (%) (n = 17) Intra-assay CV (%)
Salivary melatonin
Low 6.5 pg/ml 6.6 6.2
Medium 25.8 pg/ml 4.8 3.9
High 52.5 pg/ml 8.2 3.8
Cortisol
Low 86.7 nmol/l 2.1 2.4
Medium 518.9 nmol/l 7.8 5.3
High 784.4 nmol/l 7.4 3.7
Insulin
Low 98.1 pmol/l 8.3 4.3
High 326.4 pmol/l 8.5 6.7
Leptin
Low 7.5 ng/ml 4.1 5.5
High 20.4 ng/ml 6.7 4.2
Glucose
QC1 6.6 mmol/l 4.2 0.01
QC2 17.4 mmol/l 4.7 0.1
NEFA
QC1 1.8 mmol/l 2.5 0.1
QC2 1.2 mmol/l 2.8 0.1
TAG
QC1 1.1 mmol/l 2.5 0.1
QC2 2.8 mmol/l 2.7 0.4
aMT6s
Low 2.8 pg/ml 9.4 8.9
Medium 17.0 pg/ml 12.6 8.9
High 24.4 pg/ml 11.5 10.4
Quality controls were run in duplicate (aMT6s, melatonin, insulin, leptin and cortisol), or triplicate
(glucose, NEFA and TAG). QCs were also run before, middle and after the samples. All the quality
controls were tested to make sure they were within the normal range.
Table 5.8: Screening correlation tests in Study 2
Parameters r2 p
MSF vs. MEQ -0.6 0.01
U. melatonin onset vs MEQ -0.1 0.10
U. melatonin onset vs MEQ -0.1 0.10
U. melatonin onset vs sleep start 0.6 0.01
revealed significant differences at postprandial times (T = +120, +180, +300 and
+330). Subjective alertness, mood 2 and mood 3 showed significant effects of mela-
tonin, whereas no significant of light was seen in all 5 subjective parameters. All 5
subjective parameters showed significant effects of time (p < 0.001).
5.6.3 Hormones and metabolites
5.6.3.1 Basal level prior to the test meal (T = 0)
Basal levels of plasma and salivary hormones and metabolites from samples collected
immediately before the test meal (T = 0) are shown in Figure 5.3. Basal glucose,
insulin, TAGs and cortisol showed no significant differences between LS, DSC and
LSC. Basal NEFAs was significantly reduced in LS compared to DSC (p = 0.001)
175
LS DSC LSC
1
3
5
7
9
K
S
S
s
co
re
A  Basal KSS
Very sleepy
Very alert
p = 0.3
LS DSC LSC
1
3
5
7
9
A
le
rt
n
es
s
sc
o
re
B  Basal Alertness
Very sleepy
Very alert
p = 0.3
LS DSC LSC
1
3
5
7
9
M
o
o
d
1
sc
o
re
C  Basal Mood 1
Very miserable
Very cheerful
*
* p = 0.01
LS DSC LSC
1
3
5
7
9
M
o
o
d
2
sc
o
re
Very tense
Very calm
D  Basal Mood 2
p = 0.8
LS DSC LSC
1
3
5
7
9
M
o
o
d
3
sc
o
re
Very elated
Very depressed
E  Basal Mood 3
p = 0.1
Figure 5.1: Subjective mood and alertness at basal levels (T = 0)
Subjective KSS (A), alertness (B), mood 1 (C), mood 2 (D) and mood 3 (E) (mean ± SEM) ratings prior
to the evening test meal at time = 0, (n=9) during LS ( ), DS ( ) and LSC ( ) *p < 0.05.
and LSC (p = 0.0002). Similarly, basal melatonin showed a significant reduction in
LS compared to DSC (p = 0.0001) and LSC (p = 0.0002).
5.6.3.2 Pre-prandial and postprandial hormones and metabolites
Plasma insulin levels were significantly higher in LS than in DSC and LSC (p =
0.02), whereas no significant difference was seen between DSC and LSC. The post-
hoc test showed significant differences at +30, +45, +60, +90, +120 and +150 min.
Similarly, plasma glucose levels were significantly higher after the evening test meal
in LS compared to DSC and LSC (p = 0.002). The post-hoc test showed significant
differences at +90, +120 and +150 min between LS and DSC, and at +150 min
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Figure 5.2: Pre-prandial and postprandial subjective mood and alertness
Subjective KSS (A), alertness (B), mood 1 (C), mood 2 (D) and mood 3 (E) (mean ± SEM) ratings prior
to and after the evening test meal (time = 0 black dotted line) during LS ( ), DSC ( ) and LSC ( )
(n=9) (T = -330 to T = +360 min).
between LS and LSC. Postprandial plasma TAGs were significantly higher in LS
compared to LSC and DSC (p = 0.007). The significant differences were observed
at +90, +180, +210, +240, +270, +300 and +330 (Figure 5.4).
In contrast, plasma NEFA was significantly lower during LS compared to DSC
and LSC (p < 0.001). The post-hoc test revealed the significant points at -60 and 0
min. Salivary melatonin was significantly higher in DSC and LSC compared to LS
(p < 0.001), whereas no significant difference was observed between DSC and LSC.
The post-hoc test showed significant differences between -90 to +330 min. There
were no significant differences in plasma cortisol between the three conditions (p =
177
LS DSC LSC
4.0
4.5
5.0
5.5
6.0
P
la
sm
a
g
lu
co
se
(m
m
o
l/l
)
A   Basal glucose
p = 0.57
LS DSC LSC
0
50
100
150
P
la
sm
a
in
su
lin
(p
m
o
l/l
)
B   Basal insulin
p = 0.25
LS DSC LSC
0.2
0.4
0.6
0.8
1.0
P
la
sm
a
N
E
F
A
s
(m
m
o
l/l
)
C  Basal NEFAs
***
**
p = 0.001
p = 0.0002
LS DSC LSC
0.2
0.4
0.6
0.8
1.0
P
la
sm
a
T
A
G
s
(p
g
/m
l)
D  Basal TAGs
p = 0.15
LS DSC LSC
0
50
100
P
la
sm
a
C
o
rt
is
o
l(
n
m
o
l/l
)
E  Basal TAGs
p = 0.66
LS DSC LSC
1
10
100
1000
10000
S
.m
el
at
o
n
in
lo
g
(p
g
/m
l)
F  Basal melatonin
***
***
p = 0.001
p = 0.0002
Figure 5.3: Hormones and metabolites at basal levels (T = 0)
Plasma glucose (A), insulin (B), NEFAs (C), TAGs (D) cortisol (E), and salivary melatonin (F) (mean
SEM) levels prior to the evening test meal at time = 0, (n=9) during LS ( ), DSC ( ) and LSC ( ).
Salivary melatonin was presented as log scale in LS, DSC and LSC. ** p < 0.01, ***p < 0.001.
0.3). There were significant effects of melatonin in glucose, insulin, TAGs, NEFAs
and melatonin, with no significant effect of light in all 6 parameters. There were
significant effects of time in all 6 parameters (p < 0.0001) (Figure 5.4).
5.6.3.3 TAUC and IAUC of hormones and metabolites
TAUCs for, glucose, insulin, NEFAs, TAGs, cortisol and melatonin were calculated
between -360 to +330 min , and are shown in Figure 5.5. TAUCs showed a significant
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Figure 5.4: Pre-prandial and postprandial hormones and metabolites
Plasma glucose (A), insulin (B), NEFAs (C), TAGs (D), cortisol (E), and salivary melatonin (F) (mean ±
SEM) levels prior to and after the evening test meal (time = 0 black dotted line) during LS ( ), DSC
( ) and LSC ( ) (n=9) (T = -360 to T = +330). Salivary melatonin is presented as log scale.
increase in plasma glucose during LS compared to DSC (p = 0.008) and LSC (p =
0.04). TAUCs of plasma glucose were 118 ± 5.05 in light, 113 ± 4.8 in DSC, and
112 ± 5.2 mmol/l.min in LSC sessions. TAUCs of plasma insulin were significantly
greater in light compared DSC (p = 0.0009) and LSC (p = 0.001). TAUCs of plasma
insulin was 5315 ± 678 in LS, 4017 ± 459 in DSC and 4254 ± 574 pmol/l.min in
LSC. Plasma TAGs was significantly higher in LS than DSC (p = 0.04) and LSC
(p = 0.04). TAUCs of plasma TAGs was 24.6 ± 3.6 in LS, compared to 21.2 ± 2.6
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Figure 5.5: TAUC of hormones and metabolites
TAUC for plasma glucose (A), insulin (B), NEFAs (C), TAGs (D) cortisol (E), and salivary melatonin (F)
(mean ± SEM) during LS ( ), DSC ( ) and LSC ( ) (n = 9). Salivary melatonin is presented as log
scale. *p < 0.05, **p < 0.01, ***p < 0.001.
in DSC and 19.4 ± 2.4 mmol/min in LSC. In contrast, TAUCs showed a significant
suppression of salivary melatonin in LS compared to DSC (p = 0.002) and LSC
(p = 0.007). TAUCs of salivary melatonin was 169 ± 56 in LS, 13134 ± 3085 in
DSC and 11559 ± 3245 pg/ml.min in LSC. Also, plasma NEFA was significantly
suppressed in LS (6.52 ± 1.1) compared to DSC (7.4 ± 1.2) (p = 0.03) and LSC
(7.1 ± 1.3 mmol/l.min) (p = 0.03). No significant difference was observed in TAUC
of plasma cortisol (p = 0.9).
IAUCs of hormones and metabolites (T =-360 to T = +330 min) are shown in
Figure 5.6. IAUC of plasma insulin increased significantly in LS compared to DSC
(p = 0.0002) and LSC (p = 0.0008). IAUC of plasma insulin was 3934.8 ± 506.6 in
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LS, 2678.3 ± 325.3 in DSC, and 2961.4 ± 406.9 pmol/l.min in LSC. Similarly, IAUC
of plasma TAGs was significantly higher in LS (9.1 ± 1.4) than DSC (8.5 ± 1.9 )
(p = 0.03) and LSC (6.2 ± 1.2 mmol/min) (p = 0.02). IAUC of salivary melatonin
was significantly lower in LS compared to DSC (p = 0.002) and LSC (p = 0.002).
IAUCs for plasma glucose, NEFAs and cortisol showed no significant differences (p
= 0.7, p = 0.8 and p = 0.5) respectively (Figure 5.6).
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Figure 5.6: IAUC of hormones and metabolites
TAUC for plasma glucose (A), insulin (B), NEFAs (C), TAGs (D) cortisol (E), and salivary melatonin (F)
(mean ± SEM) during LS ( ), DSC ( ) and LSC ( ) (n = 9). Salivary melatonin is presented as log
scale. *p < 0.05, **p < 0.01, ***p < 0.001.
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5.6.3.4 HOMA-IR and HOMA-PP
HOMA-IR and HOMA-PP are shown in Figure 5.7. HOMA-IR was higher, yet not
significant, in LS (1.2 ± 0.2) compared to DSC (1.05 ± 0.1) and LSC (1.05 ± 0.1)
(p = 0.1). HOMA-PP was significantly greater in LS than in DSC (p = 0.004) and
LSC (p = 0.04).
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Figure 5.7: HOMA-IR and HOMA-PP
HOMA-IR- (A) and HOMA-PP (B) (mean ± SEM) during LS ( ), DSC ( ) and LSC ( ) (n = 9).
*p < 0.05, **p < 0.01, ***p < 0.001.
5.6.4 Subjective appetite scores and plasma leptin
5.6.4.1 Subjective appetite scores
Figure 5.8 illustrates the subjective hunger, desire to eat and fullness score during
pre-prandial and postprandial times in all three sessions. Participants felt more
hungry with greater desire to eat in LS than in DSC and LSC (p = 0.03 and p
= 0.001 respectively), whereas no significant difference was reported in subjective
fullness (p = 0.9). The pre-prandial and postprandial periods were analysed sep-
arately and showed that significant differences were reported at postprandial time
+270, +300, +330 and +360 min. ANOVA showed a significant effect of melatonin
in hunger and desire to eat, but no significant effect of light in all three subjective
parameters. There was a significant effect of time in all three subjective parameters
(p < 0.001).
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Figure 5.8: Subjective appetite questionnaires
Subjective hunger (A), desire to eat (B), and fullness (C) ratings (mean SEM) prior to and after the evening
test meal (time = 0 black dotted line) during LS ( ), DSC ( ) and LSC ( ) in all participants (n=9)
(T = -330 to T = +360 min).
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Figure 5.9: Plasma leptin at basal level (T = 0)
Plasma leptin (A) (mean ± SEM) levels prior to the evening test meal at time = 0, in all participants (n=9)
during LS ( ), DS ( ) and LSC ( )..
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Basal levels of plasma leptin collected immediately before the test meal (T = 0)
are shown in Figure 5.9. Basal leptin showed no significant differences between LS,
DSC and LSC (p = 0.5).
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Figure 5.10: Pre-prandial and postprandial plasma leptin
Pre-prandial and postprandial plasma leptin (mean ± SEM) levels prior to and after a standard evening
meal (time = 0 black dotted line) during LS ( ), DSC ( ) and LSC ( ) (n=9). A: plasma leptin
between -360 to +330 mins, B: pre-prandial leptin between -360 to 0 min, and C: postprandial leptin
between +15 to +330 mins.
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Figure 5.11: % basal leptin concentration
% basal leptin (mean ± SEM) levels directly prior to the test meal (T = 0) (A) and at time -360 (B) during
LS ( ), DSC ( ) and LSC ( ) (n=9) (T = -360 to T = +330 min)
5.6.4.2 Pre-prandial and postprandial of plasma leptin
Plasma leptin was significantly higher, in LSC and DSC compared to LS (p = 0.007)
on the raw data (Figure 5.10-A). This increase can be clearly observed when data
are plotted as pre-prandial or postprandial periods (p = 0.02) (Figure 5.10 B-C).
The post-hoc test showed significant differences at +210 and +330 min. When the
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data were calculated as a % of leptin concentration at T = 0 or T = -360, the leptin
response was higher during DSC and LSC compared to LS.
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Figure 5.12: TAUC and IAUC of plasma leptin
TAUC (A) and IAUC (B) for plasma leptin (mean ± SEM) during LS ( ), DSC ( ) and LSC ( ) (n
= 9). *p < 0.01, **p < 0.01.
5.6.4.3 TAUC and IAUC of plasma leptin
Figure 5.12 shows the TAUC and IAUC of plasma leptin in LS, DSC and LSC
(T = -360 to T = +330 min). TAUC of plasma leptin in LS was 137.9 ± 21.1,
143.6 ± 22.2 in DSC, and 146.7 ± 27.5 ng/ml.min in LSC. TAUC of plasma leptin
was significantly higher in DSC and LSC compared to LS (p = 0.03, and p = 0.006
respectively). IAUC of plasma leptin was lower, but not significant, in LS compared
to DSC (p = 0.2) and LSC (p = 0.09). IAUC of plasma leptin in LS was 15.5 ±
2.5, 25.1 ± 7.1 in DSC, and 28.2 ± 8.1 ng/ml.min in LSC.
5.6.5 Peripheral temperature
5.6.5.1 Pre-prandial and postprandial wrist temperature
Wrist temperature immediately before the evening test meal (T = 0) is shown in
Figure 5.17. No significant difference was seen at basal level in wrist temperature
between LS (34.4 ± 0.4), DSC (34.5 ± 0.3) and LSC (34.3 ± 0.3 ◦C/min) (p = 0.8).
Figure 5.14 and 5.15 show that WT was significantly higher in LS than in DSC
and LSC (p < 0.001). The post-hoc test showed significant differences at -90, +90
and +105 min. Data were analysed over the pre-prandial and postprandial periods
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Figure 5.13: Wrist temperature (◦C) at basal level (T = 0).
Wrist temperature (◦C) (mean ± SEM) levels prior to the evening test meal at time = 0, (n=9) during LS
( ), DSC ( ) and LSC ( )
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Figure 5.14: Pre-prandial and postprandial wrist temperature (◦C)
Wrist temperature (mean ± SEM) levels prior to and after the evening test meal (time = 0 black dotted
line) LS ( ), DSC ( ) and LSC ( ) (n=9). A: represent WT full data between -285 to +285 mins, B:
WT full data with no error bars
separately to indicate the effect of the evening meal. There was a significant effect
of melatonin and time, but not light, in all three session. Figure 5.16 showed that
the differences appear at pre-prandial and postprandial times.
5.6.5.2 TAUC and IAUC of wrist temperature
TAUC and IAUC of wrist temperature (T = -285 to T = +285 min) are shown in
Figure 5.17. TAUC of wrist temperature is signifcantly higher in LS compared to
DSC (p = 0.01) and LSC (p = 0.001). IAUCs reported higher, but not statistically
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Figure 5.15: Pre-prandial and postprandial wrist temperature (◦C) at 15 min
intervals
Wrist temperature (mean ± SEM) levels prior to and after the evening test meal (time = 0 black dotted
line) LS ( ), DS ( ) and LSC ( ) (n=9). Data were averaged every 15 min, between -285 to +285
mins
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Figure 5.16: Wrist temperature (◦C) for pre-prandial and postprandial periods
Wrist temperature (mean ± SEM) levels prior to and after the evening test meal (time = 0 black dotted
line) LS ( ), DS ( ) and LSC ( ) in all participants (n=9). Data were averaged every 15 mins, and
plotted for better representation. A: WT between -285 to 0 mins, B: WT between +15 to +285 min
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Figure 5.17: TAUC and IAUC of wrist temperature (◦C)
TAUC (A) and IAUC (B) for wrist temperature (mean ± SEM) during LS ( ), DS ( ) and LSC ( )
in all participants (n=9). *p < 0.01, **p < 0.01.
significant, wrist temperature in LS (627 ± 148) than in DSC (407 ± 88) and LSC
(428 ± 109 ◦C.min) (p = 0.2).
5.6.6 Activity level
5.6.6.1 Pre-prandial and postprandial activity level
Graphical representation of the activity levels between -300 to +300 mins are shown
in Figure 5.19. For better visualization, data were averaged every 10 mins and
plotted as Figure 5.19-B. Activity levels showed no significant differences between
three sessions (p = 0.8). The data were also plotted as the pre-prandial and post-
prandial periods (Figure 5.20 A-B), indicating no significant differences present at
pre-prandial and postprandial periods (p = 0.5 and p = 0.6 respectively). The
basal level prior to the test meal indicates that activity level was higher in DSC
than in LS and LSC (p = 0.25) (Figure 5.18). ANOVA showed no significant effects
of melatonin or light on activity level, but a significant effect of time was observed
in all three sessions.
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Figure 5.18: Pre-prandial and postprandial activity levels
Activity levels (mean ± SEM) prior to and after the evening test meal (time = 0 black dotted line) LS
( ), DSC ( ) and LSC ( ) in all participants (n=9). A: represent complete activity data, B: activity
averaged every 10 mins.
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Figure 5.19: Pre-prandial and postprandial activity levels
Activity levels (mean ± SEM) prior to and after the evening test meal (time = 0 black dotted line) LS
( ), DSC ( ) and LSC ( ) in all participants (n=9). A: represent complete activity data, B: activity
levels averaged every 10 mins.
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Figure 5.20: Activity levels at pre-prandial and postprandial periods
Activity levels (mean ± SEM) prior to and after the evening test meal (time = 0 black dotted line) LS
( ), DSC ( ) and LSC ( ) in all participants (n=9). Data were averaged every 10 mins, and plotted
for better representation. A: Activity between -300 to 0 mins, B: Activity between +10 to +300.
5.6.7 Relationship between melatonin and other parameters
Figure 5.21, 5.22 and 5.23 show the interaction between salivary melatonin levels
and subjective KSS, alertness, mood scores, WT, hunger, desire to eat and full-
ness in in LS, DSC and LSC. As melatonin levels rise, sleepiness, miserable, tense,
hunger, desire to eat and WT increase, whereas alertness, elation, fullness and leptin
decrease.
5.7 Discussion
The possible effects of LAN on hormones and metabolites, subjective appetite
scores, behavioural responses, vascular function were shown in Study 1. The major
findings were a reduction in glucose tolerance, insulin sensitivity, circulating fatty
acids, a reduction in subjective depression, and an increase in subjective hunger and
desire to eat. No definite conclusion of the mechanism behind these findings could
be drawn but it was hypothesized that changes seen were due to endogenous mela-
tonin. Study 2 aimed to investigate the role of exogenous melatonin on hormones
and metabolites, appetite and behavioural responses prior to and after the evening
test meal in healthy young males by exposing them to three different conditions;
light (> 500 lux), dark (<5 lux) + exogenous melatonin, and light (>500 lux) and
exogenous melatonin.
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Figure 5.21: Melatonin interaction with subjective behavioural ratings, appetite
scores, wrist temperature and plasma leptin in LS
Data are presented as mean. Melatonin levels vs wrist temperature (A), KSS (B), alertness (C), mood 1
(D), mood 2 (E), mood 3 (F), hunger (G), desire to eat (H), fullness (I), and plasma leptin (J) (T = -360
to T = + 360 mins, n=9).
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Figure 5.22: Melatonin interaction with subjective behavioural ratings, appetite
scores, wrist temperature and plasma leptin in DSC
Data are presented as mean. Melatonin levels vs wrist temperature (A), KSS (B), alertness (C), mood 1
(D), mood 2 (E), mood 3 (F), hunger (G), desire to eat (H), fullness (I), and plasma leptin (J) (T = -360
to T = + 360 mins, n=9).
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Figure 5.23: Melatonin interaction with subjective behavioural ratings, appetite
scores, wrist temperature and plasma leptin in LSC
Data are presented as mean. Melatonin levels vs wrist temperature (A), KSS (B), alertness (C), mood 1
(D), mood 2 (E), mood 3 (F), hunger (G), desire to eat (H), fullness (I), and plasma leptin (J) (T = -360
to T = + 360 mins, n=9).
193
5.7.1 Participant demographics & screening
Nine male participants who met the criteria for age, weight and BMI were recruited.
All participants were non-smokers with no adverse medical history, and haematology
tests showed the normal range of RBC, WBC, HGB and PLT. Despite the wide
variation in caffeine and alcohol consumption among the participants, no caffeine,
alcohol and carbonated drinks were allowed 24 hours prior to the study session to
exclude their effects (see Table 5.5).
All participants reported good sleep quality based on the PSQI over the month
before the study. The average MEQ showed that participants were neither morning
nor evening types, yet 3 participants were moderately morning. Those morning type
participants reported an earlier mid-sleep time in comparison to other participants
(neither chronotype). This indicates the importance of mid-sleep time in defining
the chronotype of participants based on participants lifestyle. All participants were
university students and the wide range of mid-sleep times was expected, compared
to workers who compensate for the sleep debt accumulated during the workdays. It
is worth mentioning that mid-sleep time used in MCTQ is highly correlated with
sleep preference scores obtained with the MEQ (r2 = -0.7, p = 0.03), indicating
that mid-sleep in free days (MSF), in particular, is a good predictor of chronotype
(Zavada et al., 2005). This is in agreement with our findings that showed a strong
correlation between MSF and MEQ scores reported during screening (r2 = -0.6,
p = 0.01). However, our results disagree with the correlation reported between
chronotype questionnaires such as MEQ & MCTQ, and physiological phase markers
such as melatonin, and body temperature (Andrade et al., 1992; Dijk and Duffy,
1999; Bailey and Heitkemper, 2001). We reported no correlation between melatonin
onset and MCTQ or MEQ (Table 5.8).
To ensure that all participants maintained a consistent sleep pattern prior to
each clinical session, sleep parameters from actigraphy were analysed prior to each
session. Participants showed no significant differences in sleep parameters such as
sleep start, sleep end, sleep duration, sleep efficiency, and sleep latency or fragmen-
tation index. This is important as an irregular sleep pattern may alter melatonin
onset, as a positive correlation between sleep start and urinary melatonin onset was
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observed (r2 = 0.6, p = 0.01). In this study, melatonin onset was estimated from a
sequential 48-h urine collection at least 5 days before the study session, to calculate
the timing of the evening test meal as shown in Table 5.2. The significance of lo-
cating evening meal based on melatonin onset was to ensure that sufficient plasma
melatonin was circulating at the meal time. It is noteworthy that a high degree of
correlation between urinary aMT6s and plasma and serum melatonin levels have
been reported in many human studies (Graham et al., 1998; Cook et al., 2000). In
our study, aMT6s was collected over two consecutive days to obtain a full aMT6s
profile. Melatonin onset determined from urine collection was also compared with
salivary melatonin onset. Salivary melatonin onset was at least 1 hour earlier than
urinary melatonin onset. The data indicates that evening meal timing was targeted
after melatonin onset (see Table 5.3).
5.7.2 Salivary melatonin
Since melatonin was the major factor under investigation in Study 2, salivary sam-
ples were analysed to monitor the melatonin profile and levels in the body. Our
results confirmed a significantly lower salivary melatonin in LS, compared to DSC
and LSC. In Study 2, melatonin suppression in light condition was expected as seen
in Study 1 due to the light intensity, whereas high melatonin levels in DSC and LSC
were due to slow release exogenous melatonin (Circadin). The mean amplitude of
melatonin in the light condition was 12.1 pg/ml, 3858.2 pg/ml in DSC and 3158.4
pg/ml in LSC, indicating an increase of salivary melatonin by 318 and 261 times
in DSC and LSC respectively. The light intensity delivered at the angle of gaze
was 344 lux compared to Study 1 305 lux (Table 5.4). All participants showed a
significant presence of melatonin at -90 min to the end of sampling period in both
DSC and LSC, indicating the presence of slow release Circadin (2mg). Our data
showed no significant earlier melatonin onset in DSC and LSC compared to LS,
since Circadin was administered 90 mins prior to the evening test meal during DSC
and LSC, at which point endogenous melatonin was suppressed in LS. To ensure
that melatonin levels were not influenced by the body position as demonstrated in
Kozaki et al. (2013), participants remained in a semi-recumbent position through-
out the studies (Kozaki et al., 2013). Light exposure was from 18:00h until 06:00h
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the next day, which spans the normal nocturnal melatonin secretion period. It was
crucial to use slow-release Circadin to ensure MT was present across the whole time
period. This was achieved however the levels of melatonin measured were much
greater than endogenous melatonin. Participants remained inside from lunch time
until beginning of the session (preparation period) to limit the light exposure which
could modulate melatonin suppression responses to the light (sensitization). This
was confirmed by assessing light levels using Actiwatch L data collected during the
preparation period. There was no significant difference in light exposure before each
light session (p = 0.3).
5.7.3 Hormones and metabolites
Plasma hormones and metabolites assessed in Study 1 showed significant effects of
LAN on glucose, insulin and NEFAs, yet the mechanism process could not be es-
tablished. Exogenous melatonin administration was applied to test the hypothesis
that LAN-suppression of melatonin results in a reduction in glucose tolerance and
insulin sensitivity and changes in pre-prandial NEFAs. Our results showed signifi-
cantly lower glucose and insulin levels after the evening test meal in DSC and LSC
compared to LS. Raised glucose and insulin responses suggest a reduction in glu-
cose tolerance and insulin sensitivity. Plasma glucose and insulin were also assessed
using TAUC and IAUC which confirmed these findings. These results agree with
rodent studies that showed decreased blood glucose and insulin in constant dark-
ness (Zhang et al., 2006; Arasteh et al., 2010). Fonken et al. (2010) observed that
male mice in constant light increased body mass with reduced glucose tolerance
compared to those in a standard light/dark cycle with similar food intake (Fonken
et al., 2010). It is important to note that rodents are nocturnal while humans
are diurnal mammals with reversed rest-activity cycles and hormonal rhythms, in-
cluding those important in metabolic regulation, except for melatonin which peaks
during the dark phase in both (Jha et al., 2015). The difference observed in glucose
tolerance, and insulin sensitivity were confirmed by HOMA-PP which was signifi-
cantly higher in LS than in DSC and LSC. These findings could be explained by
the inhibitory effect of melatonin on insulin secretion, which could also influence
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blood glucose (Peschke et al., 2002, 2013). Our results agreed with the ability of
exogenous melatonin to improve impaired glucose tolerance and insulin resistance
that was reported in high-fat-diet-fed insulin resistant mice (Sartori et al., 2009). It
was suggested that melatonin enhances vasodilation in skeletal muscle and thereby
increases glucose utilization (Sartori et al., 2009), or increases glucose uptake and
promotes glycogen synthesis (Shieh et al., 2009).
It has been reported in human studies that consumption of nutrients at in-
appropriate times of day results in metabolic imbalances as a result of circadian
desynchrony (Bailey et al., 2014). In our present study, participants were sleep de-
prived in both sessions, and melatonin onset was not significantly different between
the three light sessions, indicating that postprandial changes obtained are unlikely
to be due to sleep deprivation or circadian misalignment. Other factors such as
cortisol and catecholamine effects must be considered. Plasma cortisol was assessed
in this study, yet no significant difference in plasma cortisol was observed between
all three sessions. Plasma cortisol was hypothesized to be higher in LS (?), which
could have explained the increase in plasma glucose, as cortisol counteracts insulin
actions. Epinephrine and norepinephrine were not analysed in this study but could
possibly explain the glucose and insulin findings as both enhance glucose release and
inhibit insulin production in the pancreas. Melatonin has been reported to increase
glucagon secretion via IP3 and DAG signalling, however plasma glucagon was not
analysed in this study (Gromada et al., 1997; Peschke et al., 2013).
Our present study disagrees with Cagnacci et al. (2010), and Rubio-Sastre
(2014) which showed that administration of melatonin immediately before an oral
glucose tolerance test results in impaired glucose tolerance without changes in
insulin levels in the morning (Cagnacci et al., 2001; Rubio-Sastre et al., 2014).
The major differences between their studies and our study, is the usage of single-
immediate release melatonin, also time of day, compared to slow release exogenous
melatonin. The lack of sleep history data and the use of OGTT compared to our
study that incorporates a complex standard evening meal with melatonin intake.
Also, the effects of melatonin during fasting period in previous studies were not
assessed, in comparison to our study that showed no difference at fasting period.
Our study protocol were different from Rubio-Sastres (2014) protocol which assess
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postprandial hormones and metabolites over 3 hours after OGTT, and no sleep
deprivation was included in their study. Our results agree with studies that show
a link between impaired melatonin and the risk of type 2 diabetes. For instance,
genomic studies have proposed an association between an allelic variant of MT2
receptor and glycaemic traits such as elevated fasting glucose, impaired insulin se-
cretion and risk of T2D (Staiger et al., 2008; Prokopenko et al., 2009). Irregular
reduction of melatonin levels was related to diabetes, suggesting that melatonin
regulation is crucial to maintain glucose homoeostasis (Peschke et al., 2006, 2007).
Lipids such as NEFAs and TAGs were investigated in this study. Study 1 re-
ported a significant increase of plasma NEFA in DS during the pre-prandial period
when endogenous melatonin was already high. In this study, plasma NEFAs was
significantly greater in DSC and LSC prior to the test meal than in LS. Since bright
light suppresses melatonin, any melatonin action on plasma NEFA was absent in
LS. Any significant differences in NEFAs were seen when salivary melatonin levels
were high. Melatonin has been reported to induce sympathetic responses which in
turn enhance HSL activity via activating β-adrenoreceptors (Song and Bartness,
2001). Melatonin administration also resulted in increased glucagon secretion, thus
increasing glucagon stimulatory effects on HSL. The main stimulatory effect of HSL
activity is known to be the absence of the inhibitory effect of insulin. Plasma
insulin levels before the test meal showed no significant difference between the ses-
sions. Our data reported no significant difference in plasma NEFAs after the meal
which could be due to the hyperinsulinaemic state enhancing hepatic conversion
of NEFAs to TAGs. In this study, plasma TAGs were significantly higher in LS
than in DSC and LSC, whereas no significant differences were reported in Study
1. It is suggested that lower insulin sensitivity at night could lower LPL activity,
thus impairing TAGs clearance (Pan et al., 2010). Therefore, nocturnal insulin re-
sistance could be associated with higher circulating TAG levels of hepatic origin.
Hypertriglyceridemia in diabetic patients is due to low LPL activity. Also, CLOCK
gene disruption which could occur by LAN caused constant high level of TAGs due
to disrupted MTP. MTP plays a role in the delivery of TAGs into the bloodstream,
which may explain the impaired TAGs clearance and high nocturnal TAGs levels
at night (Pan et al., 2010). TAG levels reported in this study include VLDL and
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chylomicrons which could be the outcome from either the small intestine (chylomi-
crons) or the liver (VLDL). It is not possible to define the source of TAGs in this
study, therefore analysing apolipoprotein B (apoB) such as apoB-100 and apoB-48
could determine the source of TAGs. The results obtained from the study indicate
that LAN-melatonin suppression is the key contributing factor of these findings,
yet the exact mechanism of action of melatonin on hormones and metabolites needs
further investigations.
5.7.4 KSS, Mood and alertness
Melatonin administration in Study 2 also investigated the effect of melatonin on
mood and alertness. Our results showed no significant differences in sleepiness, but
there was a significant difference in alertness between the three sessions. This agrees
with previous studies that showed an increase in alerting response, and a reduction
in sleepiness after bright light exposure (Chellappa et al., 2011; Mu¨nch et al., 2011;
Cheung et al., 2016). However, monochromatic blue-enriched light (Chellappa et al.,
2011) and LED light (Cajochen et al., 2011) were used in these studies, compared
to polychromatic fluorescent and LED light in our study. Previous studies hy-
pothesized that light suppression of melatonin would reduce sleepiness and increase
alertness. Melatonin administration during the day resulted in a reduction in core
body temperature and alertness (Deacon and Arendt, 1995; Kra¨uchi et al., 1997b).
Our study was run at night analysing WT when CBT drops and DST increases
(Martinez-Nicolas et al., 2013) and showed a significant effect of exogenous mela-
tonin on WT. Our results are in agreement with other studies which illustrated that
light-induced melatonin suppression is not the only factor modulating sleepiness and
alertness.
Subjective mood ratings including calmness, cheerfulness and depression scores
were also assessed with melatonin administration. Monochromatic light exposure
has been associated with increased calmness and cheerfulness (Sletten et al., 2009).
Our study showed no significant difference in calmness scores, yet reported a signif-
icantly higher cheerfulness in LS compared to LSC and DSC. The depression score
was altered with exogenous melatonin intake, with a significantly higher depression
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score reported in DSC and LSC compared to LS. These results indicate that LAN
may improve mood scores, particularly cheerfulness, by altering melatonin levels
in the body, or LAN can act acutely to modulate emotional process via amygdala
structures in the brain as reported in blue-enriched light exposure (Vandewalle et al.,
2007). Other masking factors such as the test meal were assessed in this study by
splitting the data into pre- and postprandial periods. There was no meal effect
on sleepiness, alertness, and calmness and depression scores; however, cheerfulness
was significantly increased in LS after the meal intake, suggesting that LAN effect
had potentially occurred during postprandial period but the effect could just be
due to the meal. Elevated cortisol levels have been observed in studies showing
elevated mood and alertness (Carrier et al., 1996; Kakooei et al., 2010) implying
that cortisol may enhance mood and alertness. In our study, cortisol levels were not
significantly different between LS, DSC and LSC, excluding the impact of cortisol
on the cheerfulness score.
5.7.5 Appetite analysis
The impact of exogenous melatonin on plasma leptin as the primary appetite hor-
mone was investigated in this study. Recent studies have reported contradictory
results on melatonin-leptin interactions. Melatonin administration has been re-
ported to cause an increase in leptin levels in some mammalian species (Ambid
et al., 1998; Mustonen et al., 2000), and a decrease in middle-aged rats and goldfish
(Rasmussen et al., 1999; Pinillos et al., 2001). These controversies were due to 1)
different species; 2) changes in glucocorticoids levels due to the negative action of
melatonin on the adrenal glands (?), or pinealectomy causing an increase in the
hypothalmo-pituitary-adrenal axis (Alonso-Vale et al., 2004); 3) leptin suppression
due to weight reduction (Rasmussen et al., 1999; Prunet-Marcassus et al., 2003).
Our results showed that plasma leptin was significantly higher in DSC and LSC than
in LS indicating significant increases in leptin level with melatonin administration.
This rise was clearer when the data were split to pre- and post-prandial periods,
and confirmed by TAUC and IAUC. Our study contradicts Figueiro et al. (2012)
who reported an increase in leptin level after morning light exposure, and disagrees
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with Cheung et al. (2016) who reported no changes in leptin or ghrelin after blue-
enriched light exposure (Figueiro et al., 2012; Cheung et al., 2016). Both studies did
not investigate melatonin levels which could explain some of their findings. Also, the
design of the studies did not target the melatonin profile window, at which endoge-
nous melatonin could exert metabolic effects. Glucocorticoids such as cortisol were
reported to stimulate leptin gene expression and release (Alonso-Vale et al., 2005).
In this study, cortisol was investigated, yet no significant difference was observed
between all three sessions indicating the absence of possible stimulatory effects of
cortisol. The effect of insulin on leptin is more controversial (Kolaczynski et al.,
1996; Vidal et al., 1996; Tuominen et al., 1997). However, Alonso-Vale et al. (2005)
indicated that insulin and melatonin alone did not affect leptin gene expression,
but that insulin acted synergistically with melatonin to enhance leptin gene expres-
sion (Alonso-Vale et al., 2005). They reported that melatonin could completely
prevent the inhibitory effects of forskolin on both leptin synthesis and secretion
in adipocytes through the PTX-sensitive Gi protein-coupled membrane receptor.
Melatonin can also potentiate insulin signalling which is involved in insulin-induced
leptin expression via MT1 (Alonso-Vale et al., 2005). Despite the fact that insulin
levels were significantly lower with melatonin administration, the melatonin-insulin
action upon adipocytes cannot be ignored. It is worth mentioning that endocrine
and metabolic status can be exacerbated in major depression (Luppino et al., 2010;
Marijnissen et al., 2011), such as reportedly the increase in food intake in indi-
viduals experiencing a depressed mood (Macht, 2008). In this study, participants
reported no difference in depressive mood between the three sessions, whereas the
significant increase in subjective miserable score during LSC compared to LS is at
odds with this hypothetical mechanism. Analysing other appetite biomarkers such
as CCK and ghrelin which are associated with short-term appetite control could
be more useful in this condition. The impact of sleep deprivation on leptin levels
are well documented (Spiegel et al., 2004), yet in this study participants were sleep
deprived in all three sessions which indicates that sleep deprivation was not the key
contributing factor to leptin changes.
Significant increases in subjective hunger and desire to eat scores in LS compared
to DSC and LSC were seen in Study 2, with the opposite in fullness score. Our data
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showed a significant effect of melatonin administration on subjective appetite scores.
The subjective hunger and desire to eat explain the signifcant differences reported
in plasma leptin. These results are in disagreement with Cheung et al. (2016) who
reported no changes in subjective hunger after blue-enriched light administration
either in the morning or evening (Cheung et al., 2016). The smell of food by some
subjects, while other subjects with earlier DLMO had their meals could potentially
influence the food VAS results, as the meals were served in the same room.
5.7.6 Peripheral body temperature and activity levels
As discussed in section 1.5.4, peripheral temperature rises in the evening and early
nighttime, causing heat dispersion with a reduction in core temperature, thus facil-
itating sleep. A strong relationship between melatonin levels and WT was observed
in LS, DSC and LSC. This indicated that as melatonin levels rose, WT increasesd,
to facilitate sleep. However, our results showed a statistically significant increase in
WT in LS compared to DSC and LSC, indicating that WT drops with exogenous
melatonin intake. Our results are in disagreements with studies that showed mela-
tonin suppression by bright light results in increased CBT (Wright Jr et al., 2000;
Burgess et al., 2001). Thus, possibly a reduction in WT due to the inverse response
between CBT and WT, however, WT were not measured in these studies. It was
demonstrated that LAN exerts an alerting effect via an increase in CBT, and this
alerting effect was not blocked by melatonin administration suggesting that LAN
alerting effects were not necessarily mediated by melatonin. Our results contradict
with LAN alerting effects, as no significant differences were reported in WT (inverse
CBT), and exogenous melatonin caused a reduction in DST when it was expected
to cause an increase instead. Sleep deprivation was associated with heat loss (high
DST) as a result of disrupted coordinated sympathetic control of skin blood vessels
in extremities (hands and feet). This factor was less likely to occur in this study,
as participants were sleep deprived in all three sessions, and sympathetic system
parameters were not examined here. Some masking factors such as activity level
were demonstrated in our study, as an increase in activity is associated with in-
creased CBT. Interestingly, activity levels were higher, but not significant, in DSC
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compared to LS and LSC. This could contribute to the reduction in DST during
DSC and the increase in LS. Throughout the study room temperature was kept con-
stant and at a comfortable temperature, however, the numerical value in ◦C was not
documented. In future, room temperature value should be documented at hourly
intervals to account for any changes/fluctuations that may need to be adjusted.
5.7.7 Conclusion
This study demonstrates that exogenous melatonin caused the considerable impacts
on hormones, metabolites, appetite and behavioral responses. LAN via melatonin
suppression can exert an acute effect on subjective mood (cheerfulness), hormones
(leptin, insulin and melatonin), and metabolites (glucose, NEFA and TAGs). Bright
light during LS exerts positive impacts on mood 1 (cheerfullness), agreeing with
many studies indicating the usage of light treatment for mood disorders. The sig-
nificant effect of exogenous melatonin on leptin, was strengthened by the results
reported in subjective appetite scores. This explains the nocturnal lifestyle which is
described by irregular food schedule as a result of disruption in appetite hormones.
Our current study agrees with the hormone and metabolite changes seen in night-
shift workers. We can conclude that LAN suppressed endogenous melatonin, thus
results in reduced glucose tolerance and insulin sensitivity. An increase in TAGs
levels could be a consequence of reduced insulin sensitivity. Our study agrees with
shift-worker studies that demonstrate irregular hormones and metabolites disorders,
and risk of cardiovascular diseases. Also, irregular reduction of melatonin regulation
could be related to metabolic syndrome such as in diabetic patients. It is important
to illustrate that melatonin levels reported in Study 2 were supraphysiological and
normal endogenous melatonin levels may not have the same effect. Further investi-
gations are needed to define the mechanism of melatonin in altering hormones and
metabolites.
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CHAPTER 6
GENERAL DISCUSSION
204
6.1 Introduction
Artificial light exposure has become commonplace throughout the developed world
with many people experiencing night time illumination (Navara and Nelson, 2007;
Fonken and Nelson, 2011). Light exposure in places, at times and intensities that
does not naturally occur such as LAN, has been associated with health risks. Light
can exert acute effects that vary from hormones and metabolites to behavioural
responses and vascular function, . The acute impact of light can either occur by
direct action on brain areas, or by melatonin suppression. Light with sufficient
intensity has been associated with an increase in the alerting response (Cajochen
et al., 2000). Short-wavelength light exposure (blue & green) caused an improved
mood score such as calmness and cheerfulness (Sletten et al., 2009), and lessening
depressive symptoms (Strong et al., 2009). It has been suggested that melatonin
suppression is solely responsible for changes in alertness and CBT. This assumption
comes from human studies that showed increased body temperature and perfor-
mance in both nocturnal bright light and caffeine administration (Wright Jr et al.,
2000). Melatonin has also been linked to changes in vascular function (section
1.5.7.2) and structure (section 1.5.7.3), in addition to an acute effect of LAN on
heart rate (Scheer et al., 1999) and arterial blood pressure (Hadeel et al., 2012).
The effects of light and melatonin on hormones and metabolites are controversial.
Melatonin administration in vivo and in vitro resulted in a reduction in insulin se-
cretion (Peschke et al., 2013), whereas the administration of exogenous melatonin
in healthy women caused an increase in glucose and insulin in the evening after a
glucose tolerance test (Rubio-Sastre et al., 2014). The effects of melatonin on in-
sulin and glucagon secretion (Peschke et al., 2013) could potentially alter HSL and
LPL that regulate lipid metabolism. Melatonin has also been reported to increase
VLDL in normolipidaemic postmenopausal women by inhibiting the activity of LPL
(Wakatsuki et al., 2001). In terms of appetite, daily administration of melatonin in
middle-aged rats resulted in a reduction in plasma leptin (Rasmussen et al., 1999),
whereas the effect of melatonin on leptin was reversed in goldfish by the adminis-
tration of a melatonin antagonist (Pinillos et al., 2001).
This project aimed to investigate the effect of light at night and/or melatonin
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on hormones, metabolites, appetite control, vascular function and behavioural re-
sponses before and after an evening test meal. Since melatonin is known as the
primary hormone influenced by light at night, the effects were investigated under
different light conditions. The timing of the evening test meal was individualised
based on the estimated melatonin onset, pre-prandial and postprandial hormones
and metabolites, subjective behavioural parameters, and vascular parameters were
assessed in relation to measured melatonin levels. A majority of the previous stud-
ies investigating the effect of light on hormone and metabolic responses have either
been carried out in experimental animals (Arasteh et al., 2010), or under restricted
conditions in humans such as constant routine (Scheer et al., 2009; Wehrens et al.,
2010; Peschke et al., 2013) with some including the administration of exogenous
melatonin (Wakatsuki et al., 2001; Rubio-Sastre et al., 2014). There is a paucity
of human studies that have investigated the effect of LAN and/or melatonin on
hormone and metabolites, vascular function, and behavioural responses under field
conditions. To the investigators knowledge, this is the first study illustrating the
impact of LAN melatonin suppression on hormones, metabolites, appetite control,
vascular function, and behavioural responses. This is the first study that simulated
the nocturnal lifestyle of people who work at night and who are reported to be
healthy and have no history of shift work.
6.2 Strengths and considerations of the study protocol
Power size calculation was performed to determine the number of participants
needed for both Study 1 and 2. Power size calculation indicated the need to recruit
at least 18 participants for Study 1, and 12 participants for Study 2, however the
number completing each study was less. The participants in Study 1 (n = 17, males
and females) and Study 2 (n = 9, only males) conformed to strict criteria. All
participants were young of varying ethnicity with no documented physiological or
psychological illness, physically fit (healthy BMI) and non-smokers. Twenty-four
hours prior to the study days, participants were asked to refrain from any carbon-
ated or alcoholic drinks, as well as physical exercise, yet these factors were not
monitored. Applying strict criteria in a human study enables control over the de-
mographic characteristics but possibly limits the variability in the acquired data.
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Restricted age criteria were crucial to avoid the age related differences in NVRs in
human (Brainard et al., 1997; Charman, 2003), yet the differences in melatonin pro-
duction between genders and individuals cannot be excluded. One of the strengths
of the current studies is the strictly monitored compliance of the participants. Par-
ticipants had the chance to select the sleep-wake schedule within limits, yet they
were monitored to ensure maintenance of a regular sleep-wake cycle using an Acti-
watchL and sleep diaries. Sleep quality and participants chronotypes were assessed
before recruiting the participants. Forty-eight hours of sequential urine collection
was performed to estimate the plasma melatonin onset, thus enabling individu-
alisation of the timing of the evening test meal. aMT6s obtained from the urine
collection was also correlated to sleep data from Actiwatch and the chronotype data
obtained from screening questionnaires. This step was to ensure that the screening
data of the participants were consistent, and to ensure that participants maintained
a consistent melatonin onset in across sessions, a stable circadian phase throughout
the in-laboratory sessions and the intervening days spent at home (as indicated by
non-significant changes in salivary melatonin onset between the sessions).
A further strength of the study protocol was the highly controlled in-laboratory
sessions. The experimental sessions were carried out between December to April to
avoid major seasonal variations in photoperiod. Light exposure during daytime was
monitored using the ActiwatchL indicating no significant differences in light expo-
sure before in-laboratory sessions. During the preparation period (between lunch
and evening test meal), participants were not allowed to leave the unit to stan-
dardise light-exposure and minimise the effects of sensitisation (Chang et al., 2013).
Add to this that peripheral temperature using iButtons was monitored during the
preparation periods, and no significant differences were reported. The timing of the
evening test meal was individualised based on estimated melatonin onset, to ensure
that sufficient melatonin was present in the circulation when the evening test meal
was consumed. This step was also applied in Study 2, with the adminstration of
Circadin (2 mg) 90 minutes prior to the evening test meal. Having the evening test
meal at the same Circadian phase was crucial to avoid differences in metabolites and
hormones due to circadian factors such as time of day. The fasting period between
the lunch and the evening test meal for all participants ranged between 9 to 10.5
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hours, to allow sufficient time for collection of pre-prandial samples, and to allow
hormones and metabolites to return to basal fasting levels. Lighting was built-in,
centrally controlled, and monitored three times using a power meter during each
clinical session, to ensure that a stable light intensity was provided during the ses-
sions. Light intensity and irradiance were measured at horizontal (facing the light
source) and vertical (direction of gaze) planes to ensure that participants received
the same amount of light of correct intensity. Lighting was also controlled in the
corridor and toilet. Other possible non-photic factors capable of affecting melatonin
such as posture and caloric intake were restricted. Participants were in the semi-
recumbent position throughout the session except for toilet visits, yet they were
required to be semi-recumbent for at least 15 mins before each sample collection,
thus minimising the dynamic effect on circulation. All meals during the study day
were provided in the clinical unit, and no other food or drink were consumed apart
from water.
Randomisation was performed in both studies to avoid accidental bias and pre-
vent selection bias. It is important to ensure measurement of the effects due to the
intervention rather than other underlying variables or order effects. In Study 1,
participants were randomly coded alpha-numerically divided into groups A and B
using the sealed envelope method. Group A attended LS and then the DS session,
while group B completed LS followed by DS, all in the single-blind fashion. Under
the restriction of the study and timescale only two randomised sessions were used
in Study 2, as group A attended LS, whereas group B attended LSC, then both
groups attended DSC. After that, group A completed LSC, while group B attended
LS. Any possible order effect was assessed using sequencing analysis in SAS, and
no such effects were observed. There was a week between each clinical session to
allow for sleep compensation and wash out of any sleep deprivation effects. During
this period, participants had to maintain a regular sleep-wake cycle again, to avoid
any changes in circadian phase, thus affecting melatonin onset. Females who were
recruited in Study 1, were all on contraceptive pills, were not allowed to attend
the clinical sessions during menses, and were in the same menstrual phase in both
conditions. This was to remove any variation due to the difference in sex hormones
at different stages of the menstrual cycle.
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6.3 Overall discussion
This section will discuss the major findings reported in hormone and metabolites,
appetite parameters, and behavioural responses. Vascular functions are not in-
cluded in this section, since no significant differences were reported in Study 1, and
no strengthened hypothetical mechanism could be drawn from using the Vicorder.
Both Study 1 and Study 2 findings are integrated below.
Study 1 showed that endogenous melatonin could be involved with changes in
glucose tolerance and insulin sensitivity. The reported reduction in glucose tolerance
and insulin sensitivity in Study 1, was examined in Study 2 to clarify whether
melatonin or light caused these changes. We found that our participants showed a
significant reduction in glucose tolerance and insulin sensitivity when the melatonin
level was suppressed compared to when exogenous melatonin was administered.
This indicates that the presence of melatonin is associated with improved glucose
tolerance and insulin sensitivity at night. Melatonin has been reported to inhibit
insulin secretion (Peschke et al., 2013), which is removed by melatonin suppression in
LS, leading to increased plasma insulin. Melatonin could reduce circulating glucose
by increasing glucose utilisation (Sartori et al., 2009), or increasing glucose uptake
and promotion of glycogen synthesis (Shieh et al., 2009). HOMA-PP confirmed
that the insulin resistance score was significantly higher in LS when melatonin was
suppressed, strengthening the previous conclusion of reduced insulin sensitivity.
Our study is also in agreement with the ability of exogenous melatonin to improve
glucose tolerance and insulin resistance in high-fat-diet-fed insulin resistant mice
(Sartori et al., 2009).
The reduction in insulin sensitivity (an indication of insulin resistance) could
potentially result in an abnormal lipid profile. Hyperlipidaemia, which is defined
as an abnormal increase in circulating NEFAs and TAGs, has been associated with
insulin resistance (Verge`s, 2015). In Study 1, postprandial plasma TAGs showed
no difference, in comparison to Study 2 which indicated an increase in TAGs. This
could be a consequence of using slow release exogenous melatonin which resulted
in supraphysiological melatonin levels in the circulation, and thus significant effects
of melatonin in DSC and LSC. The primary source of high plasma TAGs after the
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test meal was either an increase in production or a delay in the catabolism of chy-
lomicrons or VLDL as reported in insulin resistance. There are several mechanisms
that could explain the high chylomicron level in insulin resistance such as:- 1) in-
creased plasma levels of ApoC-III, an inhibitor of LPL (Olivieri et al., 2003), 2)
decreased activity of hepatic LDL receptor-related protein (LRP, which is respon-
sible for chylomicron remnant uptake) (Laatsch et al., 2009), 3) reduced activity
of LPL needed for chylomicron hydrolysis (Taskinen et al., 1982; Cianflone et al.,
2008). The overproduction of VLDL could be explained by a reduction in ApoB
degradation, thus an increase in the VLDL pool for VLDL assembly (Taghibiglou
et al., 2002; Chirieac et al., 2004). It has also been suggested that insulin resistance
induces the activity of phospholipase D1 and ADP-ribosylation factor 1 (ARF-1),
both involved in the formation of VLDL (Brown and Gibbons, 2001). Insulin is an
activator of LPL, and attenuation of LPL activity was reported in obese-resistant
men due to insulin deficiency and/or insulin resistance (Taskinen et al., 2011). Pre-
prandial plasma NEFA was significantly lower in LS compared to DS in Study 1.
A possible explanation was the role of melatonin in enhancing HSL activity. In
Study 2, the significance was clearly seen with melatonin administration during the
pre-prandial period. This is potentially due to the ability of melatonin to induce a
sympathetic response which in turn enhances HSL via β-adrenoceptors (Song and
Bartness, 2001). The stimulatory effect of glucagon on HSL cannot be ruled out,
but plasma glucagon was not investigated in this study due to time limitation. The
absence of insulin inhibitory effects is known be the main stimulatory factor for HSL
activity, yet no significant differences were reported in pre-prandial insulin levels.
Subjective appetite scores for hunger and desire to eat showed a significant
increase with melatonin suppression in LS. The possibility of a melatonin-leptin in-
teraction was strengthened with melatonin administration in Study 2. Participants
reported higher hunger and desire to eat scores in LS, most likely due to the lower
plasma leptin. It has been suggested that melatonin and insulin act synergistically
to enhance leptin expression (Alonso-Vale et al., 2005). Melatonin has been reported
to prevent the inhibitory effects of forskolin on both leptin synthesis and secretion
in adipocytes, as well as to potentiate signalling involved in insulin-induced leptin
expression via MT1 (Alonso-Vale et al., 2005). It is worth noting the importance
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of the adipo-insular axis which is defined as the hormonal regulatory loop involving
leptin-insulin interaction. Leptin directly decreases insulin secretion by 1) affecting
pancreatic β-cell gene expression (Seufert et al., 1999; Seufert, 2004), 2) influencing
β-cell mass via changes in proliferation, apoptosis and cell growth (Marroqu´ı et al.,
2012), 3) suppressing GLP-stimulated Ca2+ concentrations which is needed for in-
sulin secretion (Morioka et al., 2012). This may add further suppressive effects on
the insulin level, on top of melatonin action. Therefore, dysfunction of the adipo-
insular crosstalk may be associated with the development of hyperinsulinaemia and
type 2 diabetes (Amitani et al., 2013).
High intensity of LAN was administered to healthy participants in a highly con-
trolled protocol (studies 1 and 2). As anticipated from the literature, melatonin
levels were suppressed significantly indicating that the light intensity used in this
project was sufficient to suppress melatonin. Since melatonin receptors are widely
distributed in different body tissues, its action would be partially removed or less-
ened by light exposure. The outcomes of melatonin suppression were clearly shown
when exogenous melatonin was administered in Study 2. LAN caused a reduction in
melatonin level which was associated with an increase in alertness, cheerfulness, and
elation (i.e., low depression) score according to subjective mood and alertness ques-
tionnaires. This indicates that suppression of melatonin, could potentially improve
mood and alertness, yet the possibility of LAN acutely modulating the amygdala
cannot be ignored (Vandewalle et al., 2007).
6.4 Limitation of the study
There are few limitations that have to be addressed in this project. The limita-
tions are classified into four categories: pre-study measurements, study design and
protocol, technical problems and statistical issues.
6.4.1 Pre-study measurements
Despite the medical history and GP report provided by the participants, screening
samples would be beneficial. For instance, screening blood samples for glucose,
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insulin, TAGs, NEFA, and cholesterols can define the metabolic status of each
participant before proceeding to the clinical sessions. Body composition analysis
using ”Tanita” was not utilised in Study 1, which would help to classify participants
based on their fat mass. This is crucial to assist in understanding the changes in
the lipid profile as some participants showed more significant changes in lipid profile
compared to others. It would be interesting to measure peripheral temperature over
the week before the clinical sessions for correlation with sleep analysis performed
as a part of the screening. Factors like occupational and sporting activities were
not taken into consideration. Individuals adopting particular eating patterns such
as gymnasts, athletes and ballet dancers may influence appetite analysis despite
the presence of external cues (Haworth-Hoeppner, 2000). Moreover, different eating
pattern amongst the mixed cultural backgrounds of our participants is very crucial
in this study (Kral, 2006; Su and Arab, 2006; Ohkuma et al., 2013). To determine
sample size, hormone and metabolites were used for power size calculation in Study
1 and 2. However, if behavioural measures had been used, the sample size would
have been >20. Therefore, it should be noted that the number of participants
determined were not sufficient to assess subjective appetite, mood and alertness,
which could increase the chance of type 2 errors.
6.4.2 Study design and protocol
A limitation of the study protocol was the lack of continuous monitoring of the
room temperature. Temperature control was set centrally and adjusted accordingly
to maintain temperature, but room temperature was not documented at hourly
intervals to account for any changes/or fluctuations. Some participants complained
of the cold temperature, and preferred to stay underneath the blanket at times,
whereas others preferred not using the blanket. This could lead to behavioural
masking of DST, thus allowing inter-individual variability in wrist temperature.
To avoid this, the environmental temperature needs to be kept high enough to
maintain the preferred temperature and eliminate the environmental/behavioural
masking effect.
Pre-prandial plasma hormones and metabolites were collected hourly, compared
to 15 and 30 min intervals during the postprandial period. Increasing the number
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of pre-prandial samples would definitely give a better representation of the changes
in pre-prandial hormones and metabolites, particularly in NEFAs. This was not
possible due to ethical reasons, as collecting sufficient volume of blood at each time
point was limited. The smell of food by some participants, while other subjects
with earlier melatonin onset had their meals could have potentially influenced the
food VAS results, as the meals were served in the same room. Individual differences
in the meal portion size participants are accustomed to could influence subjective
fullness and desire to eat, yet these factors were not investigated in this study.
Analysing other appetite biomarkers such as CCK and ghrelin that are associated
with short-term appetite control could be useful in these studies. It is worth noting
the inter-individual variability in eating habits such as different eating patterns are
related to various cultural backgrounds. For instance, African and American will
eat relatively large portions (Su and Arab, 2006), while the Japanese and French will
select smaller portions (Kral, 2006). Eating relatively slowly such as the Chinese
with chopsticks can induce satiation ahead of time and reduce the amount of food
consumed (Kral, 2006; Ohkuma et al., 2013). Although the same portion size of the
meal was given to all participants, understanding individual perceptions about the
portion size and eating patterns are worth considering.
Salivary melatonin is highly correlated to plasma melatonin for the measure-
ment of circadian phase (Leibenluft et al., 1996), melatonin onset, acrophase time
(Voultsios et al., 1997), and as a reliable indices for serum melatonin concentra-
tions (Nowak et al., 1987). While some studies have suggested the lower correlation
between plasma and saliva melatonin levels in individuals secreting less melatonin
(Laakso et al., 1989; Gooneratne et al., 2003), yet participants included in our two
studies were screened for melatonin output before inclusion by measurement of the
urinary metabolite, 6-sulphatoxymelatonin. Therefore, analysing plasma melatonin
would definitely indicate the role of plasma melatonin, in the changes observed in
plasma hormones and metabolites. For ethical reasons, there was insufficient volume
of plasma available to measure plasma melatonin.
The results could not determine the mechanisms involved in the changes ob-
served in glucose tolerance, insulin sensitivity, and lipid profile. A few theoretical
interpretations were addressed in Chapters 4 and 5 such as the role of catecholamines
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including epinephrine and nor-epinephrine that were not collected in this study. In
Study 1, no significant difference was reported in postprandial TAGs which was
potentially explained by the short time period of postprandial sampling, and mon-
itoring TAG responses for longer may have been useful since TAG levels normally
take ∼9h to return to basal levels after a meal (Ribeiro et al., 1998; Lund et al.,
2001; Sopowski et al., 2001). However, TAGs differences were observed when exoge-
nous melatonin was used indicating the need for high melatonin levels to exert its
impact, which can only occur with exogenous melatonin. Further analyses would be
beneficial to elaborate the mechanisms involved in the lipid profile such as analysing
LPL and HSL using HPLC. These enzymes are known as the rate-limiting enzymes
in TAGs and NEFAs metabolism. TAG levels reported in this study include VLDL
and chylomicrons produced from the small intestine (chylomicrons) or the liver
(VLDL). It is not possible to define the source of TAGs in this study, therefore
analysing apolipoprotein B (ApoB) such as ApoB-100 and ApoB-48 could deter-
mine the source of TAGs. For instance, ApoB-100 is produced in the liver and
found on the chylomicrons surface, whereas ApoB-48 is produced in the proximal
small intestine and is known as the unique apolipoprotein of chylomicrons (Olofsson
and Bore´n, 2012; Ai et al., 2014). Melatonin causes a reduction in glucose tolerance
and insulin sensitivity in these reported studies, however, the exact mechanism of
melatonin action on insulin-sensitive tissues is unknown. Analysing the transcript
expression of certain genes involved in glucose and insulin metabolism would assist
in understanding the enzymes involved in the glucose and insulin changes. Despite
the menstrual phase and contraceptive details provided by the female participants,
changes in oestrogen and progesterone were not identified, thus analysis of plasma
sex hormones would be interesting.
As participants were kept busy during the session giving blood and saliva sam-
ples, as well as completing other questionnaires, this may influence the results by
keeping them more alert than if they were held in individual rooms with less stim-
ulation. The limitations of the subjective mood and alertness assessment (paper
scale) used in this study have to be considered. Subjective mood and alertness scale
were used to detect the change in mood and alertness rather than the actual mood
score. Different participants may have different interpretations to the same level
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of change in mood. Also, with the mood scores, participants were limited to score
values from 1-9. This did not give participants the flexibility to give an accurate
score on how they felt, and could also suggest that normalising the scores could
have reduced/removed individual variations.
The Vicorder and CGM devices have been validated and widely used in clinical
trials, few errors were reported during the sessions. The Vicorder reported several
technical errors, which required repeating the measurement several times, yet in-
consistencies were the major features of this device. Vicorder varies with mobility
factor, which was partially controlled during the study. CGM main errors were
need of re-calibration against plasma glucose, which is based on a linear regression
technique (Rossetti et al., 2010). This could be explained by the possibility that the
calibration algorithm may neglect the physiological time lag between the two com-
partments (plasma-interstitial fluid). Leal et al., (2010) applied a new algorithm
technique based on an autoregressive model which estimate blood glucose from the
sensors intensity signal (Leal et al., 2010).
6.4.3 Statistical limitations
It was not possible to define the light x melatonin interaction in Study 2. The
major reason for this is the small number of degrees of freedom (df = 1). In
order to get an interaction between two or more factors, the degree of freedom
has to be > 1. This means, to get light x melatonin, or light x melatonin x time
interaction, another clinical session (dark with no melatonin) would be needed. To
achieve this, endogenous melatonin would need to be removed, potentially by using
a beta-blocker such as atenolol which blocks melatonin production via inhibition of
beta-1 adrenergic receptors (Stoschitzky et al., 1999), however using atenolol would
influence other hormones and metabolites under investigation (Fonseca, 2010). It
would therefore not give a definitive answer to the question and therefore only three
sessions were completed.
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6.5 Future work
Based on the limitations addressed previously, some aspects associated with the
study design and further analyses have to be considered for clarification. It is
suggested that future work should include the following:
In order to define the source of postprandial TAGs increases in LS, ApoB such
as ApoB-100 and ApoB-48 should be analysed. Apolipoprotein B is the primary
protein constituent of lipoproteins such as chylomicrons, VLDL, LDL and HDL, that
are involved in lipid transport and metabolism. ApoB-48 is the principal protein
of chylomicrons, whereas VLDL contains ApoB-100 as the primary apolipoprotein,
both are necessary for binding to cell receptors and activating LPL. Analysing
ApoB-48 would define if the major changes in TAGs came from chylomicrons (known
as the primary dietary lipid), while ApoB-100 would determine if liver metabolism
was the source of elevated TAGs.
Further hormone and metabolite analyses such as catecholamines, sex, and ap-
petite hormones have been proposed. For instance, epinephrine and norepinephrine
stimulate the activity of rate-limiting enzymes involved in gluconeogenesis and lipol-
ysis such as fructose-bis-phosphatase and HSL (Silverthorn et al., 2009; Lieberman
et al., 2013). Therefore, catecholamine analysis could, in part, explain the increase
in glucose and lipid profile. Although females menstrual phase and contraception
details have been reported in Study 1, sex hormone analysis such as oestrogen and
progesterone are needed to detect if these hormones show any differences between LS
and DS, which could contribute to the significant findings. In addition to plasma
leptin, other satiation biomarkers such as ghrelin and CCK should be measured.
CCK, in particular, is considered as a classic biomarker of the satiation response
to the fat and protein components of meals (Overduin et al., 2014). A few criteria
have been addressed in some studies to evaluate the best-established satiation hor-
mone among CCK, leptin and ghrelin. The main criteria applied was the concept
of coupled and uncoupled hormone effects which assess the linking of specific food
stimuli with altered hormone changes, and secondly, the hormonal changes involved
with a distinct change in eating, e.g., meal initiation or termination. According
to these criteria, CCKs satiating action in humans is the ideal physiological and
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hormonal change (Geary, 2004). Regarding plasma ghrelin, active ghrelin (acylated
ghrelin) which possess endocrinological activity by binding to ghrelin/growth hor-
mone secretagogue receptor (GHSR), in comparison to total ghrelin which is the
sum of acylated and des-acyl ghrelin would also be interesting to analyse (Seim
et al., 2010).
When correlation tests were applied to assess melatonin levels versus subjective
questionnaires such as mood and alertness, some participants showed no relationship
with melatonin or WT. Since the subjective questionnaires have some limitations
as mentioned previously, objective measures of sleepiness and alertness would be of
interest. For instance, EOG and EEG are the widely used techniques that measure
eye movement and electrical activity of the brain (Cajochen et al., 1999; Regen et al.,
2013). However, there are significant disadvantages to EOG and EEG measurements
as they are expensive and time consuming. Another technique to measure sleepiness
has been used by Johns and colleagues (2008) and involves the use of a video camera
to film a persons’ eyes and uses infrared reflectance oculography to measure the
speed and duration of eyelid movements during blinks (Dinges et al., 1998; Johns
et al., 2008). Using 10cm VAS in place of a numerical 1-9 scale would provide a
more sensitive assessment.
Insulin and counter-regulatory hormones such as epinephrine and cortisol are
influenced by the circadian system, with growth hormone and cortisol showing a
night surge which causes an elevation in glucose production. In non-diabetic peo-
ple, insulin offsets this process, and allows glucose production to remain relatively
stable. Our findings were that light at night suppressed melatonin resulting in re-
duced glucose tolerance, insulin insensitivity, and increased postprandial TAGs. It
would be of interest to investigate the effect of light exposure and/or melatonin
administration during the daytime when insulin and counter-regulatory hormones
are not at peak levels (Gamble et al., 2014).
The use of targeted metabolomics and lipidomics would allow examination of
nearly two hundred of metabolites. Targeted metabolomics can detect and quan-
tify over 180 metabolites including amino acids, biogenic amines, acylcarnitines,
glycerophospholipids and sphingolipids. The advantage of using metabolomics is
the fact that it measures the final downstream production of transcription and
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translation, and the dynamics of metabolism that operate in seconds. These char-
acteristics allow metabolomics to be a sensitive and rapid measure of the system
phenotype. Also, by using metabolomics we can group metabolites according to
metabolic pathways. This is a more appropriate biomarker than metabolites mea-
sured independently (Altmaier et al., 2008; Mamas et al., 2011). PAX-gene RNA
analysis could be used in future studies, to investigate the expression of certain
genes for enzymes that are involved in metabolism. For instance, studying the
rate-limiting enzymes in glucose and lipid metabolism would provide a significant
indication of the metabolic processes and mechanisms behind our findings.
6.6 Applications of the current results
It is important to note that melatonin deficiency syndrome has not yet been defined
as an independent condition, and no definite guidelines for the identification of
patients with low melatonin levels have been formulated. Secondly, the controversy
in the correlation between salivary and plasma melatonin requires further validity
and feasibility assessments. Add to this, several factors must be considered before
administration of melatonin such as variable oral absorption, short biological half,
and first-pass metabolism (Vlachou et al., 2006). Therefore, further substantive
clinical evidence for the use of LAN and/or melatonin in metabolic syndrome patient
is needed before any recommendations can be made.
According to the major findings of this project, our data suggested a positive
impact of LAN on alertness, cheerfulness and depression. However, LAN caused
adverse effects on glucose tolerance, insulin resistance, TAGs levels and appetite
parameters. These findings represent the short-term effect of LAN and/or mela-
tonin which may become exacerbated in long-term exposure such as in shift-work.
These results may have implications for shift workers who are exposed to light at
night and concomitant melatonin suppression. Since melatonin is involved in sev-
eral metabolic processes, any disturbance in its rhythm or secretion may lead to
several consequences. The short-term use of exogenous melatonin improves glucose
tolerance and insulin sensitivity, agreeing with the evidence from animal and human
studies indicating the positive effects of melatonin on glycaemic control (Forrestel
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et al., 2016). Also, using slow-release melatonin that covered the entire melatonin
secretion period, reduced high TAGs levels after an evening test meal, compared
to melatonin suppression due to LAN. This is an indication of the possibility of
using melatonin as a supplementary treatment in dyslipidaemia and related disor-
ders. Add to this, the ability of melatonin to reduce hunger and desire to eat by
increasing plasma leptin, which may regulate food intake, helping to minimise the
risk of obesity. On the other hand, the use of exogenous melatonin was associated
with low alertness and cheerfulness and increased depression. It is hard to draw
a definite conclusion on the effect of melatonin behavioural responses since these
were subjective questionnaires which have their limitations. Using polychromatic
fluorescent light which consists of broad spectrum light makes it difficult to exclude
any significant role of blue wavelength light on mood and alertness. Therefore,
it would be of interest to test the use of exogenous melatonin on objective mood
and alertness with blue-enriched light. Although melatonin is available ”over the
counter”, in some countries the newly developed MT1/MT2 receptor agonist has
been suggested for greater efficacy. It remains to be determined whether these drugs
can be used clinically as an effective means for improving glycaemic control, lipid
metabolism and appetite control.
6.7 Conclusion
The growing interest in the effect of light, particularly light at night, on human
physiology, and its adverse consequences, has led researchers to establish appro-
priate interventions to mitigate the harmful effects of LAN. In this project, the
impact of LAN and/or exogenous melatonin on hormones, metabolites, appetite
control, vascular function and behaviours was investigated in healthy participants.
This project demonstrates that LAN exerts its effects by suppressing melatonin
levels which in turn involves many physiological regulations due to its nature and
widely distributed receptors. Our study illustrated that melatonin improves glu-
cose tolerance and insulin sensitivity after an evening test meal. It also reduced
TAGs levels and appetite. In contrast, LAN exposure was associated with glucose
intolerance and insulin insensitivity which could be the explanation for high TAGs
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and increased subjective appetite, thus potentially increased food intake. Despite
the negative impacts of LAN on hormones and metabolites, LAN improves sub-
jective alertness, cheerfulness and elation feelings at night. This project may have
an implication on shift workers who are exposed to LAN. Despite the strengths of
the controlled protocol used in this study, future work is needed to elucidate the
mechanism behind the effect of melatonin on hormones and metabolites. The study
demonstrates the possible role of melatonin in lessening the chance of developing
glucose intolerance, insulin resistance and high TAGs in shift workers. It is sug-
gested to use slow release melatonin and/ or melatonin receptor agonist in shift
workers developing insulin resistance and dyslipidaemia. This project supports the
idea that a nocturnal lifestyle, such as in night shift work, is likely to be one of the
risk factors to health in modern society, including diabetes.
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Abstract
Many animal studies have reported an association between melatonin suppression and 
the disturbance of metabolic responses; yet, few human studies have investigated bright 
light effects on metabolic and hormonal responses at night. This study investigated the 
impact of light on plasma hormones and metabolites prior to, and after, an evening 
meal in healthy participants. Seventeen healthy participants, 8 females (22.2 ± 2.59 years, 
mean ± s.d.) and 9 males (22.8 ± 3.5 years) were randomised to a two-way cross-over 
design protocol; dim light (DL) (<5 lux) and bright light (BL) (>500 lux) sessions, 
separated by at least seven days. Saliva and plasma samples were collected prior to 
and after a standard evening meal at specific intervals. Plasma non-esterified fatty acid 
(NEFA) levels were significantly higher pre-meal in DL compared to BL (P < 0.01). Plasma 
glucose and insulin levels were significantly greater post-meal in the BL compared to 
DL session (P = 0.02, P = 0.001), respectively. Salivary melatonin levels were significantly 
higher in the DL compared to those in BL session (P = 0.005). BL at night was associated 
with significant increases in plasma glucose and insulin suggestive of glucose intolerance 
and insulin insensitivity. Raised pre-prandial NEFA levels may be due to changes in 
insulin sensitivity or the presence of melatonin and/or light at night. Plasma triglyceride 
(TAG) levels were the same in both sessions. These results may explain some of the 
health issues reported in shift workers; however, further studies are needed to elucidate 
the cause of these metabolic changes.
Introduction
Artificial light exposure at night has become commonplace 
throughout the developed world (1, 2). Light has been 
linked to various complex mechanisms such as the 
synchronisation of the circadian system (3). Circadian 
rhythms are seen in any biological processes that display an 
endogenous oscillation of about 24 h. They are generated 
by the suprachiasmatic nuclei (SCN) located in the anterior 
hypothalamus and influenced by external cues called 
zeitgebers (commonly daylight). Melatonin is considered 
the classical phase marker for assessing the timing of the 
mammalian biological clock. The SCN drives the daily 
rhythms in hormone concentrations such as insulin, 
glucagon, corticosterone (4, 5, 6) and enzymes involved 
in lipid and glucose metabolism, such as glucose-6-
phosphate dehydrogenase (7, 8). Therefore, disruption of 
circadian coordination may be manifested by endocrine 
imbalances (9), incidence of obesity (10) and type 2 
diabetes (11, 12). This raises a controversial issue as to 
whether aberrant light exposure may influence metabolism 
by changing the time of the circadian system (13). 
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It has been reported that blood glucose increases during 
light exposure and decreases during darkness in rats (14, 
15). Others have reported the melatonin-induced inhibition 
of insulin secretion via cyclic adenosine monophosphate 
(cAMP) and cyclic guanine monophosphate (cGMP), 
and the presence of melatonin receptors 1 (MT1) and 
2 (MT2) in pancreatic tissues of both rats and humans 
(16). Additionally, acute melatonin administration in 
healthy women has been reported to impaired glucose 
tolerance in both the morning and evening (17). The 
impact of melatonin administration on lipid metabolism 
has been demonstrated in experimental animals (18, 19) 
and humans (20, 21). In addition, melatonin has been 
reported to influence insulin (16) and glucagon (22), which 
in turn affect enzymes involved in lipid metabolism such as 
hormone-sensitive lipase (HSL) and lipoprotein lipase (LPL).
A majority of the previous studies investigating the effect 
of light on hormone and metabolic responses have either 
been carried out on experimental animals (14) or under-
restricted conditions in humans such as constant routine 
(16, 23, 24) including the administration of exogenous 
melatonin (17, 21). The aim of this study was to investigate 
the impact of broad spectrum bright light exposure (>500 
lux) on healthy young participants prior to and after a late-
evening meal. The hypothesis being that a single night of 
light exposure would be associated with changes in glucose 
tolerance, insulin sensitivity and lipid profiles. The findings 
could have health implications for individuals with a 
nocturnal lifestyle including nightshift work.
Participants and methods
Recruitment
All procedures received a favourable ethical opinion from 
the University of Surrey Ethics Committee (UEC/2013/93/
FHMS) and were conducted in accordance with the 
Declaration of Helsinki (1975) as revised in 1983 and 
conformed to international ethical standards. Volunteer 
information was coded and held securely in compliance 
with the Data Protection Act, UK (1998). All participants 
gave written informed consent after full explanation of 
the purpose and nature of all procedures involved.
Participants and screening
Seventeen healthy participants, 8 females (22.2 ± 2.59 years; 
mean ± s.d.) and 9 males (22.8 ± 3.5  years) were recruited 
from students and staff at the University of Surrey. The two 
genders were matched for age and body mass index (BMI) 
(Table 1). Participants were all non-smokers and taking no 
medication except for mild analgesics. All females were on 
oral contraceptive pills. Participants had not crossed more 
than two time zones and/or worked night shifts during 
the month before the study. All participants completed 
screening questionnaires including Pittsburgh Sleep Quality 
Index (PSQI), Horne-Östberg (HÖ) and Munich chronotype.
Pre-laboratory measurements
All participants maintained a standard self-selected regular 
sleep–wake cycle (nocturnal sleep duration of 6.5–8 h, 
with sleep onset between 23:00 h and 01:00 h) for at least 
7 days before the in-laboratory sessions, as confirmed by 
actigraphy (AWL, Cambridge Neurotechnology, UK) and 
sleep diaries (Table 2). 24-h prior to the laboratory sessions, 
participants were required to refrain from caffeinated 
drinks, alcohol, excessive exercise and medicine intake. 
In addition, participants performed a 48-h sequential 
urine collection to measure 6-sulfatoxymelatonin 
(αMT6s), the major urinary metabolite of melatonin, via 
radioimmunoassay (Stockgrand Ltd., University of Surrey, 
Guildford, UK). The acrophase of 6-sulfatoxymelatonin 
was determined by cosinor analysis, enabling meal intakes 
(supper) to be individually scheduled to occur on the rising 
phase of each participants’ endogenous melatonin rhythm.
Laboratory session
All participants were randomised to a two-way cross-over 
design protocol; dim light and bright light. All study 
sessions were held at the Clinical Investigation Unit 
(CIU), which was equipped with overhead light control. 
During the dim light session, lighting levels were <5 
Table 1 Participant demographics.
 Male (n = 9) Female (n = 8) P (M vs F)
Age (year) 22.3 ± 3.6 22.6 ± 2.2 0.84
Body weight (kg) 68.4 ± 7.9 63.8 ± 8.5 0.26
Height (m) 1.8 ± 1.7 1.7 ± 0.1 0.14
BMI (kg/m2) 22.9 ± 2.5 22.7 ± 2.2 0.88
Caffeine (week) 10.1 ± 6.2 11.4 ± 9.1 0.74
Alcohol (week) 2.8 ± 2.3 3.8 ± 4.2 0.56
PSQIa 3.3 ± 1.2 4.1 ± 1.5 0.24
HÖa 51.2 ± 8.1 52.4 ± 10.9 0.81
MCTQa (h) 4.7 ± 1.2 4.9 ± 1.1 0.87
Values are mean ± s.d., P values were calculated by 2-tailed unpaired test.
aValues given are those obtained during the screening session.
BMI, body mass index; HÖ, Horne–Östberg questionnaire; MCTQ, Munich 
Chronotype Questionnaire; PSQI, Pittsburgh Sleep Quality Index.
This work is licensed under a Creative Commons 
Attribution 4.0 International License.DOI: 10.1530/EC-16-0097
http://www.endocrineconnections.org © 2017 The authors
Published by Bioscientifica Ltd
Research M S Albreiki et al. LAN alters endogenous 
responses to a meal
En
d
o
cr
in
e 
C
o
n
n
ec
ti
o
n
s
6:102102–110
lux and in the bright light session, lighting was >500 
lux between 18:00 h and 06:00 h the next day (Fig.  1). 
Participants were randomly coded alphanumerically 
divided into groups A and B using the sealed envelope 
method. Group A attended BL session and then the DL 
session, whereas group B completed the sessions in reverse 
order. Participants were kept awake and semi-recumbent 
throughout the study session, except during visits to the 
toilet. A set breakfast was provided at 08:00 h, whereas 
lunch and supper (test meal) times were individualised 
on the basis of the acrophase time of urinary aMT6s. The 
fasting period between lunch and supper was 9–10 h. 
Participants consumed an isocaloric and non-carbonated 
evening meal at a time estimated to be within 30 min of 
endogenous melatonin onset (1066 kcal, 38 g protein, 
104 g CHO, 54 g fat, 7 g fibre) (Table 3).
Blood samples were collected hourly from 18:00 h 
until the evening meal; then, every 15 min for the first 
hour after the meal, then at 30-min intervals until the end 
of the session. In total, 22 blood samples were collected in 
each session from each participant for analysis of insulin, 
glucose, triglyceride (TAG) and non-esterified fatty acids 
(NEFAs). Saliva samples were collected every 30 min 
from 18:00 h to 06:00 h the following day for analysis of 
melatonin levels.
Light measurements
Light intensity was measured at 2 different positions 
horizontal level (direction of gaze) (n = 221; DL 1.06 ± 0.06 
lux, BL 305 ± 10.1 lux; mean ± s.e.m.) and vertical level 
towards the lights (n = 221; DL 1.21 ± 0.13, BL 552.7 ± 16; 
mean ± s.e.m.).
Spectral composition of the light source was 
measured using a R203 power radiometer at horizontal 
(DL 0.001 w/m2, BL 0.98 w/m2) and vertical level (DL 
0.0008 w/m2, BL 0.73 w/m2). The light source provided 
in both studies are fluorescent light, and the spectral 
composition of the light is shown in Fig. 2.
Assay procedures
Plasma glucose, TAG (Werfen Ltd, Warrington, UK) 
and NEFAs (Randox Laboratories Ltd, Crumlin, UK) 
were analysed by standard automated enzymatic 
spectrophotometric methods (ILAB600). The 
interassay coefficients of variation were less than 5% 
for glucose, NEFAs and TAGs. Plasma immunoreactive 
insulin was measured using radioimmunoassay 
(RIA) (Millipore). Salivary melatonin and urinary 
aMT6s were analysed using in-house RIAs (25, 26). 
The interassay coefficients of variation were less than 
10% for melatonin (control 1 = 6.5 pg/mL (6.7%), 
control 2 = 24.5 (6.7%) and control 3 = 49.6 pg/mL 
Table 2 Screening sleep and basal hormone and  
metabolite data.
 BL DL P
Sleep starta (h:min) 23:54 ± 00:14 00:18 ± 00:14 0.1
Sleep enda (h:min) 07:21 ± 00:10 07:35 ± 00:09 0.1
Sleep durationa (h) 06:37 ± 00:16 06:24 ± 00:14 0.5
% Sleep efficiencya 81.9 ± 2.8 78.06 ± 3.5 0.4
Sleep latencya (h:min) 00:35 ± 00:12 00:48 ± 00:12 0.5
Fragmentation indexa 26.4 ± 2.9 28.81 ± 3.4 0.5
Basal glucoseb (mmol/L) 4.9 ± 0.3 4.8 ± 0.2 0.7
Basal insulinb (pmol/L) 107 ± 34 105 ± 28 0.9
Basal NEFAsb (mmol/L) 0.75 ± 0.1 0.91 ± 0.1 0.07
Basal TAGsb (mmol/L) 1.1 ± 0.1 1.2 ± 0.2 0.4
Basal melatoninb (pg/mL) 1.8 ± 0.4 2.6 ± 0.6 0.05
Values are mean ± s.e.m. Sleep parameters n = 15 hormone and metabolic 
basal data n = 17.
aValues are obtained from 7 days prior to BL and DL sessions. bValues 
represented the basal samples (T = −360 min) from each clinical session. 
Sleep parameters were analysed based on data obtained from sleep 
diaries and Actiwatch data. *P < 0.05.
Figure 1
Study protocol of BL and DL sessions. The schematic figure represents the study protocol for a participant with plasma melatonin onset at 22:30 h. All 
interventions (see key) were relative to each participants’ melatonin onset.
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(6.8%)) and insulin (control 1 = 100.3 pmol/L (10%), 
and control 2 = 332.2 pmol/L (9.5%)).
Measurement of insulin resistance
An index of fasting insulin resistance (HOMA-IR) 
and postprandial insulin resistance (HOMA-PP) were 
determined for the evening meal in both BL and DL 
sessions.
HOMA-IR was calculated using the HOMA calculator 
based on HOMA model 2 developed by Jonathan Levy (27).
HOMA-PP was calculated as the incremental area 
under the curve (IAUC) glucose (mmol/L  min) × IAUC 
insulin (U/L min).
This equation has been validated against the 
intravenous glucose tolerance (28).
Data and statistical analysis
A power calculation was performed using PS software 
(Vanderbilt University, Nashville, Tennessee, USA) with a 
power of 80% and a significance level 0.05 utilising NEFA 
data obtained from a previous pilot investigation. From 
this power calculation, ≥18 participants were required.
Urine aMT6s data were subjected to cosinor analysis 
(Dr D S Minors at the University of Manchester, UK), to 
ascertain calculated peak time of aMT6s (acrophase).
All data were checked for normality using D’Agostino 
Pearson omnibus normality test (Graphpad). The mean 
value plus the standard deviation (s.d.) and standard error 
of mean (s.e.m.) were calculated from individual data sets. 
All hormonal and metabolic data were subjected to three-
factor repeated measures ANOVA (condition, gender 
and time) followed by Tukey’s honest significance post 
hoc test to locate individual differences, using Statistica 
Statsoft (Tulsa, OK, USA). The trapezoidal rule was used to 
determine the total area under curve (TAUC). All hormone 
and metabolite data were analysed using TAUC, followed 
by 2-tailed paired Student’s t-test. The significance level 
was set at P < 0.05.
Results
Comparison of male and female participants
The mean age, body weight, height and BMI of 9 males 
and 8 females in this study were matched (Table  1). 
Caffeine and alcohol consumption over the two weeks 
prior to the study were not significantly different between 
male and female groups. Both genders were classified as 
neither morning nor evening types by the HÖ, and all 
reported a good sleep quality over a month prior to the 
study using the PSQI. Sleep parameters screened prior 
to BL and DL sessions are given in Table 2. Participants 
reported no significant difference in sleep prior to BL and 
DL sessions. No differences were observed in hormone 
and metabolic concentrations at the start of the each 
study session (Table 2).
Plasma levels prior to the test meal (T = 0)
Basal levels of plasma insulin, glucose, TAGs and NEFAs 
from samples collected immediately prior to the meal 
(T = 0) are shown in Fig.  3. Basal glucose and insulin 
showed no significant differences between BL and DL 
sessions. Basal NEFAs were significantly higher in DL than 
those in BL (P = 0.02). No significant difference was seen in 
basal TAGs between DL and BL (P = 0.81). Basal melatonin 
levels were significantly greater in DL than those in BL 
(P < 0.001) (Fig. 2).
Table 3 Carbohydrate, protein, fat, fibre and energy for 
each of the meals and overall composition of all three meals.
 
Meal (g)
Energy 
(kcal)
 
Protein (g)
 
CHO (g)
 
Fat (g)
Fibre 
(g)
Breakfast 627 15 98 16 14
Lunch 927 25 115 38 19
Test meal ‘supper’ 1066 38 104 54 7
Total 2620 78 317 105 40
% composition*  15% 59% 19% 7%
*Percentages were calculated proportionally from the total daily 
consumption.
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Figure 2
Fluorescent light composition.
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Hormone and metabolic responses prior to the meal 
(T-360-0)
There were no significant differences between BL 
and DL sessions in plasma glucose, insulin and TAGs 
concentrations prior to evening meal. Pre-evening meal 
NEFAs showed a significant increase in DL compared 
to that in BL session (P = 0.03). Similarly, salivary 
melatonin was significantly higher in the DL session 
(P < 0.001) (Fig. 4).
Postprandial hormone and metabolic responses
Postprandial plasma glucose and insulin responses 
to the test meal showed a significant increase in BL 
compared to those in DL (P = 0.01, P = 0.008), respectively. 
Salivary melatonin was significantly greater in DL than 
that in BL sessions (P < 0.001). There were no differences 
in postprandial TAGs responses after BL and DL 
sessions (Fig. 3).
Pre-prandial and postprandial hormone and 
metabolic responses (T = −360 to T = +330)
Graphical representations of the female, male and all 
participants during DL and BL sessions are shown in 
Fig. 3. Plasma insulin levels were significantly greater in BL 
than those in DL sessions (P = 0.001). Post hoc tests showed 
significant differences at +180, +210 and +270 min. 
Similarly, plasma glucose showed a significant increase in 
BL compared to that in DL sessions (P = 0.02). Post hoc test 
showed significant differences at +180 and +210 min after 
the meal. In contrast, there was a significant pre-prandial 
increase of plasma NEFA in DL session (P = 0.005). Post 
hoc tests showed the difference was directly prior to the 
evening meal (T = 0). Plasma TAGs showed no significant 
difference between the DL and BL sessions. All 4 plasma 
parameters showed significant effects of time, whereas no 
significant effects of gender were observed.
Salivary melatonin levels were significantly greater 
in DL than those in BL session (P < 0.001). Post hoc 
tests showed significant differences at pre-prandial and 
postprandial time points between −120 and +330 min. 
Both males and females show similar increase in salivary 
melatonin in DL compared to those in BL sessions, 
females showed higher levels of salivary melatonin than 
males although not significant (Fig. 4).
Total area under the curve
TAUCs for, insulin, glucose, NEFAs, TAGs and melatonin 
were calculated and are shown in Fig. 5. TAUCs for NEFAs 
showed a significant reduction in BL (290 ± 17 mmol/L min) 
compared to those in DL (350 ± 18 mmol/L min) sessions 
(P = 0.009). In contrast, a significant increase in TAUCs for 
plasma insulin and glucose were shown in BL compared 
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Figure 3
Plasma glucose (A), insulin (B), NEFAs (C), TAGs (D) and melatonin (E) levels (mean ± s.e.m.) prior to the test meal at time = 0 in all participants (n = 17) 
during DL ( ) and BL ( ) sessions. *P < 0.05, and ***P < 0.001.
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Figure 4
Plasma glucose (A), insulin (B), NEFAs (C), TAGS (D) and salivary melatonin (E) (mean ± s.e.m.) levels prior to and after a standard evening meal (time = 0 
red dotted line) during DL ( ) and BL ( ) sessions in males (n = 9), females (n = 8) and all participants (n = 17).
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to DL (P = 0.004 and P = 0.03), respectively. TAUC of 
plasma insulin was 129,119 ± 10,343 pmol/L min in DL 
and 109,875 ± 9817 pmol/L min BL, whereas TAUCs of 
plasma glucose were 3805.76 ± 60 mmol/L min in DL and 
3985 ± 73 mmol/L min in BL. No significant difference 
was observed in plasma TAGs responses. TAUCs showed 
a significant suppression of salivary melatonin in BL 
compared to those in DL sessions (P < 0.0001), and 
TAUCs were 3171 ± 530 pg/mL min in BL session and 
10,362 ± 1777 pg/mL min in DL sessions.
HOMA-PP and HOMA-IR
HOMA-PP and HOMA-IR are shown in Fig. 6. HOMA-PP 
was greater but not significant in BL (49,802 ± 6428) than 
that in DL (41,607 ± 6141) session. Similarly, HOMA-IR was 
higher, yet not significantly, in BL (1.2 ± 0.1) compared to 
that in DL (1.1 ± 0.1) sessions.
Discussion
Few studies have investigated the influence of light at 
night on plasma hormones and metabolites in healthy 
humans as a majority of the studies reported to have 
either been carried out on experimental animals (29) or 
under-restricted conditions in humans such as constant 
routine (16, 23, 30) or involved in the administration of 
exogenous melatonin (18, 20). To the author’s knowledge, 
this is the first study to investigate bright light exposure at 
night on hormonal and metabolic responses prior to and 
after a standard evening meal in healthy young individuals 
by exposing them to two light sessions: bright (>500 lux), 
equivalent to light the intensity in the workplace, and 
dim light (<5 lux) equivalent to candle light.
The salivary melatonin profile was significantly 
reduced by bright light exposure at night. This was 
expected as the light intensity delivered at the angle 
of gaze was 305 lux, and previous human studies have 
shown that 200 lux was sufficient to suppress salivary 
melatonin by 50% in healthy participants (31). In this 
study, a reduction of 62% in melatonin amplitude was 
observed in the BL session. The evening meal was targeted 
between 30 min and 1 h after estimated melatonin onset in 
both light sessions to ensure the presence of endogenous 
melatonin at the meal time. All participants showed the 
presence of endogenous melatonin at evening meal time 
in DL session. Our results indicate that salivary melatonin 
levels appear higher, but not statistically significant, in 
females than those in males under both light sessions 
agreeing with previously published research (32).
Plasma glucose responses were significantly elevated 
three hours after the meal in the BL session, confirmed 
by TAUC analysis. Insulin levels were significantly 
elevated after the meal in BL compared to those in the 
DL sessions. Raised glucose and insulin responses suggest 
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Total area under the curve (TAUCs) for glucose (A), insulin (B), NEFAs (C), TAGs (D) and melatonin (E) (mean ± s.e.m.) during BL  and DL ▬ sessions in all 
participant (n = 17). *P < 0.05, **P < 0.01.
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changes in glucose tolerance and insulin sensitivity. 
Calculation of HOMA-PP and HOMA-IR confirmed these 
findings although significance was not achieved. These 
results agree with rodent studies that showed decreased 
blood glucose and insulin in constant darkness (14, 15). 
Fonken and coworkers observed that male mice in 
constant light increased body mass with reduced glucose 
tolerance compared to those in a standard light/darkness 
cycle with similar food intake (33). It is important to 
note that rodents are nocturnal, whereas humans are 
diurnal mammals with reversed rest activity cycles 
and hormonal rhythms, including those important in 
metabolic regulation, except for melatonin, which peaks 
during the darkness phase in both (34). Our results are 
also in agreement with recent evidence observed in sleep 
deprivation (23, 35, 36) and circadian misalignment 
(37) such as in jet lag and shift work, which have shown 
an increase of postprandial glucose and insulin that 
denotes insulin insensitivity and failure of beta cell 
compensation (38). Reduced insulin sensitivity reported 
in sleep debt could be due to an altered balance between 
the sympathetic (SNS) and parasympathetic nervous 
system (PNS) (35, 38), which may influence beta cell 
activity indirectly via cortisol and epinephrine (35, 
39). High night-time cortisol has been reported to be 
associated with sleep loss and insulin resistance (40). 
Overstimulation of the SNS as a result of the wake-
promoting factor orexin (36) has been reported to result 
in increased glucose mobilisation and altered insulin 
sensitivity (41, 42). It has been suggested in human 
studies that consumption of nutrients at inappropriate 
times of day results in metabolic imbalances as a result 
of circadian desynchrony (37). In our present study, 
participants were sleep deprived in both sessions, and 
melatonin onset was not significantly different between 
BL and DL, indicating that postprandial changes obtained 
are unlikely to be due to sleep deprivation or circadian 
misalignment. The difference observed in glucose 
tolerance and insulin sensitivity could be due to the 
presence of melatonin in the DL session, as melatonin 
has been reported to inhibit insulin secretion in both rat 
insulinoma cells and pancreatic islets, thus influencing 
blood glucose (43, 44). Furthermore, light exposure 
during sleep deprivation in humans has been reported to 
increase insulin resistance compared to sleep deprivation 
in the darkness (45). The explanation being possible due 
to dysregulation of the SCN that coordinates peripheral 
organs and energy homeostasis, in addition to altered 
melatonin levels, which have been associated with 
increased insulin resistance in experimental animals 
(46), while melatonin secretion was inversely correlated 
with insulin in healthy humans (47). An increase 
in evening light exposure and a decrease in urinary 
6-sulfatoxymelatonin excretion have been associated 
with an increase in the prevalence of type 2 diabetes in 
elderly individuals (48). However, the effects of evening 
light exposure on glucose metabolism may be greater 
in the young compared to an older population due to 
reduced transmission of light through the lenses (49).
In contrast, a human study by Rubio-Sastre and 
coworkers gave exogenous melatonin prior to an oral 
glucose tolerance test (OGTT) in the morning and 
evening and resulted in raised insulin and glucose 
responses compared to placebo (17). This study conflicts 
with our results; however, this may be due to differences 
between the two study protocols. We utilised endogenous 
melatonin and a consumption of an evening meal, 
whereas Rubio-Sastre and coworkers administered a single 
dose of immediate-release melatonin and a drink of oral 
glucose. The sleep–wake cycle of participants in the Rubio-
Sastre study was not recorded, which could influence 
metabolite changes. Using a single dose of immediate-
release melatonin would saturate melatonin receptors 
with supraphysiological melatonin levels. Variability of 
absorption rates in oral glucose tolerance tests (OGTT) 
compared to our study that provide a standard evening 
meal could contribute to the result differences (17).
Pre-prandial plasma NEFA was significantly elevated 
in the DL session, which may be due to the physiological 
response to fasting itself. However, all participants had 
the same fasting period between lunch and the test 
meal during both sessions, and the main significant 
difference was observed just prior to the test meal 
(T = 0) when melatonin levels were already high in the 
DL. This potentially suggests the possible stimulatory 
effect of melatonin on glucagon (42). Other potential 
mechanism could be increased sympathetic action due to 
endogenous melatonin inducing HSL activity (50, 51, 52). 
It is suggested that the major activating factor for HSL is 
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HOMA-IR (A) and HOMA-PP (B) (mean ± s.e.m.) during BL  and DL ▬ 
sessions (n = 17).
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the absence of the inhibitory effects of insulin (53). No 
difference in plasma TAGs could be due to the absence of 
melatonin effects on LPL activity. Also, it is important to 
note that TAG levels normally take approximately 9 h to 
return to basal levels after a meal (54, 55, 56).
One of the limitation of this study was that 
postprandial response was only measured for up to 5 h 
after the standard evening meal, which does not provide 
a complete profile of postprandial TAGs. Future research 
needs to include a longer sampling period. Further 
hormonal analyses such glucagon and cortisol would 
be interesting to determine if NEFA changes were due to 
glucagon effects and to determine the role of cortisol in 
metabolic changes of glucose and insulin. The protocol 
used in this study can only explain changes due to different 
light sessions or endogenous melatonin action. A future 
study involving exogenous melatonin administration 
during light exposure would help to determine whether 
the metabolic changes seen are due to melatonin or other 
processes.
In conclusion, this is the first study to assess the 
influence of bright light exposure (room light) at night 
on metabolic and hormonal responses in healthy young 
participants. Significantly higher glucose and insulin in 
the BL session suggests glucose intolerance and insulin 
insensitivity. Elevated NEFAs level in the DL session prior 
to the meal could either be due to the stimulatory effects 
of melatonin on glucagon or the inhibitory effects on 
insulin, resulting in higher HSL activity. Our recent results 
could be due to light or melatonin or a combination of 
the two. These results support the idea that nocturnal 
lifestyle, such as in night shift work, is likely to be one 
of the risk factors to health in modern society, including 
diabetes. Further studies are needed to determine whether 
melatonin causes the present metabolic changes or other 
processes are involved.
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Appendix-E
STUDY 1- Participant information sheet
The effects of light on vascular function, behavioural and metabolic
responses
Introduction
This research project is supervised by Dr. Shelagh Hampton and Dr. Benita Mid-
dleton. I am Mohammed Al Breiki, PhD student at Faculty of Health and Medical
Sciences. I am investigating the effect of light on metabolic responses and vascular
function.
We would like to invite you to take part in a research project. Before you decide
you need to understand why the research is being done and what it will involve for
you. Please take the time to read the following information carefully. Talk to others
about the study if you wish.
What is the purpose of the study?
This study seeks to investigate the influence of the role of light on metabolic re-
sponses and vascular function. We will collect blood samples and investigate some
of the substances released into the blood after a meal from the body to see if light
has any effect on these processes.
Why have I been invited to take part in the study?
we are looking for healthy volunteers aged between 18-60 years. You can be a
student undergraduate or postgraduate or a member of staff at the University of
Surrey, or a member of the general public.
Do I have to take part?
No, you do not have to participate. There will be no adverse consequences if you
decide not to participate. You can withdraw at any time without giving a reason.
What will happen to me if I take part?
You will be asked to attend an induction session where the study will be explained in
detail. You will have already received the participant information sheet so that you
could read it before attending. If you are still happy to participate then you will be
asked to complete a consent form and some questionnaires. If you still fit the criteria
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you will be asked to attend two sessions (Dim light and bright light sessions). Both
sessions will be held in Clinical Investigation Unit (AX00) at School of Biosciences
and Medicine. You will be provided with all meals on each of the study days in
the unit. The first being breakfast at 08:00h follows by lunch at 14:00h. You will
be allowed to leave the unit after breakfast. You will return to the unit at 14:00h
and finish the study at 07:00h the following day. No other foods will be allowed
to be consuming apart from the meals provided by the research team throughout
the study. Water is allowed throughout the study. You will also have a glucose
sensor insert at 15:00h, this monitor you interstitial glucose level. It is a tiny sensor
(Eyelash size) that will be inserted under your skin in the abdominal area.Also
cannula (see figure small plastic tube inserted under the skin) for collecting blood
samples will be inserted at 17.30h by trained nurse and/or doctor and blood samples
will be collected at specific time intervals from 18:00h until 07:00h the following
morning (total no of samples 25).You will be also asked to collect saliva samples
during the session (total no of samples 22). Vascular function test will be performed
during each leg four times in total (two times before and twice after the supper).
You will be reimbursed for you time and inconvenience with a maximum payment
of £200 for completion of the study. Should you withdraw before completion of the
study you will receive a pro-rata payment at the discretion of the investigators
What will I have to do?
If you would like to take part please make sure to follow
the instructions stated by the investigators. Prior to
the study you will have to maintain a regular sleep-wake
cycle (sleep time at 23:00h and wake time at 07:00h)
for two weeks. You will also have to wear an actiwatch
for two weeks prior to the study, as well as complete the sleep diary to compare its
results with actiwatch data. Additionally, 24 hours urinary collection will be carried
out for 2 days in order to investigate that a melatonin rhythm is produced. This
will be collected on the week prior to the study. According to the sleep analysis
results and the melatonin data participants will be able to continue onto the main
study. You must refrain from coffee, carbonated drinks (Pepsi, Fanta-etc) twenty
four hours prior to the study. You will be asked to avoid any exercise activity during
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the study day. All meals will be provided by the research team, and no extra foods
shall be consumed by participants. You will have to stay at the CIU between 14:00h
until 07:00h the following day for each session.
What are the possible disadvantages or risks of taking part?
There will be no serious risks of taking part in this study.Trained doctors / nurses
will be responsible for inserting the cannula. The cannula may be required to be
relocated if uncomfortable. This again will be carried out by trained personnel.
Re-location at another site on the arm will be discussed with you in order to ensure
that you are fully informed what will happen. In the researchers experience this
only happen occasionally. During dim light session, all participants will be provided
with red filter torches. Also, tiredness and discomfort from sleep deprivation can
be solved by allowing a recovery sleep after sleep deprivation; also participants will
be allowed to sleep in CIU after the end of the session if they wish.
What are the possible benefits of taking part?
There will be no direct benefit obtained from this study apart from the expenses
that will be paid to you. We also hope that your participation could assist us in
future research and lead to some interesting data that can be investigated in future.
What if there is a problem?
Any complaint or concern about any aspect of the way you have been dealt with
during the course of the study will be addressed; please contact:
• Dr. Shelagh Hampton, Tel: 01483 689732, Email: s.hampton@surrey.ac.uk,
• Dr. Benita Middleton, Tel: 1483 689712, Email: b.middleton@surrey.ac.uk,
• Mohammed Al Breiki, Tel: 07733377703, Email: ma00451@surrey.ac.uk.
Will my taking part in the study be kept confidential? The information
collected will be stored at the University of Surrey. This may be inspected by
regulatory authorities to check that the study is being carried out correctly. Your
name, however, will not be disclosed outside of the research team. Records held will
be identified only by code numbers and are kept in a secure place for 10 year at the
University of Surrey. The results from the study may be used for publication but
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all results will be kept strictly anonymous. All data used will be within the terms
of the Data Protection Act 1998
Contact details of researcher and, where appropriate supervisor?
• Principal Investigator and Supervisor: Dr. Shelagh Hampton Department of
Biochemistry and Physiology, School of Biosciences and Medicine, University
of Surrey, Guildford - Tel:01483 689732 - Email: s.hampton@surrey.ac.uk
• Co-Investigator: Dr. Benita Middleton Department of Biochemistry and
Physiology, School of Biosciences and Medicine, University of Surrey, Guild-
ford - Email:-b.middleton@surrey.ac.uk - Tel: 01483 689712.
• Prinicpal Investigator: Mohammed Al Breiki - Department of Biochemistry
and Physiology, School of Biosciences and Medices University of Surrey, Guild-
ford - Tel: 07733377703 - Email: ma00451@surrey.ac.uk
Who is organising and funding the research?
The research is organised as part of Mohammed Al Breiki PhD research studies in
School of Biosciences and Medicine.
Who has reviewed the project?
The study has been reviewed and received a favourable opinion from the University
of Surrey Ethics Committee.
Thank you for taking the time to read this Information Sheet.
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Appendix-F
STUDY 2- Participant information sheet
The effects of light and exogenous melatonin on hormone and metabolic
responses
Introduction
This research project is supervised by Dr. Shelagh Hampton and Dr. Benita Mid-
dleton. I am Mohammed Al Breiki, PhD student in the Faculty of Health and
Medical Sciences at the University of Surrey. I am investigating the effects of light
and exogenous melatonin on hormone and metabolic responses. We would like to
invite you to take part in a research project. Before you decide you need to under-
stand why the research is being done and what it will involve for you. Please take
the time to read the following information carefully. Talk to others about the study
if you wish.
What is the purpose of the study?
We have previously shown that light and melatonin affect metabolic responses. This
study aims to establish whether light or melatonin is responsible for these changes
in metabolic responses. Exogenous melatonin (in the form of a 2mg Circadin tablet)
will therefore be given in 2 of the 3 sessions of this study. We will collect blood
samples and investigate some of the substances released into the blood from the
body after a meal is consumed.
Why have I been invited to take part in the study?
We are looking for healthy male volunteers aged between 18-30 years.
Do I have to take part?
No, you do not have to participate. There will be no adverse consequences if you
decide not to participate. You can withdraw at any time without giving a reason.
What will happen to me if I take part?
You will be asked to attend an induction session where the study will be explained in
detail. The induction session will take about 15 minutes. You will have already re-
ceived this participant information sheet so that you could read it before attending.
If you are still happy to participate then you will be asked to complete a consent form
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and some questionnaires. You will need to be aware that your data will be checked
and stored on the internet based system to prevent over-volunteering clinical trials
(TOPS). Then, you will be asked to provide a 48h urine collection. Also, you will be
asked to wear an Actiwatch to monitor your sleep-wake cycle. Based on the urine
and actiwatch screening tests, you will either be included or excluded.If you still fit
the criteria you will be asked to attend three sessions (bright light, dim light with
exogenous melatonin and bright light with exogenous melatonin). Before attending
the sessions, the results obtained from urine collection will assist to determine your
lunch and supper times. All sessions will be held in either the Clinical Investigation
Unit (CIU) or the Clinical Research Centre(CRC) at the School of Biosciences and
Medicine at the University of Surrey. You will be provided with all meals on each
of the study days. These meals, breakfast, lunch and supper will be consumed in
the CIU/CRC. You will be allowed to leave the unit after breakfast but must not
consume any food before returning to eat lunch. You will return to the unit at
lunch time and finish the study at 06:00h the following day. Participants will not
be allowed to leave the unit after lunch time until the end of the study. Lunch and
supper time will be determined based on the results obtained from urine collection.
No other foods will be allowed to be consumed apart from the meals provided by
the research team throughout the study. Water is allowed throughout the study.
A cannula (see picture) for collecting blood samples will be inserted at 17.30h by
a trained nurse and/or doctor and blood samples will be collected at specific time
intervals from 18:00h until 06:00h the following morning (total no. of samples 22).
Also, you will be asked to collect saliva samples during the session (total no. of
samples 25). Circadin tablets will be given 1-2 hours before the supper time in
two of the sessions. You will be reimbursed for your time and inconvenience with
a maximum payment of £300 for completion of the study. Should you withdraw
before completion of the study you will receive a pro-rata payment at the discretion
of the investigators. Study schematic diagram is included.
What will I have to do?
If you would like to take part please make sure to follow the instructions given by
the investigators. You will have to maintain a regular sleep-wake cycle (e.g. sleep
time at 23:00h and wake time at 07:00h) for two weeks prior to the study. The
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sleep / wake time is flexible, however you will need to maintain a regular sleep-wake
pattern with a sleep duration between 6.5 to 8 hours, and to go to bed within a
time frame 23:00-01:00h. You will collect urine samples over 24-hours 2 days before
the study starts, and you will be given an instruction sheet for urine collection. All
participants must refrain from drinking coffee, carbonated drinks (Pepsi, Fanta-etc)
and any other foods apart from foods supplied by the research investigators on the
study day. You must also avoid any exercise activity during the study day. You will
have to stay at the unit between approximately 14:00h until 06:00h the following
day for each session. TV and DVD are available in the clinical unit, you can use
your personal computers, and phone, during the sessions.
What are the possible disadvantages or risks of taking part?
There will be no serious risks of taking part in this study. Trained doctors / nurses
will be responsible for inserting the cannula. The cannula may be required to be re-
located if uncomfortable. Bruising and pain may be associated with re-cannulation,
however this again will be carried out by trained personnel. Re-location at another
site on the arm will be discussed with you in order to ensure that you are fully aware
of what will happen. In the researchers experience this only happens occasionally.
During the dim light session, all participants will be provided with red filter torches.
Tiredness and discomfort from sleep deprivation will be addressed by allowing a re-
covery sleep in CIU/CRC after the end of the session this is recommended. The
bright light used in the clinical unit is between 500-600 lux, whereas the outside
daylight exposure can reach 100000 lux, plus the light will not be pointed directly
at the eye, so this should not cause discomfort.
What are the possible benefits of taking part?
There will be no direct benefit obtained from this study apart from the expenses
that will be paid to you. We also hope that your participation could assist us in
future research and lead to scientific publications.
What if there is a problem?
Any complaint or concern about any aspect of the way you have been dealt with
during the course of the study will be addressed; please contact
• Dr. Shelagh Hampton, Tel: 01483 689732, Email: s.hampton@surrey.ac.uk,
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• Dr. Benita Middleton, Tel: 1483 689712, Email: b.middleton@surrey.ac.uk,
• Mohammed Al Breiki, Tel: 07733377703, Email: ma00451@surrey.ac.uk.
An emergency contact card will be given to you before the session starts.
Will my taking part in the study be kept confidential?
The information collected will be stored at the University of Surrey. This may be
inspected by regulatory authorities to check that the study is being carried out
correctly. Your name, however, will not be disclosed outside of the research team.
Records held will be identified only by code numbers and are kept in a secure place
for at least 10 years at the University of Surrey. The results from the study may be
used for publication but all results will be kept strictly anonymous and also will be
used for writing up my PhD project. All data used will be within the terms of the
Data Protection Act 1998
Contact details of researcher and, where appropriate supervisor?
• Principal Investigator and Supervisor: Dr. Shelagh Hampton Department of
Biochemistry and Physiology, School of Biosciences and Medicine, University
of Surrey, Guildford - Tel:01483 689732 - Email: s.hampton@surrey.ac.uk
• Co-Investigator: Dr. Benita Middleton Department of Biochemistry and
Physiology, School of Biosciences and Medicine, University of Surrey, Guild-
ford - Email:-b.middleton@surrey.ac.uk - Tel: 01483 689712.
• Prinicpal Investigator: Mohammed Al Breiki - Department of Biochemistry
and Physiology, School of Biosciences and Medices University of Surrey, Guild-
ford - Tel: 07733377703 - Email: ma00451@surrey.ac.uk
Who is organising and funding the research?
The research is organised as part of Mohammed Al Breiki PhD research studies in
the School of Biosciences and Medicine.
Who has reviewed the project?
The study has been reviewed and received a favourable ethical opinion from the
University of Surrey Ethics Committee.
Thank you for taking the time to read this Information Sheet.
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Appendix-G
STUDY 1 - Consent form
• I the undersigned voluntarily agree to take part in the study on ..
• I have read and understood the Information Sheet provided. I have been
given a full explanation by the investigators of the nature, purpose, location
and likely duration of the study, and of what I will be expected to do. I
have been advised about any discomfort and possible ill-effects on my health
and well-being which may result. I have been given the opportunity to ask
questions on all aspects of the study and have understood the advice and
information given as a result.
• I agree to comply with any instruction given to me during the study and to
co-operate fully with the investigators. I shall inform them immediately if I
suffer any deterioration of any kind in my health or well-being, or experience
any unexpected or unusual symptoms.
• I consent to my personal data, as outlined in the accompanying information
sheet, being used for this study and other research. I understand that all
personal data relating to volunteers is held and processed in the strictest
confidence, and in accordance with the Data Protection Act (1998).
• I understand that I am free to withdraw from the study at any time without
needing to justify my decision and without prejudice.
• I acknowledge that in consideration for completing the study I shall receive
the sum of 200 I recognise that the sum would be less, and at the discretion
of the Principal Investigator, if I withdraw before completion of the study.
• I understand that in the event of my suffering a significant and enduring injury
(including illness or disease) as a direct result of my participation in the study,
compensation will be paid to me by the University (or sponsor where a clinical
trial is sponsored by a pharmaceutical company), subject to certain provisos
and limitations. The amount of compensation will be appropriate to the
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nature, severity and persistence of the injury and will, in general terms, be
consistent with the amount of damages commonly awarded for similar injury
by an English court in cases where the liability has been admitted
• I confirm that I have read and understood the above and freely consent to
participating in this study. I expect to be willing and able to comply with the
requirements of the study that have been outlined to me.
Name of volunteer (BLOCK CAPITALS)....................
Signed & Date ....................
Name of witness (where appropriate) (BLOCK CAPITALS) ....................
Signed & Date ....................
Name of researcher/person taking consent (BLOCK CAPITALS) ....................
Signed & Date....................
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Appendix-H
STUDY 2 Consent form
• I the undersigned voluntarily agree to take part in the study The effects of
light and exogenous melatonin on hormone and metabolic responses
• I have read and understood the Information Sheet provided (version 8, 01/04/2015).I
have been given a full explanation by the investigators of the nature, purpose,
location and likely duration of the study, and of what I will be expected to
do. I have been advised about any discomfort and possible ill-effects on my
health and well-being which may result. I have been given the opportunity to
ask questions on all aspects of the study and have understood the advice and
information given as a result.
• I agree to comply with any instruction given to me during the study and to
co-operate fully with the investigators. I shall inform them immediately if I
suffer any deterioration of any kind in my health or well-being, or experience
any unexpected or unusual symptoms.
• I consent to my personal data, as outlined in the accompanying information
sheet, being used for this study. I understand that all personal data relating to
volunteers is held and processed in the strictest confidence, and in accordance
with the Data Protection Act (1998).
• I agree to the investigators contacting my general practitioner about my par-
ticipation in the study, and I authorise my GP to disclose details of my relevant
medical or drug history, in confidence.
• I understand that I am free to withdraw from the study at any time without
needing to justify my decision and without prejudice, and your data will be
disposed according to University regulations.
• I acknowledge that in consideration for completing the study I shall receive
the sum of 300. I recognise that the sum would be less, and at the discretion
of the Principal Investigator, if I withdraw before completion of the study.
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• I understand that in the event of my suffering a significant and enduring injury
(including illness or disease) as a direct result of my participation in the study,
compensation will be paid to me by the University, subject to certain provisos
and limitations. The amount of compensation will be appropriate to the
nature, severity and persistence of the injury and will, in general terms, be
consistent with the amount of damages commonly awarded for similar injury
by an English court in cases where the liability has been admitted
• I confirm that I have read and understood the above and freely consent to
participating in this study. I expect to be willing and able to comply with the
requirements of the study that have been outlined to me
Name of volunteer (BLOCK CAPITALS) ........................................................
Signed & Date........................................................
Name of witness (where appropriate) (BLOCK CAPITALS) ........................................................
Signed & Date ........................................................
Name of researcher/person taking consent (BLOCK CAPITALS) ........................................................
Signed & Date ........................................................
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Appendix-I
General health questionnaire
Date .............. Reference number: ..............
PERSONAL DETAILS
Title: .............. Family name: ..............
Initials: .............. Address: ..............
Telephone: Day .............. Evening ..............
Weight (kg): .............. Height (m):..............
DOB: .............. Age: ..............(18 60)
GENERAL HEALTH
Condition/Disorder YES NO
Psychiatric Disorders
Drug/Alcohol dependence
Epilepsy
Sleep Disorders eg Insomnia
Endocrine Disorders (inc. Diabetes
Cardiovascular Disease
Blood Pressure-Hypertension
Renal Disease
Hepatic Disease
Gastrointestinal Disease
Any food allergies YES/NO
IF YES: Food/s ..............
GENERAL QUESTIONS
Nicotine (tick the relevant box) Smoker How many a day ..............
Non-smoker
Average caffeine consumption/day
How many cups/day :- Tea..............
Coffee..............
Cola..............
Average alcohol consumption/week ...............
Pint of beer is 2 units Glass of wine (125ml)1.5 units
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Typical breakfast ( cereal /toast-tea,coffee)
............................................................................................................................
Women only
Are you on the pill?
if yes which type ...............................................
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Identification Code: ........... DATE: ...........
Appendix-J
Horne & o¨stberg questionnaire
This questionnaire will used to assess whether you are a morning type (i.e. a lark)
or an evening type (i.e. an owl) person.
• Please read each question very carefully before answering.
• Answer all questions
• Answer questions in numerical order
• Each question should be answered independently of others. Do NOT go back
and check your answers.
• For some questions you are required to respond by placing a cross alongside
your answer. In such cases, select ONE answer only.
• Please answer each question as honestly as possible. Both your answers and
results will be kept in strict confidence.
QUESTION 1
Considering only your own feeling best rhythm, at what time would you get up if
you were entirely free to plan your day?
QUESTION 2
Considering only your own feeling best rhythm, at what time would you go to bed
if you were entirely free to plan your evening?
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QUESTION 3
If there is a specific time you have to get up in the morning, to what extent are you
dependent on being woken up by an alarm clock?
a. Not at all dependent [ ]
b. Slightly dependent [ ]
c. Fairly dependent [ ]
d. Very dependent [ ]
QUESTION 4
Assuming adequate environmental conditions, how easy do you find getting up in
the morning?
a. Not at all easy [ ]
b. Not very easy [ ]
c. Fairly easy [ ]
d. Very easy [ ]
QUESTION 5
How alert do you feel during the first half hour after having woken in the morning?
a. Not at all alert [ ]
b. Slightly alert [ ]
c. Fairly alert [ ]
d. Very alert [ ]
QUESTION 6
How is your appetite during the first half hour after having woken in the morning?
a. Very poor [ ]
b. Fairly poor [ ]
c. Fairly good [ ]
d. Very good [ ]
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QUESTION 7
During the first half hour after having woken in the morning, how tired do you feel?
a. Very tired [ ]
b. Fairly tired [ ]
c. Fairly refreshed [ ]
d. Very refreshed [ ]
QUESTION 8
When you have no commitments the next day, at what time do you go to bed
compared to your usual bedtime?
a. Seldom or never later [ ]
b. Less than one hour later [ ]
c. 1-2 hours later [ ]
d. More than 2 hours later [ ]
QUESTION 9
You have decided to engage in some physical exercise. A friend suggests that you
do this one hour twice a week and the best time for him is between 0700 and 0800h.
Bearing in mind nothing else but your own inclinations, how do you think you would
perform?
a. Would be on good form [ ]
b. Would be on reasonable form [ ]
c. Would find it difficult [ ]
d. Would find it very difficult [ ]
QUESTION 10
At what time in the evening do you feel tired and as a result in need of sleep?
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QUESTION 11
You wish to be at your peak for a test which you know is going to be mentally
exhausting and lasting for two hours. You are entirely free to plan your day and
considering only your own ”feeling best” rhythm, which ONE of the four testing
times would you choose?
a. 0800 1000 [ ]
b. 1100 1300 [ ]
c. 1500 1700 [ ]
d. 1900 2100 [ ]
QUESTION 12
If you went to bed at 2300h at what level of tiredness would you be?
a. Not at all tired [ ]
b. A little tired [ ]
c. Fairly tired [ ]
d. Very tired [ ]
QUESTION 13
For some reason you have gone to bed several hours later than usual, but there is
no need to get up at any particular time the next morning. Which ONE of the
following events are you most likely to experience:
a. Wake up at the usual time and not go back to sleep [ ]
b. Wake up at the usual time and doze [ ]
c. Wake up at the usual time and go back to sleep [ ]
d. Wake up later than usual [ ]
QUESTION 14
One night you have to remain awake between 0400 and 0600h. You have no com-
mitments the next day. Which ONE of the following suits you best:
a. Not to go to bed until 0600h [ ]
b. Nap before 0400h and sleep after 0600h [ ]
c. Sleep before 0400h and nap after 0600h [ ]
d. Sleep before 0400h and remain awake after 0600h [ ]
QUESTION 15
You have to do two hours of hard physical work. You are entirely free to plan
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your day and considering only your own ”feeling best” rhythm which ONE of the
following times would you choose?
a. 0800 1000 [ ]
b. 1100 1300 [ ]
c. 1500 1700 [ ]
d. 1900 2100 [ ]
QUESTION 16
You have decided to engage in some physical exercise. A friend suggests that you
do this between 2200 and 2300h twice a week. Bearing in mind nothing else but
your own ”feeling best” rhythm how well do you think you would perform?
a. Would be on good form [ ]
b. Would be on reasonable form [ ]
c. Would find it difficult [ ]
d. Would find it very difficult [ ]
QUESTION 17
Suppose that you can choose your own work hours. Assume that you worked a
FIVE hour day (including breaks)) and that your job was interesting and paid by
results. Which FIVE CONSECUTIVE HOURS would you select:
QUESTION 18
At what time of day do you think that you reach your ”feelingbest” peak?
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QUESTION 19
One hears of morning and evening types. Which do you consider yourself to be?
a. Morning type [ ]
b. More morning than evening [ ]
c. More evening than morning [ ]
d. Evening type [ ]
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Appendix-K
Pittsburgh sleep quality index questionnaire
Identification Code: ........... DATE: ...........
Instructions:
The following questions relate to your usual sleep habits during the past month
only. Your answers should indicate the most accurate reply for the majority of days
and nights in the past month. Please answer all the questions.
1. During the past month, when have you usually gone to bed at night? Usual
bed time
2. During the past month, how long (in minutes) has it usually take you to fall
asleep each night? Number of minutes
3. During the past month, when have you usually got up in the morning? Usual
getting up time
4. During the past month, how many hours of actual sleep did you get at night?
(This may be different from the number of hours spent in bed.) Hours of sleep
per night
For each of the remaining questions, check the one best response. Please
answer all questions.
5. During the past month, how often have you had trouble sleeping because
you....
a) Cannot get to sleep within 30 minutes
Not during the
past month
Less than
once a week
Once or
twice a week
Three or more
times a week
b) Wake up in the middle of the night or early morning
Not during the
past month
Less than
once a week
Once or
twice a week
Three or more
times a week
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c) Have to get up to use the bathroom
Not during the
past month
Less than
once a week
Once or
twice a week
Three or more
times a week
d) Cannot breathe comfortably
Not during the
past month
Less than
once a week
Once or
twice a week
Three or more
times a week
e) Cough or snore loudly
Not during the
past month
Less than
once a week
Once or
twice a week
Three or more
times a week
f) Feel too cold
Not during the
past month
Less than
once a week
Once or
twice a week
Three or more
times a week
g) Feel too hot
Not during the
past month
Less than
once a week
Once or
twice a week
Three or more
times a week
h) Had bad dreams
Not during the
past month
Less than
once a week
Once or
twice a week
Three or more
times a week
i) Have pain
Not during the
past month
Less than
once a week
Once or
twice a week
Three or more
times a week
j) Other reason(s), please describe
...........................................................................................
K) How often during the past month have you had trouble sleeping
because of this?
Not during the
past month
Less than
once a week
Once or
twice a week
Three or more
times a week
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6. During the past month, how would you rate your sleep quality overall?
Very good .............
Fairly good .............
Fairly bad .............
Very bad .............
7. During the past month, how often have you taken medicine (prescribed or
over the counter) to help you sleep?
Not during the
past month
Less than
once a week
Once or
twice a week
Three or more
times a week
8. During the past month, how often have you had trouble staying awake while
driving, eating meals, or engaging in social activity?
Not during the
past month
Less than
once a week
Once or
twice a week
Three or more
times a week
9. During the past month, how much of a problem has it been for you to show
enthusiasm to get things done?
No problem at all .............
Only a very slight problem .............
Somewhat of a problem .............
A very big problem .............
10. Do you have a bed partner or roommate?
No bed partner or roommate? .............
Partner/roommate in other room .............
Partner in same room, but not
same bed
.............
Partner in same bed .............
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If you have a roommate or bed partner, ask him/her how often in
the past month you have had ....
a) Loud snoring
Not during the
past month
Less than
once a week
Once or
twice a week
Three or more
times a week
b) Long pauses between breaths while asleep
Not during the
past month
Less than
once a week
Once or
twice a week
Three or more
times a week
c) Legs twitching or jerking while you sleep
Not during the
past month
Less than
once a week
Once or
twice a week
Three or more
times a week
d) Episodes of disorientation or confusion during sleep?
Not during the
past month
Less than
once a week
Once or
twice a week
Three or more
times a week
e) Other restlessness while you sleep; please describe
................................................................................................................
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Appendix-L
Munich chronotype questionnaire
Identification Code: ........... DATE: ...........
All aspects of this study have received a favourable ethical opinion from the Uni-
versity of Surrey Ethics Committee.
The following data are essential for the analysis of your chronotype to be compre-
hensive.
Birth date (YY/MM/DD): .......... / .......... / ..........
Gender: Male / Female
Place of birth: .....................
Height: .................... cm
Weight: .................... kg
Important: in the following sections, please give your answers as they hold
true in your current, present-time situation. For changing conditions (for example,
beginning of work), please choose the most frequent or appropriate value.
On workdays (dont fill out if you are retired)
I have to get up at ................ oclock
I need ................ min to wake up
I regularly wake up ................ (min before the alarm / with the alarm)
From ................ o’clock, I am fully awake
At around ................ o’clock, I have an energy dip
On nights before workdays, I go to bed at ................ o’clock
and it then takes me ................ min to fall asleep
If I get the chance, I like to take a siesta/nap
Correct ..... I then sleep for .................... min
not correct ......I would feel terrible afterwards
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On free days (please only judge normal free days, i.e., without parties etc.)
My dream would be to sleep until ................ o’clock
I normally wake up at ................ o’clock
If I wake up at around the normal (workday) alarm time, I try to get back to
sleep Correct / Not correct
If I get back to sleep, I sleep for another ................ min
I need ................ min to wake up
From ................ o’clock, I am fully awake
At around ................ o’clock, I have an energy dip
On nights before free days, I go to bed at ................ o’clock
and it then takes me ................ min to fall asleep
If I get the chance, I like to take a siesta/nap
correct ........... I then sleep for .................... min
not correct ....... I would feel terrible afterwards
Once I am in bed, I would like to read for ................ min, but generally fall
asleep after no more than ................ min
I prefer to sleep in a completely dark room
Correct / Not correct
I wake up more easily when morning light shines into my room
Correct / Not correct
How long per day do you spend on average outside ( really outside) exposed
to day light?
On work days: ................ hrs ................ min
On free days: ................ hrs ................ min
Self-assessment
After you have answered the preceding questions, you should have a feeling
339
of the chronotype you belong to. If, for example, you like (and manage) to
sleep quite a bit longer on free days than on workdays, or if you cannot get
out of bed on Monday mornings, even without a Sunday-night party, then you
are more likely a late type. If, however, you regularly wake up and feel fresh
right from the moment you jump out of bed, and if you would go to bed early
rather than to an evening concert, then you are more an early type. In the
following questions, please characterize yourself and your family members in
terms of early/late types.
Extreme early type Moderately early type Slight early type Normal type Slight late type Moderately late type Extreme late type
I am ... 0 1 2 3 4 5 6
As a child, I was ... 0 1 2 3 4 5 6
As a teenager, I was ... 0 1 2 3 4 5 6
In case you are older than 65: in the middle of my life, I was ...
0 1 2 3 4 5 6
My parents are/were ...
0 1 2 3 4 5 6
Mother 0 1 2 3 4 5 6
Father 0 1 2 3 4 5 6
My siblings are/were ... (please underline Brother or Sister)
Brother/Sister 0 1 2 3 4 5 6
Brother/Sister 0 1 2 3 4 5 6
Brother/Sister 0 1 2 3 4 5 6
Brother/Sister 0 1 2 3 4 5 6
Brother/Sister 0 1 2 3 4 5 6
Brother/Sister 0 1 2 3 4 5 6
340
Appendix-M
Sleep and nap diary
Participant’s Code: ...........
DATE: ........... Day of week ...........
This form is to be completed in the morning EACH DAY
throughout the entire study.
What time did you go to bed?
(hh:mm)
At what time did you try to sleep?
(if different to above answer)
How long did it take you to fall
asleep? (minutes)
How many times did you wake up?
How long were you awake for?
(minutes)Please estimate the time
& duration of each night awaken-
ing!
Woke up Fell asleep Reason
1.
2.
3.
4.
5.
What time did you wake up?
(hh:mm)
What was the reason for waking up?
Alarm Noise Person Just awoke
What time did you turn on the
light? (hh:mm)
What time did you get up?
(hh:mm)
Would you describe this as a typi-
cal night?
YES / NO
If permitted, could you have slept
longer?
YES / NO
How would you rate your quality of sleep? (circle one)
best ever 1 2 3 4 5 6 7 8 9 worst ever
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Nap diary
Participant’s Code: ...........
DATE: ........... Day of week ...........
Please complete one column of this table after each day-time nap
Nap 1 Nap 2 Nap 3 Nap 4 Nap 5
What time did the nap start?
What time did the nap end?
How long was the nap? (min)
Please record any times you would have liked to nap but were unable to for
whatever reason,
e.g. wanted a nap 16:00 17:30 ................
Instructions for completing sleep, nap and activity di-
aries
Please complete a sleep diary every day for the entire study. Questions need to be
answered as accurately as possible. But dont worry too much if you dont remember
the exact times, an approximation is fine.
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Appendix-N
Urine collection
Details for collection of urine samples for assessment of
phase position by measurement of 6-sulphatoxymelatonin
(AMT6S)
You are provided with the following to collect urine samples over
a 48 hour period:-
• 1 x Litre Plastic Bottle with graduated markings
• 1 x funnel
• 11 x small labelled plastic bottles
• 2 x plastic pastettes
• 1 x form to fill in volumes
PROCEDURE TO FOLLOW
1. Empty bladder before going to bed. Note time of going to bed.
2. Collect all urine passed during the night and on first getting up in the morning.
(This should be approximately an 8 hour period e.g. midnight - 8.00am.)
3. Measure volume, fill in volume on form noting exact time of sampling.
4. Retain 2-3ml sample in small tube. Clearly label tube using a permanent pen
biro or pencil. Water soluble ink tends to run on thawing the samples!
5. Collect all urine passed to 12:00h Measure volume, fill in volume on form
noting exact time of sampling.
6. Retain 2-3ml sample in small tube. Fill in label.
7. Collect all urine passed to 16:00h Measure volume, fill in volume on form
noting exact time of sampling.
8. Retain 2-3ml sample in small tube. Fill in label.
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9. Collect all urine passed to 20:00h Measure volume, fill in volume on form
noting exact time of sampling.
10. Retain 2-3ml sample in small tube. Fill in label.
11. Collect all urine passed to 24:00h or bed time. Measure volume, fill in volume
on form noting exact time of sampling.
12. Retain 2-3ml sample in small tube. Fill in label.
13. Repeat for second day
N.B. Please note that you can start the urine collection at any time that is convenient
to you provided you do 48h with 2 overnight collections. Just note the time you
emptied your bladder as the start of the collection period. The 4h collection periods
do not need to be precise but it is important for analysis purposes that you note
the exact time of sampling and an accurate volume. The more samples you collect
the more accurate your results will be.
PLEASE DELIVER COLLECTED SAMPLES TO DR BENITA MIDDLETON,
18AY02 OR BRING THEM TO THE PRACTICAL WITH YOU.
Time period Sample number Actual time Volume (mls)
Midnight-08:00h
08:00-12:00h
12:00h-16:00h
16:00h-20:00h
20:00h-24:00h
Midnight-08:00h
08:00-12:00h
12:00h-16:00h
16:00h-20:00h
20:00h-24:00h
Example 1 1 23:45-07:20h 550ml
Example 2 2 07:20h-11:35h 320ml
Subject Number: .............
Date Collected: ..................
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Appendix-P
Food and visual analogue scale
Identification Code: ........... DATE: ...........
Leg: ........... Time ...........
Answer the questions by placing a vertical mark through the line for each question.
Mark the line according to how you feel at this moment. Regard both the ends
of the lines as indicating the most extreme sensations you have ever felt.
Time:.........
How drowsy do you feel?
Drowsy Alert
Time:.........
How tense do you feel?
Tense Relaxed
Time:.........
How happy do you feel?
Happy Sad
Time:.........
How friendly do you feel?
Friendly Angry
Time:.........
How uncertain do you feel?
Uncertain Confident
Time:.........
How clear-headed do you feel?
Muddled Clear-headed
Time:.........
How interested do you feel?
Interested Not Interested
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Time:.........
How hungry do you feel?
I am not
hungry at
all
I have never
been more
hungry
Time:.........
How much do you think you can eat?
Nothing at all A lot
Time:.........
How full do you feel?
Not at all full Extremely full
Time:.........
How thirsty do you feel?
Not at all thirsty Extremely thirsty
Time:.........
Would you like to eat something sweet?
No, not at all Yes, very much
Time:.........
Would you like to eat something salty?
No, not at all Yes, very much
Time:.........
Would you like to eat something savoury?
No, not at all Yes, very much
Time:.........
Would you like to eat something fatty?
No, not at all Yes, very much
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Appendix-Q
Mood and alertness scale
Identification Code: ........... DATE: ...........
Leg: ........... Time ...........
These will be recorded (a) 15 min after getting out of bed, (b) at lunch, and (c) at
evening 1-2 h prior to bedtime. Completion will take 10 min.
Karolinska Sleepiness Scale
Time of rating: .........
Please indicate your sleepiness during the 10 minutes before this rating.
Very alert 1
2
Alert normal level 3
4
Neither alert nor sleepy 5
6
Sleepy, but no effort to keep awake 7
8
Very sleepy, great effort to keep awake 9
Answer the questions by placing a vertical mark through the line for each question .
Circle the number according to how you feel at this moment. Regard
both the ends of the scale as indicating the most extreme sensations you
have ever felt.
350
How would you rate your alertness?
1 2 3 4 5 6 7 8 9
1=very
alert
9=very
sleepy
How would you rate your mood?
1 2 3 4 5 6 7 8 9
1 = very
cheerful
9 = very
miserable
How would you rate your mood?
1 2 3 4 5 6 7 8 9
1 = very
calm
9 = very
tense
How would you rate your mood?
1 2 3 4 5 6 7 8 9
1 = very
depressed
9 = very
elated
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Appendix-R
STUDY 1 Participant Flow Chart
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(9 M & 8 F)] 
 
Withdrew [n = 1 F] 
 
DS 
Group B 
(n=5) 
Attended the induction sessions – Interview (n =25) 
(13 M & 12 F)  
LS 
Group B 
(n=5) 
Screened (n = 21) 
(11 M & 10 F)  
DS  
Group A 
(n=5) 
Group A completed BL session first, then DL session, 
whereas group B attended DL session, then BL session. 
Randomisation method used was sealed envelope, single-
blind fashion. Group participants, genders and intended 
interventions were randomly determined. 
 
Included & attended the study 
sessions [n = 18 (9M & 9F)] 
 
Excluded (n = 3) 
Irregular sleep schedule [n = 1M] 
Failure in urine analysis [n = 2 (1M & 1F)] 
 
 
 
Excluded [n =4] 
Not meeting inclusion criteria [n =3 (2M 
& 1F)] 
Declined to participate [n = 1 F]  
Randomized [n = 18] 
 
Analysed [n = 17  
(9M & 8 F)] 
 
Subjects contacted the investigators (n 
= 47) 
(25 M & 22F)  
Received participant information sheet 
& failed to reply [n =15 (9 M & 6 F)] 
Received participant information sheet 
& replied [n =32 (18 M & 14F)]  
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sessions [n =7 (5 M 
& 2 F)]  
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Appendix-S
STUDY 2 Participant Flow Chart
           
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Completed the study [n = 9] 
 
Withdrew [n = 3] 
 
Attended the induction sessions – Interview (n =14) 
 
LSC 
Group B 
(n=5) 
Screened (n = 12) 
  
DSC  
Group A 
(n=5) 
Group A completed LS session first, then DSC and LSC 
session, whereas group B attended LSC session first, then 
DSC and LS session. Randomisation method used was sealed 
envelope, single-blind fashion. Group participants, and 
intended interventions were randomly determined. 
 
Included & attended the study 
sessions [n = 12] 
 
Excluded (n = 0) 
 
 
 
Excluded [n =2] 
Not meeting inclusion criteria [n =1] 
Declined to participate [n = 1]  
Randomized [n = 12] 
 
Analysed [n = 9] 
 
Subjects contacted the investigators (n 
= 17) 
(25 M & 22F)  
Received participant information sheet 
& failed to reply [n =17 (15 M)] 
Received participant information sheet 
& replied [n =17]  
Missed the induction 
sessions [n = 3]  
LS  
Group A 
(n=5) 
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Appendix-T
Scoring instructions for Horne & O¨stberg
INSTRUCTIONS
1. Please read each question very carefully before answering.
2. Answer all questions.
3. Answer questions in numerical order.
4. Each question should be answered independently of others. Do NOT go back
and check your answers.
5. For some questions, you are required to respond by placing a cross alongside
your answer. In such cases, select ONE answer only.
6. Please answer each question as honestly as possible. Both your answers and
results will be kept in strict confidence.
QUESTION 1
Considering only your own feelings, at what time would you get up if you were
entirely free to plan your day?
a. 05:00-06:29 5
b. 06:30-07:45 4
c. 07:45-09:44 3
d. 09:45-10:59 2
e. 11:00-12:00 1
Time:
.......
QUESTION 2
Considering only your own feelings, at what time would you go to bed if you were
entirely free to plan your day?
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a. 20:00-20:59 5
b. 21:00-22:14 4
c. 22:15-00:29 3
d. 00:30-01:44 2
e. 01:45-03:00 1
Time:
.......
QUESTION 3
If there is a specific time you have to get up in the morning, to what extent are you
dependent on being woken up by an alarm clock?
a. Not at all dependent [ 4 ]
b. Slightly dependent [ 3 ]
c. Fairly dependent [ 2 ]
d. Very dependent [ 1 ]
QUESTION 4
Assuming adequate environmental conditions, how easy do you find getting up in
the morning?
a. Not at all easy [ 1 ]
b. Slightly easy [ 2 ]
c. Fairly easy [ 3 ]
d. Very easy [ 4 ]
QUESTION 5
How alert do you feel during the first half hour after having woken in the morning?
a. Not at all alert [ 1 ]
b. Slightly alert [ 2 ]
c. Fairly alert [ 3 ]
d. Very alert [ 4 ]
QUESTION 6
How is your appetite during the first half hour after having woken in the morning?
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a. Not at all good [ 1 ]
b. Slightly good [ 2 ]
c. Fairly good [ 3 ]
d. Very good [ 4 ]
QUESTION 7
During the first half hour after having woken in the morning, how tired do you feel?
a. Not at all tired [ 1 ]
b. Slightly tired [ 2 ]
c. Fairly refreshed [ 3 ]
d. Very refreshed [ 4 ]
QUESTION 8
When you have no commitments the next day, at what time do you go to bed
compared to your usual bedtime?
a. Seldom or never later [ 4 ]
b. Less than one hour later [ 3 ]
c. 1-2 hours later [ 2 ]
d. More than 2 hours later [ 1 ]
QUESTION 9
You have decided to engage in some physical exercise. A friend suggests that you
do this one hour twice a week and the best time for him is between 0700 and 0800h.
Bearing in mind nothing else but your own inclinations, how do you think you would
perform?
a. Would be on good form [ 4 ]
b. Would be on reasonable form [ 3 ]
c. Would find it difficult [ 2 ]
d. Would find it very difficult [ 1 ]
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Question 10
At what time in the evening do you feel tired and in need of sleep?
20:00-20:59 5
21:00-22:14 4
22:15-00:44 3
00:45-01:59 2
02:00-03:00 1
Time: .......
QUESTION 11
You wish to be at your peak for a test which you know is going to be mentally
exhausting and lasting for two hours. You are entirely free to plan your day, when
would you do this task?
a. 0800 1000 [ 6 ]
b. 1100 1300 [ 4 ]
c. 1500 1700 [ 2 ]
d. 1900 2100 [ 0 ]
QUESTION 12
If you went to bed at 2300h at what level of tiredness would you be?
a. Not at all tired [ 0 ]
b. A little tired [ 2 ]
c. Fairly tired [ 3 ]
d. Very tired [ 5 ]
QUESTION 13
For some reason you have gone to bed several hours later than usual, but there is
no need to get up at any particular time the next morning. Will you:
a. Wake up at the usual time and not go back to sleep [ 4 ]
b. Wake up at the usual time and doze [ 3 ]
c. Wake up at the usual time and go back to sleep [ 2 ]
d. Wake up later than usual [ 1 ]
QUESTION 14
One night you have to remain awake between 0400 and 0600h. You have no com-
mitments the next day. Which suits you best:
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a. Not to go to bed until 0600h [ 1 ]
b. Nap before 0400h and sleep after 0600h [ 2 ]
c. Sleep before 0400h and nap after 0600h [ 3 ]
d. Sleep before 0400h and remain awake after 0600h [ 4 ]
QUESTION 15
You have to do hours physical work. Which hours would you prefer to do it between:
a. 0800 1000 [ 4 ]
b. 1100 1300 [ 3 ]
c. 1500 1700 [ 2 ]
d. 1900 2100 [ 1 ]
QUESTION 16
You have decided to engage in some physical exercise. A friend suggests that you do
this between 2200 and 2300h twice a week. How do you think you would perform:
a. Would be on good form [ 1 ]
b. Would be on reasonable form [ 2 ]
c. Would find it difficult [ 3 ]
d. Would find it very difficult [ 4 ]
QUESTION 17
Suppose that you can choose your own work hours, but had to work five hours in
the day. Which five consecutive hours would you choose:
a. 00:00-02:59 [ 6 ]
b. 03:00-07:59 [ 5 ]
c. 08:00-09:59 [ 4 ]
d. 10:00-13:59 [ 3 ]
d. 14:00-15:59 [ 2 ]
d. 16:00-23:59 [ 1 ]
QUESTION 18
At what time of day do you feel your best?
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a. 00:00-04:59 [ 6 ]
b. 05:00-08:59 [ 5 ]
c. 09:00-10:59 [ 4 ]
d. 11:00-16:59 [ 3 ]
d. 17:00-21:59 [ 2 ]
d. 22:00-23:59 [ 1 ]
QUESTION 19
One hears of morning and evening types. Which do you consider yourself to be?
a. Morning type [ 6 ]
b. More morning than evening [ 4 ]
c. More evening than morning [ 2 ]
d. Evening type [ 0 ]
QUESTION 19
One hears of ”morning” and ”evening” types. Which do you consider yourself to
be?
Definitely morning Type 70-86
Moderately Morning Type 59-69
Neither Type 42-58
Moderately Evening Type 31-41
Definitely Evening Type 16-30
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Appendix-U
Scoring instructions for PSQI
The Pittsburgh Sleep Quality Index (PSQI) contains 10 self-rated questions and 5
questions rated by the bed partner or room mate (if one is available). Only self-
rated questions are included in the scoring. The 19 self-rated items are combined
to form seven ”component” scores, each of which has a range of 0 3 points. In
all cases a score of ”0” indicates no difficulty, while a score of ”3” indicates severe
difficulty. The seven component scores are then added to yield one ”global” score
with a range of 0 21 points. ”0” indicating no difficulty and ”21” indicating severe
difficulties in all areas.
Scoring proceeds as follows:
Component 1: Sleep quality
Examine # 6, and assign score as follows
Response Component 1 score
Very good 0
Fairly good 1
Fairly bad 2
Very bad 3
Component 1 score .........
Component 2: Sleep latency
(1) Examine # 2, and assign scores as follows
Response Component 2 score
≤ 15 minutes 0
16-30 minutes 1
31-60 minutes 2
> 60 minutes 3
Question #2 score .........
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(2) Examine question # 5a, and assign scores as follows
Response score
Not during the past month 0
Less than once a week 1
Once or twice a week 2
Three or more times a week 3
Question #5a score .........
(3) Add #2 score and #5a score . . . . . . Sum of #2a and #5a . . . . .
.
(4) Assign component 2 score as follows:
0 0
1-2 1
3-4 2
5-6 3
Component 2 score .........
Component 3: Sleep duration
Examine question # 4, and assign scores as follows:
Response Component 3 score
> 7 hours 0
6-7 hours 1
5-6 hours 2
< 5 hours 3
Component 3 score .........
Component 4: Habitual sleep efficiency
(1) Write the number of hours slept (question # 4) here . . . . . . . . .
(2) Calculate the number of hours spent in bed
Getting up time (question # 3) . . . . . . . . . .
- Bedtime (question # 1) . . . . . . . . . .
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Number of hours spent in bed: . . . . . . . . .
(3) Calculate the habitual sleep efficiency as follows:
(Number of hours slept / Number of hours spent in bed) x 100 = habitual sleep
efficiency (%)
( . . . . . . . . . / . . . . . . . .) x 100 = . . . . . . . . . %
(4) Assign component 4 score as follows:
Habitual sleep efficiency (%) Component 4 score
> 85% 0
75-84% 1
65-74% 2
< 65% 3
Component 3 score .........
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Component 5: Sleep disturbances
(1) Examine questions # 5b-5j, and assign scores for each question as follows:
Response Component score
Not during the past month 0
Less than once a week 1
Once or twice a week 2
Three or more times a week 3
#5b score . . . . . . .
#5c score . . . . . . .
#5d score . . . . . . .
#5e score . . . . . . . .
#5f score . . . . . . . .
#5g score . . . . . . . .
#5h score . . . . . . . .
#5i score . . . . . . . .
#5j score . . . . . . . .
(2) Add the scores for questions # 5b-5j
Sum of # 5b-5j . . . . . . . .
. .
(3) Assign component 5 score as follows:
Sum of # 5b 5j Component 4 score
0 0
1-9 1
10-18 2
10-18 3
Component 5 score . . . . . .
.
Component 6: Use of sleeping medication
Examine question # 7 and assign scores as follows:
Response Component 6 score
Not during the past month 0
Less than once a week 1
Once or twice a week 2
Three or more times a week 3
Component 6 score . . . . . .
.
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Component 7: Daytime dysfunction
(1) Examine question # 8, and assign scores as follows:
Response Component 7 score
Never 0
Once or twice 1
Once or twice each week 2
Three or more times each week 3
Question # 8 score . . . . . .
.
(2) Examine question # 9, and assign scores as follows:
Response Component score
No problem at all 0
Only a very slight problem 1
Somewhat of a problem 2
A very big problem 3
Question # 9 score . . . . . .
.
(3) Add the scores for question ∼ 8 and # 9:
Sum of # 8 and # 9 . . . . .
. . . . . . . .
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Appendix-V
Correlation tests in Study 1
LS
Parameter r2 p
MT vs Sleepiness 0.19 <0.0001
MT vs Alertness 0.18 <0.0001
MT vs Mood 1 0.16 <0.0001
MT vs Mood 2 0.06 <0.0001
MT vs Mood 3 0.05 <0.0001
MT vs WT* 0.12 <0.0001
WT vs Sleepiness* 0.08 <0.0001
WT vs Alertness* 0.21 <0.0001
WT vs Mood 1* 0.06 <0.0001
WT vs Mood 2* 0.03 0.002
WT vs Mood 3* 0.009 0.13
DS
Parameter r2 p
MT vs Sleepiness 0.13 <0.0001
MT vs Alertness 0.09 <0.0001
MT vs Mood 1 0.01 <0.0001
MT vs Mood 2 <0.001 0.68
MT vs Mood 3 0.08 <0.0001
MT vs WT* 0.12 <0.0001
WT vs Sleepiness* 0.001 0.51
WT vs Alertness* 0.03 0.003
WT vs Mood 1* <0.004 0.9
WT vs Mood 2* 0.11 <0.0001
WT vs Mood 3* 0.003 0.36
* represents the correlation test of only 10 participants due to missing WT data of S001, S003, S004, S005,
S006, S007, and S008
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Appendix-W
Correlation tests in Study 2
LS
Parameter r2 p
MT vs Sleepiness 0.06 0.0004
MT vs Alertness 0.12 <0.0001
MT vs Mood 1 0.04 0.0041
MT vs Mood 2 0.22 <0.0001
MT vs Mood 3 0.12 <0.0001
MT vs WT 0.12 <0.0001
WT vs Sleepiness 0.23 <0.0001
WT vs Alertness 0.24 <0.0001
WT vs Mood 1 0.003 0.008
WT vs Mood 2 0.11 <0.0001
WT vs Mood 3 0.05 0.0009
DSC
Parameter r2 p
MT vs Sleepiness 0.004 0.38
MT vs Alertness 0.009 0.89
MT vs Mood 1 -0.09 0.47
MT vs Mood 2 0.002 0.47
MT vs Mood 3 0.001 0.58
MT vs WT* 0.03 0.01
WT vs Sleepiness 0.13 <0.0001
WT vs Alertness 0.14 <0.0001
WT vs Mood 1 0.02 0.04
WT vs Mood 2 0.01 0.12
WT vs Mood 3 0.02 0.02
LSC
Parameter r2 p
MT vs Sleepiness 0.002 0.5
MT vs Alertness 0.001 0.6
MT vs Mood 1 0.007 0.24
MT vs Mood 2 0.06 0.47
MT vs Mood 3 0.004 0.3
MT vs WT* 0.4 <0.0001
WT vs Sleepiness 0.26 <0.0001
WT vs Alertness 0.23 <0.0001
WT vs Mood 1 0.08 <0.0001
WT vs Mood 2 0.03 0.008
WT vs Mood 3 0.17 <0.0001
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